
<html lang="en"     class="pb-page"  data-request-id="9fed076d-73d9-4bac-9baf-5c809225c3a7"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.0c00914;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-12;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Adenosine A2AR/A1R Antagonists Enabling Additional H3R Antagonism for the Treatment of Parkinson’s Disease" /></meta><meta name="dc.Creator" content="Stefanie  Hagenow" /></meta><meta name="dc.Creator" content="Anna  Affini" /></meta><meta name="dc.Creator" content="Elsa Y.  Pioli" /></meta><meta name="dc.Creator" content="Sonja  Hinz" /></meta><meta name="dc.Creator" content="Yan  Zhao" /></meta><meta name="dc.Creator" content="Gregory  Porras" /></meta><meta name="dc.Creator" content="Vigneshwaran  Namasivayam" /></meta><meta name="dc.Creator" content="Christa E.  Müller" /></meta><meta name="dc.Creator" content="Jian-Sheng  Lin" /></meta><meta name="dc.Creator" content="Erwan  Bezard" /></meta><meta name="dc.Creator" content="Holger  Stark" /></meta><meta name="dc.Description" content="Adenosine A1/A2A receptors (A1R/A2AR) represent targets in nondopaminergic treatment of motor disorders such as Parkinson’s disease (PD). As an innovative strategy, multitargeting ligands (MTLs) we..." /></meta><meta name="Description" content="Adenosine A1/A2A receptors (A1R/A2AR) represent targets in nondopaminergic treatment of motor disorders such as Parkinson’s disease (PD). As an innovative strategy, multitargeting ligands (MTLs) we..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 9, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00914" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00914" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00914" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00914" /></link>
        
    
    

<title>Adenosine A2AR/A1R Antagonists Enabling Additional H3R Antagonism for the Treatment of Parkinson’s Disease | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00914" /></meta><meta property="og:title" content="Adenosine A2AR/A1R Antagonists Enabling Additional H3R Antagonism for the Treatment of Parkinson’s Disease" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0012.jpeg" /></meta><meta property="og:description" content="Adenosine A1/A2A receptors (A1R/A2AR) represent targets in nondopaminergic treatment of motor disorders such as Parkinson’s disease (PD). As an innovative strategy, multitargeting ligands (MTLs) were developed to achieve comprehensive PD therapies simultaneously addressing comorbid symptoms such as sleep disruption. Recognizing the wake-promoting capacity of histamine H3 receptor (H3R) antagonists in combination with the “caffeine-like effects” of A1R/A2AR antagonists, we designed A1R/A2AR/H3R MTLs, where a piperidino-/pyrrolidino(propyloxy)phenyl H3R pharmacophore was introduced with overlap into an adenosine antagonist arylindenopyrimidine core. These MTLs showed distinct receptor binding profiles with overall nanomolar H3R affinities (Ki &lt; 55 nM). Compound 4 (ST-2001, Ki (A1R) = 11.5 nM, Ki (A2AR) = 7.25 nM) and 12 (ST-1992, Ki (A1R) = 11.2 nM, Ki (A2AR) = 4.01 nM) were evaluated in vivo. l-DOPA-induced dyskinesia was improved after administration of compound 4 (1 mg kg–1, i.p. rats). Compound 12 (2 mg kg–1, p.o. mice) increased wakefulness representing novel pharmacological tools for PD therapy." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00914"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00914">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00914&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00914&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00914&amp;href=/doi/10.1021/acs.jmedchem.0c00914" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 8246-8262</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00091" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00141" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Adenosine A<sub>2A</sub>R/A<sub>1</sub>R Antagonists Enabling Additional H<sub>3</sub>R Antagonism for the Treatment of Parkinson’s Disease</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Stefanie Hagenow</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stefanie Hagenow</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Duesseldorf, Universitaets street 1, 40225 Duesseldorf, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stefanie++Hagenow">Stefanie Hagenow</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anna Affini</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anna Affini</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Duesseldorf, Universitaets street 1, 40225 Duesseldorf, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anna++Affini">Anna Affini</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elsa Y. Pioli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elsa Y. Pioli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Motac Neuroscience Limited, SK10 4TF Macclesfield, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elsa+Y.++Pioli">Elsa Y. Pioli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sonja Hinz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sonja Hinz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany</div><div class="loa-info-affiliations-info">Institute of Pharmacology and Toxicology, School of Medicine, University of Witten/Herdecke, Center for Biomedical Education and Research (ZBAF), Faculty of Health, Alfred-Herrhausen-Street 50, 58448 Witten, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sonja++Hinz">Sonja Hinz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yan Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yan Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Integrative Physiology of the Brain Arousal Systems, Lyon Neuroscience Research Center, INSERM UI028, CNRS UMR 5292, Claude Bernard University, 8 Avenue Rockefeller, 69373 Lyon, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yan++Zhao">Yan Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gregory Porras</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gregory Porras</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Motac Neuroscience Limited, SK10 4TF Macclesfield, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gregory++Porras">Gregory Porras</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vigneshwaran Namasivayam</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vigneshwaran Namasivayam</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vigneshwaran++Namasivayam">Vigneshwaran Namasivayam</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-3031-3377" title="Orcid link">https://orcid.org/0000-0003-3031-3377</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christa E. Müller</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christa E. Müller</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christa+E.++M%C3%BCller">Christa E. Müller</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-0013-6624" title="Orcid link">https://orcid.org/0000-0002-0013-6624</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jian-Sheng Lin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jian-Sheng Lin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Integrative Physiology of the Brain Arousal Systems, Lyon Neuroscience Research Center, INSERM UI028, CNRS UMR 5292, Claude Bernard University, 8 Avenue Rockefeller, 69373 Lyon, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jian-Sheng++Lin">Jian-Sheng Lin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Erwan Bezard</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Erwan Bezard</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Motac Neuroscience Limited, SK10 4TF Macclesfield, U.K.</div><div class="loa-info-affiliations-info">Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France</div><div class="loa-info-affiliations-info">CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000 Bordeaux, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Erwan++Bezard">Erwan Bezard</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Holger Stark</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Holger Stark</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Duesseldorf, Universitaets street 1, 40225 Duesseldorf, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#daa9aebba8b19ab2b2aff4bebf"><span class="__cf_email__" data-cfemail="631017021108230b0b164d0706">[email protected]</span></a>. Phone: +49 211 8110478.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Holger++Stark">Holger Stark</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-3336-1710" title="Orcid link">https://orcid.org/0000-0003-3336-1710</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00914&amp;href=/doi/10.1021%2Facs.jmedchem.0c00914" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 8246–8262</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 9, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>25 January 2021</li><li><span class="item_label"><b>Published</b> online</span>9 June 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 June 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00914" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00914</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8246%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DStefanie%2BHagenow%252C%2BAnna%2BAffini%252C%2BElsa%2BY.%2BPioli%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D12%26contentID%3Dacs.jmedchem.0c00914%26title%3DAdenosine%2BA2AR%252FA1R%2BAntagonists%2BEnabling%2BAdditional%2BH3R%2BAntagonism%2Bfor%2Bthe%2BTreatment%2Bof%2BParkinson%25E2%2580%2599s%2BDisease%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8262%26publicationDate%3DJune%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00914"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">513</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00914" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Adenosine A2AR/A1R Antagonists Enabling Additional H3R Antagonism for the Treatment of Parkinson’s Disease&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Stefanie&quot;,&quot;last_name&quot;:&quot;Hagenow&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Affini&quot;},{&quot;first_name&quot;:&quot;Elsa&quot;,&quot;last_name&quot;:&quot;Y. Pioli&quot;},{&quot;first_name&quot;:&quot;Sonja&quot;,&quot;last_name&quot;:&quot;Hinz&quot;},{&quot;first_name&quot;:&quot;Yan&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Gregory&quot;,&quot;last_name&quot;:&quot;Porras&quot;},{&quot;first_name&quot;:&quot;Vigneshwaran&quot;,&quot;last_name&quot;:&quot;Namasivayam&quot;},{&quot;first_name&quot;:&quot;Christa&quot;,&quot;last_name&quot;:&quot;E. Müller&quot;},{&quot;first_name&quot;:&quot;Jian-Sheng&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Erwan&quot;,&quot;last_name&quot;:&quot;Bezard&quot;},{&quot;first_name&quot;:&quot;Holger&quot;,&quot;last_name&quot;:&quot;Stark&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;8246-8262&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00914&quot;},&quot;abstract&quot;:&quot;Adenosine A1/A2A receptors (A1R/A2AR) represent targets in nondopaminergic treatment of motor disorders such as Parkinson’s disease (PD). As an innovative strategy, multitargeting ligands (MTLs) were developed to achieve comprehensive PD therapies simultaneously addressing comorbid symptoms such as sleep disruption. Recognizing the wake-promoting capacity of histamine H3 receptor (H3R) antagonists in combination with the “caffeine-like effects” of A1R/A2AR antagonists, we designed A1R/A2AR/H3R MTLs, where a piperidino-/pyrrolidino(propyloxy)phenyl H3R pharmacophore was introduced with overlap into an adenosine antagonist arylindenopyrimidine core. These MTLs showed distinct receptor binding profiles with overall nanomolar H3R affinities (Ki &lt; 55 nM). Compound 4 (ST-2001, Ki (A1R) = 11.5 nM, Ki (A2AR) = 7.25 nM) and 12 (ST-1992, Ki (A1R) = 11.2 nM, Ki (A2AR) = 4.01 nM) were evaluated in vivo. l-DOPA-induced dyskinesia was improved after administration of compound 4 (1 mg kg–1, i.p. rats). Compound 12 (2 mg kg–&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00914&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00914" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00914&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00914" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00914&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00914" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00914&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00914&amp;href=/doi/10.1021/acs.jmedchem.0c00914" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00914" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00914" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00914%26sid%3Dliteratum%253Aachs%26pmid%3D34107215%26genre%3Darticle%26aulast%3DHagenow%26date%3D2021%26atitle%3DAdenosine%2BA2AR%252FA1R%2BAntagonists%2BEnabling%2BAdditional%2BH3R%2BAntagonism%2Bfor%2Bthe%2BTreatment%2Bof%2BParkinson%25E2%2580%2599s%2BDisease%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D12%26spage%3D8246%26epage%3D8262%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (4)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290663" title="Pharmacophores">Pharmacophores</a>,</li><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=291181" title="Amines">Amines</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/medium/jm0c00914_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00914&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Adenosine A<sub>1</sub>/A<sub>2A</sub> receptors (A<sub>1</sub>R/A<sub>2A</sub>R) represent targets in nondopaminergic treatment of motor disorders such as Parkinson’s disease (PD). As an innovative strategy, multitargeting ligands (MTLs) were developed to achieve comprehensive PD therapies simultaneously addressing comorbid symptoms such as sleep disruption. Recognizing the wake-promoting capacity of histamine H<sub>3</sub> receptor (H<sub>3</sub>R) antagonists in combination with the “caffeine-like effects” of A<sub>1</sub>R/A<sub>2A</sub>R antagonists, we designed A<sub>1</sub>R/A<sub>2A</sub>R/H<sub>3</sub>R MTLs, where a piperidino-/pyrrolidino(propyloxy)phenyl H<sub>3</sub>R pharmacophore was introduced with overlap into an adenosine antagonist arylindenopyrimidine core. These MTLs showed distinct receptor binding profiles with overall nanomolar H<sub>3</sub>R affinities (<i>K</i><sub>i</sub> < 55 nM). Compound <b>4</b> (<b>ST-2001</b>, <i>K</i><sub>i</sub> (A<sub>1</sub>R) = 11.5 nM, <i>K</i><sub>i</sub> (A<sub>2A</sub>R) = 7.25 nM) and <b>12</b> (<b>ST-1992</b>, <i>K</i><sub>i</sub> (A<sub>1</sub>R) = 11.2 nM, <i>K</i><sub>i</sub> (A<sub>2A</sub>R) = 4.01 nM) were evaluated <i>in vivo</i>. <span class="smallcaps smallerCapital">l</span>-DOPA-induced dyskinesia was improved after administration of compound <b>4</b> (1 mg kg<sup>–1</sup>, i.p. rats). Compound <b>12</b> (2 mg kg<sup>–1</sup>, p.o. mice) increased wakefulness representing novel pharmacological tools for PD therapy.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52180" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52180" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Adenosine receptors (ARs) are abundantly expressed in the dorsal and ventral striatum.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> The cortico-basal ganglia circuit, which controls initiation and inhibition of body movement, is modulated at the striatal level by dopaminergic input from the substantia nigra pars compacta (SNpc). Heterodimerization of ARs with dopaminergic receptors in striatum suggests that they act as modulators for fine-tuning of dopaminergic neurotransmission,<a onclick="showRef(event, 'ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6">(3−6)</a> and thus, they represent suitable targets for the treatment of motor disorders such as Parkinson’s disease (PD).<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> Adenosine can act via four distinct G-protein-coupled receptors (GPCRs), namely, adenosine A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub>, and A<sub>3</sub> receptors (A<sub><i>x</i></sub>R), showing either G<sub>i</sub>-(A<sub>1</sub>Rs and A<sub>3</sub>Rs) or G<sub>s</sub>-coupling (A<sub>2A</sub>Rs and A<sub>2B</sub>Rs). A<sub>1</sub>Rs and A<sub>2A</sub>Rs are highly enriched in specific parts of the central nervous system (CNS), while A<sub>2B</sub>Rs and A<sub>3</sub>Rs display lower expression levels and are mainly localized in peripheral tissues. In the CNS, A<sub>1</sub>Rs are widely distributed in several (sub)cortical areas, whereas A<sub>2A</sub>Rs are predominantly found in striatal areas.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a></div><div class="NLM_p">Already in the late 1990’s, A<sub>1</sub>R/A<sub>2A</sub>R antagonists were suggested as nondopaminergic therapy for PD, one of the most prominent motor disorders.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> PD patients suffer from distinct motor abnormalities exemplified by cardinal symptoms, such as bradykinesia, rigidity, postural changes, and tremor.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Progressive loss of dopaminergic neurons in the SNpc leads to disruption of dopaminergic neurotransmission in the cortico-basal ganglia circuit and consequently, a loss of controlling voluntary body movements.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> With dimerization of A<sub>2A</sub>Rs and dopamine D<sub>2</sub>-like receptors, for example, dopamine D<sub>2</sub> receptors (D<sub>2</sub>Rs), on striatal neurons, A<sub>2A</sub>R antagonists are assumed to modulate the “indirect pathway” of the cortico-basal ganglia circuit.<a onclick="showRef(event, 'ref8 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref8 ref13 ref14">(8,13,14)</a> This pathway attenuates body movement controlled by dopamine acting via G<sub>i</sub>-coupled D<sub>2</sub>-like receptors in a healthy brain. The motor-activating “direct pathway” on the other hand is regulated by G<sub>s</sub>-coupled D<sub>1</sub>Rs, which were found to form heterodimers with A<sub>1</sub>Rs. In both cases, stimulation of ARs, dimerized with either D<sub>1</sub>R or D<sub>2</sub>R, results in decrease of dopamine binding to the respective receptors.<a onclick="showRef(event, 'ref2 ref10'); return false;" href="javascript:void(0);" class="ref ref2 ref10">(2,10)</a> The impact on motor activity via A<sub>2A</sub>Rs has been studied in numerous animal studies, proving the ability of A<sub>2A</sub>R antagonists to stimulate locomotor activity in naïve animals and in parkinsonian animals, either alone or in combination with dopaminergic treatment.<a onclick="showRef(event, 'ref10 ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref10 ref15 ref16 ref17">(10,15−17)</a> Regarding contributing effects via A<sub>1</sub>R, less is known in context of PD motor symptoms, while selective A<sub>1</sub>R antagonists do not show motor improvement in PD models,<a onclick="showRef(event, 'ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20">(18−20)</a> but they may provide a therapeutic potential in PD-associated cognitive dysfunction due to increase of cholinergic transmission via A<sub>1</sub>R blockade.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a></div><div class="NLM_p">A small number of A<sub>1</sub>R/A<sub>2A</sub>R and selective A<sub>2A</sub>R antagonists, respectively, reached advanced clinical trials for motor disabilities in PD patients, such as the xanthine derivatives caffeine and istradefylline, as well as the nonxanthines tozadenant and preladenant (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In Japan, istradefylline received drug approval for therapy of PD motor fluctuations, evidencing a prospective utility of A<sub>2A</sub>R antagonists for treatment of movement disorders.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Very recently, istradefylline has also been approved by the Food and Drug Administration (FDA) in the U.S. for the adjunct treatment of PD. It was also suggested that istradefylline improves postural abnormalities, which is a hardly treatable condition in mid- or late-stage PD patients.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Caffeine, a mixed A<sub>1</sub>R/A<sub>2A</sub>R antagonist frequently examined in the context of PD, is implemented in multiple clinical trials and investigated on an epidemiological scale for early PD.<a onclick="showRef(event, 'ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27">(25−27)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/medium/jm0c00914_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. H<sub>3</sub>R ligands UCL2190 (hH<sub>3</sub>R <i>K</i><sub>i</sub> = 1.6 nM)<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> and <b>I</b>,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> as well as potent adenosine antagonists (preladenant and JNJ-40255293)<a onclick="showRef(event, 'ref45 ref50'); return false;" href="javascript:void(0);" class="ref ref45 ref50">(45,50)</a> taken as lead structures for the synthesis of MTLs (<b>1–12</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00914&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The fact, that motor disorders such as PD are commonly associated with multiple nonmotor complications such as cognitive or sleep impairment, often demand application of comedications for therapeutic success.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> Generally, with a high pathological complexity in CNS disorders, the development of multitargeting ligands (MTLs) became an accepted strategy to overcome the multiplicity of symptoms, with the potential to challenge conventional combination therapies. These MTLs may enable synergistic responses via simultaneous target modulation and bear several advantages compared to comedications, that is, a unified and optimized pharmacodynamic/–kinetic profile. Separate drug evaluation and drug regimen alignment prior to coapplication can be avoided with MTLs.<a onclick="showRef(event, 'ref30 ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32 ref33">(30−33)</a> During the last decades, a number of MTLs were developed and investigated for the treatment of neurodegenerative diseases,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> while the histamine H<sub>3</sub> receptor (H<sub>3</sub>R) has been suggested as a novel and suitable target. A great variety of H<sub>3</sub>R MTLs have been described, showing biological activities at other neurotransmitter-regulating targets, for example, different types of GPCRs, thus, proving its overall utility in multitargeting drug design.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_p">Antagonists of the H<sub>3</sub>R are able to modulate distinct neurotransmitters via presynaptic H<sub>3</sub>R heteroreceptor blockades. They are abundantly expressed in the basal ganglia and currently under investigation for various CNS disorders, in particular, cognitive and sleep disorders.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a> In 2016, pitolisant was approved by the European Medicine Agency for the treatment of narcolepsy with and without cataplexy (and in 2019 by FDA), while additional H<sub>3</sub>R antagonists are currently in clinical trials for treatment of sleep disorders.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Pitolisant is also in clinical trial (phase III) for treatment of excessive daytime sleepiness (EDS) in PD patients as well as for cognitive impairment associated with schizophrenia.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Thus, H<sub>3</sub>R antagonists may represent suitable tools against frequently observed nonmotor symptoms accompanying CNS movement disorders such as PD.</div><div class="NLM_p">Furthermore, an additional pharmacological effect in regulation of basal ganglia function might be obtained via heterodimerization of H<sub>3</sub>R not only with dopamine<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> but also with ARs.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> Just recently, the existence of functional A<sub>2A</sub>R-H<sub>3</sub>R heteromers were confirmed in recombinant overexpressing cells as well as in the rat striatum.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> H<sub>3</sub>R activation counteracts A<sub>2A</sub>R stimulation in rat globus pallidus on the striatal neuron terminals at the functional level of adenosine 3′,5′-cyclic monophosphate (cAMP) formation.<a onclick="showRef(event, 'ref39 ref41'); return false;" href="javascript:void(0);" class="ref ref39 ref41">(39,41)</a> These results suggest that A<sub>2A</sub>R/H<sub>3</sub>R antagonists might be able to control motor symptoms of PD via a connected pathway.</div><div class="NLM_p last">To obtain innovative MTLs for the treatment of PD, we introduced an H<sub>3</sub>R antagonist pharmacophore with structural merging into an A<sub>1</sub>R/A<sub>2A</sub>R antagonist core motif. Pyrrolidino-/piperidino(propyloxy)phenyl moieties were chosen as the structural H<sub>3</sub>R element,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> which can be found in numerous H<sub>3</sub>R antagonists/inverse agonists (e.g., <b>UCL2190</b>) and were successfully applied in our recently described dual-targeting H<sub>3</sub>R/monoamine oxidase B (MAO B) inhibitors (compound <b>I</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Arylindenopyrimidines, structurally distinct from traditional xanthine-based AR antagonists, were used as A<sub>1</sub>R/A<sub>2A</sub>R antagonist core motifs, which possess nanomolar receptor affinities and functional antagonist efficacies.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> Great effort has been invested in the design and optimization of heterocycle-substituted arylindenopyrimidines.<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45,46)</a> Multiple variations were performed either on the basic heterocyclic amine motif itself or its linkage (via amide, amino, or ether groups), resulting in A<sub>1</sub>R/A<sub>2A</sub>R antagonists with low toxicity, suitable pharmacokinetics, and potent <i>in vivo</i> efficacies.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Promising A<sub>1</sub>R/A<sub>2A</sub>R antagonists of this class, such as JNJ-40255293, were developed, which showed therapeutic potential in multiple preclinical models of PD.<a onclick="showRef(event, 'ref45 ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref47 ref48">(45−48)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53445" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53445" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A knowledge-based MTL design strategy was pursued by merging a generally accepted H<sub>3</sub>R pharmacophore, that is, a cyclic aminopropyloxy-linked phenyl motif, with an A<sub>1</sub>R/A<sub>2A</sub>R antagonist arylindenopyrimidine core.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Within this series, the H<sub>3</sub>R pharmacophore (referred as Y) was merged with the tricyclic core motif either as R<sup>7</sup> and R<sup>8</sup> of the indenyl moiety or as R<sup>4′</sup> with the “outside” phenyl group. Furthermore, the merger of the H<sub>3</sub>R pharmacophore with both an oxidized and a nonoxidized tricyclic arylindenopyrimidine core was conducted, resulting in two subseries of MTLs.</div><div class="NLM_p">The synthesized 5- and 6-hydroxy-1-indanones, <b>P1–P2</b>, and the commercially available 1-indanone (<b>P3</b>) were used as the starting material for the development of novel MTLs (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). <b>P1</b> and <b>P2</b> were prepared from the corresponding methoxy derivatives, which were demethylated with yields higher than 90%.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The 1-(3-chloropropyl)piperidine and 1-(3-chloropropyl)pyrrolidine precursors were synthesized in quantitative yields by alkylation of piperidine or pyrrolidine with 3-chloropropan-1-ol, followed by chlorination.<a onclick="showRef(event, 'ref53 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref53 ref54 ref55">(53−55)</a> Depending on whether 3-piperidinopropyloxy or 3-pyrrolidinopropyloxy H<sub>3</sub>R structural elements were introduced, two different reaction pathways were followed. For the synthesis of MTLs <b>1–4</b> and <b>7–10</b>, the H<sub>3</sub>R pharmacophore was introduced as R<sup>7</sup> or R<sup>8</sup> (path 1), whereas for compounds <b>5</b> and <b>6</b> or <b>11</b> and <b>12</b>, 1-(3-chloropropyl)piperidine was reacted in the C5 or C6 position with the corresponding hydroxyindanones (path 2), respectively.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/medium/jm0c00914_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route for the Design of MTLs <b>1–12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00914&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(I) Benzyl bromide, K<sub>2</sub>CO<sub>3</sub>, dimethylformamide, r.t., 15 h; (II) 1-(3-chloropropyl)piperidine, K<sub>2</sub>CO<sub>3</sub>, KI, acetone, reflux, 15–24 h; (III) appropriate benzaldehyde, NaOH, ethanol, r.t., 30 min; (IV) guanidine hydrochloride, NaOH, ethanol or methanol, N<sub>2</sub>, reflux, 18–24 h; (V) Pd/C (wt 10%), ethanol, H<sub>2</sub>, r.t., 18 h; (VI) 1-(3-chloropropyl)piperidine or 1-(3-chloropropyl)pyrrolidine, K<sub>2</sub>CO<sub>3</sub>, dimethylformamide, N<sub>2</sub>, 80 °C, 4 h; (VII) NaOH, dimethylformamide, O<sub>2</sub>, 80 °C, 2 h; Bn = benzyl; Y<sup>1</sup> = 3-piperidinopropyloxy; Y<sup>2</sup> = 3-pyrrolidinopropyloxy; <b>4</b> (<b>ST-2001</b>), <b>12</b> (<b>ST-1992</b>).</p></p></figure><div class="NLM_p">Following path 1, the hydroxyindanones were protected using the commercially available benzyl bromide to obtain compounds <b>P4–P5</b>.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Aldol condensation of the latter compounds or 1-indanone (<b>P3</b>) with benzaldehyde or 4-(benzyloxy)benzaldehyde was performed to obtain the corresponding 2-benzylidene-1-indanone derivatives <b>P8–P11</b> in good yields (80–90%).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> By reaction of the obtained ketones with guanidine, benzyl ether pyrimidine intermediates were formed, followed by deprotection using palladium-catalyzed hydrogenation to give the key intermediates <b>P14–P17</b> with a yield ranging from 72 to 85%.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Then, nucleophilic substitution was performed between the phenol derivatives and 1-(3-chloropropyl)piperidine or 1-(3-chloropropyl)pyrrolidine, respectively, to give compounds <b>1–4</b> (yields ranging from 65 to 70%).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Synthesis of compounds <b>P14–P17</b> was performed analogously by using a methoxy group instead of the benzyl ether moiety to protect the hydroxy indanones. Attempts to deprotect methoxy pyrimidine intermediates using aluminum chloride, lithium chloride, and sodium ethoxide were unsuccessful.<a onclick="showRef(event, 'ref52 ref58'); return false;" href="javascript:void(0);" class="ref ref52 ref58">(52,58)</a> However, a mixture of acetic and hydrobromic acid was effective in removing the methoxy group (yield <15%) but was not as efficient as the palladium-catalyzed hydrogenation of the benzyl moiety.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div><div class="NLM_p">Following path 2, the synthesis of compounds <b>5</b> and <b>6</b> started with the alkylation of the hydroxy indanones <b>P1</b> and <b>P2</b> with 1-(3-chloropropyl)piperidine by the Williamson ether reaction.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> The same procedure described for compounds <b>P4</b> and <b>P5</b> was used to convert, via aldol condensation, compounds <b>P6</b> and <b>P7</b> into the corresponding 2-benzylidene-1-indanone derivatives <b>P12</b> and <b>P13</b> with yields higher than 80%. The latter compounds were then treated with guanidine to obtain the corresponding arylindenopyrimidine compounds <b>5</b> and <b>6</b> with a yield of 50 and 54%, respectively.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><div class="NLM_p">To identify the potential role of the carbonyl moiety, the substituted arylindenopyrimidines, <b>1–4</b> and <b>5</b> and <b>6</b> were oxidized via a radical mechanism to the corresponding ketones <b>7–12</b> by passing air through the solution (yields ranging from 62 to 79%).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Reaction time longer than 2 h caused further oxidation and C–C cleavage to carboxylic acid.</div><div class="NLM_p">The structures of final compounds <b>1–12</b> were confirmed by <sup>1</sup>H NMR, <sup>13</sup>C NMR, and electrospray ionization high-resolution mass spectrometry (ESI-HRMS). The chemical purity (>95%) was determined via high-performance liquid chromatography (HPLC).</div><div class="NLM_p">Furthermore, some of the oxidized A<sub>1</sub>R/A<sub>2A</sub>R/H<sub>3</sub>R MTLs possess potentially useful fluorescence properties. As a representative, <b>12</b> was investigated and the emission spectrum showed a prominent peak at 546 nm with high Stokes shift (λ<sub>em</sub> – λ<sub>abs</sub> = 200 nm) (cf. <a href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_001.pdf" class="ext-link">Supporting Information</a>). The emission spectra obtained for <b>12</b> were comparable to those of previously reported fluorescent C8-substituted indenopyrimidine derivatives, used to stabilize quadruplex and duplex DNAs as possible anticancer therapy.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> These physicochemical properties may be optimized to facilitate additional applications as possible pharmacological tools, for example, for detection or labeling of H<sub>3</sub>Rs, A<sub>1</sub>Rs, and/or A<sub>2A</sub>Rs, similar to the recently described fluorescence xanthine A<sub>2B</sub>R antagonist used for binding assays.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> <i>In Vitro</i> AR/H<sub>3</sub>R Receptor Binding Properties</h3><div class="NLM_p">The designed AR/H<sub>3</sub>R MTLs were evaluated for in vitro binding affinities in radioligand competition binding studies, as described previously using recombinant human ARs<a onclick="showRef(event, 'ref63 ref64 ref65 ref66 ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref63 ref64 ref65 ref66 ref67 ref68">(63−68)</a> and H<sub>3</sub>R (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref43 ref69'); return false;" href="javascript:void(0);" class="ref ref43 ref69">(43,69)</a> Within this small series, submicromolar AR affinities were obtained, while some of the compounds (<b>4</b>, <b>6</b>, <b>10</b>, and <b>12</b>) showed the desired multitargeting properties with affinities in low nanomolar concentration ranges for both types of receptors. These most potent MTLs preserved comparable A<sub>1</sub>R/A<sub>2A</sub>R affinity to promising previously described arylindenopyrimidines, such as JNJ-40255293 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>),<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> but with additional affinity for A<sub>2B</sub>Rs (<i>K</i><sub>i</sub> (A<sub>2A</sub>R)/<i>K</i><sub>i</sub> (A<sub>2B</sub>R) = 0.08–0.19). Highest A<sub>1</sub>R/A<sub>2A</sub>R affinities were observed for MTLs having the H<sub>3</sub>R pharmacophore attached as R<sup>8</sup>, cf. <b>4</b>, <b>6</b>, <b>10</b>, and <b>12</b>, while attachment as R<sup>7</sup> led to more than 10- and 100-fold decrease in A<sub>2A</sub>R affinity for oxidized and nonoxidized/reduced MTLs, respectively (e.g., <b>10</b><i>vs</i><b>8</b> and <b>4</b><i>vs</i><b>2</b>). These observations confirm previous structure–activity relationships (SARs) for arylindenopyrimidines, pointing out that substitution at C8 (as well as C9) led to high affinity at A<sub>1</sub>R/A<sub>2A</sub>R, while substitution at C7 (as well as C6) resulted in a decrease or abolishment of A<sub>2A</sub>R binding.<a onclick="showRef(event, 'ref44 ref47'); return false;" href="javascript:void(0);" class="ref ref44 ref47">(44,47)</a> As demonstrated previously,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> the carbonyl moiety is neither necessary for AR binding nor significantly improving AR subtype selectivity comparing the most potent MTLs within this series. Interestingly, introducing the H<sub>3</sub>R pharmacophore as R<sup>4′</sup> is less tolerated by ARs, especially for nonoxidized/reduced MTLs but may increase subtype selectivity for A<sub>2A</sub>Rs over A<sub>1</sub>R, as represented by oxidized representatives <b>7</b> (<i>K</i><sub>i</sub> (A<sub>2A</sub>R)/<i>K</i><sub>i</sub> (A<sub>1</sub>R) = 0.3) or <b>9</b> (<i>K</i><sub>i</sub> (A<sub>2A</sub>R)/<sub>i</sub> (A<sub>1</sub>R) < 0.2). For MTLs having the H<sub>3</sub>R pharmacophore attached at unfavorable sites, that is, such as R<sup>7</sup> or R<sup>4</sup>′, oxidation status of the indenyl ring (X = −CH<sub>2</sub><i>vs</i> −C═O) led to significant differences in AR affinities (e.g., <b>1</b><i>vs</i><b>7</b> or <b>2</b><i>vs</i><b>11</b>). Minor but significant differences are observed between five-membered (3-pyrrolidinopropyloxy, Y<sup>2</sup>) and six-membered (3-piperidinopropyloxy, Y<sup>1</sup>) cyclic amine derivatives (<b>4</b><i>vs</i><b>6</b> and <b>10</b><i>vs</i><b>12</b>), which is again in accordance with previously designed arylindenopyrimidines.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Histamine H<sub>3</sub>R and Adenosine (A<sub><i>x</i></sub>R) Receptor Affinities (<i>K</i><sub>i</sub> Values) of Designed MTLs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/medium/jm0c00914_0009.gif" alt="" id="GRAPHIC-d7e1448-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" align="center">compound</th><th class="rowsep1 colsep0" align="center">R<sup>7</sup></th><th class="rowsep1 colsep0" align="center">R<sup>8</sup></th><th class="rowsep1 colsep0" align="center">R4<sup>′</sup></th><th class="rowsep1 colsep0" align="center">X</th><th class="rowsep1 colsep0" align="center">hA<sub>1</sub>R<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" align="center">hA<sub>2A</sub>R<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" align="center">hA<sub>2B</sub>R<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="rowsep1 colsep0" align="center">hA<sub>3</sub>R<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th><th class="rowsep1 colsep0" align="center">hH<sub>3</sub>R<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" colspan="4" align="center"><i>K</i><sub>i</sub> [nM] <i>x̅</i> ± SEM (or % inhibition, <i>x̅</i> ± SEM at 1 μM)</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> [nM] <i>x̅</i> [95% CI]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Y<sup>1</sup></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">2510 ± 454</td><td class="colsep0 rowsep0" align="left">717 ± 132</td><td class="colsep0 rowsep0" align="left">>1000 (28 ±0)</td><td class="colsep0 rowsep0" align="left">>1000 (24 ±4)</td><td class="colsep0 rowsep0" align="left">0.49 [0.18, 1.34]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">Y<sup>2</sup></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">828 ± 166</td><td class="colsep0 rowsep0" align="left">>1000 (40 ± 7)</td><td class="colsep0 rowsep0" align="left">>1000 (25 ±5)</td><td class="colsep0 rowsep0" align="left">>1000 (35 ±11)</td><td class="colsep0 rowsep0" align="left">2.1 [1.1, 4.1]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">Y<sup>1</sup></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Y<sup>1</sup></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">>1000 (23 ± 6)</td><td class="colsep0 rowsep0" align="left">941 ± 160</td><td class="colsep0 rowsep0" align="left">>1000 (13 ±2)</td><td class="colsep0 rowsep0" align="left">>1000 (50 ±5)</td><td class="colsep0 rowsep0" align="left">0.60 [0.05, 7.4]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b> (<b>ST-2001)</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Y<sup>2</sup></td><td class="colsep0 rowsep0" align="left">–H</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">11.5 ± 1.6</td><td class="colsep0 rowsep0" align="left">7.25 ± 1.53</td><td class="colsep0 rowsep0" align="left">36.9 ± 8.3</td><td class="colsep0 rowsep0" align="left">150 ± 10</td><td class="colsep0 rowsep0" align="left">11 [0.45, 255]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">Y<sup>1</sup></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">>1000 (24 ± 6)</td><td class="colsep0 rowsep0" align="left">>1000 (34 ± 3)</td><td class="colsep0 rowsep0" align="left">>1000 (34 ± 4)</td><td class="colsep0 rowsep0" align="left">>1000 (39 ± 4)</td><td class="colsep0 rowsep0" align="left">2.3 [1.2, 4.1]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Y<sup>1</sup></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">18.7 ± 1.3</td><td class="colsep0 rowsep0" align="left">4.85 ± 0.90</td><td class="colsep0 rowsep0" align="left">58.1 ± 3.4</td><td class="colsep0 rowsep0" align="left">231 ± 38</td><td class="colsep0 rowsep0" align="left">4.5 [1.7, 12]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Y<sup>1</sup></td><td class="colsep0 rowsep0" align="left">C═O</td><td class="colsep0 rowsep0" align="left">133 ± 8</td><td class="colsep0 rowsep0" align="left">35.5 ± 8.9</td><td class="colsep0 rowsep0" align="left">331 ± 57</td><td class="colsep0 rowsep0" align="left">>1000 (33 ± 4)</td><td class="colsep0 rowsep0" align="left">0.28 [0.19, 0.42]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">Y<sup>2</sup></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">C═O</td><td class="colsep0 rowsep0" align="left">129 ± 7</td><td class="colsep0 rowsep0" align="left">104 ± 18</td><td class="colsep0 rowsep0" align="left">180 ± 18</td><td class="colsep0 rowsep0" align="left">846 ± 117</td><td class="colsep0 rowsep0" align="left">31 [14, 69]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">Y<sup>1</sup></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Y<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></td><td class="colsep0 rowsep0" align="left">C═O</td><td class="colsep0 rowsep0" align="left">≥1000 (44 ± 3)</td><td class="colsep0 rowsep0" align="left">203 ± 80</td><td class="colsep0 rowsep0" align="left">>1000 (15 ± 1)</td><td class="colsep0 rowsep0" align="left">>1000 (32 ± 8)</td><td class="colsep0 rowsep0" align="left">0.31 [0.12, 0.80]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Y<sup>2</sup></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">C═O</td><td class="colsep0 rowsep0" align="left">12.6 ± 2.3</td><td class="colsep0 rowsep0" align="left">6.24 ± 1.93</td><td class="colsep0 rowsep0" align="left">47.5 ± 3.4</td><td class="colsep0 rowsep0" align="left">199 ± 9</td><td class="colsep0 rowsep0" align="left">27 [3.0, 237]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">Y<sup>1</sup></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">C═O</td><td class="colsep0 rowsep0" align="left">367 ± 77</td><td class="colsep0 rowsep0" align="left">142 ± 28</td><td class="colsep0 rowsep0" align="left">114 ± 20</td><td class="colsep0 rowsep0" align="left">>1000 (12 ± 3)</td><td class="colsep0 rowsep0" align="left">36 [13, 100]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>ST-1992</b> (<b>12</b>)</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Y<sup>1</sup></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">C═O</td><td class="colsep0 rowsep0" align="left">11.2 ± 0.7</td><td class="colsep0 rowsep0" align="left">4.01 ± 1.0</td><td class="colsep0 rowsep0" align="left">43.5 ± 16.0</td><td class="colsep0 rowsep0" align="left">150 ± 13</td><td class="colsep0 rowsep0" align="left">52 [15, 174]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>JNJ-40255293</b><a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Morph</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">C═O</td><td class="colsep0 rowsep0" align="left">48<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a>± 16</td><td class="colsep0 rowsep0" align="left">7.5 ± 4.9</td><td class="colsep0 rowsep0" align="left">230<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a>± 92</td><td class="colsep0 rowsep0" align="left">430 ± 150</td><td class="colsep0 rowsep0" align="left">n.d.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>Preladenant</b><a class="ref internalNav" href="#t1fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">295 ± 10</td><td class="colsep0 rowsep0" align="left">0.88 ± 0.23</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">n.d.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>UCL2190</b><a class="ref internalNav" href="#t1fn9" aria-label="j">j</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">≫>1000 (−5%)</td><td class="colsep0 rowsep0" align="left">≫ 1000 (−3%)</td><td class="colsep0 rowsep0" align="left">≫1000 (0%)</td><td class="colsep0 rowsep0" align="left">≫1000 (−2%)</td><td class="colsep0 rowsep0" align="left">11 [3.5, 33]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>Ciproxifan</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">≫1000 (−6%)</td><td class="colsep0 rowsep0" align="left">≫1000 (−1%)</td><td class="colsep0 rowsep0" align="left">≫1000 (8%)</td><td class="colsep0 rowsep0" align="left">≫1000 (3%)</td><td class="colsep0 rowsep0" align="left">224 [106, 475]</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Data were obtained in radioligand competition binding studies (<i>n</i> ≥ 3), each performed at least in duplicate using [<sup>3</sup>H]CCPA.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">[<sup>3</sup>H]MSX-2.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">[<sup>3</sup>H]PSB-603.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">[<sup>3</sup>H]PSB-11.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">[<sup>3</sup>H]<i>N</i><sup>α-</sup>methylhistamine for A<sub>1</sub>R, A<sub>2A</sub>R, A<sub>2B</sub>R, A<sub>3</sub>R, and H<sub>3</sub>R, respectively; <i>K</i><sub>i</sub> values are given as means either within the 95% CI or with error (SEM) for hH<sub>3</sub>R or hA<sub><i>x</i></sub>Rs, respectively.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">Atack et al.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></p></div><div class="footnote" id="t1fn7"><sup><sup>g</sup></sup><p class="last">Functional activity cAMP assay, EC<sub>50</sub>.</p></div><div class="footnote" id="t1fn8"><sup><sup>h</sup></sup><p class="last">Burbiel et al.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></p></div><div class="footnote" id="t1fn9"><sup><sup>j</sup></sup><p class="last">Affini et al.;<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Morph, 2-morpholinoethoxy; n.d. not determined.</p></div></div></div><div class="NLM_p">The successful introduction of the H<sub>3</sub>R pharmacophore into arylindenopyrimidine AR antagonists with structural overlap at the respective phenyl elements could be shown for all MTLs having nanomolar H<sub>3</sub>R affinities. Once more, these findings prove the high variation tolerance in H<sub>3</sub>R ligands when maintaining the generally accepted H<sub>3</sub>R blueprint. Negligible impact on H<sub>3</sub>R affinities were observed by modifications in either cyclic amine (<b>2</b><i>vs</i><b>5</b>; <b>8</b><i>vs</i><b>11</b>) or the substitution position of the indanone moiety (e.g., R<sup>7</sup><i>vs</i> R<sup>8</sup> in <b>5</b><i>vs</i><b>6</b>), while the nonoxidized derivatives are around 10-fold more potent at H<sub>3</sub>R compared to oxidized ones (e.g., <b>2</b><i>vs</i><b>8</b> or <b>6</b><i>vs</i><b>12</b>) with exception of <b>4</b><i>versus</i><b>10</b>, where no significant difference was found. <i>K</i><sub>i</sub> values in the subnanomolar concentration range for H<sub>3</sub>R could be obtained by attaching the H<sub>3</sub>R pharmacophore to the phenyl moiety as R<sup>4′</sup> (cf. <b>1</b> and <b>7</b>). Also, MTL <b>9</b> and <b>3</b> bearing the H<sub>3</sub>R pharmacophore in two positions (as R<sup>7</sup> and R<sup>4′</sup>) demonstrate excellent, subnanomolar H<sub>3</sub>R bindings. However, these compounds are the poorest AR ligands. For compounds bearing two H<sub>3</sub>R pharmacophores, these findings may reflect a higher probability for entering the H<sub>3</sub>R binding pocket in either orientation, while these ligands may demonstrate an unfavorable two-dimensional expansion for fitting the A<sub>1</sub>R/A<sub>2A</sub>R binding pockets.</div><div class="NLM_p">Remarkably, in this small series, we were able to design MTLs with distinct target affinity profiles, despite using the same structural elements. Major impacts, especially on AR subtype selectivity and also on H<sub>3</sub>R affinity could be demonstrated, that is, MTL <b>5</b> as the pure H<sub>3</sub>R ligand or <b>9</b> as A<sub>2A</sub>R-preferring MTL, stressing the importance of the different attachment sites for the H<sub>3</sub>R pharmacophore. Particularly, these findings provide deeper insights into the SAR of AR subtypes and should aid the development of further pharmacological tools for ARs. In previous studies, A<sub>2A</sub>R preference of arylindenopyrimidines could be improved by <i>para</i>-fluorination of the R<sup>4′</sup> phenyl group<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> or by replacement of the phenyl with (un)substituted furan moieties.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Distinct substitutions at R<sup>4′</sup> or scaffold variations in this position may be a convenient strategy to increase AR subtype selectivity.</div><div class="NLM_p">Functional screening at A<sub>2A</sub> receptors based on cAMP accumulation has been performed for compounds <b>4</b> and <b>12</b> with the ribose-modified adenosine analogue <i>N</i>-ethylcarboxamidoadenosine (NECA) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Both compounds did not show any agonist activity but were able to block the response induced by the agonist NECA, similar to the effect observed with the standard A<sub>2A</sub>R antagonist MSX-2 (3-(3-hydroxypropyl)-8-(<i>m</i>-methoxystyryl)-7-methyl-1-propargylxanthine).</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/medium/jm0c00914_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. cAMP accumulation experiments. Stimulation of cAMP accumulation in CHO cells expressing the human adenosine A<sub>2A</sub>R was induced by 0.3 μM of the agonist NECA (set at 100%). The one-way ANOVA with Dunnett’s posthoc test indicated significant differences (***<i>p</i> < 0.001, ****<i>p</i> < 0.0001) between the effect of NECA in the absence and in the presence of A<sub>2A</sub>R antagonists (<b>4</b>, <b>12</b>, and for comparison MSX-2 [3-(3-hydroxypropyl)-8-(<i>m</i>-methoxystyryl)-7-methyl-1-propargylxanthine)].</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00914&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Preclinical Profiling of Selected AR/H<sub>3</sub>R MTLs</h3><div class="NLM_p">In vitro binding affinities at related histamine receptor subtypes (H<sub>4</sub>R and H<sub>1</sub>R) and also additional PD-relevant targets (dopamine D<sub>1</sub>/D<sub>5</sub>/D<sub>2S</sub>/D<sub>3</sub> receptors, MAO A/B) were determined for the most promising MTLs <b>4</b> (<b>ST-2001)</b> and <b>12</b> (<b>ST-1992)</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Both MTLs showed low affinity at H<sub>1</sub>Rs as well as good to excellent selectivity for H<sub>3</sub>Rs over most homologous H<sub>4</sub>Rs (<b>ST-1992</b>, <i>K</i><sub>i</sub> (H<sub>4</sub>R)/<i>K</i><sub>i</sub> (H<sub>3</sub>R) > 190; <b>ST-2001</b>, <i>K</i><sub>i</sub> (H<sub>4</sub>R)/<i>K</i><sub>i</sub> (H<sub>3</sub>R) > 900), respectively.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Off-Target Affinities of Most Promising A<sub>1</sub>R/A<sub>2A</sub>R/H<sub>3</sub>R MTLs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/medium/jm0c00914_0010.gif" alt="" id="GRAPHIC-d7e2519-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center"><i>K</i><sub>i</sub> [nM]<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a><i>x̅</i> [95% CI]</th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">IC<sub>50</sub> [nM]<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> (% inhibition at 10 μM) <i>x̅</i> ± SD</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">MTL</th><th class="colsep0 rowsep0" align="center">hH<sub>1</sub>R</th><th class="colsep0 rowsep0" align="center">hH<sub>4</sub>R</th><th class="colsep0 rowsep0" align="center">hD<sub>1</sub>R</th><th class="colsep0 rowsep0" align="center">hD<sub>5</sub>R</th><th class="colsep0 rowsep0" align="center">hD<sub>2S</sub>R</th><th class="colsep0 rowsep0" align="center">hD<sub>3</sub>R</th><th class="colsep0 rowsep0" align="center" char="±">hMAO A</th><th class="colsep0 rowsep0" align="center">hMAO B</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>ST-2001</b> (<b>4</b>)</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">1246 [697–2228]</td><td class="colsep0 rowsep0" align="left">290 [272–309]</td><td class="colsep0 rowsep0" align="char" char="±">(7.4 ± 12)</td><td class="colsep0 rowsep0" align="left">>1000 (57 ± 8.6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>ST-1992</b> (<b>12</b>)</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">1586 [304–8266]</td><td class="colsep0 rowsep0" align="left">364 [175–759]</td><td class="colsep0 rowsep0" align="char" char="±">(16 ± 3.6)</td><td class="colsep0 rowsep0" align="left">(50 ± 16)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Off-target binding data were obtained in radioligand binding studies (<i>n</i> = 2–4) using [<sup>3</sup>H]pyrilamine, [<sup>3</sup>H]histamine, [<sup>3</sup>H]SCH23390, and [<sup>3</sup>H]spiperone for hH<sub>1</sub>R, hH<sub>4</sub>R, D<sub>1</sub>R/D<sub>5</sub>R, and D<sub>2S</sub>R/D<sub>3</sub>R, respectively.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Spectrophotometric monoamine oxidase inhibition assay using Kynuramine as the substrate and either 7–10 concentrations (between 10<sup>–10</sup> and 10<sup>–4</sup> M) or 10 μM of test ligand for IC<sub>50</sub> determination or one-point screening, respectively. <i>K</i><sub>i</sub> values are given as mean within the 95% CI, whereas MAO screening data are given as % inhibition mean ± standard deviation (SD), <i>n</i> ≥ 3).</p></div></div></div><div class="NLM_p">Binding affinities at dopamine receptors were evaluated in radioligand binding studies<a onclick="showRef(event, 'ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref70 ref71">(70,71)</a> since they are enriched in the SNpc, as part of the basal ganglia circuit and are affected by neurodegenerative processes in PD.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Activated D<sub>2</sub>-like receptors inhibit the “indirect pathway”, while activated D<sub>1</sub>-like receptors stimulate the “direct pathway”, leading to motor cortex activation. Additional modulation of these receptors would probably influence regulation of motor activity obtained by the A<sub>1</sub>R/A<sub>2A</sub>R blockade, especially due to evident heterodimerization of these types of GPCRs.<a onclick="showRef(event, 'ref2 ref14'); return false;" href="javascript:void(0);" class="ref ref2 ref14">(2,14)</a> However, also heterodimerization of H<sub>3</sub>R with D<sub>1</sub>R and D<sub>2</sub>R receptors are described,<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> which further complicates the understanding of therapeutic relevance of AR/H<sub>3</sub>R MTLs in PD motor symptoms. At D<sub>1</sub>-like receptors (D<sub>1</sub>R and D<sub>5</sub>R), <b>ST-2001</b> and <b>ST-1992</b> show low affinity. However, investigations at PD-relevant D<sub>2</sub>R and D<sub>3</sub>R revealed moderate binding capabilities with higher affinities at D<sub>3</sub>Rs for both MTLs. Still, selectivity indices for <b>ST-2001</b> and <b>ST-1992</b> demonstrate 1–2 orders of magnitude higher preference for the desired target receptors (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Overall, <b>ST-2001</b> possesses more desirable selectivity with 10-fold and 100-fold higher for each target receptor over D<sub>3</sub>Rs and D<sub>2S</sub>Rs, respectively. While exact mechanisms are hardly understood, there is no doubt about involvement of mesolimbic D<sub>3</sub>Rs in PD motor symptomology, which are significantly reduced by around 40% in PD patients.<a onclick="showRef(event, 'ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref72 ref73">(72,73)</a> Some prominent dopamine agonists, that is, pramipexole, ropinirole, or dopamine itself, show a clear D<sub>3</sub>R preference over D<sub>2</sub>Rs, prompting a therapeutic relevance of D<sub>3</sub>Rs.<a onclick="showRef(event, 'ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref73 ref74">(73,74)</a> Despite only moderate D<sub>3</sub>R binding of MTLs, a D<sub>3</sub>R-mediated influence on <i>in vivo</i> activity cannot be ruled out. In the most unfavorable case, as the designed AR/H<sub>3</sub>R MTLs show rather structural overlap with D<sub>3</sub>R antagonists,<a onclick="showRef(event, 'ref75 ref76 ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref75 ref76 ref77 ref78">(75−78)</a> their desired motor-improving capacities might be counteracted via D<sub>3</sub>R blockade. Thus, design-out of any D<sub>3</sub>R binding is mandatory in the future when designing AR/H<sub>3</sub>R MTLs using an arylindenopyrimidine core motif.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Target Selectivity Indices (SI)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> for <b>ST-2001</b> and <b>ST-1992</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/medium/jm0c00914_0011.gif" alt="" id="gr8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">SI calculated as <i>K</i><sub>i</sub> (b)/<i>K</i><sub>i</sub> (a) for <b>ST-1992</b> and <i>K</i><sub>i</sub> (a)/K<sub>i</sub> (b) for <b>ST-2001</b>, respectively. Desired “on-targets” are underlined. <b>SI > 100</b> appear in bold.</p></div></div><div></div></div><div class="NLM_p">As especially MAO B participates in dopamine degradation after cellular reuptake,<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> inhibitors of these enzymes represent a suitable therapy for PD in early stages or as add-on therapy to dopaminergic treatment (e.g., <span class="smallcaps smallerCapital">l</span>-DOPA; 3,4-dihydroxyphenylalanine) in order to increase dopamine levels in the synaptic cleft.<a onclick="showRef(event, 'ref80 ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref80 ref81 ref82">(80−82)</a> Multitargeting MAO B inhibitors as innovative strategy in PD therapy were previously described, such as our recently reported series of structurally related indanone H<sub>3</sub>R/MAO B MTLs,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> which are synthetic precursor molecules or A<sub>2A</sub>R/MAO B dual acting phenylxanthine derivatives.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Thus, <b>ST-2001</b> and <b>ST-1992</b> were evaluated for potential MAO A/B inhibition, as described previously.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> At a concentration of 10 μM, negligible MAO inhibition (≤50%) could be found with exception of <b>ST-2001</b>, where concentration-dependent evaluation at MAO B revealed an IC<sub>50</sub> > 1000 nM. Thus, AR/H<sub>3</sub>R MTLs demonstrated weak MAO inhibition properties, whereas a certain MAO B inhibition might have some beneficial effect on synaptic dopamine availability.</div><div class="NLM_p">Prior to <i>in vivo</i> testing, selected MTLs (<b>ST-2001</b>, <b>2</b>, <b>6</b>) were tested for potential cytotoxic or antiproliferative effects in human neuroblastoma cells (SH-SY5Y). At a concentration of 1000 nM, these compounds showed a negligible impact (remaining cell viability >75%) on cell viability after 24 h incubation time (cf. <a href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_001.pdf" class="ext-link">Supporting Information</a>).</div><div class="NLM_p last">In order to evaluate drug-likeness of the synthetized compounds, physicochemical properties and ligand efficiency (LE) metrics were calculated (cf. <a href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_001.pdf" class="ext-link">Supporting Information</a>). Compounds <b>4</b> und <b>12</b> do not violate Lipinski’s rule of five as all calculated descriptors and properties were within the expected threshold, suggesting a good oral absorption of these MTLs. LE metrics of compounds <b>4</b> and <b>12</b> were calculated for H<sub>3</sub>R, A<sub>1</sub>R, and A<sub>2A</sub>R. These MTLs showed acceptable LE values (LE ≥ 0.3) but with respective target specificity at a cost of lipophilicity, as indicated by lipophilicity-corrected ligand efficiency values, which were slightly outside the limits.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> A<sub>2A</sub>R Docking Study</h3><div class="NLM_p">To validate results of in vitro receptor binding assays, molecular docking studies were performed using the C8-substituted arylindenopyrimidine derivative <b>ST-1992</b> fitted into the A<sub>2A</sub>R binding pocket. <b>ST-1992</b>, protonated at the piperidine nitrogen atom, modeled into the crystal structure of the chimeric protein of A<sub>2A</sub>R-BRIL (1.8 Å resolution),<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(104)</a> was compared with ZM241385, a structurally related A<sub>2A</sub>R inverse agonist with similar affinity at this receptor subtype (<i>K</i><sub>i</sub> hA<sub>2A</sub>R = 1.6 nM and with preladenant (<i>K</i><sub>i</sub> hA<sub>2A</sub>R = 0.88 nM), both compounds representing analogues of adenine derivatives.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> The 3D and 2D images of binding showed that the exocyclic amino group of ZM241385 and preladenant allows not only interactions with Glu169 but also hydrogen bonding interactions with Asn253 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). In addition, due to the π-conjugated system, the selective A<sub>2A</sub>R antagonist was able to form π–π stacking interactions with Phe168. The arylindenopyrimidine moiety of the AR/H<sub>3</sub>R ligand <b>ST-1992</b> appears to share these interactions and could therefore constitute a good alternative as a central aromatic core. The ligands demonstrated a similar orientation in the binding pocket, where the phenyl moiety of <b>ST-1992</b> is likely to occupy the subpocket formed by Leu85, Met177, His250, Trp246, Leu249, and Ile274 like the furan ring in ZM241385 and in preladenant, as well as the basic 3-piperidinopropyloxy H<sub>3</sub>R fragment is postulated to occupy the same pocket as the phenol moiety of ZM241385 and the piperazine moiety of preladenant. Overall, molecular docking studies confirmed the experimentally determined receptor affinities by demonstrating that arylindenopyrimidine-based ligands bearing the H<sub>3</sub>R pharmacophore in the C8-position, including MTL 6, <b>ST-2001</b>, and <b>ST-1992</b> almost perfectly fit into the A<sub>2A</sub>R binding pocket.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/medium/jm0c00914_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A–C) 3D docking model and (D–F) 2D schematic diagram of the docking model of ZM241385 (colored in green, A), preladenant (colored in magenta, B) and compound <b>ST-1992</b> (colored in cyan, C) with the human A<sub>2A</sub>R. For modeling studies, the structure of the A<sub>2A</sub>R cocrystallized with ZM241385 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EIY">4EIY</a>) was used, displayed in a cartoon representation (gray). Oxygen atoms are colored in red, nitrogen atoms in blue, and hydrogen atoms in silver white.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00914&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> H<sub>3</sub>R Docking Study</h3><div class="NLM_p">The dual ligand <b>ST-1992</b> was additionally docked into a homology model of the human H<sub>3</sub>R. The predicted binding pose of <b>ST-1992</b> in the H<sub>3</sub>R binding pocket indicated that the exocyclic amino group at the arylindenopyrimidine moiety forms a strong hydrogen bond interaction with Asp114 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The protonated piperidine may form hydrogen bond interactions with the side chain of Tyr374 and the subpocket formed by Trp110, His187, Tyr374, Phe398, and Trp402. The phenyl substituent on the aminopyrimidine ring is predicted to occupy another subpocket formed by Cys118, Ala122, Phe207, Phe367, and Trp371. The predicted binding pose indicates that there is space to insert additional substituents on the phenyl ring (as in compounds <b>3</b> and <b>9</b>). This double substitution might lock the arylindenopyrimidine ring system into the binding pocket of the H<sub>3</sub>R, favoring the interaction of its amino group with Asp114. However, such bulky compounds do not fit into the binding pocket of the ARs due to limited space and therefore show low AR affinity.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/medium/jm0c00914_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) 3D docking model and (B) 2D schematic diagram of compound <b>ST-1992</b> using a homology model of the human H<sub>3</sub>R (based on the X-ray structure of the human H<sub>1</sub>R, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RZE">3RZE</a>). The homology model of the H<sub>3</sub>R is displayed in a cartoon representation (light brown). Carbon atoms are colored in cyan, oxygen atoms in red, nitrogen atoms in blue, and hydrogen atoms on the amino group are shown in silver white.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00914&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> 6-OHDA-Lesioned Rat Model of <span class="smallcaps smallerCapital">l</span>-DOPA-Induced Dyskinesia</h3><div class="NLM_p">To assess the effect of AR/H<sub>3</sub>R MTLs on <span class="smallcaps smallerCapital">l</span>-DOPA-induced dyskinesia (LID), <b>ST-2001</b> and <b>ST-1992</b> were evaluated in the rat analogue of LID, that is, the <span class="smallcaps smallerCapital">l</span>-DOPA-treated 6-hydroxydopamine (6-OHDA)-lesioned rats scoring the abnormal involuntary movements (AIMs). In brief, after 6-OHDA-induced degeneration of dopaminergic neurons, animals were primed with 6 mg/kg <span class="smallcaps smallerCapital">l</span>-DOPA + 15 mg/kg benzerazide (i.p.) once per day until AIM severity stabilized, as previously described.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> The effect of AR/H<sub>3</sub>R MTLs <b>ST-2001</b> and <b>ST-1992</b> at two doses (0.1 and 1 mg/kg) in the presence of <span class="smallcaps smallerCapital">l</span>-DOPA (6 mg/kg) was investigated (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Compared to AIMs of control rats (<span class="smallcaps smallerCapital">l</span>-DOPA alone), coapplication of both MTLs tends to decrease LID either dose-dependently, as shown for <b>ST-2001</b>, or at least for one dose, that is, 0.1 mg/kg of <b>ST-1992</b>. Significant differences could be demonstrated for <b>ST-2001</b> (1 mg/kg) in axial AIM scores (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C). Less pronounced effects on limb and orolingual AIM scores were observed (cf. <a href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_001.pdf" class="ext-link">Supporting Information</a>), explaining the missing statistical significance in the overall axial/limb/orolingual (ALO) AIM score. Noteworthily, variations of AIMs in control groups (0 mg/kg, <i>n</i> = 5) hampered statistical analysis. Positive control groups treated with amantadine (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>E,F) do not always reach the level of significance, suggesting a limited validity of respective data sets. Observed tendencies in AIMs might point out a slight antidyskinetic efficacy of AR/H<sub>3</sub>R MTLs <b>ST-2001</b> and <b>ST-1992</b>. Combination of <span class="smallcaps smallerCapital">l</span>-DOPA (6 mg/kg) with mixed A<sub>1</sub>R/A<sub>2A</sub>R antagonists tends to mildly improve LID, whereas selective A<sub>2A</sub>R antagonists were shown to have no significant effect on LID, that is, preladenant<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> or istradefylline.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> This might indicate a benefit by additional A<sub>1</sub>R antagonism for the treatment of dyskinesia as hypothesized previously.<a onclick="showRef(event, 'ref89 ref90'); return false;" href="javascript:void(0);" class="ref ref89 ref90">(89,90)</a> Although cotreatment of A<sub>2A</sub>R antagonists with <span class="smallcaps smallerCapital">l</span>-DOPA could not prevent the occurrence of dyskinesia, the incidence of LID might be reduced via lowering the effective dose of <span class="smallcaps smallerCapital">l</span>-DOPA.<a onclick="showRef(event, 'ref88 ref91'); return false;" href="javascript:void(0);" class="ref ref88 ref91">(88,91)</a> Recently, it was reported that preladenant, in combination with the serotonin receptor agonist eltoprazine, attenuated LID without exacerbating the PD disability score in MPTP-treated macaques when administrated in a subthreshold dose of <span class="smallcaps smallerCapital">l</span>-DOPA.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a></div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/medium/jm0c00914_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Time-course panels reporting the effect of best MTLs <b>ST-2001</b> (<b>4</b>) (A–C) and <b>ST-1992</b> (<b>12</b>) (D–F) and amantadine on either overall ALO or axial AIM scores induced by <span class="smallcaps smallerCapital">l</span>-DOPA (6 mg/kg, i.p.). AIM scores are expressed as individual data and median. Control (★), amantadine (●) 40 mg/kg (i.p.), <span class="smallcaps smallerCapital">l</span>-DOPA + <b>4</b> (*) 0.1 mg/kg (i.p.), <span class="smallcaps smallerCapital">l</span>-DOPA + <b>4</b> (☆) 1 mg/kg (i.p.), <span class="smallcaps smallerCapital">l</span>-DOPA + <b>12</b> (▲) 0.1 mg/kg (i.p.), and <span class="smallcaps smallerCapital">l</span>-DOPA + <b>12</b> (▼) 1 mg/kg (i.p.). ST-2001 and ST-1992 testing followed a within-subject escalation dose design (5 male rats per compound). The data were analyzed by the Friedman test, followed by Dunn’s multiple comparison test; *<i>p</i> < 0.05 and **<i>p</i> < 0.01 <i>vs</i> control (0 mg/kg).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00914&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Moderate <i>in vitro</i> affinity of the tested MTLs at hD<sub>3</sub>Rs were observed, that is, <b>ST-2001</b> with D<sub>3</sub>R SI (calculated as <i>K</i><sub>i</sub> (A<sub>1</sub>R/A<sub>2A</sub>R/H<sub>3</sub>R)/<i>K</i><sub>i</sub> (D<sub>3</sub>R)) of 0.03–0.04 and <b>ST-1992</b> with SI = 0.01–0.14. Moderate D<sub>3</sub>R binding might have affected AIMs in rats treated with <b>ST-2001</b> and <b>ST-1992</b>. Previous studies demonstrated that development of LID is modulated by D<sub>3</sub>Rs, where D<sub>3</sub>R-selective partial agonists or antagonists were able to improve LID without influencing the antiparkinsonian effect of <span class="smallcaps smallerCapital">l</span>-DOPA.<a onclick="showRef(event, 'ref93 ref94 ref95'); return false;" href="javascript:void(0);" class="ref ref93 ref94 ref95">(93−95)</a></div><div class="NLM_p last">As A<sub>2A</sub>R antagonists as an adjunct treatment extend or improve the therapeutic efficacy of <span class="smallcaps smallerCapital">l</span>-DOPA,<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> the antiparkinsonian capacity of designed AR/H<sub>3</sub>R MTLs should be evaluated in future studies. In multiple studies, A<sub>2A</sub>R-selective but also mixed A<sub>1</sub>R/A<sub>2A</sub>R antagonists were shown to enhance <span class="smallcaps smallerCapital">l</span>-DOPA-mediated contralateral rotation.<a onclick="showRef(event, 'ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref96 ref97">(96,97)</a> The effect of <span class="smallcaps smallerCapital">l</span>-DOPA in 6-OHDA-lesioned rat was potentiated by cotreatment with the structurally related A<sub>1</sub>R/A<sub>2A</sub>R antagonist JNJ-40255293 (1 mg/kg) or the A<sub>2A</sub>R-selective preladenant (0.1 mg/kg, p.o.).<a onclick="showRef(event, 'ref48 ref98'); return false;" href="javascript:void(0);" class="ref ref48 ref98">(48,98)</a></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> EEG and Sleep–Wake Study in Mice</h3><div class="NLM_p">The MTL <b>ST-1992</b> was investigated for its wake-promoting activity using electroencephalogram (EEG) and polysomnographic studies in mice (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). While <b>ST-1992</b> administrated orally had no clear effects at a dose of 1 mg/kg, it significantly increased the time spent awake at a dose of 2 mg/kg, effects being at the expense of slow-wave sleep (SWS), which was considerably reduced. Paradoxical sleep (PS), on the other hand, was barely affected. These results are in good accordance, first, with the wake-promoting effects of H3R inverse agonists such as pitolisant and, second, with previous findings for the structurally related potent A<sub>1</sub>R/A<sub>2A</sub>R antagonist JNJ-40255293.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a><b>ST-1992</b> is effective at a dosage of 2 mg/kg (p.o.) on waking and slow-wave sleeping state, but not on PS. These studies prove per oral bioavailability. However, obtained drug efficiency metrics suggest moderate drug-likeness of <b>ST-1992</b>, what possibly explains the differences in effective dosing compared to that of JNJ-40255293.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/medium/jm0c00914_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Sleep–wake patterns following p.o. administration of compound <b>ST-1992</b> (<b>12</b>) at 1 mg/kg (A) and 2 mg/kg (B) showing cumulative indices after 4 h (a) and time-dependent effects on wake (W) (b), SWS (c), and PS phases (d) (*<i>p</i> < 0.05 <i>vs</i>. control (black bar, 0 mg/kg); Dunnett’s <i>t</i>-test after significant ANOVA; <i>n</i> = 5).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00914&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The herein designed mixed AR/H<sub>3</sub>R MTLs, a simultaneous blockade of A<sub>1</sub>R/A<sub>2A</sub>Rs and H<sub>3</sub>Rs, might provide a modulation of the waking state in a synergistic manner. While the wake-promoting capacity of H<sub>3</sub>R antagonists/inverse agonists is beyond any doubt, a certain role of A<sub>2A</sub>Rs in regulation of the sleep-wake cycle is suggested in preclinical studies. In a study with A<sub>1</sub>R and A<sub>2A</sub>R knockout (KO) mice, it was confirmed that only A<sub>2A</sub>R-competent mice showed increased waking after application of the mixed A<sub>1</sub>R/A<sub>2A</sub>R antagonist caffeine.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> This suggest<b>s</b> that A<sub>1</sub>Rs plays a negligible role in sleep–wake regulation.<a onclick="showRef(event, 'ref100 ref101'); return false;" href="javascript:void(0);" class="ref ref100 ref101">(100,101)</a> However, caffeine failed to improve EDS in PD patients.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> On the contrary, recent studies reported that the A<sub>2A</sub>R-selective antagonist istradefylline improved daytime sleepiness in PD patients.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Thus, A<sub>1</sub>R/A<sub>2A</sub>R/H<sub>3</sub>R MTLs might represent an innovative pharmacotherapy to simultaneously improve motor and nonmotor symptoms.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52362" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52362" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Within this study, multitargeting A<sub>1</sub>R/A<sub>2A</sub>R/H<sub>3</sub>R ligands were described for the first time by applying a knowledge-based MTL design approach. The H<sub>3</sub>R fragments 3-piperidinopropyloxy or the pyrrolidino analogue were attached to an aromatic A<sub>1</sub>R/A<sub>2A</sub>R arylindenopyrimidine scaffold in three different positions. Within this series of compounds, those bearing the H<sub>3</sub>R pharmacophore such as R<sup>8</sup> showed the most promising multitargeting features with affinities in nanomolar concentration ranges at the desired targets. With these innovative in vitro profiles, <b>ST-2001</b> (1 mg/kg, i.p.) and <b>ST-1992</b> (2 mg/kg, p.o.) improved LID and increased wakefulness in rodents, respectively. These initial studies demonstrate suitable but so far moderate therapeutic features of A<sub>1</sub>R/A<sub>2A</sub>R/H<sub>3</sub>R MTLs for the treatment of PD.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33702" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33702" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> General Information</h3><div class="NLM_p last">Reagent-grade chemicals and solvents were obtained from various producers (Sigma-Aldrich, VWR Chemicals, Fisher Scientific, Panreac AppliChem, Alfa Aesar, Chemsolute) and were used without further purifications (unless stated otherwise). <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker AMX spectrometer (Bruker, Germany) at 300 and 75 MHz, respectively, where CDCl<sub>3</sub> or DMSO-<i>d</i><sub>6</sub> was used as a solvent. Tetramethylsilane was used as the standard, and chemical shifts are reported in parts per million (ppm). Spin multiplicities are given as s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quintet), or m (multiplet) with approximate coupling constants (<i>J</i>) in Hertz (Hz); number and assignment of protons: aip, arylindenopyrimidine; ax, axial; eq, equatorial; ph, phenyl; prop, propyl; pip, piperidine; pyr, pyrrolidine. ESI-HRMS was performed on an amaZon speed (Bruker, Germany) with an ionization source operating in the positive mode. Data are listed as mass number ([M + H<sup>+</sup>]) and relative intensity (%). HRMS was run in ESI mode. Melting points (mp, uncorrected) were determined on a M-564 Büchi melting-point apparatus (Büchi, Germany). Preparative column chromatography was performed on silica gel 60 M, 0.04–0.063 mm (Macherey-Nagel, Germany) and thin-layer chromatography was carried out using precoated silica gel 60 with fluorescence indicator at UV 254 nm (Macherey-Nagel, Germany). Compound purity ≥95% was determined by HPLC (Knauer, Germany) with a TC-C18 column, an acetonitrile/water (0.1% TFA) mobile phase, and a flow rate of 1 mL/min. Detailed experimental procedures for the synthesis of precursors are described in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_001.pdf" class="ext-link">Supporting Information</a>. The data below are for the final MTLs <b>1–12</b>.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> General Procedure for the Synthesis of 3-Piperidino/pyrrolidinopropyloxy Arylindenopyrimidine Derivatives (<b>1–6</b>)</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Compounds <b>1–4</b><a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></h4><div class="NLM_p last">Under a N<sub>2</sub> atmosphere, the corresponding hydroxy arylindenopyrimidine derivatives (<b>P14–P17</b>, 1 equiv), K<sub>2</sub>CO<sub>3</sub> (1.5 equiv), potassium iodide (1 equiv), and 1-(3-chloropropyl)piperidine or -pyrrolidine (1.2) were dissolved in dimethylformamide and heated to 80 °C. After 4 h, the mixture was cooled down to room temperature and the inorganic salts were filtered off. The filtrate was concentrated to dryness and resuspended in dichloromethane. The crude product was taken up in methylene chloride and 2 N NaOH solution. The organic phase was then washed with saturated NaCl solution and water, dried over magnesium sulfate, and concentrated under vacuum. Crude products were purified with column chromatography (methylene chloride/NH<sub>3</sub> methanol = 9.5:0.5).</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Compounds <b>5–6</b><a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></h4><div class="NLM_p last">A solution of guanidine hydrochloride (1 equiv) in ethanol was treated with powder NaOH (1 equiv). After 30 min, the free base was added to a solution of <b>P12</b> and <b>P13</b> (0.4 equiv) in ethanol and the reaction mixture was refluxed for 18 h. The crude product was purified by column chromatography (methylene chloride/NH<sub>3</sub> methanol = 97:3) and recrystallized from methanol or ethanol.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 4-(4-(3-(Piperidin-1-yl)propoxy)phenyl)-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-2-amine (<b>1</b>)</h4><div class="NLM_p last">Yield: 69%; mp 166.1 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 8.14–8.05 (m, 2H, ph<sup>1</sup>-2′,6′<i>H</i>), 7.94–7.87 (d, 1H, <i>J</i> = 7.8, ph<sup>1</sup>-3′<i>H</i>), 7.72–7.64 (d, 1H, <i>J</i> = 7.1, ph<sup>1</sup>-5′<i>H</i>), 7.59–7.44 (m, 2H, aip-6,7<i>H</i>), 7.13–7.03 (m, 2H, aip-8,9<i>H</i>), 6.60 (s, 2H, aip-N<i>H</i><sub>2</sub>), 4.12 (s, 2H, aip-5<i>H</i><sub>2</sub>), 4.11–4.02 (t, 2H, <i>J</i> = 5.9, prop-1″<i>H</i><sub>2</sub>), 2.44–2.37 (t, 2H, <i>J</i> = 6.9, prop-3″<i>H</i><sub>2</sub>), 2.38–2.23 (m, 4H, pip-5″, 9″<i>H</i><sub>2</sub>), 1.97–1.82 (q, 2H, <i>J</i> = 6.4, 1.9, prop-2″<i>H</i><sub>2</sub>), 1.58–1.44 (m, 4H, pip-6″, 8″<i>H</i><sub>2</sub>), 1.43–1.30 (m, 2H, pip-7″<i>H</i><sub>2</sub>). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 162.2, 163.5, 159.9, 159.2, 145.8, 138.9, 130.0, 129.8, 127.1, 125.4, 121.0, 117.9, 114.2, 66.0, 55.0, 53.9, 34.3, 26.0, 25.4, 23.0. ESI-HRMS <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>28</sub>N<sub>4</sub>O (MH<sup>+</sup>), 401.2341; found, 401.2333. HPLC: 97.3%.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 4-Phenyl-7-(3-(pyrrolidin-1-yl)propoxy)-5<i>H</i>-indeno[1,2 <i>d</i>]pyrimidin-2-amine (<b>2</b>)</h4><div class="NLM_p last">Yield: 65%; mp 141.6 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub><i>H</i></sub> 8.10–8.02 (m, 2H, ph<sup>1</sup>-2′,6′<i>H</i>), 7.84–7.77 (d, 1H, <i>J</i> = 7.8, aip-9<i>H</i>), 7.58–7.45 (m, 3H, aip-6<i>H</i>, ph<sup>1</sup>-3′,5′<i>H</i>), 7.26–7.20 (d, 1H, <i>J</i> = 7.2, ph<sup>1</sup>-4′<i>H</i>), 7.08–7.0 (dd, 1H, <i>J</i> = 7.1, aip-8<i>H</i>), 6.58 (s, 2H, aip-N<i>H</i><sub>2</sub>), 4.16–4.07 (t, 2H, <i>J</i> = 6.3, prop-1″<i>H</i><sub>2</sub>), 4.01 (s, 2H, aip-5<i>H</i><sub>2</sub>), 2.62–2.53 (t, 2H, <i>J</i> = 6.7, prop-3″<i>H</i><sub>2</sub>), 2.49–2.37 (m, 4H, pyr-5″, 8″<i>H</i><sub>2</sub>), 1.99–1.85 (q, 2H, <i>J</i> = 5.6, prop-2″<i>H</i><sub>2</sub>), 1.76–1.59 (m, 4H, pyr-6″, 7″<i>H</i><sub>2</sub>). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 168.9, 163.6, 160.9, 158.8, 148.3, 138.0, 131.4, 129.5, 128.3, 128.1, 122.2, 118.1, 114.3, 110.9, 66.1, 55.0, 54.1, 34.09, 28.09, 23.07. ESI-HRMS <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>26</sub>N<sub>4</sub>O (MH<sup>+</sup>), 387.2185; found, 387.2177. HPLC: 96.3%.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 7-(3-(Piperidin-1-yl)propoxy)-4-(4-(3-(piperidin-1-yl)propoxy)phenyl)-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-2-amine (<b>3</b>)</h4><div class="NLM_p last">Yield: 66%; mp 165.3 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub><i>H</i></sub> 8.16–8.05 (m, 2H, ph<sup>1</sup>-2′,6′<i>H</i>), 7.60–7.51 (m, 1H, aip-9<i>H</i>), 7.42–7.32 (d, 1H, <i>J</i> = 7.4, aip-6<i>H</i>), 7.18–7.03 (m, 3H, ph<sup>1</sup>-3′,5′<i>H</i>, aip-8<i>H</i>), 6.58 (s, 2H, aip-N<i>H</i><sub>2</sub>), 4.18–4.05 (t, 4H, <i>J</i> = 6.5, prop/prop<sup>1</sup>-1″H<sub>2</sub>), 4.03 (s, 2H, aip-5<i>H</i><sub>2</sub>), 2.48–2.23 (m, 12H, prop/prop<sup>1</sup>-3″<i>H</i><sub>2</sub>, pip/pip<sup>1</sup>-5″, 9″<i>H</i><sub>2</sub>), 1.83–1.61 (m, 4H, prop/prop<sup>1</sup>-2″<i>H</i><sub>2</sub>), 1.44–1.30 (m, 12H, pip/pip<sup>1</sup>-6″, 7″, 8″<i>H</i><sub>2</sub>). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ<sub>C</sub> 169.7, 163.0, 160.3, 160.2, 158.7, 140.0, 138.1, 129.9, 128.5, 124.9, 119.0, 114.4, 106.3, 105.6, 66.6, 55.8, 54.4, 54.3, 34.1, 26.1, 25.2, 23.9. ESI-HRMS <i>m</i>/<i>z</i>: calcd for C<sub>33</sub>H<sub>43</sub>N<sub>5</sub>O<sub>2</sub> (M2H<sup>+</sup>), 543.3573; found, 543.3574. HPLC: 96.7%.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 4-Phenyl-8-(3-(pyrrolidin-1-yl)propoxy)-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-2-amine (<b>ST2001</b>)</h4><div class="NLM_p last">Yield: 70%; mp 140.5 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub><i>H</i></sub> 8.14–8.04 (m, 2H, ph<sup>1</sup>-2′,6′<i>H</i>), 7.60–7.47 (m, 4H, aip-6,9<i>H</i>, ph<sup>1</sup>-3′,5′<i>H</i>), 7.42–7.36 (d, 1H, <i>J</i> = 7.4, ph<sup>1</sup>-4′<i>H</i>), 7.14–7.06 (dd, 1H, <i>J</i> = 7.1, aip-7<i>H</i>), 6.66 (s, 2H, aip-N<i>H</i><sub>2</sub>), 4.16–4.08 (t, 2H, <i>J</i> = 6.4, prop-1″<i>H</i><sub>2</sub>), 4.02 (s, 2H, aip-5<i>H</i><sub>2</sub>), 2.65–2.55 (t, 2H, <i>J</i> = 6.8, prop-3″<i>H</i><sub>2</sub>), 2.55–2.39 (m, 4H, pyr-5″, 8″<i>H</i><sub>2</sub>), 2.01–1.85 (q, 2H, <i>J</i> = 5.9, prop-2″<i>H</i><sub>2</sub>), 1.75–1.61 (m, 4H, pyr-6″, 7″<i>H</i><sub>2</sub>). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 168.9, 163.6, 159.6, 158.2, 140.1, 138.0, 137.8, 129.7, 128.4, 128.2, 126.2, 119.6, 118.4, 104.9, 66.1, 53.5), 52.1, 33.3, 28.0, 23.0. ESI-HRMS <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>26</sub>N<sub>4</sub>O (MH<sup>+</sup>), 387.2185; found, 387.2186. HPLC: 97.3%.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 4-Phenyl-7-(3-(piperidin-1-yl)propoxy)-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-2-amine (<b>5</b>)</h4><div class="NLM_p last">Yield: 50%; mp 176.3 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub><i>H</i></sub> 8.17–8.08 (dd, 2H, <i>J</i> = 8.1, ph<sup>1</sup>-2′,6′<i>H</i>), 7.90–7.82 (d, 1H, <i>J</i> = 7.8, aip-9<i>H</i>), 7.66–7.51 (m, 3H, aip-6H, ph<sup>1</sup>-3′,5′<i>H</i>), 7.31–7.24 (d, 1H, <i>J</i> = 7.3, ph<sup>1</sup>-4′<i>H</i>), 7.15–7.05 (dd, 1H, <i>J</i> = 7.1, aip-8<i>H</i>), 6.63 (s, 2H, aip-N<i>H</i><sub>2</sub>), 4.20–4.13 (t, 2H, <i>J</i> = 6.2, prop-1″<i>H</i><sub>2</sub>), 4.12 (s, 2H, aip-5<i>H</i><sub>2</sub>), 2.51–2.42 (t, 2H, <i>J</i> = 6.9, prop-3″<i>H</i><sub>2</sub>), 2.41–2.28 (m, 4H, pip-5″, 9″<i>H</i><sub>2</sub>), 2.02–1.88 (q, 2H, <i>J</i> = 5.9, prop-2″<i>H</i><sub>2</sub>), 1.61–1.49 (m, 4H, pip-6″, 8″<i>H</i><sub>2</sub>), 1.48–1.37 (m, 2H, pip-7″<i>H</i><sub>2</sub>). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 168.9, 163.6, 160.9, 158.8, 148.3, 138.0, 131.3, 129.5, 128.3, 128.1, 122.2, 118.1, 114.3, 110.9, 66.2, 55.0, 54.0, 34.0, 26.2, 25.5, 24.1. ESI-HRMS <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>28</sub>N<sub>4</sub>O (M2H<sup>+</sup>), 402.2420; found, 402.2412. HPLC: 96.5%.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 4-Phenyl-8-(3-(piperidin-1-yl)propoxy-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-2-amine (<b>6</b>)</h4><div class="NLM_p last">Yield: 44%; mp 142.1 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub><i>H</i></sub> 8.15–8.03 (m, 2H, ph<sup>1</sup>-2′,6′<i>H</i>), 7.61–7.47 (m, 4H, aip-6,9<i>H</i>, ph<sup>1</sup>-3′,5′<i>H</i>), 7.41–7.35 (d, 1H, <i>J</i> = 7.4, ph<sup>1</sup>-4′<i>H</i>), 7.16–7.05 (dd, 1H, <i>J</i> = 7.1, aip-7<i>H</i>), 6.66 (s, 2H, aip-N<i>H</i><sub>2</sub>), 4.12–4.05 (t, 2H, <i>J</i> = 6.4, prop-1″<i>H</i><sub>2</sub>), 4.03 (s, 2H, aip-5<i>H</i><sub>2</sub>), 2.45–2.38 (t, 2H, <i>J</i> = 6.8, prop-3″<i>H</i><sub>2</sub>), 2,36–2.25 (m, 4H, pip-5″, 9″<i>H</i><sub>2</sub>), 1.97–1.84 (q, 2H, <i>J</i> = 5.8, prop-2″<i>H</i><sub>2</sub>), 1.57–1.43 (m, 4H, pip-6″, 8″<i>H</i><sub>2</sub>), 1.43–1.31 (m, 2H, pip-7″<i>H</i><sub>2</sub>). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 168.9, 163.6, 159.6, 158.0, 140.1, 137.9, 137.8, 129.7, 128.4, 128.2, 126.2, 119.6, 118.4, 104.9, 66.2, 55.1, 54.0, 33.3, 26.2, 25.6, 24.1. ESI-HRMS <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>26</sub>N<sub>4</sub>O (MH<sup>+</sup>), 401.2341; found, 401.2339. HPLC: 97.1%.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> General Procedure for the Synthesis of 3-Piperidino/Pyrrolidinopropyloxy Carbonyl Arylindenopyrimidine Derivatives (<b>7–12</b>)<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a></h3><div class="NLM_p">Derivatives <b>1–6</b> (1 equiv) and sodium hydroxide (1.2 equiv) were suspended in dimethylformamide. The resulting mixture was heated to 80 °C and air was bubbled through the solution using a steel needle. After 4 h, the reaction was cooled to room temperature, and the crude product was taken up in dichloromethane and sodium carbonate. The organic phase was then washed several times with saturated NaCl solution and water, dried over magnesium sulfate, and concentrated in vacuum. The obtained solid was purified by column chromatography (methylene chloride/NH<sub>3</sub> methanol = 95:5) and washed one night in hexane.</div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 2-Amino-4-(4-(3-(piperidin-1-yl)propoxy)phenyl)-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>7</b>)</h4><div class="NLM_p last">Yield: 73%; mp 100.5 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub><i>H</i></sub> 8.18–8.08 (m, 2H, ph<sup>1</sup>-2′,6′<i>H</i>), 7.93 (s, 2H, aip-N<i>H</i><sub>2</sub>), 7.83–7.61 (m, 4H, aip-6,7H, ph<sup>1</sup>-3′,5′), 7.10–7.0 (m, 2H, aip-8,9<i>H</i>), 4.18–4.04 (t, 2H, <i>J</i> = 6.4, prop-1″<i>H</i><sub>2</sub>), 2.48–2.39 (t, 2H, <i>J</i> = 5.8, prop-3″<i>H</i><sub>2</sub>), 2.38–2.20 (m, 4H, pip-5″, 9″<i>H</i><sub>2</sub>), 1.96–1.82 (q, 2H, <i>J</i> = 6.0, prop-2″<i>H</i><sub>2</sub>), 1.60–1.45 (m, 4H, pip-6″, 8″<i>H</i><sub>2</sub>), 1.44–1.32 (m, 2H, pip-7″<i>H</i><sub>2</sub>). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 187.6, 175.8, 164.7, 164.0, 161.0, 139.4, 136.2, 134.0, 132.8, 131.4, 127.8, 122.9, 120.7, 113.4, 110.1, 66.1, 55.0, 54.0, 26.2, 25.5, 24.1. ESI-HRMS <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub> (MH<sup>+</sup>), 415.2134; found, 415.2132. HPLC: 96.3%.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 2-Amino-7-(3-(pyrrolidin-1-yl)propoxy)-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-6-one (<b>8</b>)</h4><div class="NLM_p last">Yield: 76%; mp 145.3 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> = 8.05–7.96 (m, 2H, ph<sup>1</sup>-2′,6′<i>H</i>), 7.94 (s, 2H, aip-N<i>H</i><sub>2</sub>), 7.73–7.64 (d, 1H, J = 7.7, aip-9H), 7.60.7.44 (m, 3H, aip-6H, ph<sup>1</sup>-3′,5′<i>H</i>), 7.24–7.18 (dd, 1H, J = 7.2, ph<sup>1</sup>-4′<i>H</i>), 7.18–7.11 (d, 1H, J = 7.2, aip-8<i>H</i>), 4.22–4.06 (t, 2H, J = 6.4, prop-1″<i>H</i><sub>2</sub>), 2.64–2.53 (t, 2H, J = 5.3, prop-3″<i>H</i><sub>2</sub>), 2.49–2.41 (m, 4H, pyr-5″, 8″<i>H</i><sub>2</sub>), 2.01–1.85 (q, 2H, J = 6.7, prop-2″<i>H</i><sub>2</sub>), 1.79–1.58 (m, 4H, pyr-6″, 7″<i>H</i><sub>2</sub>). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 187.0, 175.7, 164.9, 164.3, 162.7, 138.7, 135.7, 131.3, 130.6, 129.3, 127.6, 122.5, 119.6, 110.6, 108.8, 66.6, 53.5, 51.9, 27.8, 23.0. ESI-HRMS <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub> (MH<sup>+</sup>), 401.1978; found, 401.1976. HPLC: 97.5%.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 2-Amino-7-(3-(piperidin-1-yl)propoxy)-4-(4-(3-(piperidin-1-yl)propoxy)phenyl)-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>9</b>)</h4><div class="NLM_p last">Yield: 62%; mp 116.5 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub><i>H</i></sub> 8.16–8.06 (m, 2H, ph<sup>1</sup>-2′,6′<i>H</i>), 7.80 (s, 1H, aip-N<i>H</i><sub>2</sub>), 7.63–7.55 (d, 1H, <i>J</i> = 7.6, aip-9<i>H</i>), 7.25–7.19 (d, 1H, <i>J</i> = 7.2, aip-6<i>H</i>), 7.15–7.07 (dd, 1H, <i>J</i> = 7.1, aip-8<i>H</i>), 7.06–6.96 (m, 2H, ph<sup>1</sup>-3′,5′<i>H</i>), 4.24–4.12 (t, 2H, <i>J</i> = 6.5, prop<sup>1</sup>-1″<i>H</i><sub>2</sub>), 4.12–4.00 (t, 2H, <i>J</i> = 6.5, prop-1″<i>H</i><sub>2</sub>), 2.47–2.38 (m, 4H, prop/prop<sup>1</sup>-3″H<sub>2</sub>), 2.38–2.17 (m, 8H, pip/pip<sup>1</sup>-5″, 9″<i>H</i><sub>2</sub>), 2.02–1.81 (m, 4H, prop/prop<sup>1</sup>-2″<i>H</i><sub>2</sub>), 1.58–1.44 (m, 8H, pip/pip<sup>1</sup>-6″, 8″<i>H</i><sub>2</sub>), 1.43–1.27 (m, 4H, pip/pip<sup>1</sup>-7<i>H</i><sub>2</sub>″). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 187.0, 174.9, 164.6, 163.6, 163.4, 160.9, 142.1, 131.5, 128.5, 127.8, 124.9, 118.2, 113.4, 111.0, 106.2, 67.1, 66.0, 55.0, 54.8, 54.0, 26.1, 25.9, 25.4, 24.0. ESI-HRMS <i>m</i>/<i>z</i>: calcd for C<sub>33</sub>H<sub>41</sub>N<sub>5</sub>O<sub>3</sub> (MH<sup>+</sup>), 556.3288; found, 556.3279. HPLC: 97.2%.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 2-Amino-8-(3-(pyrrolidin-1-yl)propoxy)-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>10</b>)</h4><div class="NLM_p last">Yield: 75%; mp 144.5 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> = 8.05–7.97 (m, 2H, ph<sup>1</sup>-2′, 6′<i>H</i>), 7.90 (s, 2H, aip-N<i>H</i><sub>2</sub>), 7.62–7.56 (d, 1H, <i>J</i> = 7.6, aip-6<i>H</i>), 7.56–7.45 (m, 3H, aip-9H, ph<sup>1</sup>-3′, 5′<i>H</i>), 7.27–7.22 (d, 1H, <i>J</i> = 7.2, ph<sup>1</sup>-4′<i>H</i>), 7.16–7.09 (dd, 1H, <i>J</i> = 7.1, aip-7<i>H</i>), 4.25–4.11 (t, 2H, <i>J</i> = 6.4, prop-1″<i>H</i><sub>2</sub>), 2.59–2.51 (t, 2H, <i>J</i> = 6.8, prop-3″<i>H</i><sub>2</sub>), 2.48–2.38 (m, 4H, pyr-5″, 8″<i>H</i><sub>2</sub>), 1.99–1.86 (q, 2H, <i>J</i> = 5,8, prop-2″<i>H</i><sub>2</sub>), 1.75–1.61 (m, 4H, pyr-6″, 7″<i>H</i><sub>2</sub>). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 186.5, 174.8, 164.8, 164.0, 163.6, 142.1, 135.6, 130.6, 129.5, 128.6, 128.2, 124.9, 118.3, 111.5, 106.3, 66.8, 53.5, 52.0, 29.9, 23.0. ESI-HRMS <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub> (MH<sup>+</sup>), 401.1978; found, 401.1972. HPLC: 97.1%.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 2-Amino-7-(3-(piperidin-1-yl)propoxy)-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-6-one (<b>11</b>)</h4><div class="NLM_p last">Yield: 79%; mp 182.2 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub><i>H</i></sub> = 8.02–7.96 (m, 2H, ph<sup>1</sup>-2′, 6′<i>H</i>), 7.96 (s, 2H, aip-N<i>H</i><sub>2</sub>), 7.71–7.65 (d, 1H, <i>J</i> = 7.7, aip-9H), 7.58–7.45 (m, 3H, aip-6H, ph<sup>1</sup>-3′, 5′<i>H</i>), 7.23–7.16 (dd, 1H, <i>J</i> = 7.2, ph<sup>1</sup>-4′<i>H</i>), 7.16–7.12 (d, 1H, <i>J</i> = 7.2, aip-8<i>H</i>), 4.18–4.07 (t, 2H, <i>J</i> = 6.4, prop-1″<i>H</i><sub>2</sub>), 2.47–2.25 (m, 6H, prop-3″<i>H</i><sub>2</sub>, pip-5″, 9″<i>H</i><sub>2</sub>), 1.96–1.82 (q, 2H, <i>J</i> = 5.8, prop-2″<i>H</i><sub>2</sub>), 1.55–1.44 (m, 4H, pip-6″, 8″<i>H</i><sub>2</sub>), 1.43–1.31 (m, 2H, pip-7″<i>H</i><sub>2</sub>). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 187.0, 175.7, 164.9, 164.3, 162.7, 138.7, 135.7, 131.3, 130.6, 129.3, 127.6, 122.4, 119.6, 110.6, 108.8, 66.7, 54.8, 53.9, 25.9, 25.4, 23.9. ESI-HRMS <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub> (MH<sup>+</sup>), 415.2134; found, 415.2126. HPLC: 96.5%.</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 2-Amino-8-(3-(piperidin-1-yl)propoxy)-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>ST-1992</b>)</h4><div class="NLM_p last">Yield: 74%; mp 176.6 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub><i>H</i></sub> 8.05–7.97 (m, 2H, ph<sup>1</sup>-2, 6<i>H</i>), 7.96–7.81 (s, 2H, pyrim-N<i>H</i><sub>2</sub>), 7.62–7.57 (d, 1H, <i>J</i> = 7.6, ph-6<i>H</i>), 7.57–7.45 (m, 3H, ph-9H, ph<sup>1</sup>-3, 5<i>H</i>), 7.26–7.22 (d, 1H, <i>J</i> = 7.2, ph<sup>1</sup>-4<i>H</i>), 7.16–7.09 (dd, 1H, <i>J</i> = 7.1, ph-7<i>H</i>), 4.21–4.11 (t, 2H, <i>J</i> = 6.4, prop-1<i>H</i><sub>2</sub>), 2.47–2.38 (t, 2H, <i>J</i> = 6.7, prop-3<i>H</i><sub>2</sub>), 2.37–2.23 (m, 4H, pip-2, 6<i>H</i><sub>2</sub>), 1.98–1.84 (q, 2H, <i>J</i> = 5.6, prop-2<i>H</i><sub>2</sub>), 1.57–1.45 (m, 4H, pip-3, 5<i>H</i><sub>2</sub>), 1.44–1.31 (m, 2H, pip-4<i>H</i><sub>2</sub>). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>C</sub> 186.5, 174.8, 164.8, 164.1, 163.6, 142.1, 135.6, 130.6, 129.5, 128.6, 127.6, 125.0, 118.3, 111.5, 106.3, 66.0, 54.8, 54.0, 26.0, 25.5, 24.0. ESI-HRMS <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub> (MH<sup>+</sup>), 415.2134; found, 415.2129. HPLC = 97.0%.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Docking Studies</h3><div class="NLM_p last">The X-ray structure of the human A<sub>2A</sub>R with the antagonist ZM241385 was obtained from the Protein Data Bank.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(103)</a> From the downloaded crystal structure, the cocrystallized apocytochrome bRIL was removed, and the receptor was prepared using the protein preparation tool implemented in Molecular Operating Environment (MOE 2018.01).<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(104)</a> A homology model of the H<sub>3</sub>R was downloaded from the GPCR database (<a href="https://www.gpcrdb.org" class="extLink">https://www.gpcrdb.org</a>).<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(105)</a> The model was generated using a multitemplate approach with the human H<sub>1</sub>R (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RZE">3RZE</a>) as the main template, showing a sequence similarity of 38%. For both receptors, the hydrogen atoms were assigned according to the Protonate3D module in MOE 2018.01. The prepared receptors were applied for flexible ligand docking using AutoDock 4.2, and during the docking simulations, the ligands were fully flexible and the residues of the receptors were treated as rigid.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(106)</a> The atomic partial charges were added using AutoDockTools.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(107)</a> The three-dimensional energy scoring grids for a box of 60 × 70 × 60 points with a grid spacing of 0.375 Å were computed, and the grids were centered based on the cocrystallized ligand ZM241385 in case of A<sub>2A</sub>R. Fifty independent docking simulations were calculated using the <i>var</i>CPSO-ls algorithm from <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="3060637f707145445f545f535b">[email protected]</a> implemented in AutoDock 4.2.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(108)</a> The parameters of the <i>var</i>CPSO-ls algorithm, the cognitive and social coefficients c1 and c2, were set to 6.05 with 60 individual particles as the swarm size, and the simulations were terminated after 50,000 evaluation steps. All other parameters of the algorithm were set at their default values. The possible binding modes of the compounds were explored by visual inspection of the poses resulting from docking simulations.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>In Vitro</i> Characterization</h3><div id="sec4_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Radioligand Competition Binding Studies</h4><div class="NLM_p last">The affinities (<i>K</i><sub>i</sub> values) of the designed compounds were determined in radioligand receptor binding studies. Stock solutions of the test compounds were prepared in dimethyl sulfoxide (DMSO). Membrane preparations expressing the respective receptor were incubated with the radioligand and competitor. Membranes with the bound radioligand were harvested by filtration and thereby separated from the free radioligand and subsequently analyzed by liquid scintillation counting. Specific counts per minute (cpm) were plotted <i>versus</i> −log concentrations of test ligands and analyzed via nonlinear regression fit using GraphPad Prism (version 4 or 6, San Diego, CA, USA). The resulting IC<sub>50</sub> values were transformed to <i>K</i><sub>i</sub> values using the Cheng–Prusoff equation based on previously described <i>K</i><sub>D</sub> values.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> For histamine receptor binding assays, statistical analysis was applied on −log <i>K</i><sub>i</sub> values of at least three independent experiments, each performed at least in duplicate, while mean values and confidence intervals (CI) (95%) were converted to nanomolar concentrations.</div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Adenosine Receptor Affinity</h4><div class="NLM_p last">Crude membrane preparations of CHO cells stably expressing human recombinant ARs were obtained as described previously.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Radioligand competition binding studies were performed as previously described using [<sup>3</sup>H]CCPA (0.5 nM, <i>K</i><sub>D</sub> = 0.61 nM),<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> [<sup>3</sup>H]MSX-2 (1 nM, <i>K</i><sub>D</sub> = 8 nM),<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> [<sup>3</sup>H]PSB-603 (0.3 nM, <i>K</i><sub>D</sub> = 0.41 nM),<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> and [<sup>3</sup>H]PSB-11 (0.5 nM, <i>K</i><sub>D</sub> = 4.9 nM)<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> for determination of A<sub>1</sub>R, A<sub>2A</sub>R, A<sub>2B</sub>R, and A<sub>3</sub>R affinities, respectively. At least three separate experiments were performed. Data were expressed as means ± standard error of the mean (SEM).</div></div><div id="sec4_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Histamine H<sub>3</sub> Receptor Affinity</h4><div class="NLM_p last">Radioligand depletion studies using crude membrane preparations of HEK-293 cells stably expressing the human recombinant H<sub>3</sub>R were performed as described recently.<a onclick="showRef(event, 'ref43 ref71'); return false;" href="javascript:void(0);" class="ref ref43 ref71">(43,71)</a> In brief, crude membrane preparations were incubated with test compounds (10<sup>–12</sup> to 10<sup>–4</sup> M) and [<sup>3</sup>H]<i>N</i><sup>α</sup>-methylhistamine (2 nM, <i>K</i><sub>D</sub> = 3.08 nM, PerkinElmer, Waltham, MA) in the binding buffer (total volume 0.2 mL) for 90 min under continuous shaking.</div></div><div id="sec4_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> cAMP Accumulation Experiments</h4><div class="NLM_p last">cAMP experiments in recombinant Chinese hamster ovary (CHO) cells expressing the human adenosine A<sub>2A</sub>R (CHO-A<sub>2A</sub> cells) were conducted according to De Filippo et al. with modifications.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(109)</a> Different dilutions of the antagonists were added to the CHO-A<sub>2A</sub> cells and incubated for 20 min at 37 °C and 5% CO<sub>2</sub>. Then, the agonist NECA was added and incubated for 15 min under the same conditions. The supernatant was removed, and 500 μL of hot lysis buffer (90 °C, 4 mM EDTA, 0.01% Triton X-100, pH 7.4) was added. After homogenization, the cAMP amount in the lysates was determined by radioligand competition binding experiments. Three independent experiments were performed each in duplicates. The cAMP amount in the lysates was calculated based on a calibration curve of known cAMP concentrations and normalized to the effect induced by 0.3 μM of the A<sub>2A</sub>R agonist NECA (∼EC<sub>80</sub>) set at 100%. Data analysis and statistics (one-way ANOVA followed by Dunnett’s post hoc test) were performed with GraphPad Prism version 8.0.2.</div></div><div id="sec4_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Off-Target Affinities at Dopamine and Histamine Receptor Subtypes</h4><div class="NLM_p last">Radioligand depletion studies using crude membrane preparations of either HEK-293 (D<sub>1</sub>R and D<sub>5</sub>R) and CHO cells (D<sub>2S</sub>R, D<sub>3</sub>R, and H<sub>1</sub>R) stably expressing or Sf9 cells (H<sub>4</sub>R) transiently expressing the human recombinant receptors were performed as described recently.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Off-target affinities were determined using at least five different concentrations of test ligands.</div></div><div id="sec4_5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> MAO A/B Inhibition</h4><div class="NLM_p last">Monoamine oxidase (MAO) A/B inhibition was assessed in a continuous spectrophotometric assay as described previously, using human recombinant MAO A (900 units/mL) or MAO B (375 units/mL) and Kynuramine (Sigma-Aldrich, St. Louis, MO) as the substrate for both isoforms.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> In brief, test ligands were incubated with Kynuramine (2 × <i>K</i><sub>M</sub>) and MAO in a total volume of 0.1 mL potassium phosphate buffer (50 mM). Product formation was observed spectrophotometrically at 316 nm over a period of at least 30 min. Initial enzyme conversion rates (as mAbs min<sup>–1</sup>) were plotted relative to control (no inhibitor) or, in case of IC<sub>50</sub> determinations, <i>versus</i> -log concentrations of test compounds and fitted by nonlinear regression “log (inhibitor) <i>versus</i> response (three parameters)”.</div></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> <i>In Vivo</i> Characterization</h3><div id="sec4_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 6-OHDA PD Model</h4><div class="NLM_p">To produce neurodegeneration of dopaminergic neurons, rats received a unilateral 6-OHDA injection in the medial forebrain (MFB) by stereotactic delivery. Five male Sprague–Dawley rats (Janvier, France) weighed 125–150 g before surgery and were housed in a temperature-controlled room under a 12 h light/dark cycle, with free access to food and water. All experiments were carried out in accordance with the European Committee Council Directive of 24 November 1986 (86/609/EEC) and were approved by the Animal Care and Use Committee (Bordeaux) under no 5012099-A.</div><div class="NLM_p last">Buprenorphine (0.05 mg/kg; 0.03 mg/mL) was given as an analgesic before and after the surgery. Thirty minutes prior to surgery, male Sprague–Dawley rats received the noradrenaline uptake inhibitor desipramine (25 mg/kg; i.p.) to protect noradrenergic neurons. Each animal was placed in an anesthetic chamber supplied with a continuous flow of oxygen (1.5 L/min) and 5% isoflurane. Following loss of consciousness, animals were placed in a stereotactic frame (Kopf), and 6-OHDA (5 mg/mL dissolved in sterile 0.1% ascorbic acid) was injected into the right MFB bundle at 0.4 μL/min over a 10 min period using a Hamilton 1701N syringe (30Ga/15 mm/PST3) coupled to an automatic injector UMP-3 linked to a Micro-4 controller (WPI). The injection site was located according to the following coordinates relative to bregma: −2.2 mm rostral, 1.6 mm lateral and 8.5 mm below the skull.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(103)</a> Two weeks postlesion, prior to <span class="smallcaps smallerCapital">l</span>-DOPA treatment, rats were injected subcutaneously with 0.05 mg/kg apomorphine (dissolved in 0.9% saline) and placed in rotometer bowls, where movements were observed for 15 min to assess the extent of the lesion. Animals responding with rotations were included in the subsequent study. After 3 weeks of recovery, animals were primed by administration of 6 mg/kg <span class="smallcaps smallerCapital">l</span>-DOPA + 15 mg/kg benzerazide (i.p.) once a day until AIM severity stabilization (up to 21 consecutive days). ST-2001 and ST-1992 at two concentrations (0.1, 1 mg/kg i.p.) were administered just before the <span class="smallcaps smallerCapital">l</span>-DOPA injection, whereas amantadine (40 mg/kg, s.c.) was administered 100 min before <span class="smallcaps smallerCapital">l</span>-DOPA injection. The effects of the test items in combination with <span class="smallcaps smallerCapital">l</span>-DOPA (6 mg/kg, i.p.) were evaluated via AIM scores. Briefly, animals were placed in clear Perspex boxes (22 cm × 34 cm × 20 cm). Each rat was observed for 1 min at 30 min intervals following the <span class="smallcaps smallerCapital">l</span>-DOPA administration over a 2 h time period. Three subtypes of AIMs were assessed including axial (A), limb (L), and orolingual (O). The severity of AIMs was scored between 1 and 4 depending on the duration of AIMs throughout the observational minute [(1) present for less than 30 s, (2) present for more than 30 s, (3) present throughout the minute but suppressed by external stimuli, (4) present throughout the minute but not suppressible by external stimuli]. Statistical analysis was performed using Prism 7.0 software (GraphPad Inc., La Jolla, California, USA). AIM data were subjected to a nonparametric one-way analysis of variance (ANOVA) using Friedman’s test with repeated measures for the overall treatment comparison, followed by Dunn’s multiple comparison test for the pairwise comparisons (<i>vs</i><span class="smallcaps smallerCapital">l</span>-DOPA + vehicle), where <i>p</i> < 0.05 was considered as statistically significant.</div></div><div id="sec4_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Sleep Studies in Mice</h4><div class="NLM_p">All experiments followed the European Ethics Community Directive (86/609/EEC), and every effort was made to minimize the number of animals used and their suffering. The general protocol<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(110)</a> of chronic sleep–wake recordings and pharmacological studies in mice was approved by the Ethic Committee on Animal Experimentation of Claude Bernard University (no DR2013-50).</div><div class="NLM_p">At the age of 11–14 weeks, male C57BL/6 mice weighing 25–30 mg were chronically implanted with four cortical electrodes (gold-plated tinned copper wire, Ø = 0.4 mm; Filotex, Draveil, France) and three muscle electrodes (fluorocarbon-coated gold-plated stainless steel wire, Ø = 0.03 mm; Cooner Wire, Chatsworth, CA), under deep isoflurane anesthesia (2% in oxygen with gas anesthesia machine, TEM, France), in order to record the EEG and electromyogram (EMG) and to monitor the sleep–wake cycle.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(111)</a> All electrodes were previously soldered to a multichannel electrical connector, and each was separately insulated with a covering of heat-shrinkable polyolefin/polyester tubing. The cortical electrodes were inserted into the dura through two pairs of holes (Ø = 0.5 mm) made in the skull, located in the frontal (1 mm lateral and anterior to the bregma) and parietal (1 mm lateral to the midline at the midpoint between the bregma and lambda) cortices. EMG electrodes were inserted into the neck muscle. Finally, the electrode assembly was anchored and affixed to the skull with Super-Bond (Sun Medical Co., Shiga, Japan) and dental cement.</div><div class="NLM_p">After surgery, the animals were housed individually in transparent barrels (Ø = 20 cm, height 30 cm, with open field) placed in an insulated, sound-proof recording room maintained at an ambient temperature of 23 ± 1 °C and on a 12 h light/dark cycle (light on at 7 a.m.), food and water being available <i>ad libitum</i>. After a recovery period of 2 weeks, the mice were habituated to the recording cable for one more week before starting polysomnographic recording.</div><div class="NLM_p">After a 2-day baseline recording, mice were subjected to the cortical EEG and sleep–wake recordings following oral administrations of placebo or <b>ST-1992</b> (1 and 2 mg/kg) with a washout of 7 days. Polysomnographic recordings subsequent to administration were for 12 h. Cortical EEG (ipsilateral frontoparietal leads) and EMG signals were amplified and digitized with a resolution of 256 Hz using AM system amplifiers assisted by SleepSign software for Animal (Kissei). With the assistance of EEG spectral analysis, polysomnographic records were visually scored by 10 s epochs for W, SWS, and PS.<a onclick="showRef(event, 'ref111 ref113'); return false;" href="javascript:void(0);" class="ref ref111 ref113">(110,112)</a></div><div class="NLM_p last">The EEG and sleep-wake parameters obtained after all administrations were quantified and compared between the experimental conditions. Each mouse served as its own control. One way and multiple factorial ANOVA and the post hoc Student’s <i>t</i>-test (two tailed) were used to compare and evaluate any obtained difference using Excel or/and Statgrafy softwares.<a onclick="showRef(event, 'ref111 ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref111 ref112 ref113">(110−112)</a></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00914" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37023" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37023" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00914?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00914</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Spectroscopic and analytical data; general LC–MS analytics; general synthesis, fluorescence characterization of compound <b>12</b> (<b>ST-1992</b>); drug-likeness of synthetized MTLs <b>4</b> (<b>ST-2001</b>) and <b>12</b> (<b>ST-1992</b>); cell viability of human neuroblastoma cells treated with MTLs <b>2</b>, <b>4</b> (<b>ST-2001</b>) , and <b>6</b>; <i>in vitro</i> radioligand binding experiments for compounds <b>4</b> (<b>ST-2001</b>) and <b>12</b> (<b>ST-1992</b>); <i>in vivo</i> studies of compound <b>4</b> (<b>ST-2001</b>); additional <i>in vivo</i> evaluation of compound <b>12</b> (<b>ST-1992</b>); and experimental part with references (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Modeling structure of A<sub>2A</sub>R with preladenant (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Modeling structure of A<sub>2A</sub>R with ST-1992 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_004.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_001.pdf">jm0c00914_si_001.pdf (1.93 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_002.csv">jm0c00914_si_002.csv (1.98 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_003.pdb">jm0c00914_si_003.pdb (380.87 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_004.pdb">jm0c00914_si_004.pdb (381.48 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00914" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44434" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44434" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Holger Stark</span> - <span class="hlFld-Affiliation affiliation">Institute
of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Duesseldorf, Universitaets street 1, 40225 Duesseldorf, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-3336-1710" title="Orcid link">https://orcid.org/0000-0003-3336-1710</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#384b4c594a537850504d165c5d"><span class="__cf_email__" data-cfemail="d0a3a4b1a2bb90b8b8a5feb4b5">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefanie Hagenow</span> - <span class="hlFld-Affiliation affiliation">Institute
of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Duesseldorf, Universitaets street 1, 40225 Duesseldorf, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Affini</span> - <span class="hlFld-Affiliation affiliation">Institute
of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Duesseldorf, Universitaets street 1, 40225 Duesseldorf, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elsa Y. Pioli</span> - <span class="hlFld-Affiliation affiliation">Motac
Neuroscience Limited, SK10 4TF Macclesfield, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sonja Hinz</span> - <span class="hlFld-Affiliation affiliation">PharmaCenter
Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany</span>; 
    <span class="hlFld-Affiliation affiliation">Institute
of Pharmacology and Toxicology, School of Medicine, University of
Witten/Herdecke, Center for Biomedical Education
and Research (ZBAF), Faculty of Health, Alfred-Herrhausen-Street 50, 58448 Witten, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yan Zhao</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Integrative Physiology of the Brain Arousal Systems, Lyon Neuroscience
Research Center, INSERM UI028, CNRS UMR
5292, Claude Bernard University, 8 Avenue Rockefeller, 69373 Lyon, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gregory Porras</span> - <span class="hlFld-Affiliation affiliation">Motac
Neuroscience Limited, SK10 4TF Macclesfield, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vigneshwaran Namasivayam</span> - <span class="hlFld-Affiliation affiliation">PharmaCenter
Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-3031-3377" title="Orcid link">https://orcid.org/0000-0003-3031-3377</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christa E. Müller</span> - <span class="hlFld-Affiliation affiliation">PharmaCenter
Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-0013-6624" title="Orcid link">https://orcid.org/0000-0002-0013-6624</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian-Sheng Lin</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Integrative Physiology of the Brain Arousal Systems, Lyon Neuroscience
Research Center, INSERM UI028, CNRS UMR
5292, Claude Bernard University, 8 Avenue Rockefeller, 69373 Lyon, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Erwan Bezard</span> - <span class="hlFld-Affiliation affiliation">Motac
Neuroscience Limited, SK10 4TF Macclesfield, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Univ. de
Bordeaux, Institut des Maladies Neurodégénératives,
UMR 5293, 33000 Bordeaux, France</span>; 
    <span class="hlFld-Affiliation affiliation">CNRS,
Institut des Maladies Neurodégénératives, UMR
5293, 33000 Bordeaux, France</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>S.H. and A.A. have contributed equally to this work. A.A. and S.H. wrote the main manuscript. A.A. and H.S. performed the synthesis and analyses of the compounds. S.H. and H.S. performed H3R affinity studies, selectivity studies (dopamine receptors, histamine receptors, and monoamine oxidases), and cytotoxicity assays. S.H. and C.E.M. investigated AR affinities and functional properties. V.N. performed molecular docking studies supervised by C.E.M. E.B., E.Y.P., G.P., as well as Y.Z. and J.-S.L. conducted in vivo EEG and sleep studies, respectively. H.S. designed and supervised the project and revised the manuscript. All authors contributed to writing the manuscript and approved the final version.</p></li><li><span class="author-information-subsection-header">Funding</span><p>This work was kindly supported by COST Actions CM1103, CA15135, CA18133, and CA18240, as well as DFG INST 208/664e1 FUGG (Germany) and Inserm U 628.</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">AIMs</td><td class="NLM_def"><p class="first last">abnormal involuntary movements</p></td></tr><tr><td class="NLM_term">ARs</td><td class="NLM_def"><p class="first last">adenosine receptors</p></td></tr><tr><td class="NLM_term">ALO</td><td class="NLM_def"><p class="first last">axial/lingual/oral</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">CPM</td><td class="NLM_def"><p class="first last">counts per minute</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">EDS</td><td class="NLM_def"><p class="first last">excessive daytime sleepiness</p></td></tr><tr><td class="NLM_term">EEG</td><td class="NLM_def"><p class="first last">electroencephalogram</p></td></tr><tr><td class="NLM_term">EKG</td><td class="NLM_def"><p class="first last">electrocardiogram</p></td></tr><tr><td class="NLM_term">EMA</td><td class="NLM_def"><p class="first last">European Medicines Agency</p></td></tr><tr><td class="NLM_term">EMG</td><td class="NLM_def"><p class="first last">electromyogram</p></td></tr><tr><td class="NLM_term">ESI</td><td class="NLM_def"><p class="first last">electrospray ionization</p></td></tr><tr><td class="NLM_term">GPCRs</td><td class="NLM_def"><p class="first last">G-protein-coupled receptors</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">HRMS</td><td class="NLM_def"><p class="first last">high-resolution mass spectrometry</p></td></tr><tr><td class="NLM_term">KO</td><td class="NLM_def"><p class="first last">knockout</p></td></tr><tr><td class="NLM_term">LID</td><td class="NLM_def"><p class="first last"><span class="smallcaps smallerCapital">l</span>-DOPA-induced dyskinesia</p></td></tr><tr><td class="NLM_term">MAO B</td><td class="NLM_def"><p class="first last">monoamine oxidase B</p></td></tr><tr><td class="NLM_term">MFB</td><td class="NLM_def"><p class="first last">medial forebrain</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">mass spectrometry</p></td></tr><tr><td class="NLM_term">MTL</td><td class="NLM_def"><p class="first last">multi-targeting ligand</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">Parkinson’s disease</p></td></tr><tr><td class="NLM_term">PS</td><td class="NLM_def"><p class="first last">paradoxical sleep</p></td></tr><tr><td class="NLM_term">REM</td><td class="NLM_def"><p class="first last">rapid eye movement</p></td></tr><tr><td class="NLM_term">SI</td><td class="NLM_def"><p class="first last">selectivity</p></td></tr><tr><td class="NLM_term">SNpc</td><td class="NLM_def"><p class="first last">substantia nigra pars compacta</p></td></tr><tr><td class="NLM_term">SWS</td><td class="NLM_def"><p class="first last">slow-wave sleep</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin-layer chromatography</p></td></tr><tr><td class="NLM_term">W</td><td class="NLM_def"><p class="first last">waking</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72130" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72130" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 112 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiffmann, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumont, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderhaeghen, J.-J.</span></span> <span> </span><span class="NLM_article-title">A cloned G protein-coupled protein with a distribution restricted to striatal medium-sized neurons. Possible relationship with D1 dopamine receptor</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>519</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1016/0006-8993(90)90097-u</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2F0006-8993%2890%2990097-u" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=2168785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADyaK3cXkvFWrsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=519&publication_year=1990&pages=333-337&author=S.+N.+Schiffmannauthor=F.+Libertauthor=G.+Vassartauthor=J.+E.+Dumontauthor=J.-J.+Vanderhaeghen&title=A+cloned+G+protein-coupled+protein+with+a+distribution+restricted+to+striatal+medium-sized+neurons.+Possible+relationship+with+D1+dopamine+receptor&doi=10.1016%2F0006-8993%2890%2990097-u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">A cloned G protein-coupled protein with a distribution restricted to striatal medium-sized neurons.  Possible relationship with D1 dopamine receptor</span></div><div class="casAuthors">Schiffmann, S. N.; Libert, F.; Vassart, G.; Dumont, J. E.; Vanderhaeghen, J. J.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">519</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">333-7</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    </div><div class="casAbstract">RDC8, a recently cloned new putative member of the G protein-coupled receptor family, is exclusively present in the medium-sized neurons of the dorsal and ventral striatum in the rat and dog brains.  The existence of a striatum-restricted putative G protein-coupled receptor is of major importance for the understanding of basal ganglia physiol. and degenerative diseases pathogeny such as Huntington's and Parkinson's disease.  This striatal restricted localization mimics the major striatal dopamine D1 receptor localization.  RDC7, another putative G protein-coupled receptor presenting a close sequence similarity with RDC8, is mainly distributed in the cerebral cortex, the amygdala, the hippocampus, and the claustrum.  This localization is also compatible with that expected from a subtype of dopamine D1 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV1UB3cVbAMLVg90H21EOLACvtfcHk0ljIqCzQXsu9EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXkvFWrsb8%253D&md5=13aba0568740042cea1918a5b1b7da5e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2890%2990097-u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252890%252990097-u%26sid%3Dliteratum%253Aachs%26aulast%3DSchiffmann%26aufirst%3DS.%2BN.%26aulast%3DLibert%26aufirst%3DF.%26aulast%3DVassart%26aufirst%3DG.%26aulast%3DDumont%26aufirst%3DJ.%2BE.%26aulast%3DVanderhaeghen%26aufirst%3DJ.-J.%26atitle%3DA%2520cloned%2520G%2520protein-coupled%2520protein%2520with%2520a%2520distribution%2520restricted%2520to%2520striatal%2520medium-sized%2520neurons.%2520Possible%2520relationship%2520with%2520D1%2520dopamine%2520receptor%26jtitle%3DBrain%2520Res.%26date%3D1990%26volume%3D519%26spage%3D333%26epage%3D337%26doi%3D10.1016%2F0006-8993%2890%2990097-u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiffmann, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moresco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunha, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferré, S.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptors and basal ganglia physiology</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1016/j.pneurobio.2007.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.pneurobio.2007.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=17646043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlags7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2007&pages=277-292&author=S.+N.+Schiffmannauthor=G.+Fisoneauthor=R.+Morescoauthor=R.+A.+Cunhaauthor=S.+Ferr%C3%A9&title=Adenosine+A2A+receptors+and+basal+ganglia+physiology&doi=10.1016%2Fj.pneurobio.2007.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A receptors and basal ganglia physiology</span></div><div class="casAuthors">Schiffmann, S. N.; Fisone, G.; Moresco, R.; Cunha, R. A.; Ferre, S.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">277-292</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Adenosine A2A receptors are highly enriched in the basal ganglia system.  They are predominantly expressed in enkephalin-expressing GABAergic striatopallidal neurons and therefore are highly relevant to the function of the indirect efferent pathway of the basal ganglia system.  In these GABAergic enkephalinergic neurons, the A2A receptor tightly interacts structurally and functionally with the dopamine D2 receptor.  Both by forming receptor heteromers and by targeting common intracellular signaling cascades, A2A and D2 receptors exhibit reciprocal antagonistic interactions that are central to the function of the indirect pathway and hence to basal ganglia control of movement, motor learning, motivation and reward.  Consequently, this A2A/D2 receptors antagonistic interaction is also central to basal ganglia dysfunction in Parkinson's disease.  However, recent evidence demonstrates that, in addn. to this post-synaptic site of action, striatal A2A receptors are also expressed and have physiol. relevance on pre-synaptic glutamatergic terminals of the cortico-limbic-striatal and thalamo-striatal pathways, where they form heteromeric receptor complexes with adenosine A1 receptors.  Therefore, A2A receptors play an important fine-tuning role, boosting the efficiency of glutamatergic information flow in the indirect pathway by exerting control, either pre- and/or post-synaptically, over other key modulators of glutamatergic synapses, including D2 receptors, group I metabotropic mGlu5 glutamate receptors and cannabinoid CB1 receptors, and by triggering the cAMP-protein kinase A signaling cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUH2pJWR7dD7Vg90H21EOLACvtfcHk0ljIqCzQXsu9EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlags7%252FE&md5=6257d9a3d3b5d581ae1ce8b894a04e1e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2007.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2007.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DSchiffmann%26aufirst%3DS.%2BN.%26aulast%3DFisone%26aufirst%3DG.%26aulast%3DMoresco%26aufirst%3DR.%26aulast%3DCunha%26aufirst%3DR.%2BA.%26aulast%3DFerr%25C3%25A9%26aufirst%3DS.%26atitle%3DAdenosine%2520A2A%2520receptors%2520and%2520basal%2520ganglia%2520physiology%26jtitle%3DProg.%2520Neurobiol.%26date%3D2007%26volume%3D83%26spage%3D277%26epage%3D292%26doi%3D10.1016%2Fj.pneurobio.2007.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kase, H.</span></span> <span> </span><span class="NLM_article-title">The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">605</span>– <span class="NLM_lpage">611</span>, <span class="refDoi"> DOI: 10.1523/jneurosci.16-02-00605.1996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1523%2Fjneurosci.16-02-00605.1996" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1996&pages=605-611&author=A.+Moriauthor=T.+Shindouauthor=M.+Ichimuraauthor=H.+Nonakaauthor=H.+Kase&title=The+role+of+adenosine+A2a+receptors+in+regulating+GABAergic+synaptic+transmission+in+striatal+medium+spiny+neurons&doi=10.1523%2Fjneurosci.16-02-00605.1996"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1523%2Fjneurosci.16-02-00605.1996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252Fjneurosci.16-02-00605.1996%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DA.%26aulast%3DShindou%26aufirst%3DT.%26aulast%3DIchimura%26aufirst%3DM.%26aulast%3DNonaka%26aufirst%3DH.%26aulast%3DKase%26aufirst%3DH.%26atitle%3DThe%2520role%2520of%2520adenosine%2520A2a%2520receptors%2520in%2520regulating%2520GABAergic%2520synaptic%2520transmission%2520in%2520striatal%2520medium%2520spiny%2520neurons%26jtitle%3DProg.%2520Neurobiol.%26date%3D1996%26volume%3D16%26spage%3D605%26epage%3D611%26doi%3D10.1523%2Fjneurosci.16-02-00605.1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. J.</span></span> <span> </span><span class="NLM_article-title">The adenosine A2A receptor of the basal ganglia</span>. <i>J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>532</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1111/j.1469-7793.2001.0284f.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1111%2Fj.1469-7793.2001.0284f.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=11306648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjtFOntro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=532&publication_year=2001&pages=284-286&author=P.+J.+Richardson&title=The+adenosine+A2A+receptor+of+the+basal+ganglia&doi=10.1111%2Fj.1469-7793.2001.0284f.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The adenosine A2A receptor of the basal ganglia</span></div><div class="casAuthors">Richardson, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">532</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">284</span>CODEN:
                <span class="NLM_cas:coden">JPHYA7</span>;
        ISSN:<span class="NLM_cas:issn">0022-3751</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">A review with 6 refs.  It is widely recognized that Parkinson's disease (PD) is caused by the deterioration of the dopaminergic neurons of the nigro-striatal pathway, resulting in abnormal neural processing in the basal ganglia and consequent motor abnormalities.  The current mainstay of therapy for this disease is dopamine replacement using the precursor L-DOPA.  However, the duration of L-DOPA therapy is severely limited, and it is assocd. with the development of incapacitating side-effects such as dyskinesias, on/off episodes and hallucinations.  It was therefore of considerable interest when two groups in the late 1980s and early 1990s suggested that the adenosine A2A receptor could be a suitable target for novel anti-PD drugs.  It was hoped that such agents would exhibit fewer side effects than the current dopamine-based therapies.  Indeed it appears that in primate and rodent models of PD, A2A receptor antagonists do not cause dyskinesias, unlike L-DOPA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdtiILzYnV8rVg90H21EOLACvtfcHk0lhWriojPIBmWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjtFOntro%253D&md5=75e36241290039c25fc50fc7e365d5bf</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fj.1469-7793.2001.0284f.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1469-7793.2001.0284f.x%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BJ.%26atitle%3DThe%2520adenosine%2520A2A%2520receptor%2520of%2520the%2520basal%2520ganglia%26jtitle%3DJ.%2520Physiol.%26date%3D2001%26volume%3D532%26spage%3D284%26epage%3D286%26doi%3D10.1111%2Fj.1469-7793.2001.0284f.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacey, M. G.</span></span> <span> </span><span class="NLM_article-title">A Postsynaptic Interaction between dopamine D1and NMDA receptors promotes presynaptic inhibition in the rat nucleus accumbens via adenosine release</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">5271</span>– <span class="NLM_lpage">5280</span>, <span class="refDoi"> DOI: 10.1523/jneurosci.17-14-05271.1997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1523%2Fjneurosci.17-14-05271.1997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=9204911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADyaK2sXksVSgtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1997&pages=5271-5280&author=J.+Harveyauthor=M.+G.+Lacey&title=A+Postsynaptic+Interaction+between+dopamine+D1and+NMDA+receptors+promotes+presynaptic+inhibition+in+the+rat+nucleus+accumbens+via+adenosine+release&doi=10.1523%2Fjneurosci.17-14-05271.1997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A postsynaptic interaction between dopamine D1 and NMDA receptors promotes presynaptic inhibition in the rat nucleus accumbens via adenosine release</span></div><div class="casAuthors">Harvey, Jenni; Lacey, Michael G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5271-5280</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The mechanism underlying dopamine D1 receptor-mediated attenuation of glutamatergic synaptic input to nucleus accumbens (NAcc) neurons was investigated in slices of rat forebrain, using whole-cell patch-clamp recording.  The depression by dopamine of EPSCs evoked by single-shock cortical stimulation was stimulus-dependent.  Synaptic activation of NMDA-type glutamate receptors was crit. for this effect, because dopamine-induced EPSC depressions were blocked by the competitive NMDA receptor antagonist D/L-2-amino-5-phosphonopentanoate (AP5).  Application of NMDA also depressed the EPSC, and both this effect and the dopamine depressions were blocked by the A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), implicating adenosine release in the EPSC depression.  A1 receptor agonists also depressed EPSCs by a presynaptic action, causing increased paired-pulse facilitation, but this was insensitive to AP5.  Activation of D1 receptors enhanced both postsynaptic inward currents evoked by NMDA application and the isolated NMDA receptor-mediated component of synaptic transmission.  The biochem. processes underlying the dopamine-induced EPSC depression did not involve either protein kinase A or the prodn. of cAMP and its metabolites, because this effect was resistant to the protein kinase inhibitors H89 and H7 and the cAMP-specific phosphodiesterase inhibitor rolipram.  We conclude that activation of postsynaptic D1 receptors enhances the synaptic activation of NMDA receptors in nucleus accumbens neurons, thereby promoting a transsynaptic feedback inhibition of glutamatergic synaptic transmission via release of adenosine.  Unusually for D1 receptors, this phenomenon occurs independently of adenylyl cyclase stimulation.  This process may contribute to the locomotor stimulant action of dopaminergic agents in the NAcc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod_Wz6t-JNQrVg90H21EOLACvtfcHk0lhWriojPIBmWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXksVSgtrc%253D&md5=578a0472a5475d5de5656b479ac8b846</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1523%2Fjneurosci.17-14-05271.1997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252Fjneurosci.17-14-05271.1997%26sid%3Dliteratum%253Aachs%26aulast%3DHarvey%26aufirst%3DJ.%26aulast%3DLacey%26aufirst%3DM.%2BG.%26atitle%3DA%2520Postsynaptic%2520Interaction%2520between%2520dopamine%2520D1and%2520NMDA%2520receptors%2520promotes%2520presynaptic%2520inhibition%2520in%2520the%2520rat%2520nucleus%2520accumbens%2520via%2520adenosine%2520release%26jtitle%3DJ.%2520Neurosci.%26date%3D1997%26volume%3D17%26spage%3D5271%26epage%3D5280%26doi%3D10.1523%2Fjneurosci.17-14-05271.1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciruela, F.</span></span> <span> </span><span class="NLM_article-title">Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2080</span>– <span class="NLM_lpage">2087</span>, <span class="refDoi"> DOI: 10.1523/jneurosci.3574-05.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1523%2Fjneurosci.3574-05.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=16481441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD28XitVansbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=2080-2087&author=F.+Ciruela&title=Presynaptic+control+of+striatal+glutamatergic+neurotransmission+by+adenosine+A1-A2A+receptor+heteromers&doi=10.1523%2Fjneurosci.3574-05.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers</span></div><div class="casAuthors">Ciruela, Francisco; Casado, Vicent; Rodrigues, Ricardo J.; Lujan, Rafael; Burgueno, Javier; Canals, Meritxell; Borycz, Janusz; Rebola, Nelson; Goldberg, Steven R.; Mallol, Josefa; Cortes, Antonio; Canela, Enric I.; Lopez-Gimenez, Juan F.; Milligan, Graeme; Lluis, Carme; Cunha, Rodrigo A.; Ferre, Sergi; Franco, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2080-2087</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The functional role of heteromers of G-protein-coupled receptors is a matter of debate.  In the present study, we demonstrate that heteromerization of adenosine A1 receptors (A1Rs) and A2A receptors (A2ARs) allows adenosine to exert a fine-tuning modulation of glutamatergic neurotransmission.  By means of coimmunopptn., bioluminescence and time-resolved fluorescence resonance energy transfer techniques, we showed the existence of A1R-A2AR heteromers in the cell surface of cotransfected cells.  Immunogold detection and coimmunopptn. expts. indicated that A1R and A2AR are colocalized in the same striatal glutamatergic nerve terminals.  Radioligand-binding expts. in cotransfected cells and rat striatum showed that a main biochem. characteristic of the A1R-A2AR heteromer is the ability of A2AR activation to reduce the affinity of the A1R for agonists.  This provides a switch mechanism by which low and high concns. of adenosine inhibit and stimulate, resp., glutamate release.  Furthermore, it is also shown that A1R-A2AR heteromers constitute a unique target for caffeine and that chronic caffeine treatment leads to modifications in the function of the A1R-A2AR heteromer that could underlie the strong tolerance to the psychomotor effects of caffeine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdjtEghr6th7Vg90H21EOLACvtfcHk0lhWriojPIBmWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitVansbo%253D&md5=0821e06c0c2f5880614e7f39963974d4</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1523%2Fjneurosci.3574-05.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252Fjneurosci.3574-05.2006%26sid%3Dliteratum%253Aachs%26aulast%3DCiruela%26aufirst%3DF.%26atitle%3DPresynaptic%2520control%2520of%2520striatal%2520glutamatergic%2520neurotransmission%2520by%2520adenosine%2520A1-A2A%2520receptor%2520heteromers%26jtitle%3DJ.%2520Neurosci.%26date%3D2006%26volume%3D26%26spage%3D2080%26epage%3D2087%26doi%3D10.1523%2Fjneurosci.3574-05.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soliman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fathalla, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moustafa, A. A.</span></span> <span> </span><span class="NLM_article-title">Adenosine role in brain functions: Pathophysiological influence on Parkinson’s disease and other brain disorders</span>. <i>Pharmacol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">661</span>– <span class="NLM_lpage">667</span>, <span class="refDoi"> DOI: 10.1016/j.pharep.2018.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.pharep.2018.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=29909246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFKlsbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2018&pages=661-667&author=A.+M.+Solimanauthor=A.+M.+Fathallaauthor=A.+A.+Moustafa&title=Adenosine+role+in+brain+functions%3A+Pathophysiological+influence+on+Parkinson%E2%80%99s+disease+and+other+brain+disorders&doi=10.1016%2Fj.pharep.2018.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine role in brain functions: Pathophysiological influence on Parkinson's disease and other brain disorders</span></div><div class="casAuthors">Soliman, Amira M.; Fathalla, Ahmed M.; Moustafa, Ahmed A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">661-667</span>CODEN:
                <span class="NLM_cas:coden">PRHEDU</span>;
        ISSN:<span class="NLM_cas:issn">2299-5684</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Although adenosine plays a key role in multiple motor, affective, and cognitive processes, it has received less attention in the neuroscience field compared to other neurotransmitters (e.g., dopamine).  In this review, we highlight the role of adenosine in behavior as well as its interaction with other neurotransmitters, such as dopamine.  We also discuss brain disorders impacted by alterations to adenosine, and how targeting adenosine can ameliorate Parkinson's disease motor symptoms.  We also discuss the role of caffeine (as an adenosine antagonist) on cognition as well as a neuroprotective agent against Parkinson's disease (PD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7_4b-G0k3RbVg90H21EOLACvtfcHk0lgi3opn_ZKwSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFKlsbrK&md5=eb5e4a41ab87c49926b3b624dad7fa2c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.pharep.2018.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharep.2018.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DSoliman%26aufirst%3DA.%2BM.%26aulast%3DFathalla%26aufirst%3DA.%2BM.%26aulast%3DMoustafa%26aufirst%3DA.%2BA.%26atitle%3DAdenosine%2520role%2520in%2520brain%2520functions%253A%2520Pathophysiological%2520influence%2520on%2520Parkinson%25E2%2580%2599s%2520disease%2520and%2520other%2520brain%2520disorders%26jtitle%3DPharmacol.%2520Rep.%26date%3D2018%26volume%3D70%26spage%3D661%26epage%3D667%26doi%3D10.1016%2Fj.pharep.2018.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simola, N.</span></span> <span> </span><span class="NLM_article-title">Role of adenosine A2A receptors in motor control: Relevance to Parkinson’s disease and dyskinesia</span>. <i>J. Neural. Transm.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1273</span>– <span class="NLM_lpage">1286</span>, <span class="refDoi"> DOI: 10.1007/s00702-018-1848-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1007%2Fs00702-018-1848-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=29396609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit12hsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2018&pages=1273-1286&author=A.+Pinnaauthor=M.+Serraauthor=M.+Morelliauthor=N.+Simola&title=Role+of+adenosine+A2A+receptors+in+motor+control%3A+Relevance+to+Parkinson%E2%80%99s+disease+and+dyskinesia&doi=10.1007%2Fs00702-018-1848-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Role of adenosine A2A receptors in motor control: relevance to Parkinson's disease and dyskinesia</span></div><div class="casAuthors">Pinna, Annalisa; Serra, Marcello; Morelli, Micaela; Simola, Nicola</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neural Transmission</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1273-1286</span>CODEN:
                <span class="NLM_cas:coden">JNTRF3</span>;
        ISSN:<span class="NLM_cas:issn">0300-9564</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag GmbH</span>)
        </div><div class="casAbstract">A review.  Adenosine is an endogenous purine nucleoside that regulates several physiol. functions, at the central and peripheral levels.  Besides, adenosine has emerged as a major player in the regulation of motor behavior.  In fact, adenosine receptors of the A2A subtype are highly enriched in the caudate-putamen, which is richly innervated by dopamine.  Moreover, several studies in exptl. animals have consistently demonstrated that the pharmacol. antagonism of A2A receptors has a facilitatory influence on motor behavior.  Taken together, these findings have envisaged A2A receptors as a promising target for symptomatic therapies aimed at ameliorating motor deficits.  Accordingly, A2A receptor antagonists have been extensively studied as new agents for the treatment of Parkinson's disease (PD), the epitome of motor disorders.  In this review, we provide an overview of the effects that adenosine A2A receptor antagonists elicit in rodent and primate exptl. models of PD, with regard to the counteraction of motor deficits as well as to manifestation of dyskinesia and motor fluctuations.  Moreover, we briefly present the results of clin. trials of A2A receptor antagonists in PD patients experiencing motor fluctuations, with particular regard to dyskinesia.  Finally, we discuss the interaction between A2A receptor antagonists and serotonin receptor agonists, since combined administration of these drugs has recently emerged as a new potential therapeutic strategy in the treatment of dyskinesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCLiOGmgbfiLVg90H21EOLACvtfcHk0lgi3opn_ZKwSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit12hsLw%253D&md5=865076b4e6d3843701fbcda45af0e565</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs00702-018-1848-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00702-018-1848-6%26sid%3Dliteratum%253Aachs%26aulast%3DPinna%26aufirst%3DA.%26aulast%3DSerra%26aufirst%3DM.%26aulast%3DMorelli%26aufirst%3DM.%26aulast%3DSimola%26aufirst%3DN.%26atitle%3DRole%2520of%2520adenosine%2520A2A%2520receptors%2520in%2520motor%2520control%253A%2520Relevance%2520to%2520Parkinson%25E2%2580%2599s%2520disease%2520and%2520dyskinesia%26jtitle%3DJ.%2520Neural.%2520Transm.%26date%3D2018%26volume%3D125%26spage%3D1273%26epage%3D1286%26doi%3D10.1007%2Fs00702-018-1848-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burnstock, G.</span></span> <span> </span><span class="NLM_article-title">Purinergic signalling: From discovery to current developments</span>. <i>Exp. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1113/expphysiol.2013.071951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1113%2Fexpphysiol.2013.071951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=24078669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotFWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2014&pages=16-34&author=G.+Burnstock&title=Purinergic+signalling%3A+From+discovery+to+current+developments&doi=10.1113%2Fexpphysiol.2013.071951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Purinergic signalling: from discovery to current developments</span></div><div class="casAuthors">Burnstock, Geoffrey</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Physiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-34</span>CODEN:
                <span class="NLM_cas:coden">EXPHEZ</span>;
        ISSN:<span class="NLM_cas:issn">1469-445X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  New Findings : What is the topic of this review This is a personal historical review about the discovery and the main conceptual advances leading to our current understanding of purinergic signalling.  The contributions of leading figures in the field are acknowledged.  It includes the discovery of purinergic neuromuscular and synaptic transmission, cotransmission, the identification of P1 (adenosine), P2X nucleotide ion channel and P2Y nucleotide G protein-coupled receptors, the identity of ectonucleotidases and release of ATP from cells by mech. stimulation and mechanosensory transduction.  What advances does it highlight It highlights the pathophysiol. of purinergic signalling and recent therapeutic developments.  This lecture is about the history of the purinergic signalling concept.  It begins with ref. to the paper by Paton & Vane published in 1963, which identified non-cholinergic relaxation in response to vagal nerve stimulation in several species, although they suggested that it might be due to sympathetic adrenergic nerves in the vagal nerve trunk.  Using the sucrose gap technique for simultaneous mech. and elec. recordings in smooth muscle (developed while in Feldberg's department in the National Institute for Medical Research) of the guinea-pig taenia coli prepn. (learned when working in Edith Buelbring's smooth muscle lab. in Oxford Pharmacol.), we showed that the hyperpolarizations recorded in the presence of antagonists to the classical autonomic neurotransmitters, acetylcholine and noradrenaline, were inhibitory junction potentials in response to non-adrenergic, non-cholinergic neurotransmission, mediated by intrinsic enteric nerves controlled by vagal and sacral parasympathetic nerves.  We then showed that ATP satisfied the criteria needed to identify a neurotransmitter released by these nerves.  Subsequently, it was shown that ATP is a cotransmitter in all nerves in the peripheral and central nervous systems.  The receptors for purines and pyrimidines were cloned and characterized in the early 1990s, and immunostaining showed that most non-neuronal cells as well as nerve cells expressed these receptors.  The physiol. and pathophysiol. of purinergic signalling is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFkHtMEJezobVg90H21EOLACvtfcHk0lgMXqMj2SQVXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotFWgug%253D%253D&md5=98641f7884ee39473288dc5c1d264f7a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1113%2Fexpphysiol.2013.071951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1113%252Fexpphysiol.2013.071951%26sid%3Dliteratum%253Aachs%26aulast%3DBurnstock%26aufirst%3DG.%26atitle%3DPurinergic%2520signalling%253A%2520From%2520discovery%2520to%2520current%2520developments%26jtitle%3DExp.%2520Physiol.%26date%3D2014%26volume%3D99%26spage%3D16%26epage%3D34%26doi%3D10.1113%2Fexpphysiol.2013.071951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrejew, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira-Giacomelli, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonfim
Marques, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semyanov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, H.</span></span> <span> </span><span class="NLM_article-title">Purinergic receptors in basal ganglia diseases: Shared molecular mechanisms between Huntington’s and Parkinson’s disease</span>. <i>Neurosci. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1299</span>– <span class="NLM_lpage">1314</span>, <span class="refDoi"> DOI: 10.1007/s12264-020-00582-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1007%2Fs12264-020-00582-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=33026587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BB3s%252FosV2gtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2020&pages=1299-1314&author=T.+Glaserauthor=R.+Andrejewauthor=%C3%81.+Oliveira-Giacomelliauthor=D.+E.+Ribeiroauthor=L.+Bonfim%0AMarquesauthor=Q.+Yeauthor=W.-J.+Renauthor=A.+Semyanovauthor=P.+Illesauthor=Y.+Tangauthor=H.+Ulrich&title=Purinergic+receptors+in+basal+ganglia+diseases%3A+Shared+molecular+mechanisms+between+Huntington%E2%80%99s+and+Parkinson%E2%80%99s+disease&doi=10.1007%2Fs12264-020-00582-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Purinergic Receptors in Basal Ganglia Diseases: Shared Molecular Mechanisms between Huntington's and Parkinson's Disease</span></div><div class="casAuthors">Glaser Talita; Andrejew Roberta; Oliveira-Giacomelli Agatha; Ribeiro Deidiane Elisa; Bonfim Marques Lucas; Ye Qing; Ulrich Henning; Ye Qing; Ren Wen-Jing; Tang Yong; Ren Wen-Jing; Illes Peter; Semyanov Alexey; Semyanov Alexey; Illes Peter; Tang Yong</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience bulletin</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1299-1314</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Huntington's (HD) and Parkinson's diseases (PD) are neurodegenerative disorders caused by the death of GABAergic and dopaminergic neurons in the basal ganglia leading to hyperkinetic and hypokinetic symptoms, respectively.  We review here the participation of purinergic receptors through intracellular Ca(2+) signaling in these neurodegenerative diseases.  The adenosine A2A receptor stimulates striatopallidal GABAergic neurons, resulting in inhibitory actions on GABAergic neurons of the globus pallidus.  A2A and dopamine D2 receptors form functional heteromeric complexes inducing allosteric inhibition, and A2A receptor activation results in motor inhibition.  Furthermore, the A2A receptor physically and functionally interacts with glutamate receptors, mainly with the mGlu5 receptor subtype.  This interaction facilitates glutamate release, resulting in NMDA glutamate receptor activation and an increase of Ca(2+) influx.  P2X7 receptor activation also promotes glutamate release and neuronal damage.  Thus, modulation of purinergic receptor activity, such as A2A and P2X7 receptors, and subsequent aberrant Ca(2+) signaling, might present interesting therapeutic potential for HD and PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSMij9artkVcZagfuraLLzSfW6udTcc2eYWqTkMYJexQbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3s%252FosV2gtQ%253D%253D&md5=2f47937d51c70ee9f0e8747b8b475f43</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs12264-020-00582-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12264-020-00582-8%26sid%3Dliteratum%253Aachs%26aulast%3DGlaser%26aufirst%3DT.%26aulast%3DAndrejew%26aufirst%3DR.%26aulast%3DOliveira-Giacomelli%26aufirst%3D%25C3%2581.%26aulast%3DRibeiro%26aufirst%3DD.%2BE.%26aulast%3DBonfim%2BMarques%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DRen%26aufirst%3DW.-J.%26aulast%3DSemyanov%26aufirst%3DA.%26aulast%3DIlles%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DUlrich%26aufirst%3DH.%26atitle%3DPurinergic%2520receptors%2520in%2520basal%2520ganglia%2520diseases%253A%2520Shared%2520molecular%2520mechanisms%2520between%2520Huntington%25E2%2580%2599s%2520and%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurosci.%2520Bull.%26date%3D2020%26volume%3D36%26spage%3D1299%26epage%3D1314%26doi%3D10.1007%2Fs12264-020-00582-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wichmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Factor, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLong, M. R.</span></span> <span> </span><span class="NLM_article-title">Parkinson’s disease therapeutics: New developments and challenges since the introduction of Levodopa</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.1038/npp.2011.212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1038%2Fnpp.2011.212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=21956442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ejsrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2012&pages=213-246&author=Y.+Smithauthor=T.+Wichmannauthor=S.+A.+Factorauthor=M.+R.+DeLong&title=Parkinson%E2%80%99s+disease+therapeutics%3A+New+developments+and+challenges+since+the+introduction+of+Levodopa&doi=10.1038%2Fnpp.2011.212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa</span></div><div class="casAuthors">Smith, Yoland; Wichmann, Thomas; Factor, Stewart A.; DeLong, Mahlon R.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">213-246</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The demonstration that dopamine loss is the key pathol. feature of Parkinson's disease (PD), and the subsequent introduction of levodopa have revolutionalized the field of PD therapeutics.  This review will discuss the significant progress that has been made in the development of new pharmacol. and surgical tools to treat PD motor symptoms since this major breakthrough in the 1960s.  However, we will also highlight some of the challenges the field of PD therapeutics has been struggling with during the past decades.  The lack of neuroprotective therapies and the limited treatment strategies for the nonmotor symptoms of the disease (ie, cognitive impairments, autonomic dysfunctions, psychiatric disorders, etc.) are among the most pressing issues to be addressed in the years to come.  It appears that the combination of early PD nonmotor symptoms with imaging of the nigrostriatal dopaminergic system offers a promising path toward the identification of PD biomarkers, which, once characterized, will set the stage for efficient use of neuroprotective agents that could slow down and alter the course of the disease.  Neuropsychopharmacol. Reviews (2012) 37, 213-246; doi:10.1038/npp.2011.212; published online 28 Sept. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKGa2hNY5gcbVg90H21EOLACvtfcHk0lgMXqMj2SQVXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ejsrbF&md5=d1e259530039c7e35aae30f77a939fe6</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2011.212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2011.212%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DY.%26aulast%3DWichmann%26aufirst%3DT.%26aulast%3DFactor%26aufirst%3DS.%2BA.%26aulast%3DDeLong%26aufirst%3DM.%2BR.%26atitle%3DParkinson%25E2%2580%2599s%2520disease%2520therapeutics%253A%2520New%2520developments%2520and%2520challenges%2520since%2520the%2520introduction%2520of%2520Levodopa%26jtitle%3DNeuropsychopharmacology%26date%3D2012%26volume%3D37%26spage%3D213%26epage%3D246%26doi%3D10.1038%2Fnpp.2011.212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blesa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trigo-Damas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dileone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">del Rey, N. L.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeso, J. A.</span></span> <span> </span><span class="NLM_article-title">Compensatory mechanisms in Parkinson’s disease: Circuits adaptations and role in disease modification</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>298</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1016/j.expneurol.2017.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.expneurol.2017.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=28987461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1aisLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2017&pages=148-161&author=J.+Blesaauthor=I.+Trigo-Damasauthor=M.+Dileoneauthor=N.+L.-G.+del+Reyauthor=L.+F.+Hernandezauthor=J.+A.+Obeso&title=Compensatory+mechanisms+in+Parkinson%E2%80%99s+disease%3A+Circuits+adaptations+and+role+in+disease+modification&doi=10.1016%2Fj.expneurol.2017.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Compensatory mechanisms in Parkinson's disease: Circuits adaptations and role in disease modification</span></div><div class="casAuthors">Blesa, Javier; Trigo-Damas, Ines; Dileone, Michele; Lopez-Gonzalez el Rey, Natalia; Hernandez, Ledia F.; Obeso, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">Part_B</span>),
    <span class="NLM_cas:pages">148-161</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The motor features of Parkinson's disease (PD) are well known to manifest only when striatal dopaminergic deficit reaches 60-70%.  Thus, PD has a long pre-symptomatic and pre-motor evolution during which compensatory mechanisms take place to delay the clin. onset of disabling manifestations.  Classic compensatory mechanisms have been attributed to changes and adjustments in the nigro-striatal system, such as increased neuronal activity in the substantia nigra pars compacta and enhanced dopamine synthesis and release in the striatum.  However, it is not so clear currently that such changes occur early enough to account for the pre-symptomatic period.  Other possible mechanisms relate to changes in basal ganglia and motor cortical circuits including the cerebellum.  However, data from early PD patients are difficult to obtain as most studies have been carried out once the diagnosis and treatments have been established.  Likewise, putative compensatory mechanisms taking place throughout disease evolution are nearly impossible to distinguish by themselves.  Here, we review the evidence for the role of the best known and other possible compensatory mechanisms in PD.  We also discuss the possibility that, although beneficial in practical terms, compensation could also play a deleterious role in disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE1Vg834LycrVg90H21EOLACvtfcHk0lgQZXcIulHSNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1aisLnI&md5=ae8f6cf84c0ab502194f7c9e817f0c88</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.expneurol.2017.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.expneurol.2017.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DBlesa%26aufirst%3DJ.%26aulast%3DTrigo-Damas%26aufirst%3DI.%26aulast%3DDileone%26aufirst%3DM.%26aulast%3Ddel%2BRey%26aufirst%3DN.%2BL.-G.%26aulast%3DHernandez%26aufirst%3DL.%2BF.%26aulast%3DObeso%26aufirst%3DJ.%2BA.%26atitle%3DCompensatory%2520mechanisms%2520in%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520Circuits%2520adaptations%2520and%2520role%2520in%2520disease%2520modification%26jtitle%3DExp.%2520Neurol.%26date%3D2017%26volume%3D298%26spage%3D148%26epage%3D161%26doi%3D10.1016%2Fj.expneurol.2017.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferré, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuxe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">B. Fredholm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popoli, P.</span></span> <span> </span><span class="NLM_article-title">Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia</span>. <i>Trends Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">482</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1016/s0166-2236(97)01096-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fs0166-2236%2897%2901096-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=9347617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADyaK2sXmsFKisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1997&pages=482-487&author=S.+Ferr%C3%A9author=K.+Fuxeauthor=B.+B.+Fredholmauthor=M.+Morelliauthor=P.+Popoli&title=Adenosine-dopamine+receptor-receptor+interactions+as+an+integrative+mechanism+in+the+basal+ganglia&doi=10.1016%2Fs0166-2236%2897%2901096-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia</span></div><div class="casAuthors">Ferre, Sergi; Fredholm, Bertil B.; Morelli, Micaela; Popoli, Patrizia; Fuxe, Kjell</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Neurosciences</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">482-487</span>CODEN:
                <span class="NLM_cas:coden">TNSCDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-2236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review, with 48 refs.  Increasing evidence suggests that antagonistic interactions between specific subtypes of adenosine and dopamine receptors in the basal ganglia are involved in the motor depressant effects of adenosine receptor agonists and the motor stimulant effects of adenosine receptor antagonists, such as caffeine.  The GABAergic striatopallidal neurons are regulated by interacting adenosine A2A and dopamine D2 receptors.  The GABAergic striatonigral and striatoentopeduncular neurons seem to be regulated by interacting adenosine A1 and dopamine D1 receptors.  Furthermore, behavioral studies have revealed interactions between adenosine A2A and dopamine D1 receptors that occur at the network level.  These adenosine-dopamine receptor-receptor interactions might offer new therapeutic leads for basal ganglia disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq79FXLvi2_orVg90H21EOLACvtfcHk0lgQZXcIulHSNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsFKisr4%253D&md5=986e1e4f2207c6844f000db83557cca8</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fs0166-2236%2897%2901096-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0166-2236%252897%252901096-5%26sid%3Dliteratum%253Aachs%26aulast%3DFerr%25C3%25A9%26aufirst%3DS.%26aulast%3DFuxe%26aufirst%3DK.%26aulast%3DB.%2BFredholm%26aufirst%3DB.%26aulast%3DMorelli%26aufirst%3DM.%26aulast%3DPopoli%26aufirst%3DP.%26atitle%3DAdenosine-dopamine%2520receptor-receptor%2520interactions%2520as%2520an%2520integrative%2520mechanism%2520in%2520the%2520basal%2520ganglia%26jtitle%3DTrends%2520Neurosci.%26date%3D1997%26volume%3D20%26spage%3D482%26epage%3D487%26doi%3D10.1016%2Fs0166-2236%2897%2901096-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fuxe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcellino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genedani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agnati, L.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptors, dopamine D2 receptors and their interactions in Parkinson’s disease</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1990</span>– <span class="NLM_lpage">2017</span>, <span class="refDoi"> DOI: 10.1002/mds.21440</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2Fmds.21440" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=17618524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BD2snlt1ehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2007&pages=1990-2017&author=K.+Fuxeauthor=D.+Marcellinoauthor=S.+Genedaniauthor=L.+Agnati&title=Adenosine+A2A+receptors%2C+dopamine+D2+receptors+and+their+interactions+in+Parkinson%E2%80%99s+disease&doi=10.1002%2Fmds.21440"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease</span></div><div class="casAuthors">Fuxe Kjell; Marcellino Daniel; Genedani Susanna; Agnati Luigi</div><div class="citationInfo"><span class="NLM_cas:title">Movement disorders : official journal of the Movement Disorder Society</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1990-2017</span>
        ISSN:<span class="NLM_cas:issn">0885-3185</span>.
    </div><div class="casAbstract">Future therapies in Parkinson's disease may substantially build on the existence of intra-membrane receptor-receptor interactions in DA receptor containing heteromeric receptor complexes.  The A(2A)/D(2) heteromer is of substantial interest in view of its specific location in cortico-striatal glutamate terminals and in striato-pallidal GABA neurons.  Antagonistic A(2A)/D(2) receptor interactions in this heteromer demonstrated at the cellular level, and at the level of the striato-pallidal GABA neuron and at the network level made it possible to suggest A(2A) antagonists as anti-parkinsonian drugs.  The major mechanism is an enhancement of D(2) signaling leading to attenuation of hypokinesia, tremor, and rigidity in models of Parkinson's disease with inspiring results in two clinical trials.  Other interactions are antagonism at the level of the adenylyl cyclase; heterologous sensitization at the A(2A) activated adenylyl cyclase by persistent D(2) activation and a compensatory up-regulation of A(2A) receptors in response to intermittent Levodopa treatment.  An increased dominance of A(2A) homomers over D(2) homomers and A(2A)/D(2) heteromers after intermittent Levodopa treatment may therefore contribute to development of Levodopa induced dyskinesias and to the wearing off of the therapeutic actions of Levodopa giving additional therapeutic roles of A(2A) antagonists.  Their neuroprotective actions may involve an increase in the retrograde trophic signaling in the nigro-striatal DA system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8MLoYMOhuTUewzGPswiWOfW6udTcc2ebKbIb_8BYribntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2snlt1ehug%253D%253D&md5=ef97216335cccae8e8c87baa7ff2fe8e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fmds.21440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.21440%26sid%3Dliteratum%253Aachs%26aulast%3DFuxe%26aufirst%3DK.%26aulast%3DMarcellino%26aufirst%3DD.%26aulast%3DGenedani%26aufirst%3DS.%26aulast%3DAgnati%26aufirst%3DL.%26atitle%3DAdenosine%2520A2A%2520receptors%252C%2520dopamine%2520D2%2520receptors%2520and%2520their%2520interactions%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DMov.%2520Disord.%26date%3D2007%26volume%3D22%26spage%3D1990%26epage%3D2017%26doi%3D10.1002%2Fmds.21440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarzschild, M.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential of adenosine A2A receptor antagonists in Parkinson’s disease</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">310</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2004.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.pharmthera.2004.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=15737407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhvVCjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=267-310&author=K.+Xuauthor=E.+Bastiaauthor=M.+Schwarzschild&title=Therapeutic+potential+of+adenosine+A2A+receptor+antagonists+in+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.pharmthera.2004.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease</span></div><div class="casAuthors">Xu, Kui; Bastia, Elena; Schwarzschild, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">267-310</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In the pursuit of improved treatments for Parkinson's disease (PD), the adenosine A2A receptor has emerged as an attractive nondopaminergic target.  Based on the compelling behavioral pharmacol. and selective basal ganglia expression of this G-protein-coupled receptor, its antagonists are now crossing the threshold of clin. development as adjunctive symptomatic treatment for relatively advanced PD.  The antiparkinsonian potential of A2A antagonism has been boosted further by recent preclin. evidence that A2A antagonists might favorably alter the course as well as the symptoms of the disease.  Convergent epidemiol. and lab. data have suggested that A2A blockade may confer neuroprotection against the underlying dopaminergic neuron degeneration.  In addn., rodent and nonhuman primate studies have raised the possibility that A2A receptor activation contributes to the pathophysiol. of dyskinesias-problematic motor complications of std. PD therapy-and that A2A antagonism might help prevent them.  Realistically, despite being targeted to basal ganglia pathophysiol., A2A antagonists may be expected to have other beneficial and adverse effects elsewhere in the central nervous system (e.g., on mood and sleep) and in the periphery (e.g., on immune and inflammatory processes).  The thoughtful design of new clin. trials of A2A antagonists should take into consideration these counterbalancing hopes and concerns and may do well to shift toward a broader set of disease-modifying as well as symptomatic indications in early PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3HbF9ZxHP3bVg90H21EOLACvtfcHk0lh9V1oBIk7m0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhvVCjt7s%253D&md5=ca493d29bdda09382108c0566a3a0877</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2004.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2004.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DK.%26aulast%3DBastia%26aufirst%3DE.%26aulast%3DSchwarzschild%26aufirst%3DM.%26atitle%3DTherapeutic%2520potential%2520of%2520adenosine%2520A2A%2520receptor%2520antagonists%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DPharmacol.%2520Ther.%26date%3D2005%26volume%3D105%26spage%3D267%26epage%3D310%26doi%3D10.1016%2Fj.pharmthera.2004.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Armentero, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferré, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanciego, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, R.</span></span> <span> </span><span class="NLM_article-title">Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson’s disease</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">280</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2011.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.pharmthera.2011.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=21810444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2ntrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2011&pages=280-299&author=M.+T.+Armenteroauthor=A.+Pinnaauthor=S.+Ferr%C3%A9author=J.+L.+Lanciegoauthor=C.+E.+M%C3%BCllerauthor=R.+Franco&title=Past%2C+present+and+future+of+A2A+adenosine+receptor+antagonists+in+the+therapy+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.pharmthera.2011.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease</span></div><div class="casAuthors">Armentero, Marie Therese; Pinna, Annalisa; Ferre, Sergi; Lanciego, Jose Luis; Mueller, Christa E.; Franco, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">280-299</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Several selective antagonists for adenosine A2A receptors (A2AR) are currently under evaluation in clin. trials (phases I to III) to treat Parkinson's disease, and they will probably soon reach the market.  The usefulness of these antagonists has been deduced from studies demonstrating functional interactions between dopamine D2 and adenosine A2A receptors in the basal ganglia.  At present it is believed that A2AR antagonists can be used in combination with the dopamine precursor L-DOPA to minimize the motor symptoms of Parkinson's patients.  However, a considerable body of data indicates that in addn. to ameliorating motor symptoms, adenosine A2AR antagonists may also prevent neurodegeneration.  Despite these promising indications, one further issue must be considered in order to develop fully optimized antiparkinsonian drug therapy, namely the existence of (hetero)dimers/oligomers of G protein-coupled receptors, a topic that is currently the focus of intense debate within the scientific community.  Dopamine D2 receptors (D2Rs) expressed in the striatum are known to form heteromers with A2A adenosine receptors.  Thus, the development of heteromer-specific A2A receptor antagonists represents a promising strategy for the identification of more selective and safer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2pOYdmdfQMLVg90H21EOLACvtfcHk0lj56Uok5uA2Qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2ntrzP&md5=39fa871338516f7574deb7845029e624</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2011.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2011.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DArmentero%26aufirst%3DM.%2BT.%26aulast%3DPinna%26aufirst%3DA.%26aulast%3DFerr%25C3%25A9%26aufirst%3DS.%26aulast%3DLanciego%26aufirst%3DJ.%2BL.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DFranco%26aufirst%3DR.%26atitle%3DPast%252C%2520present%2520and%2520future%2520of%2520A2A%2520adenosine%2520receptor%2520antagonists%2520in%2520the%2520therapy%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DPharmacol.%2520Ther.%26date%3D2011%26volume%3D132%26spage%3D280%26epage%3D299%26doi%3D10.1016%2Fj.pharmthera.2011.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Waarde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dierckx, R. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanapur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishiwata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luurtsema, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, E. F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsinga, P. H.</span></span> <span> </span><span class="NLM_article-title">Potential therapeutic applications of adenosine A2A receptor ligands and opportunities for A2A receptor imaging</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1002/med.21432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2Fmed.21432" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2017&pages=5-53&author=A.+Van%0AWaardeauthor=R.+A.+J.+Dierckxauthor=X.+Zhouauthor=S.+Khanapurauthor=H.+Tsukadaauthor=K.+Ishiwataauthor=G.+Luurtsemaauthor=E.+F.+J.+de+Vriesauthor=P.+H.+Elsinga&title=Potential+therapeutic+applications+of+adenosine+A2A+receptor+ligands+and+opportunities+for+A2A+receptor+imaging&doi=10.1002%2Fmed.21432"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fmed.21432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21432%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BWaarde%26aufirst%3DA.%26aulast%3DDierckx%26aufirst%3DR.%2BA.%2BJ.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DKhanapur%26aufirst%3DS.%26aulast%3DTsukada%26aufirst%3DH.%26aulast%3DIshiwata%26aufirst%3DK.%26aulast%3DLuurtsema%26aufirst%3DG.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BF.%2BJ.%26aulast%3DElsinga%26aufirst%3DP.%2BH.%26atitle%3DPotential%2520therapeutic%2520applications%2520of%2520adenosine%2520A2A%2520receptor%2520ligands%2520and%2520opportunities%2520for%2520A2A%2520receptor%2520imaging%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2017%26volume%3D1%26spage%3D5%26epage%3D53%26doi%3D10.1002%2Fmed.21432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelsey, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langelier, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oriel, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reedy, C.</span></span> <span> </span><span class="NLM_article-title">The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>201</i></span>,  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">539</span>, <span class="refDoi"> DOI: 10.1007/s00213-008-1319-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1007%2Fs00213-008-1319-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=18791705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1OntLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=2009&pages=529-539&author=J.+E.+Kelseyauthor=N.+A.+Langelierauthor=B.+S.+Orielauthor=C.+Reedy&title=The+effects+of+systemic%2C+intrastriatal%2C+and+intrapallidal+injections+of+caffeine+and+systemic+injections+of+A2A+and+A1+antagonists+on+forepaw+stepping+in+the+unilateral+6-OHDA-lesioned+rat&doi=10.1007%2Fs00213-008-1319-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat</span></div><div class="casAuthors">Kelsey, John E.; Langelier, Nicole A.; Oriel, Brad S.; Reedy, Catherine</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">201</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">529-539</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Rationale and objectives: Given that adenosine A2A antagonists appear to be therapeutic in several animal models of Parkinson's disease (PD), we examd. the extent to which caffeine and selective A2A and A1 antagonists could enhance contralateral forepaw stepping in the unilateral 6-OHDA-lesioned rat.  Materials and methods: Following unilateral injections of 12 μg 6-OHDA into the medial forebrain bundle (MFB), frequency of stepping with both front paws was counted sep. as the paws were dragged anteriorally and laterally by a treadmill.  Results: The MFB lesions decreased contralateral stepping by 74-83%, and 8 mg/kg 3,4-dihydroxy-L-phenylalanine (L-DOPA) increased contralateral stepping by 25-26%.  Caffeine given systemically (15 mg/kg) or into the dorsal striatum or external globus pallidus (GPE; 20-40 μg) increased contralateral forepaw stepping by 14%, 27%, and 26%, resp., and enhanced the effect of 8 mg/kg L-DOPA on stepping.  The selective A2A antagonist SCH-58261 (2 mg/kg) also increased stepping by 13% and enhanced the therapeutic effect of L-DOPA, whereas the selective A2A antagonist 8-cyclopentyltheophylline (3-7 mg/kg) and A1 agonist N6-cyclopentyladenosine (0.03-0.2 mg/kg) had no effect.  None of these drugs appeared to produce dyskinesic effects.  Conclusions: In this well-validated animal model of the akinesic effects of PD, caffeine and a selective A2A, but not an A1, antagonist were able to provide both monotherapeutic and adjunctive therapeutic effects.  These data are consistent with the hypothesis that A2A antagonists may be therapeutic in human PD patients and indicate that the dorsal striatum and GPE are crit. sites of therapeutic action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqITkClJvQ1rVg90H21EOLACvtfcHk0lj56Uok5uA2Qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1OntLzN&md5=407f6d6693949eea54c8c6110e44ce1f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs00213-008-1319-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-008-1319-0%26sid%3Dliteratum%253Aachs%26aulast%3DKelsey%26aufirst%3DJ.%2BE.%26aulast%3DLangelier%26aufirst%3DN.%2BA.%26aulast%3DOriel%26aufirst%3DB.%2BS.%26aulast%3DReedy%26aufirst%3DC.%26atitle%3DThe%2520effects%2520of%2520systemic%252C%2520intrastriatal%252C%2520and%2520intrapallidal%2520injections%2520of%2520caffeine%2520and%2520systemic%2520injections%2520of%2520A2A%2520and%2520A1%2520antagonists%2520on%2520forepaw%2520stepping%2520in%2520the%2520unilateral%25206-OHDA-lesioned%2520rat%26jtitle%3DPsychopharmacology%26date%3D2009%26volume%3D201%26spage%3D529%26epage%3D539%26doi%3D10.1007%2Fs00213-008-1319-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takuma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyoshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizoguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, S.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-parkinsonian mouse model</span>. <i>J. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1254/jphs.scz070058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1254%2Fjphs.scz070058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=17341841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1KltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2007&pages=329-332&author=T.+Matsuyaauthor=K.+Takumaauthor=K.+Satoauthor=M.+Asaiauthor=Y.+Murakamiauthor=S.+Miyoshiauthor=A.+Nodaauthor=T.+Nagaiauthor=H.+Mizoguchiauthor=S.+Nishimura&title=Synergistic+effects+of+adenosine+A2A+antagonist+and+L-DOPA+on+rotational+behaviors+in+6-hydroxydopamine-induced+hemi-parkinsonian+mouse+model&doi=10.1254%2Fjphs.scz070058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model</span></div><div class="casAuthors">Matsuya, Takahiro; Takuma, Kazuhiro; Sato, Kosuke; Asai, Makoto; Murakami, Yoshihiro; Miyoshi, Sosuke; Noda, Akihiro; Nagai, Taku; Mizoguchi, Hiroyuki; Nishimura, Shintaro; Yamada, Kiyofumi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-332</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">In this study, we examd. the combination effects of L-DOPA and adenosine receptor antagonists on rotational behaviors in a hemi-Parkinsonian mouse model induced by unilateral 6-hydroxydopamine (6-OHDA) injection.  The adenosine A2A antagonist SCH-58261, but not the A1-receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine or A2B-receptor antagonist alloxazine, synergistically potentiated the L-DOPA-induced rotational behaviors in the 6-OHDA-lesioned mice.  In addn., the 6-OHDA-induced lesions of the dopaminergic system did not affect the in vivo binding of an adenosine A2A-receptor tracer [11C]SCH-442416 in the striatum.  These findings suggest that adenosine A2A antagonists are extremely useful for pharmacotherapy of L-DOPA in Parkinson's disease patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzL_z0WuyimLVg90H21EOLACvtfcHk0lhitZDdC__Y8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1KltLk%253D&md5=76b850e339b9af4668ca4c177ef34825</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1254%2Fjphs.scz070058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjphs.scz070058%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuya%26aufirst%3DT.%26aulast%3DTakuma%26aufirst%3DK.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DAsai%26aufirst%3DM.%26aulast%3DMurakami%26aufirst%3DY.%26aulast%3DMiyoshi%26aufirst%3DS.%26aulast%3DNoda%26aufirst%3DA.%26aulast%3DNagai%26aufirst%3DT.%26aulast%3DMizoguchi%26aufirst%3DH.%26aulast%3DNishimura%26aufirst%3DS.%26atitle%3DSynergistic%2520effects%2520of%2520adenosine%2520A2A%2520antagonist%2520and%2520L-DOPA%2520on%2520rotational%2520behaviors%2520in%25206-hydroxydopamine-induced%2520hemi-parkinsonian%2520mouse%2520model%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2007%26volume%3D103%26spage%3D329%26epage%3D332%26doi%3D10.1254%2Fjphs.scz070058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collins, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galtieri, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennum, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sager, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hockemeyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrobak, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salamone, J. D.</span></span> <span> </span><span class="NLM_article-title">Oral tremor induced by the muscarinic agonist pilocarpine is suppressed by the adenosine A2A antagonists MSX-3 and SCH58261, but not the adenosine A1 antagonist DPCPX</span>. <i>Pharmacol. Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">569</span>, <span class="refDoi"> DOI: 10.1016/j.pbb.2009.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.pbb.2009.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=19958787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVans7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2010&pages=561-569&author=L.+E.+Collinsauthor=D.+J.+Galtieriauthor=L.+T.+Brennumauthor=T.+N.+Sagerauthor=J.+Hockemeyerauthor=C.+E.+M%C3%BCllerauthor=J.+R.+Hinmanauthor=J.+J.+Chrobakauthor=J.+D.+Salamone&title=Oral+tremor+induced+by+the+muscarinic+agonist+pilocarpine+is+suppressed+by+the+adenosine+A2A+antagonists+MSX-3+and+SCH58261%2C+but+not+the+adenosine+A1+antagonist+DPCPX&doi=10.1016%2Fj.pbb.2009.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Oral tremor induced by the muscarinic agonist pilocarpine is suppressed by the adenosine A2A antagonists MSX-3 and SCH58261, but not the adenosine A1 antagonist DPCPX</span></div><div class="casAuthors">Collins, Lyndsey E.; Galtieri, Daniel J.; Brennum, Lise T.; Sager, Thomas N.; Hockemeyer, Joerg; Mueller, Christa E.; Hinman, James R.; Chrobak, James J.; Salamone, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">561-569</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Tremulous jaw movements in rats, which can be induced by dopamine (DA) antagonists, DA depletion, and cholinomimetics, have served as a useful model for studies of tremor.  Although adenosine A2A antagonists can reduce the tremulous jaw movements induced by DA antagonists and DA depletion, there are conflicting reports about the interaction between adenosine antagonists and cholinomimetic drugs.  The present studies investigated the ability of adenosine antagonists to reverse the tremorogenic effect of the muscarinic agonist pilocarpine.  While the adenosine A2A antagonist MSX-3 was incapable of reversing the tremulous jaw movements induced by the 4.0 mg/kg dose of pilocarpine, both MSX-3 and the adenosine A2A antagonist SCH58261 reversed the tremulous jaw movements elicited by 0.5 mg/kg pilocarpine.  Systemic administration of the adenosine A1 antagonist DPCPX failed to reverse the tremulous jaw movements induced by either an acute 0.5 mg/kg dose of the cholinomimetic pilocarpine or the DA D2 antagonist pimozide, indicating that the tremorolytic effects of adenosine antagonists may be receptor subtype specific.  Behaviorally active doses of MSX-3 and SCH 58261 showed substantial in vivo occupancy of A2A receptors, but DPCPX did not.  The results of these studies support the use of adenosine A2A antagonists for the treatment of tremor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLbdsk5B8vnLVg90H21EOLACvtfcHk0ljSPG12irNZLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVans7w%253D&md5=e406879131384ba96eeb14f8458257b4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2009.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2009.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DCollins%26aufirst%3DL.%2BE.%26aulast%3DGaltieri%26aufirst%3DD.%2BJ.%26aulast%3DBrennum%26aufirst%3DL.%2BT.%26aulast%3DSager%26aufirst%3DT.%2BN.%26aulast%3DHockemeyer%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DHinman%26aufirst%3DJ.%2BR.%26aulast%3DChrobak%26aufirst%3DJ.%2BJ.%26aulast%3DSalamone%26aufirst%3DJ.%2BD.%26atitle%3DOral%2520tremor%2520induced%2520by%2520the%2520muscarinic%2520agonist%2520pilocarpine%2520is%2520suppressed%2520by%2520the%2520adenosine%2520A2A%2520antagonists%2520MSX-3%2520and%2520SCH58261%252C%2520but%2520not%2520the%2520adenosine%2520A1%2520antagonist%2520DPCPX%26jtitle%3DPharmacol.%2520Biochem.%2520Behav.%26date%3D2010%26volume%3D94%26spage%3D561%26epage%3D569%26doi%3D10.1016%2Fj.pbb.2009.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mihara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarimizu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akahane, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwashita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, N.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1<i>H</i>)-one (ASP5854), in models of Parkinson’s disease and cognition</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>323</i></span>,  <span class="NLM_fpage">708</span>– <span class="NLM_lpage">719</span>, <span class="refDoi"> DOI: 10.1124/jpet.107.121962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1124%2Fjpet.107.121962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=17684118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1ynsb%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2007&pages=708-719&author=T.+Miharaauthor=K.+Miharaauthor=J.+Yarimizuauthor=Y.+Mitaniauthor=R.+Matsudaauthor=H.+Yamamotoauthor=S.+Aokiauthor=A.+Akahaneauthor=A.+Iwashitaauthor=N.+Matsuoka&title=Pharmacological+characterization+of+a+novel%2C+potent+adenosine+A1+and+A2A+receptor+dual+antagonist%2C+5-%5B5-amino-3-%284-fluorophenyl%29pyrazin-2-yl%5D-1-isopropylpyridine-2%281H%29-one+%28ASP5854%29%2C+in+models+of+Parkinson%E2%80%99s+disease+and+cognition&doi=10.1124%2Fjpet.107.121962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition</span></div><div class="casAuthors">Mihara, Takuma; Mihara, Kayoko; Yarimizu, Junko; Mitani, Yasuyuki; Matsuda, Ritsuko; Yamamoto, Hiroko; Aoki, Satoshi; Akahane, Atsushi; Iwashita, Akinori; Matsuoka, Nobuya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">708-719</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Central adenosine A2A receptor is a promising target for drugs to treat Parkinson's disease (PD), and the central blockade of adenosine A1 receptor improves cognitive function.  In the present study, we investigated the effect of a novel adenosine A1 and A2A dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one(ASP5854),in animal models of PD and cognition.  The binding affinities of ASP5854 for human A1 and A2A receptors were 9.03 and 1.76 nM, resp., with higher specificity and no species differences.  ASP5854 also showed antagonistic action on A1 and A2A agonist-induced increases of intracellular Ca2+ concn.  ASP5854 ameliorated A2A agonist 2-[p-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamidoadenosine (CGS21680)- and haloperidol-induced catalepsy in mice, with the min. EDs of 0.32 and 0.1 mg/kg, resp., and it also improved haloperidol-induced catalepsy in rats at doses higher than 0.1 mg/kg.  In unilateral 6-hydroxydopamine-lesioned rats, ASP5854 significantly potentiated 7-dihydroxyphenylalanine (L-DOPA)-induced rotational behavior at doses higher than 0.032 mg/kg.  ASP5854 also significantly restored the striatal dopamine content reduced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment in mice at doses higher than 0.1 mg/kg.  Furthermore, in the rat passive avoidance test, ASP5854 significantly reversed the scopolamine-induced memory deficits, whereas the specific adenosine A2A antagonist 8-((E)-2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione (KW-6002; istradefylline) did not.  Scopolamine- or 5H-dibenzo[a,d]cyclohepten-5,10-imine (dizocilpine maleate) (MK-801)-induced impairment of spontaneous alternation in the mouse Y-maze test was ameliorated by ASP5854, whereas KW-6002 did not exert improvement at therapeutically relevant dosages.  These results demonstrate that the novel, selective, and orally active dual adenosine A1 and A2A receptors antagonist ASP5854 improves motor impairments, is neuroprotective via A2A antagonism, and also enhances cognitive function through A1 antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKhOITDQ8dxrVg90H21EOLACvtfcHk0ljSPG12irNZLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1ynsb%252FF&md5=2d9770179a47a228d825a49feab70ef2</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.121962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.121962%26sid%3Dliteratum%253Aachs%26aulast%3DMihara%26aufirst%3DT.%26aulast%3DMihara%26aufirst%3DK.%26aulast%3DYarimizu%26aufirst%3DJ.%26aulast%3DMitani%26aufirst%3DY.%26aulast%3DMatsuda%26aufirst%3DR.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DAoki%26aufirst%3DS.%26aulast%3DAkahane%26aufirst%3DA.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DMatsuoka%26aufirst%3DN.%26atitle%3DPharmacological%2520characterization%2520of%2520a%2520novel%252C%2520potent%2520adenosine%2520A1%2520and%2520A2A%2520receptor%2520dual%2520antagonist%252C%25205-%255B5-amino-3-%25284-fluorophenyl%2529pyrazin-2-yl%255D-1-isopropylpyridine-2%25281H%2529-one%2520%2528ASP5854%2529%252C%2520in%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%2520and%2520cognition%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D323%26spage%3D708%26epage%3D719%26doi%3D10.1124%2Fjpet.107.121962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Essawy, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawfik, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korayem, H. E.</span></span> <span> </span><span class="NLM_article-title">Effects of adenosine receptor antagonists in MPTP mouse model of Parkinson’s disease: mitochondrial DNA integrity</span>. <i>Arch. Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">659</span>– <span class="NLM_lpage">669</span>, <span class="refDoi"> DOI: 10.5114/aoms.2017.67284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.5114%2Faoms.2017.67284" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=659-669&author=S.+S.+Essawyauthor=M.+K.+Tawfikauthor=H.+E.+Korayem&title=Effects+of+adenosine+receptor+antagonists+in+MPTP+mouse+model+of+Parkinson%E2%80%99s+disease%3A+mitochondrial+DNA+integrity&doi=10.5114%2Faoms.2017.67284"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.5114%2Faoms.2017.67284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5114%252Faoms.2017.67284%26sid%3Dliteratum%253Aachs%26aulast%3DEssawy%26aufirst%3DS.%2BS.%26aulast%3DTawfik%26aufirst%3DM.%2BK.%26aulast%3DKorayem%26aufirst%3DH.%2BE.%26atitle%3DEffects%2520of%2520adenosine%2520receptor%2520antagonists%2520in%2520MPTP%2520mouse%2520model%2520of%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520mitochondrial%2520DNA%2520integrity%26jtitle%3DArch.%2520Med.%2520Sci.%26date%3D2017%26volume%3D3%26spage%3D659%26epage%3D669%26doi%3D10.5114%2Faoms.2017.67284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, A.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptor antagonists in Parkinson’s disease: Progress in clinical trials from the newly approved Istradefylline to drugs in early development and those already discontinued</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1007/s40263-014-0161-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1007%2Fs40263-014-0161-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=24687255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVWhtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=455-474&author=A.+Pinna&title=Adenosine+A2A+receptor+antagonists+in+Parkinson%E2%80%99s+disease%3A+Progress+in+clinical+trials+from+the+newly+approved+Istradefylline+to+drugs+in+early+development+and+those+already+discontinued&doi=10.1007%2Fs40263-014-0161-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A Receptor Antagonists in Parkinson's Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued</span></div><div class="casAuthors">Pinna, Annalisa</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">455-474</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Neurotransmitters other than dopamine, such as norepinephrine, 5-hydroxytryptamine, glutamate, adenosine and acetylcholine, are involved in Parkinson's disease (PD) and contribute to its symptomatol.  Thus, the progress of non-dopaminergic therapies for PD has attracted much interest in recent years.  Among new classes of drugs, adenosine A2A antagonists have emerged as promising candidates.  The development of new highly selective adenosine A2A receptor antagonists, and their encouraging anti-parkinsonian responses in animal models of PD, has provided a rationale for clin. trials to evaluate the therapeutic potential and the safety of these agents in patients with PD.  To date, the clin. research regarding A2A antagonists and their potential utilization in PD therapy continues to evolve between drugs just or previously discontinued (preladenant and vipadenant), new derivs. in development (tozadenant, PBF-509, ST1535, ST4206 and V81444) and the relatively old drug istradefylline, which has finally been licensed as an anti-parkinsonian drug in Japan.  All these compds. have been shown to have a good safety profile and be well tolerated.  Moreover, results from phase II and III trials also demonstrate that A2A antagonists are effective in reducing off-time, without worsening troublesome dyskinesia, and in increasing on-time with a mild increase of non-troublesome dyskinesia, in patients at an advanced stage of PD treated with L-DOPA.  In addn., early findings suggest that A2A antagonists might also be efficacious as monotherapy in patients at an early stage of PD.  This review summarizes pharmacol. and clin. data available on istradefylline, tozadenant, PBF-509, ST1535, ST4206, V81444, preladenant and vipadenant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9RSy9sahNnbVg90H21EOLACvtfcHk0lhah_han4Dtaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVWhtLc%253D&md5=1c12ad215ddb2384ec190027d23a3216</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs40263-014-0161-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-014-0161-7%26sid%3Dliteratum%253Aachs%26aulast%3DPinna%26aufirst%3DA.%26atitle%3DAdenosine%2520A2A%2520receptor%2520antagonists%2520in%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520Progress%2520in%2520clinical%2520trials%2520from%2520the%2520newly%2520approved%2520Istradefylline%2520to%2520drugs%2520in%2520early%2520development%2520and%2520those%2520already%2520discontinued%26jtitle%3DCNS%2520Drugs%26date%3D2014%26volume%3D28%26spage%3D455%26epage%3D474%26doi%3D10.1007%2Fs40263-014-0161-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pourcher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huot, P.</span></span> <span> </span><span class="NLM_article-title">Adenosine 2A receptor antagonists for the treatment of motor symptoms in Parkinson’s disease</span>. <i>Mov. Disord. Clin. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1002/mdc3.12187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2Fmdc3.12187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=30363540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BB3cvjsFGntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2015&pages=331-340&author=E.+Pourcherauthor=P.+Huot&title=Adenosine+2A+receptor+antagonists+for+the+treatment+of+motor+symptoms+in+Parkinson%E2%80%99s+disease&doi=10.1002%2Fmdc3.12187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson's Disease</span></div><div class="casAuthors">Pourcher Emmanuelle; Pourcher Emmanuelle; Huot Philippe; Huot Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Movement disorders clinical practice</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">331-340</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Treatment of motor fluctuations in Parkinson's disease (PD) remains an unmet challenge.  Adenosine 2A (A2A) receptors are located along the indirect pathway and represent a potential target to enhance l-3,4-dihydroxyphenylalanine (l-DOPA) antiparkinsonian action.  Methods:  This article summarizes the preclinical and clinical literature on A2A antagonists in PD, with a specific focus on their effect on off time, on time, and dyskinesia.  Findings:  Several A2A receptor antagonists have been tested in preclinical studies and clinical trials.  In preclinical studies, A2A antagonists enhanced l-DOPA antiparkinsonian action without exacerbating dyskinesia, but A2A antagonists were generally administered in combination with a subthreshold dose of l-DOPA, which is different to the paradigms used in clinical trials, where A2A antagonists were usually added to an optimal antiparkinsonian regimen.  In clinical settings, A2A antagonists generally reduced duration of off time, by as much as 25% in some studies.  The effect of on time duration is less clear, and in a few studies an exacerbation of dyskinesia was reported.  Two A2A antagonists have been tested in phase III settings: istradefylline and preladenant.  Istradefylline was effective in two phase III trials, but ineffective in another; the drug has been commercially available in Japan since 2013.  In contrast, preladenant was ineffective in a phase III trial and the drug was discontinued.  A phase III study with tozadenant will begin in 2015; the drug was effective at reducing off time in a phase IIb study.  Other A2A antagonists are in development at the preclinical and early clinical levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSejnAfV_exrv69nzq6467DfW6udTcc2eYPoJc_uSW3ibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvjsFGntA%253D%253D&md5=636bce3f59f3480abaaecb0f65a8f5fa</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fmdc3.12187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmdc3.12187%26sid%3Dliteratum%253Aachs%26aulast%3DPourcher%26aufirst%3DE.%26aulast%3DHuot%26aufirst%3DP.%26atitle%3DAdenosine%25202A%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520motor%2520symptoms%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DMov.%2520Disord.%2520Clin.%2520Pract.%26date%3D2015%26volume%3D2%26spage%3D331%26epage%3D340%26doi%3D10.1002%2Fmdc3.12187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchiyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadowaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsubara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakuramoto, H.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Istradefylline improves daytime sleepiness in patients with Parkinson’s disease: An open-label, 3-month study</span>. <i>J. Neurol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">230</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1016/j.jns.2017.07.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.jns.2017.07.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=28870576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1ynsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2017&pages=230-233&author=K.+Suzukiauthor=M.+Miyamotoauthor=T.+Miyamotoauthor=T.+Uchiyamaauthor=Y.+Watanabeauthor=S.+Suzukiauthor=T.+Kadowakiauthor=H.+Fujitaauthor=T.+Matsubaraauthor=H.+Sakuramoto&title=Istradefylline+improves+daytime+sleepiness+in+patients+with+Parkinson%E2%80%99s+disease%3A+An+open-label%2C+3-month+study&doi=10.1016%2Fj.jns.2017.07.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Istradefylline improves daytime sleepiness in patients with Parkinson's disease: An open-label, 3-month study</span></div><div class="casAuthors">Suzuki, Keisuke; Miyamoto, Masayuki; Miyamoto, Tomoyuki; Uchiyama, Tomoyuki; Watanabe, Yuka; Suzuki, Shiho; Kadowaki, Taro; Fujita, Hiroaki; Matsubara, Takeo; Sakuramoto, Hirotaka; Hirata, Koichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Neurological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">230-233</span>CODEN:
                <span class="NLM_cas:coden">JNSCAG</span>;
        ISSN:<span class="NLM_cas:issn">0022-510X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Istradefylline, a selective adenosine A2A receptor antagonist, has been reported to improve daily "off time" and motor symptoms in patients with Parkinson's disease (PD).  However, the effect of istradefylline on sleep problems has not been thoroughly investigated.  We evaluated the effect of istradefylline on daytime sleepiness, sleep disturbances, and motor symptoms in 22 PD patients who were affected by the wearing off phenomenon in an open-label, 3-mo study.  Participants received 20-40 mg/day istradefylline once daily (morning) over a 3-mo period.  The Epworth Sleepiness Scale (ESS), PD sleep scale (PDSS)-2 and PD Questionnaire (PDQ-8) were administered at baseline, 2 wk, 1 mo, 2 mo and 3 mo.  At baseline and 3 mo, patients were evaluated on the Movement Disorder Society Revision of the Unified PD Rating Scale (MDS-UPDRS) parts III and IV.  Twenty-one patients (95.5%) completed the study.  At 3 mo, MDS-UPDRS part III (- 5.3, p = 0.0002) and part IV (- 2.5, p = 0.001) scores improved and off time decreased significantly (- 50.1 min, p = 0.0004).  PDQ-8 scores were unchanged at 3 mo.  ESS scores decreased significantly at 2 mo and 3 mo (- 2.4 and - 3.3, resp., p < 0.0001), but the total PDSS-2 scores did not change.  Istradefylline improved daytime sleepiness in PD patients, possibly through its effect on enhancing alertness.  In addn., the lack of significant changes in the total PDSS-2 scores over the study period suggests istradefylline had no neg. impact on sleep.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgYau0p08DE7Vg90H21EOLACvtfcHk0ljdYe2a_8wviw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1ynsb3F&md5=9e6a88c0d11632d07c7f3dbb9371564c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.jns.2017.07.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jns.2017.07.045%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DK.%26aulast%3DMiyamoto%26aufirst%3DM.%26aulast%3DMiyamoto%26aufirst%3DT.%26aulast%3DUchiyama%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DKadowaki%26aufirst%3DT.%26aulast%3DFujita%26aufirst%3DH.%26aulast%3DMatsubara%26aufirst%3DT.%26aulast%3DSakuramoto%26aufirst%3DH.%26atitle%3DIstradefylline%2520improves%2520daytime%2520sleepiness%2520in%2520patients%2520with%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520An%2520open-label%252C%25203-month%2520study%26jtitle%3DJ.%2520Neurol.%2520Sci.%26date%3D2017%26volume%3D380%26spage%3D230%26epage%3D233%26doi%3D10.1016%2Fj.jns.2017.07.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stockwell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cayabyab, F. S.</span></span> <span> </span><span class="NLM_article-title">Adenosine A1 and A2A receptors in the brain: Current research and their role in neurodegeneration</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">676</span>, <span class="refDoi"> DOI: 10.3390/molecules22040676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.3390%2Fmolecules22040676" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFert7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=676&author=J.+Stockwellauthor=E.+Jakovaauthor=F.+S.+Cayabyab&title=Adenosine+A1+and+A2A+receptors+in+the+brain%3A+Current+research+and+their+role+in+neurodegeneration&doi=10.3390%2Fmolecules22040676"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A1 and A2A receptors in the brain: current research and their role in neurodegeneration</span></div><div class="casAuthors">Stockwell, Jocelyn; Jakova, Elisabet; Cayabyab, Francisco S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">676/1-676/18</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The inhibitory adenosine A1 receptor (A1R) and excitatory A2A receptor (A2AR) are predominantly expressed in the brain.  Whereas the A2AR has been implicated in normal aging and enhancing neurotoxicity in multiple neurodegenerative diseases, the inhibitory A1R has traditionally been ascribed to have a neuroprotective function in various brain insults.  This review provides a summary of the emerging role of prolonged A1R signaling and its potential cross-talk with A2AR in the cellular basis for increased neurotoxicity in neurodegenerative disorders.  This A1R signaling enhances A2AR-mediated neurodegeneration, and provides a platform for future development of neuroprotective agents in stroke, Parkinson's disease and epilepsy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohCTsmNnKJvLVg90H21EOLACvtfcHk0ljdYe2a_8wviw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFert7jJ&md5=1e1223b43bc5dd1ec982b1805c1667e7</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22040676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22040676%26sid%3Dliteratum%253Aachs%26aulast%3DStockwell%26aufirst%3DJ.%26aulast%3DJakova%26aufirst%3DE.%26aulast%3DCayabyab%26aufirst%3DF.%2BS.%26atitle%3DAdenosine%2520A1%2520and%2520A2A%2520receptors%2520in%2520the%2520brain%253A%2520Current%2520research%2520and%2520their%2520role%2520in%2520neurodegeneration%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26spage%3D676%26doi%3D10.3390%2Fmolecules22040676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delamarre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meissner, W. G.</span></span> <span> </span><span class="NLM_article-title">Epidemiology, environmental risk factors and genetics of Parkinson’s disease</span>. <i>Presse Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1016/j.lpm.2017.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.lpm.2017.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=28189372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BC1c3lvFWrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2017&pages=175-181&author=A.+Delamarreauthor=W.+G.+Meissner&title=Epidemiology%2C+environmental+risk+factors+and+genetics+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.lpm.2017.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology, environmental risk factors and genetics of Parkinson's disease</span></div><div class="casAuthors">Delamarre Anna; Meissner Wassilios G</div><div class="citationInfo"><span class="NLM_cas:title">Presse medicale (Paris, France : 1983)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">2 Pt 1</span>),
    <span class="NLM_cas:pages">175-181</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Parkinson's disease (PD) is a frequent neurodegenerative disease with a premotor phase that lasts several years.  Risk factors that have been linked to PD are tobacco, caffeine, black tea, pesticides and calcium channel blockers.  Some risk factors may be due to inverse causality (e.g. changes in personality during the premotor phase).  The genetics of PD are complex with a contribution of Mendelian (e.g.  SNCA, LRRK2, Parkin, Pink1,...) and non-Mendelian factors (e.g. single nucleotide polymorphisms).  Glucocerebrosidase gene mutations (Gaucher disease) are currently the strongest genetic risk factor for PD.  Studying risk factors will help to better understand the pathogenesis of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKqImwQhsvv-Lt9HypzAgQfW6udTcc2eaHg1LtnqwYf7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3lvFWrsw%253D%253D&md5=f2178a9d5543ec897690613d450e4939</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.lpm.2017.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lpm.2017.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DDelamarre%26aufirst%3DA.%26aulast%3DMeissner%26aufirst%3DW.%2BG.%26atitle%3DEpidemiology%252C%2520environmental%2520risk%2520factors%2520and%2520genetics%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DPresse%2520Med.%26date%3D2017%26volume%3D46%26spage%3D175%26epage%3D181%26doi%3D10.1016%2Fj.lpm.2017.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bastide, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meissner, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picconi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernagut, P.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feyder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francardo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcacer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brambilla, R.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1016/j.pneurobio.2015.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.pneurobio.2015.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=26209473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Crsr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2015&pages=96-168&author=M.+F.+Bastideauthor=W.+G.+Meissnerauthor=B.+Picconiauthor=S.+Fasanoauthor=P.-O.+Fernagutauthor=M.+Feyderauthor=V.+Francardoauthor=C.+Alcacerauthor=Y.+Dingauthor=R.+Brambilla&title=Pathophysiology+of+L-dopa-induced+motor+and+non-motor+complications+in+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.pneurobio.2015.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease</span></div><div class="casAuthors">Bastide, Matthieu F.; Meissner, Wassilios G.; Picconi, Barbara; Fasano, Stefania; Fernagut, Pierre-Olivier; Feyder, Michael; Francardo, Veronica; Alcacer, Cristina; Ding, Yunmin; Brambilla, Riccardo; Fisone, Gilberto; Jon Stoessl, A.; Bourdenx, Mathieu; Engeln, Michel; Navailles, Sylvia; De Deurwaerdere, Philippe; Ko, Wai Kin D.; Simola, Nicola; Morelli, Micaela; Groc, Laurent; Rodriguez, Maria-Cruz; Gurevich, Eugenia V.; Quik, Maryka; Morari, Michele; Mellone, Manuela; Gardoni, Fabrizio; Tronci, Elisabetta; Guehl, Dominique; Tison, Francois; Crossman, Alan R.; Kang, Un Jung; Steece-Collier, Kathy; Fox, Susan; Carta, Manolo; Angela Cenci, M.; Bezard, Erwan</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">96-168</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) therapy for Parkinson's disease (PD).  L-dopa-induced dyskinesia (LID) are ultimately experienced by the vast majority of patients.  In addn., psychiatric conditions often manifested as compulsive behaviors, are emerging as a serious problem in the management of L-dopa therapy.  The present review attempts to provide an overview of our current understanding of dyskinesia and other L-dopa-induced dysfunctions, a field that dramatically evolved in the past twenty years.  In view of the extensive literature on LID, there appeared a crit. need to re-frame the concepts, to highlight the most suitable models, to review the central nervous system (CNS) circuitry that may be involved, and to propose a pathophysiol. framework was timely and necessary.  An updated review to clarify our understanding of LID and other L-dopa-related side effects was therefore timely and necessary.  This review should help in the development of novel therapeutic strategies aimed at preventing the generation of dyskinetic symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbmGOnBY16j7Vg90H21EOLACvtfcHk0ljc0377wbC1VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Crsr3I&md5=3fa026d75e85fc6a595a8c59148787d9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2015.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2015.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DBastide%26aufirst%3DM.%2BF.%26aulast%3DMeissner%26aufirst%3DW.%2BG.%26aulast%3DPicconi%26aufirst%3DB.%26aulast%3DFasano%26aufirst%3DS.%26aulast%3DFernagut%26aufirst%3DP.-O.%26aulast%3DFeyder%26aufirst%3DM.%26aulast%3DFrancardo%26aufirst%3DV.%26aulast%3DAlcacer%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DBrambilla%26aufirst%3DR.%26atitle%3DPathophysiology%2520of%2520L-dopa-induced%2520motor%2520and%2520non-motor%2520complications%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DProg.%2520Neurobiol.%26date%3D2015%26volume%3D132%26spage%3D96%26epage%3D168%26doi%3D10.1016%2Fj.pneurobio.2015.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, D. J.</span></span> <span> </span><span class="NLM_article-title">Sleep disorders in Parkinson’s disease: Many causes, few therapeutic options</span>. <i>J. Neurol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>314</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1016/j.jns.2011.10.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.jns.2011.10.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=22118862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BC383it12hug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=2012&pages=12-19&author=N.+J.+Diederichauthor=D.+J.+McIntyre&title=Sleep+disorders+in+Parkinson%E2%80%99s+disease%3A+Many+causes%2C+few+therapeutic+options&doi=10.1016%2Fj.jns.2011.10.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Sleep disorders in Parkinson's disease: many causes, few therapeutic options</span></div><div class="casAuthors">Diederich Nico J; McIntyre Deborah J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the neurological sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">314</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">12-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sleep symptoms in Parkinson's disease (PD) are frequent and have multifactorial and multilayered causes.  Primary involvement of sleep/wake regulating centers in the brainstem, sleep problems caused by the nocturnal manifestation of motor and dysautonomic signs and medication-induced sleep problems are often impossible to disentangle in the individual patient.  Two syndromes, hypersomnia and REM sleep behavior disorder (RBD), are increasingly recognized as harbingers of the core PD motor syndrome.  RBD, associated with a panoply of other nonmotor symptoms, may predispose to a specific PD phenotype.  Long-acting dopaminergic stimulation, when abating nocturnal akinesia, also improves subjective sleep quantity.  While this strategy is backed up by several randomized controlled trials (RCT), other treatment recommendations are mostly based on case series or expert opinion.  Thus we identified only two other RCT, one treating insomnia with eszopiclone, the other nocturnal behavioral abnormalities in demented PD patients with memantine.  While the causal complexity of sleep problems in PD certainly hampers the design of therapeutic studies, multiple general treatment strategies against sleep disorders can however be applied efficiently in PD patients as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQA5xSdihpBVi86Js-BCLiifW6udTcc2ebURw4j79ApM7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383it12hug%253D%253D&md5=83306c5e161906ce2cd081b52c5edfd2</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.jns.2011.10.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jns.2011.10.025%26sid%3Dliteratum%253Aachs%26aulast%3DDiederich%26aufirst%3DN.%2BJ.%26aulast%3DMcIntyre%26aufirst%3DD.%2BJ.%26atitle%3DSleep%2520disorders%2520in%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520Many%2520causes%252C%2520few%2520therapeutic%2520options%26jtitle%3DJ.%2520Neurol.%2520Sci.%26date%3D2012%26volume%3D314%26spage%3D12%26epage%3D19%26doi%3D10.1016%2Fj.jns.2011.10.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: Challenges and opportunities in drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7874</span>– <span class="NLM_lpage">7887</span>, <span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+Challenges+and+opportunities+in+drug+discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0lgh1wJ9ISGkOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520Challenges%2520and%2520opportunities%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J.-U.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology - foe or friend?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8955</span>– <span class="NLM_lpage">8971</span>, <span class="refDoi"> DOI: 10.1021/jm400856t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-8971&author=J.-U.+Peters&title=Polypharmacology+-+foe+or+friend%3F&doi=10.1021%2Fjm400856t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology - Foe or Friend?</span></div><div class="casAuthors">Peters, Jens-Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8955-8971</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. describes the activity of compds. at multiple targets.  Current research focuses on two aspects of polypharmacol.: (1) unintended polypharmacol. can lead to adverse effects; (2) polypharmacol. across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects.  This perspective reviews these interconnected aspects of polypharmacol.  The first part discusses the relevance of polypharmacol. for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacol. compds. early in the drug discovery process.  The second part discusses the advantages of polypharmacol. in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing.  This perspective aims to provide a balanced view on polypharmacol., which can compromise the safety of drugs, but can also confer superior efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vnFGPfTnGLVg90H21EOLACvtfcHk0lgh1wJ9ISGkOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO&md5=f4aeb6efddd4bfdf4e94656303323cba</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.-U.%26atitle%3DPolypharmacology%2520-%2520foe%2520or%2520friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8955%26epage%3D8971%26doi%3D10.1021%2Fjm400856t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brückmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agbaba, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Polypharmacology of dopamine receptor ligands</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1016/j.pneurobio.2016.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.pneurobio.2016.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=27234980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVCmsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2016&pages=68-103&author=S.+Butiniauthor=K.+Nikolicauthor=S.+Kasselauthor=H.+Br%C3%BCckmannauthor=S.+Filipicauthor=D.+Agbabaauthor=S.+Gemmaauthor=S.+Brogiauthor=M.+Brindisiauthor=G.+Campiani&title=Polypharmacology+of+dopamine+receptor+ligands&doi=10.1016%2Fj.pneurobio.2016.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology of dopamine receptor ligands</span></div><div class="casAuthors">Butini, S.; Nikolic, K.; Kassel, S.; Bruckmann, H.; Filipic, S.; Agbaba, D.; Gemma, S.; Brogi, S.; Brindisi, M.; Campiani, G.; Stark, H.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">68-103</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Most neurol. diseases have a multifactorial nature and the no. of mol. mechanisms discovered as underpinning these diseases is continuously evolving.  The old concept of developing selective agents for a single target does not fit with the medical need of most neurol. diseases.  The development of designed multiple ligands holds great promises and appears as the next step in drug development for the treatment of these multifactorial diseases.  Dopamine and its five receptor subtypes are intimately involved in numerous neurol. disorders.  Dopamine receptor ligands display a high degree of cross interactions with many other targets including G-protein coupled receptors, transporters, enzymes and ion channels.  For brain disorders like Parkinsons disease, schizophrenia and depression the dopaminergic system, being intertwined with many other signaling systems, plays a key role in pathogenesis and therapy.  The concept of designed multiple ligands and polypharmacol., which perfectly meets the therapeutic needs for these brain disorders, is herein discussed as a general ligand-based concept while focusing on dopaminergic agents and receptor subtypes in particular.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroyjxwUVpuobVg90H21EOLACvtfcHk0lgh1wJ9ISGkOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVCmsLk%253D&md5=4e518d55c2b25e20b56a0ac4c5ff117c</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2016.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2016.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DButini%26aufirst%3DS.%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DKassel%26aufirst%3DS.%26aulast%3DBr%25C3%25BCckmann%26aufirst%3DH.%26aulast%3DFilipic%26aufirst%3DS.%26aulast%3DAgbaba%26aufirst%3DD.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DBrogi%26aufirst%3DS.%26aulast%3DBrindisi%26aufirst%3DM.%26aulast%3DCampiani%26aufirst%3DG.%26atitle%3DPolypharmacology%2520of%2520dopamine%2520receptor%2520ligands%26jtitle%3DProg.%2520Neurobiol.%26date%3D2016%26volume%3D142%26spage%3D68%26epage%3D103%26doi%3D10.1016%2Fj.pneurobio.2016.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khanfar, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Affini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutsenko, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Multiple targeting approaches on histamine H3 receptor antagonists</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">201</span>, <span class="refDoi"> DOI: 10.3389/fnins.2016.00201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.3389%2Ffnins.2016.00201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=27303254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BC2s7gtlGluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=201&author=M.+A.+Khanfarauthor=A.+Affiniauthor=K.+Lutsenkoauthor=K.+Nikolicauthor=S.+Butiniauthor=H.+Stark&title=Multiple+targeting+approaches+on+histamine+H3+receptor+antagonists&doi=10.3389%2Ffnins.2016.00201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple Targeting Approaches on Histamine H3 Receptor Antagonists</span></div><div class="casAuthors">Khanfar Mohammad A; Affini Anna; Lutsenko Kiril; Stark Holger; Nikolic Katarina; Butini Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">201</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">With the very recent market approval of pitolisant (Wakix®), the interest in clinical applications of novel multifunctional histamine H3 receptor antagonists has clearly increased.  Since histamine H3 receptor antagonists in clinical development have been tested for a variety of different indications, the combination of pharmacological properties in one molecule for improved pharmacological effects and reduced unwanted side-effects is rationally based on the increasing knowledge on the complex neurotransmitter regulations.  The polypharmacological approaches on histamine H3 receptor antagonists on different G-protein coupled receptors, transporters, enzymes as well as on NO-signaling mechanism are described, supported with some lead structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFAQnNocm8nhOk4JA3soTqfW6udTcc2ebvwRSg0gA4Irntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7gtlGluw%253D%253D&md5=f9063905722db37fa039898d9874e00a</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2016.00201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2016.00201%26sid%3Dliteratum%253Aachs%26aulast%3DKhanfar%26aufirst%3DM.%2BA.%26aulast%3DAffini%26aufirst%3DA.%26aulast%3DLutsenko%26aufirst%3DK.%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DMultiple%2520targeting%2520approaches%2520on%2520histamine%2520H3%2520receptor%2520antagonists%26jtitle%3DFront.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D201%26doi%3D10.3389%2Ffnins.2016.00201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majekova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valoti, M.</span></span> <span> </span><span class="NLM_article-title">Key targets for multi-target ligands designed to combat neurodegeneration</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">375</span>, <span class="refDoi"> DOI: 10.3389/fnins.2016.00375</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.3389%2Ffnins.2016.00375" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=27597816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BC2sznvFKhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=375&author=R.+R.+Ramsayauthor=M.+Majekovaauthor=M.+Medinaauthor=M.+Valoti&title=Key+targets+for+multi-target+ligands+designed+to+combat+neurodegeneration&doi=10.3389%2Ffnins.2016.00375"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34aR"><div class="casContent"><span class="casTitleNuber">34a</span><div class="casTitle"><span class="NLM_cas:atitle">Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration</span></div><div class="casAuthors">Ramsay Rona R; Majekova Magdalena; Medina Milagros; Valoti Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">375</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">HIGHLIGHTS Compounds that interact with multiple targets but minimally with the cytochrome P450 system (CYP) address the many factors leading to neurodegeneration.Acetyl- and Butyryl-cholineEsterases (AChE, BChE) and Monoamine Oxidases A/B (MAO A, MAO B) are targets for Multi-Target Designed Ligands (MTDL).ASS234 is an irreversible inhibitor of MAO A >MAO B and has micromolar potency against the cholinesterases.ASS234 is a poor CYP substrate in human liver, yielding the depropargylated metabolite.SMe1EC2, a stobadine derivative, showed high radical scavenging property, in vitro and in vivo giving protection in head trauma and diabetic damage of endothelium.Control of mitochondrial function and morphology by manipulating fission and fusion is emerging as a target area for therapeutic strategies to decrease the pathological outcome of neurodegenerative diseases.  Growing evidence supports the view that neurodegenerative diseases have multiple and common mechanisms in their aetiologies.  These multifactorial aspects have changed the broadly common assumption that selective drugs are superior to "dirty drugs" for use in therapy.  This drives the research in studies of novel compounds that might have multiple action mechanisms.  In neurodegeneration, loss of neuronal signaling is a major cause of the symptoms, so preservation of neurotransmitters by inhibiting the breakdown enzymes is a first approach.  Acetylcholinesterase (AChE) inhibitors are the drugs preferentially used in AD and that one of these, rivastigmine, is licensed also for PD.  Several studies have shown that monoamine oxidase (MAO) B, located mainly in glial cells, increases with age and is elevated in Alzheimer (AD) and Parkinson's Disease's (PD).  Deprenyl, a MAO B inhibitor, significantly delays the initiation of levodopa treatment in PD patients.  These indications underline that AChE and MAO are considered a necessary part of multi-target designed ligands (MTDL).  However, both of these targets are simply symptomatic treatment so if new drugs are to prevent degeneration rather than compensate for loss of neurotransmitters, then oxidative stress and mitochondrial events must also be targeted.  MAO inhibitors can protect neurons from apoptosis by mechanisms unrelated to enzyme inhibition.  Understanding the involvement of MAO and other proteins in the induction and regulation of the apoptosis in mitochondria will aid progress toward strategies to prevent the loss of neurons.  In general, the oxidative stress observed both in PD and AD indicate that antioxidant properties are a desirable part of MTDL molecules.  After two or more properties are incorporated into one molecule, the passage from a lead compound to a therapeutic tool is strictly linked to its pharmacokinetic and toxicity.  In this context the interaction of any new molecules with cytochrome P450 and other xenobiotic metabolic processes is a crucial point.  The present review covers the biochemistry of enzymes targeted in the design of drugs against neurodegeneration and the cytochrome P450-dependent metabolism of MTDLs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQjOr1PdgGetEwlCcfExbvbfW6udTcc2eZgkdUeW2DUb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sznvFKhsA%253D%253D&md5=d4262692b6fbea1a58815dca979f2c69</span></div><a href="/servlet/linkout?suffix=cit34a&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2016.00375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2016.00375%26sid%3Dliteratum%253Aachs%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DMajekova%26aufirst%3DM.%26aulast%3DMedina%26aufirst%3DM.%26aulast%3DValoti%26aufirst%3DM.%26atitle%3DKey%2520targets%2520for%2520multi-target%2520ligands%2520designed%2520to%2520combat%2520neurodegeneration%26jtitle%3DFront.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D375%26doi%3D10.3389%2Ffnins.2016.00375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit34b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaspar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouvet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouvet, M.</span></span> <span> </span><span class="NLM_article-title">The unfinished journey with modafinil and discovery of a novel population of modafinil-immunoreactive neurons</span>. <i>Sleep Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1016/j.sleep.2018.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.sleep.2018.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=30172629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BB3c3ksFKlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2018&pages=40-52&author=J.-S.+Linauthor=B.+Rousselauthor=A.+Gasparauthor=Y.+Zhaoauthor=Y.+Houauthor=M.+Schmidtauthor=A.+Jouvetauthor=M.+Jouvet&title=The+unfinished+journey+with+modafinil+and+discovery+of+a+novel+population+of+modafinil-immunoreactive+neurons&doi=10.1016%2Fj.sleep.2018.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34bR"><div class="casContent"><span class="casTitleNuber">34b</span><div class="casTitle"><span class="NLM_cas:atitle">The unfinished journey with modafinil and discovery of a novel population of modafinil-immunoreactive neurons</span></div><div class="casAuthors">Lin Jian-Sheng; Roussel Bernard; Hou Yiping; Schmidt Markus; Jouvet Michel; Gaspar Alexandre; Zhao Yan; Jouvet Anne</div><div class="citationInfo"><span class="NLM_cas:title">Sleep medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Modafinil, a wake-promoting compound now used worldwide in sleep medicine, was initially regarded as a sedative compound because mice were so quiet with respect to locomotion after receiving it that this behavioral state was qualified as sedation.  In the early 1980's when modafinil was first assessed by polysomnography in a cat in our laboratory, surprisingly, the cat spent the whole night awake without even one minute of sleep! This initial observation resulted subsequently in a series of basic and clinical studies in order to define the pharmacological profile of modafinil and its mode of action and, notably, to identify the brain targets by which modafinil acts to promote wakefulness.  These studies were undertaken using pharmacologic approach coupled with the Cerveau isole (brain transection) preparation, c-fos labelling and knockout mouse models.  It was also in this context that we have developed a purified polyclonal antibody against modafinil.  We expected that using immunohistochemistry with this antibody would allow us to localize the brain distribution of modafinil dosing.  Surprisingly, we found discrete modafinil immunoreactive neuronal populations in several brain areas of modafinil-naive cats, rodents and humans.  The most numerous and intensely labeled modafinil-immunoreactive neurons characterized by granular staining were found in the basal forebrain.  They shared the regional location with cholinergic and aspartate-containing neurons but did not colocalize with them.  In summary, we here present a newly identified neuronal population located in the basal forebrain that has never previously been published and suggests that these modafinil-immunoreactive neurons might be involved in forebrain functions such as sleep-wake control and cognition.  This paper briefly reviews our journey with modafinil research and presents new unpublished experimental data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQODDxLan-ZZ3tlzo9xastyfW6udTcc2eZgkdUeW2DUb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3ksFKlsA%253D%253D&md5=93eb8593689267536fa3aec4d2f7fad1</span></div><a href="/servlet/linkout?suffix=cit34b&amp;dbid=16384&amp;doi=10.1016%2Fj.sleep.2018.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sleep.2018.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.-S.%26aulast%3DRoussel%26aufirst%3DB.%26aulast%3DGaspar%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DSchmidt%26aufirst%3DM.%26aulast%3DJouvet%26aufirst%3DA.%26aulast%3DJouvet%26aufirst%3DM.%26atitle%3DThe%2520unfinished%2520journey%2520with%2520modafinil%2520and%2520discovery%2520of%2520a%2520novel%2520population%2520of%2520modafinil-immunoreactive%2520neurons%26jtitle%3DSleep%2520Med.%26date%3D2018%26volume%3D49%26spage%3D40%26epage%3D52%26doi%3D10.1016%2Fj.sleep.2018.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeq, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>312</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2016.06.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.bbr.2016.06.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=27363923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ekurjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2016&pages=415-430&author=B.+Sadekauthor=A.+Saadauthor=A.+Sadeqauthor=F.+Jalalauthor=H.+Stark&title=Histamine+H3+receptor+as+a+potential+target+for+cognitive+symptoms+in+neuropsychiatric+diseases&doi=10.1016%2Fj.bbr.2016.06.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases</span></div><div class="casAuthors">Sadek, Bassem; Saad, Ali; Sadeq, Adel; Jalal, Fakhreya; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">415-430</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The potential contributions of the brain histaminergic system in neurodegenerative diseases, and the possiblity of histamine-targeting treatments is attracting considerable interests.  The histamine H3 receptor (H3R) is expressed mainly in the central nervous system, and is, consequently, an attractive pharmacol. target.  Although recently described clin. trials have been disappointing in attention deficit hyperactivity disorder (ADHD) and schizophrenia (SCH), numerous H3R antagonists, including pitolisant, demonstrate potential in the treatment of narcolepsy, excessive daytime sleepiness assocd. with cognitive impairment, epilepsy, and Alzheimer's disease (AD).  This review focuses on the recent preclin. as well as clin. results that support the relevance of H3R antagonists for the treatment of cognitive symptoms in neuropsychiatric diseases, namely AD, epilepsy and SCH.  The review summarizes the role of histaminergic neurotransmission with focus on these brain disorders, as well as the effects of numerous H3R antagonists on animal models and humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu0qvZ7tUjyrVg90H21EOLACvtfcHk0lgxGXGatvzCaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ekurjN&md5=f7a95fe5f633779a98ad5968c4b714a2</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2016.06.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2016.06.051%26sid%3Dliteratum%253Aachs%26aulast%3DSadek%26aufirst%3DB.%26aulast%3DSaad%26aufirst%3DA.%26aulast%3DSadeq%26aufirst%3DA.%26aulast%3DJalal%26aufirst%3DF.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DHistamine%2520H3%2520receptor%2520as%2520a%2520potential%2520target%2520for%2520cognitive%2520symptoms%2520in%2520neuropsychiatric%2520diseases%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2016%26volume%3D312%26spage%3D415%26epage%3D430%26doi%3D10.1016%2Fj.bbr.2016.06.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghamari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarei, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arias-Montano, J.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dastmalchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamzeh-Mivehroud, M.</span></span> <span> </span><span class="NLM_article-title">Histamine H3 receptor antagonists/inverse agonists: Where do they go?</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>200</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2019.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.pharmthera.2019.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=31028835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovVOmtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=200&publication_year=2019&pages=69-84&author=N.+Ghamariauthor=O.+Zareiauthor=J.-A.+Arias-Montanoauthor=D.+Reinerauthor=S.+Dastmalchiauthor=H.+Starkauthor=M.+Hamzeh-Mivehroud&title=Histamine+H3+receptor+antagonists%2Finverse+agonists%3A+Where+do+they+go%3F&doi=10.1016%2Fj.pharmthera.2019.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Histamine H3 receptor antagonists/inverse agonists: Where do they go?</span></div><div class="casAuthors">Ghamari, Nakisa; Zarei, Omid; Arias-Montano, Jose-Antonio; Reiner, David; Dastmalchi, Siavoush; Stark, Holger; Hamzeh-Mivehroud, Maryam</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">200</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">69-84</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Since the discovery of the histamine H3 receptor in 1983, tremendous advances in the pharmacol. aspects of H3 receptor antagonists/inverse agonists have been accomplished in preclin. studies.  At present, there are several drug candidates that reached clin. trial studies for various indications.  However, entrance of these candidates to the pharmaceutical market is not free from challenges, and a variety of difficulties is engaged with their developmental process.  In this review, the potential role of H3 receptors in the pathophysiol. of various central nervous system, metabolic and allergic diseases is discussed.  Thereafter, the current status for H3 receptor antagonists/inverse agonists in ongoing clin. trial studies is reviewed and obstacles in developing these agents are emphasized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IbgM1GUg97Vg90H21EOLACvtfcHk0li32JUplQKL2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovVOmtrs%253D&md5=7129bc498b85275ffa09f839ddeb04a9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2019.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2019.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DGhamari%26aufirst%3DN.%26aulast%3DZarei%26aufirst%3DO.%26aulast%3DArias-Montano%26aufirst%3DJ.-A.%26aulast%3DReiner%26aufirst%3DD.%26aulast%3DDastmalchi%26aufirst%3DS.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DHamzeh-Mivehroud%26aufirst%3DM.%26atitle%3DHistamine%2520H3%2520receptor%2520antagonists%252Finverse%2520agonists%253A%2520Where%2520do%2520they%2520go%253F%26jtitle%3DPharmacol.%2520Ther.%26date%3D2019%26volume%3D200%26spage%3D69%26epage%3D84%26doi%3D10.1016%2Fj.pharmthera.2019.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellenbroek, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiabi, B.</span></span> <span> </span><span class="NLM_article-title">The other side of the histamine H3 receptor</span>. <i>Trends Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.1016/j.tins.2014.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.tins.2014.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=24636456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1Sgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2014&pages=191-199&author=B.+A.+Ellenbroekauthor=B.+Ghiabi&title=The+other+side+of+the+histamine+H3+receptor&doi=10.1016%2Fj.tins.2014.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The other side of the histamine H3 receptor</span></div><div class="casAuthors">Ellenbroek, Bart A.; Ghiabi, Bibinaz</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Neurosciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">191-199</span>CODEN:
                <span class="NLM_cas:coden">TNSCDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-2236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Although histamine H3 receptors are predominantly known as presynaptic receptors, regulating the release of neurotransmitters such as dopamine, acetylcholine, and histamine, in the striatal complex the vast majority of these receptors are actually located on the other side, in other words postsynaptically.  Given their strategic location, they can crucially affect signaling throughout the basal ganglia.  We describe the anatomy and function of H3 receptors within the basal ganglia with a specific focus on their colocalization with dopamine D1 and D2 receptors.  Because the basal ganglia are centrally involved in several major neurol. and psychiatric disorders, we also discuss the therapeutic potential of drugs targeting H3 receptors in the treatment of Parkinson disease (PD), schizophrenia, and addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCTyvYOgmdA7Vg90H21EOLACvtfcHk0li32JUplQKL2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1Sgtbk%253D&md5=a70fb6db22985403ec87e2fef7199a5b</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.tins.2014.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tins.2014.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DEllenbroek%26aufirst%3DB.%2BA.%26aulast%3DGhiabi%26aufirst%3DB.%26atitle%3DThe%2520other%2520side%2520of%2520the%2520histamine%2520H3%2520receptor%26jtitle%3DTrends%2520Neurosci.%26date%3D2014%26volume%3D37%26spage%3D191%26epage%3D199%26doi%3D10.1016%2Fj.tins.2014.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panula, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chazot, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutzmer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W. L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurmond, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, H. L.</span></span> <span> </span><span class="NLM_article-title">International Union of Basic and Clinical Pharmacology. XCVIII. Histamine receptors</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">655</span>, <span class="refDoi"> DOI: 10.1124/pr.114.010249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1124%2Fpr.114.010249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=26084539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCmurnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=601-655&author=P.+Panulaauthor=P.+L.+Chazotauthor=M.+Cowartauthor=R.+Gutzmerauthor=R.+Leursauthor=W.+L.+S.+Liuauthor=H.+Starkauthor=R.+L.+Thurmondauthor=H.+L.+Haas&title=International+Union+of+Basic+and+Clinical+Pharmacology.+XCVIII.+Histamine+receptors&doi=10.1124%2Fpr.114.010249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">International union of basic and clinical pharmacology. XCVIII. histamine receptors</span></div><div class="casAuthors">Panula, Pertti; Chazot, Paul L.; Cowart, Marlon; Gutzmer, Ralf; Leurs, Rob; Liu, Wai L. S.; Stark, Holger; Thurmond, Robin L.; Haas, Helmut L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">601-655</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Histamine is a developmentally highly conserved autacoid found in most vertebrate tissues.  Its physiol. functions are mediated by four 7- transmembrane G protein-coupled receptors (H1R, H2R, H3R, H4R) that are all targets of pharmacol. intervention.  The receptors displaymol. heterogeneity and constitutive activity.  H1R antagonists are long known antiallergic and sedating drugs, whereas the H2R was identified in the 1970s and led to the development of H2R-antagonists that revolutionized stomach ulcer treatment.  The crystal structure of ligand-bound H1R has rendered it possible to design new ligands with novel properties.  The H3R is an autoreceptor and heteroreceptor providing neg. feedback on histaminergic and inhibition on other neurons.  A block of these actions promotes waking.  The H4R occurs on immunocompetent cells and the development of anti-inflammatory drugs is anticipated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg14M2S2Ip6bVg90H21EOLACvtfcHk0li32JUplQKL2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCmurnF&md5=11a54133a707bab57dfb74eb54157f4f</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1124%2Fpr.114.010249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.114.010249%26sid%3Dliteratum%253Aachs%26aulast%3DPanula%26aufirst%3DP.%26aulast%3DChazot%26aufirst%3DP.%2BL.%26aulast%3DCowart%26aufirst%3DM.%26aulast%3DGutzmer%26aufirst%3DR.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DW.%2BL.%2BS.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DThurmond%26aufirst%3DR.%2BL.%26aulast%3DHaas%26aufirst%3DH.%2BL.%26atitle%3DInternational%2520Union%2520of%2520Basic%2520and%2520Clinical%2520Pharmacology.%2520XCVIII.%2520Histamine%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2015%26volume%3D67%26spage%3D601%26epage%3D655%26doi%3D10.1124%2Fpr.114.010249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morales-Figueroa, G.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera-Ramírez, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Pantoja, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escamilla-Sánchez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Hernández, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galván, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arias-Montaño, J.-A.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A and histamine H3 receptors interact at the CAMP/PKA pathway to modulate depolarization-evoked [<sup>3</sup>H]-GABA release from rat striato-pallidal terminals</span>. <i>Purinergic Signal.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1007/s11302-018-9638-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1007%2Fs11302-018-9638-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=30565027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFChsrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=85-93&author=G.-E.+Morales-Figueroaauthor=N.+Rivera-Ram%C3%ADrezauthor=R.+Gonz%C3%A1lez-Pantojaauthor=J.+Escamilla-S%C3%A1nchezauthor=U.+Garc%C3%ADa-Hern%C3%A1ndezauthor=E.+J.+Galv%C3%A1nauthor=J.-A.+Arias-Monta%C3%B1o&title=Adenosine+A2A+and+histamine+H3+receptors+interact+at+the+CAMP%2FPKA+pathway+to+modulate+depolarization-evoked+%5B3H%5D-GABA+release+from+rat+striato-pallidal+terminals&doi=10.1007%2Fs11302-018-9638-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A and histamine H3 receptors interact at the cAMP/PKA pathway to modulate depolarization-evoked [3H]-GABA release from rat striato-pallidal terminals</span></div><div class="casAuthors">Morales-Figueroa, Guadalupe-Elide; Rivera-Ramirez, Nayeli; Gonzalez-Pantoja, Raul; Escamilla-Sanchez, Juan; Garcia-Hernandez, Ubaldo; Galvan, Emilio J.; Arias-Montano, Jose-Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Purinergic Signalling</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-93</span>CODEN:
                <span class="NLM_cas:coden">PSUIA9</span>;
        ISSN:<span class="NLM_cas:issn">1573-9538</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">We previously reported that the activation of histamine H3 receptors (H3Rs) selectively counteracts the facilitatory action of adenosine A2A receptors (A2ARs) on GABA release from rat globus pallidus (GP) isolated nerve terminals (synaptosomes).  In this work, we examd. the mechanisms likely to underlie this functional interaction.  Three possibilities were explored: (a) changes in receptor affinity for agonists induced by phys. A2AR/H3R interaction, (b) opposite actions of A2ARs and H3Rs on depolarization-induced Ca2+ entry, and (c) an A2AR/H3R interaction at the level of adenosine 3',5'-cyclic monophosphate (cAMP) formation.  In GP synaptosomal membranes, H3R activation with immepip reduced A2AR affinity for the agonist 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine hydrochloride hydrate (CGS-21680) (Ki control 4.53 nM; + immepip 9.32 nM), whereas A2AR activation increased H3R affinity for immepip (Ki control 0.63 nM; + CGS-21680 0.26 nM).  Neither A2AR activation nor H3R stimulation modified calcium entry through voltage-gated calcium channels in GP synaptosomes, as evaluated by microfluorometry.  A2AR-mediated facilitation of depolarization-evoked [2,3-3H]-γ-aminobutyric acid ([3H]-GABA) release from GP synaptosomes (130.4 ± 3.6% of control values) was prevented by the PKA inhibitor H-89 and mimicked by the adenylyl cyclase activator forskolin or by 8-Bromo-cAMP, a membrane permeant cAMP analog (169.5 ± 17.3 and 149.5 ± 14.5% of controls).  H3R activation failed to reduce the facilitation of [3H]-GABA release induced by 8-Bromo-cAMP.  In GP slices, A2AR activation stimulated cAMP accumulation (290% of basal) and this effect was reduced (- 75%) by H3R activation.  These results indicate that in striato-pallidal nerve terminals, A2ARs and H3Rs interact at the level of cAMP formation to modulate PKA activity and thus GABA release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofoo4bOHwjQrVg90H21EOLACvtfcHk0lgAiUmBX505xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFChsrfE&md5=2309822165d722a471c7dec75486b34c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1007%2Fs11302-018-9638-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11302-018-9638-z%26sid%3Dliteratum%253Aachs%26aulast%3DMorales-Figueroa%26aufirst%3DG.-E.%26aulast%3DRivera-Ram%25C3%25ADrez%26aufirst%3DN.%26aulast%3DGonz%25C3%25A1lez-Pantoja%26aufirst%3DR.%26aulast%3DEscamilla-S%25C3%25A1nchez%26aufirst%3DJ.%26aulast%3DGarc%25C3%25ADa-Hern%25C3%25A1ndez%26aufirst%3DU.%26aulast%3DGalv%25C3%25A1n%26aufirst%3DE.%2BJ.%26aulast%3DArias-Monta%25C3%25B1o%26aufirst%3DJ.-A.%26atitle%3DAdenosine%2520A2A%2520and%2520histamine%2520H3%2520receptors%2520interact%2520at%2520the%2520CAMP%252FPKA%2520pathway%2520to%2520modulate%2520depolarization-evoked%2520%255B3H%255D-GABA%2520release%2520from%2520rat%2520striato-pallidal%2520terminals%26jtitle%3DPurinergic%2520Signal.%26date%3D2019%26volume%3D15%26spage%3D85%26epage%3D93%26doi%3D10.1007%2Fs11302-018-9638-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Márquez-Gómez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutiérrez-Rodelo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arias, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivares-Reyes, J.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Rijn, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arias-Montaño, J.-A.</span></span> <span> </span><span class="NLM_article-title">Functional histamine H3 and adenosine A2A receptor heteromers in recombinant cells and rat striatum</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">525</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2017.11.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.phrs.2017.11.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=29217157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFKhur3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2018&pages=515-525&author=R.+M%C3%A1rquez-G%C3%B3mezauthor=M.+T.+Robinsauthor=C.+Guti%C3%A9rrez-Rodeloauthor=J.-M.+Ariasauthor=J.-A.+Olivares-Reyesauthor=R.+M.+van+Rijnauthor=J.-A.+Arias-Monta%C3%B1o&title=Functional+histamine+H3+and+adenosine+A2A+receptor+heteromers+in+recombinant+cells+and+rat+striatum&doi=10.1016%2Fj.phrs.2017.11.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Functional histamine H3 and adenosine A2A receptor heteromers in recombinant cells and rat striatum</span></div><div class="casAuthors">Marquez-Gomez, Ricardo; Robins, Meridith T.; Gutierrez-Rodelo, Citlaly; Arias, Juan-Manuel; Olivares-Reyes, Jesus-Alberto; Rijn, Richard M. van; Arias-Montano, Jose-Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">515-525</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In the striatum, histamine H3 receptors (H3Rs) are co-expressed with adenosine A2A receptors (A2ARs) in the cortico-striatal glutamatergic afferents and the GABAergic medium-sized spiny neurons that originate the indirect pathway of the basal ganglia.  This location allows H3Rs and A2ARs to regulate the striatal GABAergic and glutamatergic transmission.  However, whether these receptors can phys. interact has not yet been assessed.  To test this hypothesis, a heteromer-selective in vitro assay was used to detect functional complementation between a chimeric A2AR302-Gαqi4 and wild-type H3Rs in transfected HEK-293T cells.  H3R activation with the agonist RAMH resulted in Ca2+ mobilization (pEC50 7.31 ± 0.23; maximal stimulation, Emax 449 ± 25% of basal) indicative of receptor heterodimerization.  Functional H3R-A2AR heteromers were confirmed by co-immunopptn. and observations of differential cAMP signaling when both receptors were co-expressed in the same cells.  In membranes from rat striatal synaptosomes, H3R activation decreased A2AR affinity for the agonist CGS-21680 (pKi values 8.10 ± 0.04 and 7.70 ± 0.04).  Moreover, H3Rs and A2ARs co-immunopptd. in protein exts. from striatal synaptosomes.  These results support the existence of a H3R-A2AR heteromer with possible physiol. implications for the modulation of the intra-striatal transmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM061OOBTBDbVg90H21EOLACvtfcHk0lgAiUmBX505xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFKhur3M&md5=beb1748c853d2b65722867ea18d1cb04</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2017.11.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2017.11.036%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A1rquez-G%25C3%25B3mez%26aufirst%3DR.%26aulast%3DRobins%26aufirst%3DM.%2BT.%26aulast%3DGuti%25C3%25A9rrez-Rodelo%26aufirst%3DC.%26aulast%3DArias%26aufirst%3DJ.-M.%26aulast%3DOlivares-Reyes%26aufirst%3DJ.-A.%26aulast%3Dvan%2BRijn%26aufirst%3DR.%2BM.%26aulast%3DArias-Monta%25C3%25B1o%26aufirst%3DJ.-A.%26atitle%3DFunctional%2520histamine%2520H3%2520and%2520adenosine%2520A2A%2520receptor%2520heteromers%2520in%2520recombinant%2520cells%2520and%2520rat%2520striatum%26jtitle%3DPharmacol.%2520Res.%26date%3D2018%26volume%3D129%26spage%3D515%26epage%3D525%26doi%3D10.1016%2Fj.phrs.2017.11.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morales-Figueroa, G.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Márquez-Gómez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Pantoja, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escamilla-Sánchez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arias-Montaño, J.-A.</span></span> <span> </span><span class="NLM_article-title">Histamine H3 receptor activation counteracts adenosine A2A receptor-mediated enhancement of depolarization-evoked [<sup>3</sup>H]-GABA release from rat globus pallidus synaptosomes</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">645</span>, <span class="refDoi"> DOI: 10.1021/cn500001m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn500001m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptVajsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=637-645&author=G.-E.+Morales-Figueroaauthor=R.+M%C3%A1rquez-G%C3%B3mezauthor=R.+Gonz%C3%A1lez-Pantojaauthor=J.+Escamilla-S%C3%A1nchezauthor=J.-A.+Arias-Monta%C3%B1o&title=Histamine+H3+receptor+activation+counteracts+adenosine+A2A+receptor-mediated+enhancement+of+depolarization-evoked+%5B3H%5D-GABA+release+from+rat+globus+pallidus+synaptosomes&doi=10.1021%2Fcn500001m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Histamine H3 Receptor Activation Counteracts Adenosine A2A Receptor-Mediated Enhancement of Depolarization-Evoked [3H]-GABA Release from Rat Globus Pallidus Synaptosomes</span></div><div class="casAuthors">Morales-Figueroa, Guadalupe-Elide; Marquez-Gomez, Ricardo; Gonzalez-Pantoja, Raul; Escamilla-Sanchez, Juan; Arias-Montano, Jose-Antonio</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">637-645</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">High levels of histamine H3 receptors (H3Rs) are found in the globus pallidus (GP), a neuronal nucleus in the basal ganglia involved in the control of motor behavior.  By using rat GP isolated nerve terminals (synaptosomes), we studied whether H3R activation modified the previously reported enhancing action of adenosine A2A receptor (A2AR) stimulation on depolarization-evoked [3H]-GABA release.  At 3 and 10 nM, the A2AR agonist CGS-21680 enhanced [3H]-GABA release induced by high K+ (20 mM) and the effect of 3 nM CGS-21680 was prevented by the A2AR antagonist ZM-241385 (100 nM).  The presence of presynaptic H3Rs was confirmed by the specific binding of N-α-[methyl-3H]-histamine to membranes from GP synaptosomes (max. binding, Bmax, 1327 ± 79 fmol/mg protein; dissocn. const., Kd, 0.74 nM), which was inhibited by the H3R ligands immepip, clobenpropit, and A-331440 (inhibition consts., Ki, 0.28, 8.53, and 316 nM, resp.).  Perfusion of synaptosomes with the H3R agonist immepip (100 nM) had no effect on K+-evoked [3H]-GABA release, but inhibited the stimulatory action of A2AR activation.  In turn, the effect of immepip was blocked by the H3R antagonist clobenpropit, which had no significant effect of its own on K+-induced [3H]-GABA release.  These data indicate that H3R activation selectively counteracts the facilitatory action of A2AR stimulation on GABA release from striato-pallidal projections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzGRDLA1e7j7Vg90H21EOLACvtfcHk0lgAiUmBX505xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptVajsb8%253D&md5=8ff84f4aeaecb9ce668bc8a8f9adb9a4</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fcn500001m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn500001m%26sid%3Dliteratum%253Aachs%26aulast%3DMorales-Figueroa%26aufirst%3DG.-E.%26aulast%3DM%25C3%25A1rquez-G%25C3%25B3mez%26aufirst%3DR.%26aulast%3DGonz%25C3%25A1lez-Pantoja%26aufirst%3DR.%26aulast%3DEscamilla-S%25C3%25A1nchez%26aufirst%3DJ.%26aulast%3DArias-Monta%25C3%25B1o%26aufirst%3DJ.-A.%26atitle%3DHistamine%2520H3%2520receptor%2520activation%2520counteracts%2520adenosine%2520A2A%2520receptor-mediated%2520enhancement%2520of%2520depolarization-evoked%2520%255B3H%255D-GABA%2520release%2520from%2520rat%2520globus%2520pallidus%2520synaptosomes%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2014%26volume%3D5%26spage%3D637%26epage%3D645%26doi%3D10.1021%2Fcn500001m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wingen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Scaffold variations in amine warhead of histamine H3 receptor antagonists</span>. <i>Drug Discov. Today Technol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e483</span>– <span class="NLM_lpage">e489</span>, <span class="refDoi"> DOI: 10.1016/j.ddtec.2013.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.ddtec.2013.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=24451638" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=e483-e489&author=K.+Wingenauthor=H.+Stark&title=Scaffold+variations+in+amine+warhead+of+histamine+H3+receptor+antagonists&doi=10.1016%2Fj.ddtec.2013.07.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2013.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2013.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DWingen%26aufirst%3DK.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DScaffold%2520variations%2520in%2520amine%2520warhead%2520of%2520histamine%2520H3%2520receptor%2520antagonists%26jtitle%3DDrug%2520Discov.%2520Today%2520Technol.%26date%3D2013%26volume%3D10%26spage%3De483%26epage%3De489%26doi%3D10.1016%2Fj.ddtec.2013.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Affini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagenow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zivkovic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson’s disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">487</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.ejmech.2018.02.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=29477889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsF2msbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2018&pages=487-497&author=A.+Affiniauthor=S.+Hagenowauthor=A.+Zivkovicauthor=J.+Marco-Contellesauthor=H.+Stark&title=Novel+indanone+derivatives+as+MAO+B%2FH3R+dual-targeting+ligands+for+treatment+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.ejmech.2018.02.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease</span></div><div class="casAuthors">Affini, Anna; Hagenow, Stefanie; Zivkovic, Aleksandra; Marco-Contelles, Jose; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">487-497</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders.  As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, the authors synthesized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the treatment of PD.  Three series of compds. were developed by attaching the H3R pharmacophore to indanone-related MAO B motifs, leading to development of MAO B/H3R DTLs.  Among synthesized indanone DTLs, compds. bearing the 2-benzylidene-1-indanone core structure showed MAO B preferring inhibition capabilities along with nanomolar hH3R affinity.  Substitution of C5 and C6 position of the 2-benzylidene-1-indanones with lipophilic substituents revealed three promising candidates exhibiting inhibitory potencies for MAO B with IC50 values ranging from 1931 nM to 276 nM and high affinities at hH3R (Ki < 50 nM).  Compd. 3f ((E)-5-((4-bromobenzyl)oxy)-2-(4-(3-(piperidin-1-yl)propoxy)benzylidene)-2,3-dihydro-1H-inden-1-one, MAO B IC50 = 276 nM, hH3R Ki = 6.5 nM) showed highest preference for MAO B over MAO A (SI > 36).  Interestingly, IC50 detns. after preincubation of enzyme and DTLs revealed also nanomolar MAO B potency for 3e (MAO B IC50 = 232 nM), a structural isomer of 3f, and 3d ((E)-5-fluoro-2-[4-[3-(piperidin-1-yl)propoxy]benzylidene]-2,3-dihydro-1H-inden-1-one) (MAO B IC50 = 541 nM), suggesting time-dependent inhibition modes.  Reversibility of inhibition for all three compds. were confirmed by diln. studies in excess of substrate.  Thus, indanone-substituted derivs. are promising lead structures for the design of MAO B/hH3R DTLs as novel therapeutic approach of PD therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozgPusP5M44bVg90H21EOLACvtfcHk0lh0RCygHjjabg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsF2msbY%253D&md5=9b915ce055294d79bfa8e585a19e6466</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DAffini%26aufirst%3DA.%26aulast%3DHagenow%26aufirst%3DS.%26aulast%3DZivkovic%26aufirst%3DA.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DNovel%2520indanone%2520derivatives%2520as%2520MAO%2520B%252FH3R%2520dual-targeting%2520ligands%2520for%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D148%26spage%3D487%26epage%3D497%26doi%3D10.1016%2Fj.ejmech.2018.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matasi, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neustadt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arik, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulshian, D. B.</span></span> <span> </span><span class="NLM_article-title">The discovery and synthesis of novel adenosine receptor (A2A) antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1333</span>– <span class="NLM_lpage">1336</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.01.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.bmcl.2005.01.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=15713381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlShuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=1333-1336&author=J.+J.+Matasiauthor=J.+P.+Caldwellauthor=J.+Haoauthor=B.+Neustadtauthor=L.+Arikauthor=C.+J.+Fosterauthor=J.+Lachowiczauthor=D.+B.+Tulshian&title=The+discovery+and+synthesis+of+novel+adenosine+receptor+%28A2A%29+antagonists&doi=10.1016%2Fj.bmcl.2005.01.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery and synthesis of novel adenosine receptor (A2A) antagonists</span></div><div class="casAuthors">Matasi, Julius J.; Caldwell, John P.; Hao, Jinsong; Neustadt, Bernard; Arik, Leyla; Foster, Carolyn J.; Lachowicz, Jean; Tulshian, Deen B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1333-1336</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In high throughput screening of our file compds., a novel structure I was identified as a potent A2A receptor antagonist with no selectivity over the A1 adenosine receptor.  The structure-activity relationship investigation using I as a template lead to identification of a novel class of compds. as potent and selective antagonists of A2A adenosine receptor.  One compd., identified to be the most potent A2A receptor antagonist (Ki = 0.8 nM) showed 100-fold selectivity over the A1 adenosine receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgJZio7c8kKbVg90H21EOLACvtfcHk0lh0RCygHjjabg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlShuro%253D&md5=e5f2ff6291e06df09dc58098f1dbfe0e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.01.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.01.019%26sid%3Dliteratum%253Aachs%26aulast%3DMatasi%26aufirst%3DJ.%2BJ.%26aulast%3DCaldwell%26aufirst%3DJ.%2BP.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DNeustadt%26aufirst%3DB.%26aulast%3DArik%26aufirst%3DL.%26aulast%3DFoster%26aufirst%3DC.%2BJ.%26aulast%3DLachowicz%26aufirst%3DJ.%26aulast%3DTulshian%26aufirst%3DD.%2BB.%26atitle%3DThe%2520discovery%2520and%2520synthesis%2520of%2520novel%2520adenosine%2520receptor%2520%2528A2A%2529%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D1333%26epage%3D1336%26doi%3D10.1016%2Fj.bmcl.2005.01.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shook, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. F.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptor antagonists and Parkinson’s disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">555</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1021/cn2000537</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn2000537" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVSrsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=555-567&author=B.+C.+Shookauthor=P.+F.+Jackson&title=Adenosine+A2A+receptor+antagonists+and+Parkinson%E2%80%99s+disease&doi=10.1021%2Fcn2000537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A Receptor Antagonists and Parkinson's Disease</span></div><div class="casAuthors">Shook, Brian C.; Jackson, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">555-567</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This Review summarizes and updates the work on adenosine A2A receptor antagonists for Parkinson's disease from 2006 to the present.  There have been numerous publications, patent applications, and press releases within this time frame that highlight new medicinal chem. approaches to this attractive and promising target to treat Parkinson's disease.  The Review is broken down by scaffold type and will discuss the efforts to optimize particular scaffolds for activity, pharmacokinetics, and other drug discovery parameters.  The majority of approaches focus on prepg. selective A2A antagonists, but a few approaches to dual A2A/A1 antagonists will also be highlighted.  The in vivo profiles of compds. will be highlighted and discussed to compare activities across different chem. series.  A clin. report and update will be given on compds. that have entered clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9jbqVC-a6P7Vg90H21EOLACvtfcHk0lh0RCygHjjabg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVSrsrc%253D&md5=81746259f96dd1a270f12c3cb2dbe1d3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fcn2000537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn2000537%26sid%3Dliteratum%253Aachs%26aulast%3DShook%26aufirst%3DB.%2BC.%26aulast%3DJackson%26aufirst%3DP.%2BF.%26atitle%3DAdenosine%2520A2A%2520receptor%2520antagonists%2520and%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2011%26volume%3D2%26spage%3D555%26epage%3D567%26doi%3D10.1021%2Fcn2000537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensenhauser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shook, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassnick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, K.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Overcoming the genotoxicity of a pyrrolidine substituted arylindenopyrimidine as a potent dual adenosine A2A/A1 antagonist by minimizing bioactivation to an iminium ion reactive intermediate</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1012</span>– <span class="NLM_lpage">1030</span>, <span class="refDoi"> DOI: 10.1021/tx1004437</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx1004437" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVGjsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1012-1030&author=H.-K.+Limauthor=J.+Chenauthor=C.+Sensenhauserauthor=K.+Cookauthor=R.+Prestonauthor=T.+Thomasauthor=B.+Shookauthor=P.+F.+Jacksonauthor=S.+Rassnickauthor=K.+Rhodes&title=Overcoming+the+genotoxicity+of+a+pyrrolidine+substituted+arylindenopyrimidine+as+a+potent+dual+adenosine+A2A%2FA1+antagonist+by+minimizing+bioactivation+to+an+iminium+ion+reactive+intermediate&doi=10.1021%2Ftx1004437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming the Genotoxicity of a Pyrrolidine Substituted Arylindenopyrimidine As a Potent Dual Adenosine A2A/A1 Antagonist by Minimizing Bioactivation to an Iminium Ion Reactive Intermediate</span></div><div class="casAuthors">Lim, Heng-Keang; Chen, Jie; Sensenhauser, Carlo; Cook, Kevin; Preston, Robert; Thomas, Tynisha; Shook, Brian; Jackson, Paul F.; Rassnick, Stefanie; Rhodes, Kenneth; Gopaul, Vedwatee; Salter, Rhys; Silva, Jose; Evans, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1012-1030</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">2-Amino-4-phenyl-8-pyrrolidin-1-ylmethyl-indeno[1,2-d]pyrimidin-5-one (1) is a novel and potent selective dual A2A/A1 adenosine receptor antagonist from the arylindenopyrimidine series that was detd. to be genotoxic in both the Ames and Mouse Lymphoma L5178Y assays only following metabolic activation.  Compd. 1 was identified as a frame-shift mutagen in Salmonella typhimurium tester strain TA1537 as indicated by a significant dose-dependent increase in revertant colonies as compared to the vehicle control.  The metabolic activation-dependent irreversible covalent binding of radioactivity to DNA, recovery of 1 and its enamine metabolite from acid hydrolysis of covalently modified DNA, and protection of covalent binding to DNA by both cyanide ion and methoxylamine suggest that the frame-shift mutation in TA1537 strain involved covalent binding instead of simple intercalation to DNA.  Compd. 1 was bioactivated to endocyclic iminium ion, aldehyde, epoxide, and α,β-unsatd. keto reactive intermediates from the detection of cyano, oxime, and glutathione conjugates by data-dependent high resoln. accurate mass measurements.  Collision-induced dissocn. of these conjugates provided evidence for bioactivation of the pyrrolidine ring of 1.  The epoxide and α,β-unsatd. keto reactive intermediates were unlikely to cause the genotoxicity of 1 because the formation of their glutathione adducts did not ameliorate the binding of compd. related material to DNA.  Instead, the endocyclic iminium ions and amino aldehydes were likely candidates responsible for genotoxicity based on, first, the protection afforded by both cyanide ion and methoxylamine, which reduced the potential to form covalent adducts with DNA, and, second, analogs of 1 designed with low probability to form these reactive intermediates were not genotoxic.  It was concluded that 1 also had the potential to be mutagenic in humans based on observing the endocyclic iminium ion following incubation with a human liver S9 prepn. and the commensurate detection of DNA adducts.  An understanding of this genotoxicity mechanism supported an evidence-based approach to selectively modify the structure of 1 which resulted in analogs being synthesized that were devoid of a genotoxic liability.  In addn., potency and selectivity against both adenosine A2A and A1 receptors were maintained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9N__9056Cr7Vg90H21EOLACvtfcHk0lhgDgBkR5SOVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVGjsLc%253D&md5=ef0a49a0c0889517eb37018fe808367f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Ftx1004437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx1004437%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DH.-K.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSensenhauser%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DK.%26aulast%3DPreston%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DT.%26aulast%3DShook%26aufirst%3DB.%26aulast%3DJackson%26aufirst%3DP.%2BF.%26aulast%3DRassnick%26aufirst%3DS.%26aulast%3DRhodes%26aufirst%3DK.%26atitle%3DOvercoming%2520the%2520genotoxicity%2520of%2520a%2520pyrrolidine%2520substituted%2520arylindenopyrimidine%2520as%2520a%2520potent%2520dual%2520adenosine%2520A2A%252FA1%2520antagonist%2520by%2520minimizing%2520bioactivation%2520to%2520an%2520iminium%2520ion%2520reactive%2520intermediate%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1012%26epage%3D1030%26doi%3D10.1021%2Ftx1004437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shook, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassnick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crooke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ault, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbay, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, K.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Design and characterization of optimized adenosine A2A/A1 receptor antagonists for the treatment of Parkinson’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1402</span>– <span class="NLM_lpage">1417</span>, <span class="refDoi"> DOI: 10.1021/jm201640m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201640m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFWqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1402-1417&author=B.+C.+Shookauthor=S.+Rassnickauthor=N.+Wallaceauthor=J.+Crookeauthor=M.+Aultauthor=D.+Chakravartyauthor=J.+K.+Barbayauthor=A.+Wangauthor=M.+T.+Powellauthor=K.+Leonard&title=Design+and+characterization+of+optimized+adenosine+A2A%2FA1+receptor+antagonists+for+the+treatment+of+Parkinson%E2%80%99s+disease&doi=10.1021%2Fjm201640m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Characterization of Optimized Adenosine A2A/A1 Receptor Antagonists for the Treatment of Parkinson's Disease</span></div><div class="casAuthors">Shook, Brian C.; Rassnick, Stefanie; Wallace, Nathaniel; Crooke, Jeffrey; Ault, Mark; Chakravarty, Devraj; Barbay, J. Kent; Wang, Aihua; Powell, Mark T.; Leonard, Kristi; Alford, Vernon; Scannevin, Robert H.; Carroll, Karen; Lampron, Lisa; Westover, Lori; Lim, Heng-Keang; Russell, Ronald; Branum, Shawn; Wells, Kenneth M.; Damon, Sandra; Youells, Scott; Li, Xun; Beauchamp, Derek A.; Rhodes, Kenneth; Jackson, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1402-1417</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design and characterization of two, dual adenosine A2A/A1 receptor antagonists in several animal models of Parkinson's disease is described.  A pyrrolidinylmethyl aminoindenopyrimidinone (I) was previously reported as a potential treatment for Parkinson's disease.  Further characterization of I revealed that it was metabolized to reactive intermediates that caused its genotoxicity in the Ames and mouse lymphoma L51784 assays.  The identification of the metabolites enabled the prepn. of two optimized compds., an aminooxoindenopyrimidinecarbonyl piperazine and a morpholinylethoxy aminoindenopyrimidinone that were devoid of the metabolic liabilities assocd. with I.  The aminooxoindenopyrimidinecarbonyl piperazine and the morpholinylethoxy aminoindenopyrimidinone are potent dual A2A/A1 receptor antagonists that have excellent activity, after oral administration, across a no. of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse and rat models of reserpine-induced akinesia, and the rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonnYVdjHJevrVg90H21EOLACvtfcHk0lhgDgBkR5SOVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFWqug%253D%253D&md5=987f8aed3e075d7caee66eb464fd94fb</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm201640m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201640m%26sid%3Dliteratum%253Aachs%26aulast%3DShook%26aufirst%3DB.%2BC.%26aulast%3DRassnick%26aufirst%3DS.%26aulast%3DWallace%26aufirst%3DN.%26aulast%3DCrooke%26aufirst%3DJ.%26aulast%3DAult%26aufirst%3DM.%26aulast%3DChakravarty%26aufirst%3DD.%26aulast%3DBarbay%26aufirst%3DJ.%2BK.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DPowell%26aufirst%3DM.%2BT.%26aulast%3DLeonard%26aufirst%3DK.%26atitle%3DDesign%2520and%2520characterization%2520of%2520optimized%2520adenosine%2520A2A%252FA1%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1402%26epage%3D1417%26doi%3D10.1021%2Fjm201640m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Atack, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shook, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassnick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drinkenburg, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahnaou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Te Riele, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrupka, B.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson’s disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1019</span>, <span class="refDoi"> DOI: 10.1021/cn5001606</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn5001606" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsV2qtr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1005-1019&author=J.+R.+Atackauthor=B.+C.+Shookauthor=S.+Rassnickauthor=P.+F.+Jacksonauthor=K.+Rhodesauthor=W.+H.+Drinkenburgauthor=A.+Ahnaouauthor=P.+Te+Rieleauthor=X.+Langloisauthor=B.+Hrupka&title=JNJ-40255293%2C+a+novel+adenosine+A2A%2FA1+antagonist+with+efficacy+in+preclinical+models+of+Parkinson%E2%80%99s+disease&doi=10.1021%2Fcn5001606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">JNJ-40255293, a Novel Adenosine A2A/A1 Antagonist with Efficacy in Preclinical Models of Parkinson's Disease</span></div><div class="casAuthors">Atack, John R.; Shook, Brian C.; Rassnick, Stefanie; Jackson, Paul F.; Rhodes, Kenneth; Drinkenburg, Wilhelmus H.; Ahnaou, Abdallah; te Riele, Paula; Langlois, Xavier; Hrupka, Brian; De Haes, Patrick; Hendrickx, Herman; Aerts, Nancy; Hens, Koen; Wellens, Annemie; Vermeire, Jef; Megens, Anton A. H. P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1005-1019</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Adenosine A2A antagonists are believed to have therapeutic potential in the treatment of Parkinson's disease (PD).  We have characterized the dual adenosine A2A/A1 receptor antagonist JNJ-40255293 (2-amino-8-[2-(4-morpholinyl)ethoxy]-4-phenyl-5H-indeno[1,2-d]pyrimidin-5-one).  JNJ-40255293 was a high-affinity (7.5 nM) antagonist at the human A2A receptor with 7-fold in vitro selectivity vs. the human A1 receptor.  A similar A2A:A1 selectivity was seen in vivo (ED50's of 0.21 and 2.1 mg/kg p.o. for occupancy of rat brain A2A and A1 receptors, resp.).  The plasma EC50 for occupancy of rat brain A2A receptors was 13 ng/mL.  In sleep-wake encephalog. (EEG) studies, JNJ-40255293 dose-dependently enhanced a consolidated waking assocd. with a subsequent delayed compensatory sleep (min. ED: 0.63 mg/kg p.o.).  As measured by microdialysis, JNJ-40255293 did not affect dopamine and noradrenaline release in the prefrontal cortex and the striatum.  However, it was able to reverse effects (catalepsy, hypolocomotion, and conditioned avoidance impairment in rats; hypolocomotion in mice) produced by the dopamine D2 antagonist haloperidol.  The compd. also potentiated the agitation induced by the dopamine agonist apomorphine.  JNJ-40255293 also reversed hypolocomotion produced by the dopamine-depleting agent reserpine and potentiated the effects of L-dihydroxyphenylalanine (L-DOPA) in rats with unilateral 6-hydroxydopamine-induced lesions of the nigro-striatal pathway, an animal model of Parkinson's disease.  Extrapolating from the rat receptor occupancy dose-response curve, the occupancy required to produce these various effects in rats was generally in the range of 60-90%.  The findings support the continued research and development of A2A antagonists as potential treatments for PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg4IuostoOT7Vg90H21EOLACvtfcHk0liwNa6l78NisQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsV2qtr3F&md5=fdad31db89148d0d2920afb8ca33788d</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fcn5001606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn5001606%26sid%3Dliteratum%253Aachs%26aulast%3DAtack%26aufirst%3DJ.%2BR.%26aulast%3DShook%26aufirst%3DB.%2BC.%26aulast%3DRassnick%26aufirst%3DS.%26aulast%3DJackson%26aufirst%3DP.%2BF.%26aulast%3DRhodes%26aufirst%3DK.%26aulast%3DDrinkenburg%26aufirst%3DW.%2BH.%26aulast%3DAhnaou%26aufirst%3DA.%26aulast%3DTe%2BRiele%26aufirst%3DP.%26aulast%3DLanglois%26aufirst%3DX.%26aulast%3DHrupka%26aufirst%3DB.%26atitle%3DJNJ-40255293%252C%2520a%2520novel%2520adenosine%2520A2A%252FA1%2520antagonist%2520with%2520efficacy%2520in%2520preclinical%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2014%26volume%3D5%26spage%3D1005%26epage%3D1019%26doi%3D10.1021%2Fcn5001606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mikó, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligneau, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertz, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrang, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robin
Ganellin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schunack, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Structural variations of 1-(4-(phenoxymethyl)benzyl)piperidines as nonimidazole histamine H3 receptor antagonists</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2727</span>– <span class="NLM_lpage">2736</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2004.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.bmc.2004.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=15110854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtl2nurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=2727-2736&author=T.+Mik%C3%B3author=X.+Ligneauauthor=H.+H.+Pertzauthor=J.-M.+Arrangauthor=C.+Robin%0AGanellinauthor=J.-C.+Schwartzauthor=W.+Schunackauthor=H.+Stark&title=Structural+variations+of+1-%284-%28phenoxymethyl%29benzyl%29piperidines+as+nonimidazole+histamine+H3+receptor+antagonists&doi=10.1016%2Fj.bmc.2004.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Structural variations of 1-(4-(phenoxymethyl)benzyl)piperidines as nonimidazole histamine H3 receptor antagonists</span></div><div class="casAuthors">Miko, Tibor; Ligneau, Xavier; Pertz, Heinz H.; Arrang, Jean-Michel; Ganellin, C. Robin; Schwartz, Jean-Charles; Schunack, Walter; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2727-2736</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Recent bioisoteric replacements in histamine H3 receptor ligands with an exchange of the imidazole moiety by a piperidino group as well as of the trimethylene chain in 4-((3-phenoxy)propyl)-1H-imidazole derivs. (proxifan class) by an α,α'-xylendiyl linker represents the starting point in the development of 1-(4-(phenoxymethyl)benzyl)piperidines as a new class of nonimidazole histamine H3 receptor antagonists.  According to different strategies in optimization of imidazole-contg. antagonists the central benzyl Ph ether moiety was replaced by numerous other polar functionalities.  Addnl., the ortho- and meta-analogs of the lead were synthesized to det. the influence of the position of the piperidinomethyl substituent.  The new compds. were tested in an in vitro binding assay for their affinities for cloned human H3 receptors stably expressed in CHO-K1 cells and for their oral in vivo potencies brain in a functional screening assay in the brain of mice.  Addnl., activities of selected compds. were detd. in the guinea-pig ileum functional test model.  In contrast to the analogs ortho-substituted compds. all other compds. maintained respectable affinities for the human H3 receptor (-logKi values 6.3-7.5).  Despite the results from other classes of compds. the 4-Me substituted derivs. generally displayed higher affinities than the corresponding 4-chloro substituted compds.  In vivo only the inverse Ph benzyl ether (3) showed worthwhile antagonist potencies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVX2atR-P62bVg90H21EOLACvtfcHk0liwNa6l78NisQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtl2nurg%253D&md5=9c7c3d41d97af2ce3d6de7d17c15df9f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2004.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2004.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DMik%25C3%25B3%26aufirst%3DT.%26aulast%3DLigneau%26aufirst%3DX.%26aulast%3DPertz%26aufirst%3DH.%2BH.%26aulast%3DArrang%26aufirst%3DJ.-M.%26aulast%3DRobin%2BGanellin%26aufirst%3DC.%26aulast%3DSchwartz%26aufirst%3DJ.-C.%26aulast%3DSchunack%26aufirst%3DW.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DStructural%2520variations%2520of%25201-%25284-%2528phenoxymethyl%2529benzyl%2529piperidines%2520as%2520nonimidazole%2520histamine%2520H3%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2004%26volume%3D12%26spage%3D2727%26epage%3D2736%26doi%3D10.1016%2Fj.bmc.2004.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span> <span> </span><span class="NLM_article-title">Recent developments in adenosine receptor ligands and their potential as novel drugs</span>. <i>Natl. Inst. Health</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1808</i></span>,  <span class="NLM_fpage">1290</span>– <span class="NLM_lpage">1308</span>, <span class="refDoi"> DOI: 10.1016/j.bbamem.2010.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.bbamem.2010.12.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1808&publication_year=2011&pages=1290-1308&author=C.+E.+M%C3%BCllerauthor=K.+A.+Jacobson&title=Recent+developments+in+adenosine+receptor+ligands+and+their+potential+as+novel+drugs&doi=10.1016%2Fj.bbamem.2010.12.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamem.2010.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamem.2010.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DRecent%2520developments%2520in%2520adenosine%2520receptor%2520ligands%2520and%2520their%2520potential%2520as%2520novel%2520drugs%26jtitle%3DNatl.%2520Inst.%2520Health%26date%3D2011%26volume%3D1808%26spage%3D1290%26epage%3D1308%26doi%3D10.1016%2Fj.bbamem.2010.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">The physicochemical challenges of designing multiple ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4961</span>– <span class="NLM_lpage">4970</span>, <span class="refDoi"> DOI: 10.1021/jm0603015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4961-4970&author=R.+Morphyauthor=Z.+Rankovic&title=The+physicochemical+challenges+of+designing+multiple+ligands&doi=10.1021%2Fjm0603015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The Physicochemical Challenges of Designing Multiple Ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4961-4970</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compds. designed to bind more than one target can provide a therapeutic benefit relative to highly target-selective ligands.  The physicochem. properties of designed multiple ligands were found to be less druglike than those for preclin. compds. in general.  These properties are controlled by the superfamily to which the targets belong and the lead discovery strategy that was followed.  The properties for peptide G-protein-coupled receptor (GPCR) ligands were the least favorable for oral delivery, whereas transporter, monoamine GPCR, and oxidase ligands were the most druglike.  The lead discovery strategy, framework combination or screening, exerts a profound influence on the property values.  Combining the frameworks from two selective ligands often results in large, complex dual ligands, but druglike ligands can be achieved if the degree of framework overlap is maximized and the size of the selective ligands minimized.  For some target combinations, a screening approach may provide a route to smaller, less complex leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonGHbXyxgv4LVg90H21EOLACvtfcHk0liwNa6l78NisQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D&md5=c7a227848516d0aa58ed037a582943fe</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm0603015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603015%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DThe%2520physicochemical%2520challenges%2520of%2520designing%2520multiple%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4961%26epage%3D4970%26doi%3D10.1021%2Fjm0603015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zewge, D.</span></span> <span> </span><span class="NLM_article-title">Recent advances in ether dealkylation</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7833</span>– <span class="NLM_lpage">7863</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2005.05.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.tet.2005.05.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2005&pages=7833-7863&author=S.+A.+Weissmanauthor=D.+Zewge&title=Recent+advances+in+ether+dealkylation&doi=10.1016%2Fj.tet.2005.05.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in ether dealkylation</span></div><div class="casAuthors">Weissman, Steven A.; Zewge, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">7833-7863</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review on the developments from 1995 through the end of 2004 with focus on reagents of practical value and some level of generality.  The following topics are discussed: deprotection of aryl and alkyl ethers (including propargylic), allyl and related ethers (including isoprenyl), benzylic ethers (including trityl), and cyclic ethers.  Aspects of regio- and chemoselectivities are also mentioned.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHYugNUDxpjLVg90H21EOLACvtfcHk0liAjEJxipq1qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFCltro%253D&md5=41a698090e3cc03e616d3c972d52e788</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2005.05.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2005.05.041%26sid%3Dliteratum%253Aachs%26aulast%3DWeissman%26aufirst%3DS.%2BA.%26aulast%3DZewge%26aufirst%3DD.%26atitle%3DRecent%2520advances%2520in%2520ether%2520dealkylation%26jtitle%3DTetrahedron%26date%3D2005%26volume%3D61%26spage%3D7833%26epage%3D7863%26doi%3D10.1016%2Fj.tet.2005.05.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tomasch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwed, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Novel chalcone-based fluorescent human histamine H(3) receptor ligands as pharmacological tools</span>. <i>Front. Syst. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">14</span>, <span class="refDoi"> DOI: 10.3389/fnsys.2012.00014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.3389%2Ffnsys.2012.00014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=22470321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFGqtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=14&author=M.+Tomaschauthor=J.+S.+Schwedauthor=L.+Weizelauthor=H.+Stark&title=Novel+chalcone-based+fluorescent+human+histamine+H%283%29+receptor+ligands+as+pharmacological+tools&doi=10.3389%2Ffnsys.2012.00014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Novel chalcone-based fluorescent human histamine H3 receptor ligands as pharmacological tools</span></div><div class="casAuthors">Tomasch, Miriam; Schwed, J. Stephan; Weizel, Lilia; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Systems Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">March</span>),
    <span class="NLM_cas:pages">14</span>CODEN:
                <span class="NLM_cas:coden">FSNRAR</span>;
        ISSN:<span class="NLM_cas:issn">1662-5137</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Novel fluorescent chalcone-based ligands at human histamine H3 receptors (hH3R) have been designed, synthesized and characterized.  Compds. described are non-imidazole analogs of ciproxifan with a tetralone motif.  Tetralones as chem. precursors and related fluorescent chalcones exhibit affinities at hH3R in the same concn. range like the ref. antagonist ciproxifan (hH3R pKi value of 7.2).  Fluorescence characterization of our novel ligands shows emission maxima about 570 nm for yellow fluorescent chalcones and ≥600 nm for the red fluorescent derivs.  Interferences to cellular autofluorescence could be excluded.  All synthesized chalcone compds. could be used to visualize hH3R proteins in stably transfected HEK-293 cells using confocal laser scanning fluorescence microscopy.  These novel fluorescent ligands possess high potential to be used as pharmacol. tools for hH3R visualization in different tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdUye1majEG7Vg90H21EOLACvtfcHk0liAjEJxipq1qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFGqtLo%253D&md5=f5347376b0c63ee9b9bbbfe58a39596c</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.3389%2Ffnsys.2012.00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnsys.2012.00014%26sid%3Dliteratum%253Aachs%26aulast%3DTomasch%26aufirst%3DM.%26aulast%3DSchwed%26aufirst%3DJ.%2BS.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DNovel%2520chalcone-based%2520fluorescent%2520human%2520histamine%2520H%25283%2529%2520receptor%2520ligands%2520as%2520pharmacological%2520tools%26jtitle%3DFront.%2520Syst.%2520Neurosci.%26date%3D2012%26volume%3D6%26spage%3D14%26doi%3D10.3389%2Ffnsys.2012.00014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sander, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kottke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffend, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camelin, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligneau, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J.-C.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">First metal-containing histamine H3 receptor ligands</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2578</span>– <span class="NLM_lpage">2581</span>, <span class="refDoi"> DOI: 10.1021/ol100419y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol100419y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsleht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=2578-2581&author=K.+Sanderauthor=T.+Kottkeauthor=C.+Hoffendauthor=M.+Walterauthor=L.+Weizelauthor=J.-C.+Camelinauthor=X.+Ligneauauthor=E.+H.+Schneiderauthor=R.+Seifertauthor=J.-C.+Schwartz&title=First+metal-containing+histamine+H3+receptor+ligands&doi=10.1021%2Fol100419y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">First Metal-Containing Histamine H3 Receptor Ligands</span></div><div class="casAuthors">Sander, Kerstin; Kottke, Tim; Hoffend, Claas; Walter, Miriam; Weizel, Lilia; Camelin, Jean-Claude; Ligneau, Xavier; Schneider, Erich H.; Seifert, Roland; Schwartz, Jean-Charles; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2578-2581</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Iron-contg. ligands targeting the human histamine H3 receptor (hH3R) were prepd.  The compds. contain ferrocene sandwich complexes coupled via different linkers to a basic hH3R antagonist/inverse agonist pharmacophore.  In a click chem. approach, a triazole was successfully inserted as a new linking element.  Two ferrocenylmethylamines and a ferrocenyltriazole were the most affine hH3R ligands within this series, showing receptor binding in the nano- and subnanomolar concn. range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKo1tojdBi5rVg90H21EOLACvtfcHk0liAjEJxipq1qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsleht7c%253D&md5=d35fed6a05a07ae59c87901147d3f987</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fol100419y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol100419y%26sid%3Dliteratum%253Aachs%26aulast%3DSander%26aufirst%3DK.%26aulast%3DKottke%26aufirst%3DT.%26aulast%3DHoffend%26aufirst%3DC.%26aulast%3DWalter%26aufirst%3DM.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DCamelin%26aufirst%3DJ.-C.%26aulast%3DLigneau%26aufirst%3DX.%26aulast%3DSchneider%26aufirst%3DE.%2BH.%26aulast%3DSeifert%26aufirst%3DR.%26aulast%3DSchwartz%26aufirst%3DJ.-C.%26atitle%3DFirst%2520metal-containing%2520histamine%2520H3%2520receptor%2520ligands%26jtitle%3DOrg.%2520Lett.%26date%3D2010%26volume%3D12%26spage%3D2578%26epage%3D2581%26doi%3D10.1021%2Fol100419y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwed, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adem, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.ejmech.2014.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=24650714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtVSitLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2014&pages=269-279&author=B.+Sadekauthor=J.+S.+Schwedauthor=D.+Subramanianauthor=L.+Weizelauthor=M.+Walterauthor=A.+Ademauthor=H.+Stark&title=Non-imidazole+histamine+H3+receptor+ligands+incorporating+antiepileptic+moieties&doi=10.1016%2Fj.ejmech.2014.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties</span></div><div class="casAuthors">Sadek, Bassem; Schwed, Johannes Stephan; Subramanian, Dhanasekaran; Weizel, Lilia; Walter, Miriam; Adem, Abdu; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">269-279</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A small series of histamine H3 receptor (H3R) ligands (1-5) incorporating different antiepileptic structural motifs has been newly synthesized.  All compds. exhibited moderate to high in vitro hH3R affinities up to a sub-nanomolar concn. range with pKi values in the range of 6.25-9.62 with varying preferences for this receptor subtype.  The compds. (1-5) were further investigated in vivo on anticonvulsant effects against max. electroshock (MES)-induced and pentylenetetrazole (PTZ)-kindled convulsions in rats having phenytoin (PHT) as the ref. antiepileptic drug (AED).  Surprisingly, animals pretreated with 1 mg/kg, i.p. of 5,5-diphenyl-3-(3-(piperidin-1-yl)propyl)imidazolidine-2,4-dione (4) were only moderately protected and no protection was obsd. for compds. 1-3 and 5 in three different doses (1 mg, 5 mg, and 10 mg/kg i.p.).  Compd. 4 (1 mg/kg, i.p.) failed to modify PTZ-kindled convulsion.  However, a dose of 10 mg/kg significantly reduced convulsions in both models.  In contrast, 5,5-diphenyl-3-(4-(3-(piperidin-1-yl)propoxy)benzyl)imidazolidine-2,4-dione (5) (1, 5, and 10 mg/kg, i.p.) showed proconvulsant effects in the MES model with further confirmation of these results in the PTZ model as no protection was obsd. against convulsion in the doses tested (1 and 10 mg/kg).  In addn., compd. 4 (10 mg/kg, i.p.) significantly prolonged myoclonic latency time and shortened total convulsion duration when compared to control, PHT or std. H3R inverse agonist/antagonist pitolisant (PIT).  Our results showed that H3R pharmacophores could successfully be structurally combined to antiepileptic moieties, esp. phenytoin partial structures, maintaining the H3R affinity.  However, the new derivs. for multiple-target approaches in epilepsy models are complex and show that pharmacophore elements are not easily pharmacol. combinable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCcEDmmdlPXrVg90H21EOLACvtfcHk0liAjEJxipq1qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtVSitLc%253D&md5=4ca60e1ca75828355c78caf5e126fbba</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DSadek%26aufirst%3DB.%26aulast%3DSchwed%26aufirst%3DJ.%2BS.%26aulast%3DSubramanian%26aufirst%3DD.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DWalter%26aufirst%3DM.%26aulast%3DAdem%26aufirst%3DA.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DNon-imidazole%2520histamine%2520H3%2520receptor%2520ligands%2520incorporating%2520antiepileptic%2520moieties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D77%26spage%3D269%26epage%3D279%26doi%3D10.1016%2Fj.ejmech.2014.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patil, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bari, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firke, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donda, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, D. A.</span></span> <span> </span><span class="NLM_article-title">A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer’s disease</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2434</span>– <span class="NLM_lpage">2450</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.bmc.2013.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=23517722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktlSiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2434-2450&author=P.+O.+Patilauthor=S.+B.+Bariauthor=S.+D.+Firkeauthor=P.+K.+Deshmukhauthor=S.+T.+Dondaauthor=D.+A.+Patil&title=A+comprehensive+review+on+synthesis+and+designing+aspects+of+coumarin+derivatives+as+monoamine+oxidase+inhibitors+for+depression+and+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.bmc.2013.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease</span></div><div class="casAuthors">Patil, Pravin O.; Bari, Sanjay B.; Firke, Sandip D.; Deshmukh, Prashant K.; Donda, Shailesh T.; Patil, Dilip A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2434-2450</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Monoamine oxidase (MAO) enzyme inhibition is a crucial target for the management of depression and Alzheimer disease and inhibitors of MAO are the most important drugs for their management.  Coumarins are a large family of compds., of natural and synthetic origin, that exhibit a variety of pharmacol. activities, including MAO inhibition.  The current review highlights the design and synthetic methods of coumarin derivs. as well as coumarins obtained from plant source as MAO inhibitors for treatment of depression and Alzheimer disease with salient finding related to structure-activity relationship.  The aim of present review is to find out natural as well as synthetic coumarins as MAO inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBZYAH89AyobVg90H21EOLACvtfcHk0lhc4veIjfS1OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktlSiuro%253D&md5=15c84861ae6fc00bcf9ffba764223694</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DP.%2BO.%26aulast%3DBari%26aufirst%3DS.%2BB.%26aulast%3DFirke%26aufirst%3DS.%2BD.%26aulast%3DDeshmukh%26aufirst%3DP.%2BK.%26aulast%3DDonda%26aufirst%3DS.%2BT.%26aulast%3DPatil%26aufirst%3DD.%2BA.%26atitle%3DA%2520comprehensive%2520review%2520on%2520synthesis%2520and%2520designing%2520aspects%2520of%2520coumarin%2520derivatives%2520as%2520monoamine%2520oxidase%2520inhibitors%2520for%2520depression%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2434%26epage%3D2450%26doi%3D10.1016%2Fj.bmc.2013.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Llàcer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romea, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urpí, F.</span></span> <span> </span><span class="NLM_article-title">Studies on the hydrogenolysis of benzyl ethers</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">5815</span>– <span class="NLM_lpage">5818</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2006.05.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.tetlet.2006.05.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFers7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=5815-5818&author=E.+Ll%C3%A0cerauthor=P.+Romeaauthor=F.+Urp%C3%AD&title=Studies+on+the+hydrogenolysis+of+benzyl+ethers&doi=10.1016%2Fj.tetlet.2006.05.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Studies on the hydrogenolysis of benzyl ethers</span></div><div class="casAuthors">Llacer, Enric; Romea, Pedro; Urpi, Felix</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">5815-5818</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Selective hydrogenolysis of arom. and aliph. benzyl ethers in the presence of benzylic Me ether can be achieved by the appropriate choice of the catalyst, solvent, and concn., which facilitates the design of O-benzyl-based protecting group strategies for the synthesis of natural products, such as debromoaplysiatoxin and oscillatoxin D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYW5eqs5y677Vg90H21EOLACvtfcHk0lhc4veIjfS1OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFers7Y%253D&md5=fe0d822be716067fb885a61f6182b3a4</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2006.05.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2006.05.109%26sid%3Dliteratum%253Aachs%26aulast%3DLl%25C3%25A0cer%26aufirst%3DE.%26aulast%3DRomea%26aufirst%3DP.%26aulast%3DUrp%25C3%25AD%26aufirst%3DF.%26atitle%3DStudies%2520on%2520the%2520hydrogenolysis%2520of%2520benzyl%2520ethers%26jtitle%3DTetrahedron%2520Lett.%26date%3D2006%26volume%3D47%26spage%3D5815%26epage%3D5818%26doi%3D10.1016%2Fj.tetlet.2006.05.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bei, D.</span></span> <span> </span><span class="NLM_article-title">Lithium chloride-catalyzed selective demethylation of aryl methyl ethers under microwave irradiation</span>. <i>J. Mol. Catal.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1016/j.molcata.2007.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.molcata.2007.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2sXos1anu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=2007&pages=16-23&author=Z.+Fangauthor=G.-C.+Zhouauthor=S.-L.+Zhengauthor=G.-L.+Heauthor=J.-L.+Liauthor=L.+Heauthor=D.+Bei&title=Lithium+chloride-catalyzed+selective+demethylation+of+aryl+methyl+ethers+under+microwave+irradiation&doi=10.1016%2Fj.molcata.2007.04.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Lithium chloride-catalyzed selective demethylation of aryl methyl ethers under microwave irradiation</span></div><div class="casAuthors">Fang, Zhuan; Zhou, Guo-Chuan; Zheng, Shi-Long; He, Guang-Li; Li, Ju-Lian; He, Ling; Bei, Di</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Catalysis A: Chemical</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">16-23</span>CODEN:
                <span class="NLM_cas:coden">JMCCF2</span>;
        ISSN:<span class="NLM_cas:issn">1381-1169</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A rapid method for the selective cleavage of aryl Me ether was developed in the LiCl-DMF system under microwave irradn.  Effects of substituent, metal salt, and solvent on the activity and selectivity in the cleavage were investigated.  Microwave improves the reaction yield and the selectivity of demethylation for electron-deficient arom. Me ethers.  The catalytic mechanism of demethylation by LiCl salt is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbqALUc8Sp4rVg90H21EOLACvtfcHk0lhc4veIjfS1OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXos1anu7k%253D&md5=1355452eb985f4c5f921ab5b228ec459</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.molcata.2007.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcata.2007.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DG.-C.%26aulast%3DZheng%26aufirst%3DS.-L.%26aulast%3DHe%26aufirst%3DG.-L.%26aulast%3DLi%26aufirst%3DJ.-L.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DBei%26aufirst%3DD.%26atitle%3DLithium%2520chloride-catalyzed%2520selective%2520demethylation%2520of%2520aryl%2520methyl%2520ethers%2520under%2520microwave%2520irradiation%26jtitle%3DJ.%2520Mol.%2520Catal.%26date%3D2007%26volume%3D274%26spage%3D16%26epage%3D23%26doi%3D10.1016%2Fj.molcata.2007.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettit, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herald, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNulty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgs, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumberg, P. M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Antineoplastic agents 491.1 Synthetic conversion of aaptamine to isoaaptamine, 9-demethylaaptamine, and 4-methylaaptamine</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">2251</span>– <span class="NLM_lpage">2256</span>, <span class="refDoi"> DOI: 10.1021/jo0300486</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0300486" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1CmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=2251-2256&author=G.+R.+Pettitauthor=H.+Hoffmannauthor=D.+L.+Heraldauthor=J.+McNultyauthor=A.+Murphyauthor=K.+C.+Higgsauthor=E.+Hamelauthor=N.+E.+Lewinauthor=L.+V.+Pearceauthor=P.+M.+Blumberg&title=Antineoplastic+agents+491.1+Synthetic+conversion+of+aaptamine+to+isoaaptamine%2C+9-demethylaaptamine%2C+and+4-methylaaptamine&doi=10.1021%2Fjo0300486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Antineoplastic Agents 491. Synthetic Conversion of Aaptamine to Isoaaptamine, 9-Demethylaaptamine, and 4-Methylaaptamine</span></div><div class="casAuthors">Pettit, George R.; Hoffmann, Holger; Herald, Delbert L.; McNulty, James; Murphy, Alison; Higgs, Kerianne C.; Hamel, Ernest; Lewin, Nancy E.; Pearce, Larry V.; Blumberg, Peter M.; Pettit, Robin K.; Knight, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2251-2256</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aaptamine [I; R1 = H, R2 = R3 = Me (II)] was used as starting material for synthetic transformation to isoaaptamine I [R1 = R3 = Me, R2 = H (III)], 9-demethylaaptamine I [R1 = R2 = H, R3 = Me (IV)], and 4-methylaaptamine (V).  A general method for the selective O-demethylation of such 1H-benzo[de][1,6]-naphthyridine II marine sponge constituents at position C-9 has been developed.  Selective O-demethylation of II and 1-methylaaptamine I (R1 = R2 = R3 = Me) with 48% hydrobromic acid led to IV and III, resp.  A selection of other aaptamine derivs. were synthesized, and their structures were unambiguously detd. by X-ray methods.  In addn., their cancer cell growth inhibitory properties were evaluated against the murine P388 lymphocytic cell line and a minipanel of human cancer cell lines.  Evaluation as inhibitors of the PKC signal transduction pathway and against a selection of microorganisms was also undertaken.  Aaptamine derivs. I (R1 = R2 = R3 = H).HBr and IV.HBr had broad-spectrum antimicrobial activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAlJE_3AUCCrVg90H21EOLACvtfcHk0lhqDybWETnIcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1CmtLY%253D&md5=3da5c0dd56e23831b295376c3b098996</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjo0300486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0300486%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DHoffmann%26aufirst%3DH.%26aulast%3DHerald%26aufirst%3DD.%2BL.%26aulast%3DMcNulty%26aufirst%3DJ.%26aulast%3DMurphy%26aufirst%3DA.%26aulast%3DHiggs%26aufirst%3DK.%2BC.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DLewin%26aufirst%3DN.%2BE.%26aulast%3DPearce%26aufirst%3DL.%2BV.%26aulast%3DBlumberg%26aufirst%3DP.%2BM.%26atitle%3DAntineoplastic%2520agents%2520491.1%2520Synthetic%2520conversion%2520of%2520aaptamine%2520to%2520isoaaptamine%252C%25209-demethylaaptamine%252C%2520and%25204-methylaaptamine%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D2251%26epage%3D2256%26doi%3D10.1021%2Fjo0300486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, A.</span></span> <span> </span><span class="NLM_article-title">Ueber die Theorie der Aetherbildung</span>. <i>Ann. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1851</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1002/jlac.18510770104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2Fjlac.18510770104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADyaD28XkslY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1851&pages=37-49&author=A.+Williamson&title=Ueber+die+Theorie+der+Aetherbildung&doi=10.1002%2Fjlac.18510770104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Theory of ether formation</span></div><div class="casAuthors">Williamson, Al.</div><div class="citationInfo"><span class="NLM_cas:title">Justus Liebigs Annalen der Chemie</span>
        (<span class="NLM_cas:date">1851</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">37-49</span>CODEN:
                <span class="NLM_cas:coden">JLACBF</span>;
        ISSN:<span class="NLM_cas:issn">0075-4617</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoBsulJDxWmrVg90H21EOLACvtfcHk0lhqDybWETnIcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaD28XkslY%253D&md5=1804f12d6796401fac1b63bcc3431a1e</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1002%2Fjlac.18510770104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlac.18510770104%26sid%3Dliteratum%253Aachs%26aulast%3DWilliamson%26aufirst%3DA.%26atitle%3DUeber%2520die%2520Theorie%2520der%2520Aetherbildung%26jtitle%3DAnn.%2520Chem.%26date%3D1851%26volume%3D77%26spage%3D37%26epage%3D49%26doi%3D10.1002%2Fjlac.18510770104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diveshkumar, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakrikar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harikrishna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhamodharan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradeepkumar, P. I.</span></span> <span> </span><span class="NLM_article-title">Targeting promoter G-quadruplex DNAs by indenopyrimidine-based ligands</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2754</span>– <span class="NLM_lpage">2765</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201402394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2Fcmdc.201402394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=25359695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVaksbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=2754-2765&author=K.+V.+Diveshkumarauthor=S.+Sakrikarauthor=S.+Harikrishnaauthor=V.+Dhamodharanauthor=P.+I.+Pradeepkumar&title=Targeting+promoter+G-quadruplex+DNAs+by+indenopyrimidine-based+ligands&doi=10.1002%2Fcmdc.201402394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Promoter G-Quadruplex DNAs by Indenopyrimidine-Based Ligands</span></div><div class="casAuthors">Diveshkumar, K. V.; Sakrikar, Saaz; Harikrishna, S.; Dhamodharan, V.; Pradeepkumar, P. I.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2754-2765</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The formation of G-quadruplex structures can regulate telomerase activity and the expression of oncogenes at the transcriptional and translational levels.  Therefore, stabilization of G-quadruplex DNA structures by small mols. has been recognized as a promising strategy for anticancer drug therapy.  One of the major challenges in this field is to impart stabilizing mols. with selectivity toward quadruplex structures over duplex DNAs, and to maintain specificity toward a particular quadruplex topol.  Herein we report the synthesis and binding interactions of indenopyrimidine derivs., endowed with drug-like properties, with oncogenic promoters of c-myc and c-kit, telomeric and duplex DNAs.  The results show specific stabilization of promoter over telomeric quadruplexes and duplex DNAs.  Mol. modeling studies support the exptl. observations by unraveling the dual binding mode of ligands by exploiting the top and bottom quartets of a G-quadruplex structure.  This study underscores the potential of the indenopyrimidine scaffold, which can be used to achieve specific G-quadruplex-mediated anticancer activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXUsrnuMBWCbVg90H21EOLACvtfcHk0lhqDybWETnIcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVaksbfK&md5=09fcc4d763aede71428b9c107b148321</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402394%26sid%3Dliteratum%253Aachs%26aulast%3DDiveshkumar%26aufirst%3DK.%2BV.%26aulast%3DSakrikar%26aufirst%3DS.%26aulast%3DHarikrishna%26aufirst%3DS.%26aulast%3DDhamodharan%26aufirst%3DV.%26aulast%3DPradeepkumar%26aufirst%3DP.%2BI.%26atitle%3DTargeting%2520promoter%2520G-quadruplex%2520DNAs%2520by%2520indenopyrimidine-based%2520ligands%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D2754%26epage%3D2765%26doi%3D10.1002%2Fcmdc.201402394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Köse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gollos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karcz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiene, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heisig, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrenswerth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieć-Kononowicz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namasivayam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span> <span> </span><span class="NLM_article-title">Fluorescent-labeled selective adenosine A2B receptor antagonist enables competition binding assay by flow cytometry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4301</span>– <span class="NLM_lpage">4316</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01627</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01627" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BC1Mjlt1Onsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4301-4316&author=M.+K%C3%B6seauthor=S.+Gollosauthor=T.+Karczauthor=A.+Fieneauthor=F.+Heisigauthor=A.+Behrenswerthauthor=K.+Kie%C4%87-Kononowiczauthor=V.+Namasivayamauthor=C.+E.+M%C3%BCller&title=Fluorescent-labeled+selective+adenosine+A2B+receptor+antagonist+enables+competition+binding+assay+by+flow+cytometry&doi=10.1021%2Facs.jmedchem.7b01627"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorescent-Labeled Selective Adenosine A2B Receptor Antagonist Enables Competition Binding Assay by Flow Cytometry</span></div><div class="casAuthors">Kose Meryem; Gollos Sabrina; Fiene Amelie; Heisig Fabian; Behrenswerth Andrea; Namasivayam Vigneshwaran; Muller Christa E; Karcz Tadeusz; Kiec-Kononowicz Katarzyna</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4301-4316</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Fluorescent ligands represent powerful tools for biological studies and are considered attractive alternatives to radioligands.  In this study, we developed fluorescent antagonists for A2B adenosine receptors (A2BARs), which are targeted by antiasthmatic xanthines and were proposed as novel targets in immuno-oncology.  Our approach was to merge a small borondipyrromethene (BODIPY) derivative with the pharmacophore of 8-substituted xanthine derivatives.  On the basis of the design, synthesis, and evaluation of model compounds, several fluorescent ligands were synthesized.  Compound 29 (PSB-12105), which displayed high affinity for human, rat, and mouse A2BARs ( Ki = 0.2-2 nM) and high selectivity for this AR subtype, was selected for further studies.  A homology model of the human A2BAR was generated, and docking studies were performed.  Moreover, 29 allowed us to establish a homogeneous receptor-ligand binding assay using flow cytometry.  These compounds constitute the first potent, selective fluorescent A2BAR ligands and are anticipated to be useful for a variety of applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcShJSPcTqEx0ZVVjGoY74BafW6udTcc2eae5ot7TK72Pbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mjlt1Onsg%253D%253D&md5=9d595306619272562da897096f630b92</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01627%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6se%26aufirst%3DM.%26aulast%3DGollos%26aufirst%3DS.%26aulast%3DKarcz%26aufirst%3DT.%26aulast%3DFiene%26aufirst%3DA.%26aulast%3DHeisig%26aufirst%3DF.%26aulast%3DBehrenswerth%26aufirst%3DA.%26aulast%3DKie%25C4%2587-Kononowicz%26aufirst%3DK.%26aulast%3DNamasivayam%26aufirst%3DV.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DFluorescent-labeled%2520selective%2520adenosine%2520A2B%2520receptor%2520antagonist%2520enables%2520competition%2520binding%2520assay%2520by%2520flow%2520cytometry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4301%26epage%3D4316%26doi%3D10.1021%2Facs.jmedchem.7b01627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burbiel, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghattas, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Küppers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzner, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kombu, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akkinepally, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hockemeyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span> <span> </span><span class="NLM_article-title">2-Amino[1,2,4]triazolo[1,5-c]quinazolines and derived novel heterocycles: Syntheses and structure-activity relationships of potent adenosine receptor antagonists</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2272</span>– <span class="NLM_lpage">2286</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2Fcmdc.201600255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=27531666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlCht7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2272-2286&author=J.+C.+Burbielauthor=W.+Ghattasauthor=P.+K%C3%BCppersauthor=M.+K%C3%B6seauthor=S.+Lacherauthor=A.-M.+Herznerauthor=R.+S.+Kombuauthor=R.+R.+Akkinepallyauthor=J.+Hockemeyerauthor=C.+E.+M%C3%BCller&title=2-Amino%5B1%2C2%2C4%5Dtriazolo%5B1%2C5-c%5Dquinazolines+and+derived+novel+heterocycles%3A+Syntheses+and+structure-activity+relationships+of+potent+adenosine+receptor+antagonists&doi=10.1002%2Fcmdc.201600255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">2-Amino[1,2,4]triazolo[1,5-c]quinazolines and Derived Novel Heterocycles: Syntheses and Structure-Activity Relationships of Potent Adenosine Receptor Antagonists</span></div><div class="casAuthors">Burbiel, Joachim C.; Ghattas, Wadih; Kueppers, Petra; Koese, Meryem; Lacher, Svenja; Herzner, Anna-Maria; Kombu, Rajan Subramanian; Akkinepally, Raghuram Rao; Hockemeyer, Joerg; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2272-2286</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">2-Amino[1,2,4]triazolo[1,5-c]quinazolines, e.g., I were identified as potent adenosine receptor (AR) antagonists.  Synthetic strategies were devised to gain access to a broad range of derivs. including novel polyheterocyclic compds.  Potent and selective A3AR antagonists were discovered, including 3,5-diphenyl[1,2,4]triazolo[4,3-c]quinazoline (Ki human A3AR 1.16 nM) and 5'-phenyl-1,2-dihydro-3'H-spiro[indole-3,2'-[1,2,4]triazolo[1,5-c]quinazolin]-2-one (Ki human A3AR 6.94 nM).  In addn., multitarget antagonists were obtained, such as the dual A1/A3 antagonist 2,5-diphenyl[1,2,4]triazolo[1,5-c]quinazoline (Ki human A1AR 51.6 nM, human A3AR 11.1 nM), and the balanced pan-AR antagonists 5-(2-thienyl)[1,2,4]triazolo[1,5-c]quinazolin-2-amine (Ki human A1AR 131 nM, A2AAR 32.7 nM, A2BAR 150 nM, A3AR 47.5 nM) and 9-bromo-5-phenyl[1,2,4]triazolo[1,5-c]quinazolin-2-amine (Ki human A1AR 67.7 nM, A2AAR 13.6 nM, A2BAR 75.0 nM, A3AR 703 nM).  In many cases, significantly different affinities for human and rat receptors were obsd., which emphasizes the need for caution in extrapolating conclusions between different species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFDHybKVAIpbVg90H21EOLACvtfcHk0lht0DImyc_XFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlCht7bE&md5=6cf719986efb0218f12f1fe3e265d45c</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600255%26sid%3Dliteratum%253Aachs%26aulast%3DBurbiel%26aufirst%3DJ.%2BC.%26aulast%3DGhattas%26aufirst%3DW.%26aulast%3DK%25C3%25BCppers%26aufirst%3DP.%26aulast%3DK%25C3%25B6se%26aufirst%3DM.%26aulast%3DLacher%26aufirst%3DS.%26aulast%3DHerzner%26aufirst%3DA.-M.%26aulast%3DKombu%26aufirst%3DR.%2BS.%26aulast%3DAkkinepally%26aufirst%3DR.%2BR.%26aulast%3DHockemeyer%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3D2-Amino%255B1%252C2%252C4%255Dtriazolo%255B1%252C5-c%255Dquinazolines%2520and%2520derived%2520novel%2520heterocycles%253A%2520Syntheses%2520and%2520structure-activity%2520relationships%2520of%2520potent%2520adenosine%2520receptor%2520antagonists%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D2272%26epage%3D2286%26doi%3D10.1002%2Fcmdc.201600255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurinsh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, R.</span></span> <span> </span><span class="NLM_article-title">Binding of [<sup>3</sup>H]MSX-2-(3-(3-hydroxypropyl)-7-methyl-8-(<i>m</i>-methoxystyryl)-1-propargylxanthine) to rat striatal membranes—a new, selective antagonist radioligand for A2A adenosine receptors</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1016/s0928-0987(00)00064-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fs0928-0987%2800%2900064-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10838015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjs1Cgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=259-265&author=C.+E.+M%C3%BCllerauthor=J.+Maurinshauthor=R.+Sauer&title=Binding+of+%5B3H%5DMSX-2-%283-%283-hydroxypropyl%29-7-methyl-8-%28m-methoxystyryl%29-1-propargylxanthine%29+to+rat+striatal+membranes%E2%80%94a+new%2C+selective+antagonist+radioligand+for+A2A+adenosine+receptors&doi=10.1016%2Fs0928-0987%2800%2900064-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Binding of [3H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes - a new, selective antagonist radioligand for A2A adenosine receptors</span></div><div class="casAuthors">Muller, C. E.; Maurinsh, J.; Sauer, R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">259-265</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">The present study describes the prepn. and binding properties of a new, potent, and selective A2A adenosine receptor (AR) antagonist radioligand, [3H]3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine ([3H]MSX-2).  [3H]MSX-2 binding to rat striatal membranes was saturable and reversible.  Satn. expts. showed that [3H]MSX-2 labeled a single class of binding sites with high affinity (Kd=8.0 nM) and limited capacity (Bmax=1.16 fmol·mg-1 of protein).  The presence of 100 μM GTP, or 10 mM magnesium chloride, resp., had no effect on [3H]MSX-2 binding.  AR agonists competed with the binding of 1 nM [3H]MSX-2 with the following order of potency: 5'-N-ethylcarboxamidoadenosine (NECA)°2-[4-(carboxyethyl)phenylethylamino]-5'-N-ethylcarboxamidoadenosine (CGS-21680)°2-chloroadenosine (2-CADO)°N6-cyclopentyladenosine (CPA).  AR antagonists showed the following order of potency: 8-(m-bromostyryl)-3,7-dimethyl-1-propargylxanthine (BS-DMPX)°1,3-dipropyl-8-cyclopentylxanthine (DPCPX)°(R)-5,6-dimethyl-7-(1-phenylethyl)-2-(4-pyridyl)-7H-pyrrolo[2,3-d]pyrimidine-4-amine (SH-128)°3,7-dimethyl-1-propargylxanthine (DMPX)°caffeine.  The Ki values for antagonists were in accordance with data from binding studies with the agonist radioligand [3H]CGS21680, while agonist affinities were 3-7-fold lower. [3H]MSX-2 is a highly selective A2A AR antagonist radioligand exhibiting a selectivity of at least two orders of magnitude vs. all other AR subtypes.  The new radioligand shows high specific radioactivity (85 Ci/mmol, 3150 GBq/mmol) and acceptable nonspecific binding at rat striatal membranes of 20-30%, at 1 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8VMEXXUj3RbVg90H21EOLACvtfcHk0lht0DImyc_XFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjs1Cgsrs%253D&md5=012d1ae18ba96e8768e7652b25308998</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fs0928-0987%2800%2900064-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0928-0987%252800%252900064-6%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DMaurinsh%26aufirst%3DJ.%26aulast%3DSauer%26aufirst%3DR.%26atitle%3DBinding%2520of%2520%255B3H%255DMSX-2-%25283-%25283-hydroxypropyl%2529-7-methyl-8-%2528m-methoxystyryl%2529-1-propargylxanthine%2529%2520to%2520rat%2520striatal%2520membranes%25E2%2580%2594a%2520new%252C%2520selective%2520antagonist%2520radioligand%2520for%2520A2A%2520adenosine%2520receptors%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2000%26volume%3D10%26spage%3D259%26epage%3D265%26doi%3D10.1016%2Fs0928-0987%2800%2900064-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diekmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozola, V.</span></span> <span> </span><span class="NLM_article-title">[<sup>3</sup>H]8-Ethyl-4-methyl-2-phenyl-(8<i>R</i>)-4,5,7,8-tetrahydro-1<i>H</i>-imidazo[2,1-<i>i</i>]-purin-5-one ([3H]PSB-11), a novel high-affinity antagonist radioligand for human A3 adenosine receptors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">503</span>, <span class="refDoi"> DOI: 10.1016/s0960-894x(01)00785-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fs0960-894x%2801%2900785-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=11814828" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=501-503&author=C.+E.+M%C3%BCllerauthor=M.+Diekmannauthor=M.+Thorandauthor=V.+Ozola&title=%5B3H%5D8-Ethyl-4-methyl-2-phenyl-%288R%29-4%2C5%2C7%2C8-tetrahydro-1H-imidazo%5B2%2C1-i%5D-purin-5-one+%28%5B3H%5DPSB-11%29%2C+a+novel+high-affinity+antagonist+radioligand+for+human+A3+adenosine+receptors&doi=10.1016%2Fs0960-894x%2801%2900785-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fs0960-894x%2801%2900785-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0960-894x%252801%252900785-5%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DDiekmann%26aufirst%3DM.%26aulast%3DThorand%26aufirst%3DM.%26aulast%3DOzola%26aufirst%3DV.%26atitle%3D%255B3H%255D8-Ethyl-4-methyl-2-phenyl-%25288R%2529-4%252C5%252C7%252C8-tetrahydro-1H-imidazo%255B2%252C1-i%255D-purin-5-one%2520%2528%255B3H%255DPSB-11%2529%252C%2520a%2520novel%2520high-affinity%2520antagonist%2520radioligand%2520for%2520human%2520A3%2520adenosine%2520receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D501%26epage%3D503%26doi%3D10.1016%2Fs0960-894x%2801%2900785-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klotz, K.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohse, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwabe, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristalli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vittori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grifantini, M.</span></span> <span> </span><span class="NLM_article-title">2-Chloro-N<sup>6</sup>-[<sup>3</sup>H]cyclopentyladenosine ([<sup>3</sup>H]CCPA) a high affinity agonist radioligand for A1 adenosine receptors</span>. <i>Naunyn-Schmiedeberg’s Arch. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>340</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">683</span>, <span class="refDoi"> DOI: 10.1007/bf00717744</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1007%2Fbf00717744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=2615857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADyaK3cXhtFGhsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=1989&pages=679-683&author=K.-N.+Klotzauthor=M.+J.+Lohseauthor=U.+Schwabeauthor=G.+Cristalliauthor=S.+Vittoriauthor=M.+Grifantini&title=2-Chloro-N6-%5B3H%5Dcyclopentyladenosine+%28%5B3H%5DCCPA%29+a+high+affinity+agonist+radioligand+for+A1+adenosine+receptors&doi=10.1007%2Fbf00717744"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">2-Chloro-N6-[3H]cyclopentyladenosine ([3H]CPPA) - a high affinity agonist radioligand for A1 adenosine receptors</span></div><div class="casAuthors">Klotz, Karl Norbert; Lohse, Martin J.; Schwabe, Ulrich; Cristalli, Gloria; Vittori, Sauro; Grifantini, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">679-83</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    </div><div class="casAbstract">The tritiated analog of 2-chloro-N6-cyclopentyladenosine (CCPA) (I), an adenosine deriv. with subnanomolar affinity and a 10,000-fold selectivity for A1 adenosine receptors, has been examd. as a new agonist radioligand.  [3H]CCPA was prepd. with a specific radioactivity of 1.58 TBq/mmol (43 Ci/mmol) and bound in a reversible manner to A1 receptors from rat brain membranes with a high affinity KD value of 0.2 nmol/L.  In the presence of GTP, a KDvalue of 13 nmol/L was detd. for the low affinity state for agonist binding.  Competition of several adenosine receptor agonists and antagonists for [3H]CCPA binding to rat brain membranes confirmed binding to an A1 receptor.  Solubilized A1 receptors bound [3H]CCPA with similar affinity for the high affinity state.  At solubilized receptors a reduced assocn. rate was obsd. in the presence of MgCl2, as has been shown for the agonist [3H]N6-phenylisopropyladenosine ([3H]PIA).  [3H]CCPA was also used for detection of A1 receptors in rat cardiomyocyte membranes, a tissue with a very low receptor d.  Kd-Value of 0.4 nmol-L and a Bmax-value of 16 fmol-platelet membranes, no specific binding of [3H]CCPA was measured at concns. up to 400 nmol/L, indicating that A2 receptors did not bind [3H]CCPA.  Based on the subnanomolar affinity and the high selectivity for A1 receptors, [3H]CCPA proved to be a useful agonist radioligand for characterization of A1 adenosine receptors also in tissues with very low receptor d.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquP1vlbGByYrVg90H21EOLACvtfcHk0lhtyGgsut3Zog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhtFGhsL8%253D&md5=d44acdedb7aa0c3b3c6f7d79666ae139</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1007%2Fbf00717744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fbf00717744%26sid%3Dliteratum%253Aachs%26aulast%3DKlotz%26aufirst%3DK.-N.%26aulast%3DLohse%26aufirst%3DM.%2BJ.%26aulast%3DSchwabe%26aufirst%3DU.%26aulast%3DCristalli%26aufirst%3DG.%26aulast%3DVittori%26aufirst%3DS.%26aulast%3DGrifantini%26aufirst%3DM.%26atitle%3D2-Chloro-N6-%255B3H%255Dcyclopentyladenosine%2520%2528%255B3H%255DCCPA%2529%2520a%2520high%2520affinity%2520agonist%2520radioligand%2520for%2520A1%2520adenosine%2520receptors%26jtitle%3DNaunyn-Schmiedeberg%25E2%2580%2599s%2520Arch.%2520Pharmacol.%26date%3D1989%26volume%3D340%26spage%3D679%26epage%3D683%26doi%3D10.1007%2Fbf00717744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borrmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertarelli, D. C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florin, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiff, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span> <span> </span><span class="NLM_article-title">1-Alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: Development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">3994</span>– <span class="NLM_lpage">4006</span>, <span class="refDoi"> DOI: 10.1021/jm900413e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900413e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsVOmtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3994-4006&author=T.+Borrmannauthor=S.+Hinzauthor=D.+C.+G.+Bertarelliauthor=W.+Liauthor=N.+C.+Florinauthor=A.+B.+Scheiffauthor=C.+E.+M%C3%BCller&title=1-Alkyl-8-%28piperazine-1-sulfonyl%29phenylxanthines%3A+Development+and+characterization+of+adenosine+A2B+receptor+antagonists+and+a+new+radioligand+with+subnanomolar+affinity+and+subtype+specificity&doi=10.1021%2Fjm900413e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">1-Alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: Development and Characterization of Adenosine A2B Receptor Antagonists and a New Radioligand with Subnanomolar Affinity and Subtype Specificity</span></div><div class="casAuthors">Borrmann, Thomas; Hinz, Sonja; Bertarelli, Daniela C. G.; Li, Wenjin; Florin, Nicole C.; Scheiff, Anja B.; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3994-4006</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new series of 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines was designed, synthesized, and characterized in radioligand binding and functional assays at A2B adenosine receptors.  A2B antagonists with subnanomolar affinity and high selectivity were discovered.  The most potent compds. were 1-ethyl-8-(4-(4-(4-trifluoromethylbenzyl)piperazine-1-sulfonyl)phenyl)xanthine (PSB-09120, Ki (human A2B) = 0.157 nM) and 8-(4-(4-(4-chlorobenzyl)piperazine-1-sulfonyl)phenyl)-1-propylxanthine (PSB-0788, Ki (human A2B) = 0.393 nM).  Moreover, 8-(4-(4-(4-chlorophenyl)piperazine-1-sulfonyl)phenyl)-1-propylxanthine ( PSB-603) was developed as an A2B-specific antagonist exhibiting a Ki value of 0.553 nM at the human A2B receptor and virtually no affinity for the human and rat A1 and A2A and the human A3 receptors up to a concn. of 10 μM.  A tritiated form of the compd. was prepd. as a new radioligand and characterized in kinetic, satn., and competition studies.  It was shown to be a useful pharmacol. tool for the selective labeling of human as well as rodent A2B receptors (KD human A2B 0.403 nM, mouse A2B 0.351 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWuka8J5BT1LVg90H21EOLACvtfcHk0lhtyGgsut3Zog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsVOmtLg%253D&md5=c32619fcbde66b6f4237b0467d9d2950</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fjm900413e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900413e%26sid%3Dliteratum%253Aachs%26aulast%3DBorrmann%26aufirst%3DT.%26aulast%3DHinz%26aufirst%3DS.%26aulast%3DBertarelli%26aufirst%3DD.%2BC.%2BG.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DFlorin%26aufirst%3DN.%2BC.%26aulast%3DScheiff%26aufirst%3DA.%2BB.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3D1-Alkyl-8-%2528piperazine-1-sulfonyl%2529phenylxanthines%253A%2520Development%2520and%2520characterization%2520of%2520adenosine%2520A2B%2520receptor%2520antagonists%2520and%2520a%2520new%2520radioligand%2520with%2520subnanomolar%2520affinity%2520and%2520subtype%2520specificity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3994%26epage%3D4006%26doi%3D10.1021%2Fjm900413e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span> <span> </span><span class="NLM_article-title">Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: Toward the development of sulfonic acid prodrugs with peroral bioavailability</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1031</span>– <span class="NLM_lpage">1043</span>, <span class="refDoi"> DOI: 10.1021/jm0310030</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0310030" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkvVKltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1031-1043&author=L.+Yanauthor=C.+E.+M%C3%BCller&title=Preparation%2C+properties%2C+reactions%2C+and+adenosine+receptor+affinities+of+sulfophenylxanthine+nitrophenyl+esters%3A+Toward+the+development+of+sulfonic+acid+prodrugs+with+peroral+bioavailability&doi=10.1021%2Fjm0310030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation, Properties, Reactions, and Adenosine Receptor Affinities of Sulfophenylxanthine Nitrophenyl Esters: Toward the Development of Sulfonic Acid Prodrugs with Peroral Bioavailability</span></div><div class="casAuthors">Yan, Luo; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1031-1043</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Many currently known antagonists for P2 purinergic receptors are anionic mols. bearing one or several phenylsulfonate groups.  Among the P1 (adenosine) receptor antagonists, the xanthine phenylsulfonates are a potent class of compds.  Due to their high acidity, phenylsulfonates are neg. charged at physiol. pH values and do not easily penetrate cell membranes.  The present study was aimed at developing lipophilic, perorally bioavailable prodrugs of sulfonates by converting them into chem. stable nitrophenyl esters.  Initial stability tests at different pH values using nitrophenyl tosylates as model compds. showed that m-nitrophenyl esters were stable over a wide pH range, while the ortho and para isomers were less stable under strongly acidic or basic conditions.  A series of m- and p-nitrophenyl esters of p-sulfophenylxanthine derivs., I (R1 = Me, n-Pr, n-Bu, R2 = Me, n-Pr, H, nitro position = 3, 4), were synthesized as model compds.  The target xanthine derivs. were obtained in high yields by condensation of the appropriate 5,6-diaminouracils with 4-(nitrophenoxysulfonyl)benzoic acids in the presence of a carbodiimide, followed by ring closure with polyphosphoric acid trimethylsilyl ester.  The chem. and enzymic stability of the m-nitrophenyl esters was investigated in vitro by means of capillary electrophoresis.  High stability in aq. soln., in artificial gastric acid, and in serum was obsd.  However, compd. I (R1 = n-Pr, R2 = H, nitro position = 3), used as a prototypic xanthine m-nitrophenylsulfonate, was hydrolyzed by rat liver homogenate indicating an enzymic pathway of hydrolysis.  Thus, nitrophenyl esters of sulfonic acids have a potential as peroral prodrugs of drugs bearing a sulfonate group.  The nitrophenyl esters of sulfophenylxanthines were addnl. investigated for their adenosine receptor affinities.  They showed high affinity at A1, A2A, and A2B, but not at A3 ARs.  One of the most potent compds. was 1-propyl-8-[4-[[p-nitrophenoxy]sulfonyl]phenyl]xanthine I (R1 = n-Pr, R2 = H, nitro position = 4), a mixed A1/A2B antagonist (KiA1 3.6 nM, KiA2B 5.4 nM) selective vs. the other subtypes.  As a further result of this study, the m-nitrophenoxy group was found to be a suitable protecting group for sulfonates in org. synthesis due to its high lipophilicity and stability; it can be split off under strongly basic conditions.  This new protection strategy allowed for the upscaling of the synthesis of 1-propyl-8-p-sulfophenylxanthine (PSB-1115), a selective A2B antagonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLwuTkcmC9DbVg90H21EOLACvtfcHk0lhtyGgsut3Zog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkvVKltQ%253D%253D&md5=9cfcfc3bee9c9ad1a9a3c1cdfd65baad</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm0310030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0310030%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DL.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DPreparation%252C%2520properties%252C%2520reactions%252C%2520and%2520adenosine%2520receptor%2520affinities%2520of%2520sulfophenylxanthine%2520nitrophenyl%2520esters%253A%2520Toward%2520the%2520development%2520of%2520sulfonic%2520acid%2520prodrugs%2520with%2520peroral%2520bioavailability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1031%26epage%3D1043%26doi%3D10.1021%2Fjm0310030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kottke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Receptor-specific functional efficacies of alkyl imidazoles as dual histamine H3/H4 receptor ligands</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>654</i></span>,  <span class="NLM_fpage">200</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2010.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.ejphar.2010.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=21237145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFeqt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=654&publication_year=2011&pages=200-208&author=T.+Kottkeauthor=K.+Sanderauthor=L.+Weizelauthor=E.+H.+Schneiderauthor=R.+Seifertauthor=H.+Stark&title=Receptor-specific+functional+efficacies+of+alkyl+imidazoles+as+dual+histamine+H3%2FH4+receptor+ligands&doi=10.1016%2Fj.ejphar.2010.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor-specific functional efficacies of alkyl imidazoles as dual histamine H3/H4 receptor ligands</span></div><div class="casAuthors">Kottke, Tim; Sander, Kerstin; Weizel, Lilia; Schneider, Erich H.; Seifert, Roland; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">654</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">200-208</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histamine H3 and H4 receptors are highly related G protein-coupled receptors.  Preclin. and clin. data strongly suggest the potential therapeutic application of selectively acting histamine H4 receptor ligands to inflammatory conditions but also hint at a certain interference of the two receptors in diseases attended with itch and pain.  The aim of this investigation was to identify dual acting ligands as pharmacol. tools.  Receptor binding profiles of ω-(1H-imidazol-4-yl)alkyl derivs. structurally defined as amides, carbamates, esters, ethers, ketones and ureas were evaluated with respect to their potencies at histamine H3 and H4 receptors.  A two-step screening method based on in vitro radioligand binding studies and functional [35S]GTPγS binding expts. was performed.  The examd. series of imidazole-contg. compds. displayed both, selective histamine H4 receptor and dual acting histamine H3/H4 receptor ligands.  Slight structural modifications caused major differences in selectivity profiles and on functional properties at the human histamine H4 receptor.  N-(3-(1H-Imidazol-4-yl)propyl)-2-cyclohexylacetamide 11 was identified as most potent and selective human histamine H4 receptor ligand in this series (K i = 45 nM).  Amide- and ether-contg. structures consistently exhibited partial agonist efficacies, whereas ureas, ketones, esters and carbamates mainly acted as antagonists and inverse agonists.  We identified novel dual acting histamine H3/H4 receptor ligands with varying efficacies at the histamine H4 receptor subtype, whereas histamine H3 receptor antagonism was kept const., e.g. 3-(1H-imidazol-4-yl)propyl (cyclohexylmethyl)carbamate 19 or 4-(3-(3-phenylpropylthio)propyl)-1H-imidazole 30.  These compds. state valuable pharmacol. tools in studies of diseases, in which histamine H3 and H4 receptor signalling contributes to pathophysiol. conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsv9f0qBmwObVg90H21EOLACvtfcHk0ljkdcMFrLAAqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFeqt7s%253D&md5=3adf59287c8109cd516eeeee25459c5a</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2010.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2010.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DKottke%26aufirst%3DT.%26aulast%3DSander%26aufirst%3DK.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DSchneider%26aufirst%3DE.%2BH.%26aulast%3DSeifert%26aufirst%3DR.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DReceptor-specific%2520functional%2520efficacies%2520of%2520alkyl%2520imidazoles%2520as%2520dual%2520histamine%2520H3%252FH4%2520receptor%2520ligands%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D654%26spage%3D200%26epage%3D208%26doi%3D10.1016%2Fj.ejphar.2010.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schübler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kottke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis, molecular properties estimations, and dual dopamine D2 and D3 receptor activities of benzothiazole-based ligands</span>. <i>Front. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.3389/fchem.2017.00064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.3389%2Ffchem.2017.00064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=28955709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVGms7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=64-19&author=M.+Sch%C3%BCblerauthor=B.+Sadekauthor=T.+Kottkeauthor=L.+Weizelauthor=H.+Stark&title=Synthesis%2C+molecular+properties+estimations%2C+and+dual+dopamine+D2+and+D3+receptor+activities+of+benzothiazole-based+ligands&doi=10.3389%2Ffchem.2017.00064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, molecular properties estimations, and dual dopamine D2 and D3 receptor activities of benzothiazole-based ligands</span></div><div class="casAuthors">Schuebler, Moritz; Sadek, Bassem; Kottke, Tim; Weizel, Lilia; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Chemistry (Lausanne, Switzerland)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">64/1-64/19</span>CODEN:
                <span class="NLM_cas:coden">FCLSAA</span>;
        ISSN:<span class="NLM_cas:issn">2296-2646</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Neurleptic drugs, e.g., aripiprazole, targeting the dopamine D2S and D3 receptors (D2SR and D3R) in the central nervous system are widely used in the treatment of several psychotic and neurodegenerative diseases.  Therefore, a new series of benzothiazole-based ligands (3-20) was synthesized by applying the bioisosteric approach derived from the selective D3Rs ligand BP-897 (1) and its structurally related benz[d]imidazole deriv. (2).  Herein, introduction of the benzothiazole moiety was well tolerated by D2SR and D3R binding sites leading to antagonist affinities in the low nanomolar concn. range at both receptor subtypes.  However, all novel compds. showed lower antagonist affinity to D3R when compared to that of 1.  Further exploration of different substitution patterns at the benzothiazole heterocycle and the basic 4-phenylpiperazine resulted in the discovery of high dually acting D2SR and D3R ligands.  Moreover, the methoxy substitution at 2-position of 4-phenylpiperazine resulted in significantly (22-fold) increased D2SR binding affinity as compared to the parent ligand 1, and improved physicochem. and drug-likeness properties of ligands 3-11.  However, the latter structural modifications failed to improve the drug-able properties in ligands having un-substituted 4-phenylpiperazine analogs (12-20).  Accordingly, compd. 9 showed in addn. to high dual affinity at the D2SR and D3R [Ki (hD2SR) = 2.8 ± 0.8 nM; Ki (hD3R) = 3.0 ± 1.6 nM], promising clogS, clogP, LE (hD2SR, hD3R), LipE (hD2SR, hD3R), and drug-likeness score values of -4.7, 4.2, (0.4, 0.4), (4.4, 4.3), and 0.7, resp.  Also, the deaminated analog 10 [Ki (hD2SR) = 3.2 ± 0.4 nM; Ki (hD3R) = 8.5 ± 2.2 nM] revealed clogS, clogP, LE (hD2SR, hD3R), LipE (hD2SR, hD3R) and drug-likeness score values of -4.7, 4.2, (0.4, 0.4), (3.9, 3.5), and 0.4, resp.  The results obsd. for the newly developed benzothiazole-based ligands 3-20 provide clues for the diversity in structure activity relationships (SARs) at the D2SR and D3R subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqglTMkwann9LVg90H21EOLACvtfcHk0ljkdcMFrLAAqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVGms7nE&md5=1331655955d94f33249ceb1156aa384b</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.3389%2Ffchem.2017.00064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffchem.2017.00064%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25BCbler%26aufirst%3DM.%26aulast%3DSadek%26aufirst%3DB.%26aulast%3DKottke%26aufirst%3DT.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DSynthesis%252C%2520molecular%2520properties%2520estimations%252C%2520and%2520dual%2520dopamine%2520D2%2520and%2520D3%2520receptor%2520activities%2520of%2520benzothiazole-based%2520ligands%26jtitle%3DFront.%2520Chem.%26date%3D2017%26volume%3D5%26spage%3D64%26epage%3D19%26doi%3D10.3389%2Ffchem.2017.00064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bautista-Aguilera, Ó. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagenow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palomino-Antolin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farré-Alins, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismaili, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joffrin, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soukup, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janočková, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinowsky, L.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Multitarget-directed ligands combining cholinesterase and monoamine oxidase inhibition with histamine H3R antagonism for neurodegenerative diseases</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">12765</span>– <span class="NLM_lpage">12769</span>, <span class="refDoi"> DOI: 10.1002/anie.201706072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2Fanie.201706072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVekt73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=12765-12769&author=%C3%93.+M.+Bautista-Aguileraauthor=S.+Hagenowauthor=A.+Palomino-Antolinauthor=V.+Farr%C3%A9-Alinsauthor=L.+Ismailiauthor=P.+L.+Joffrinauthor=M.+L.+Jimenoauthor=O.+Soukupauthor=J.+Jano%C4%8Dkov%C3%A1author=L.+Kalinowsky&title=Multitarget-directed+ligands+combining+cholinesterase+and+monoamine+oxidase+inhibition+with+histamine+H3R+antagonism+for+neurodegenerative+diseases&doi=10.1002%2Fanie.201706072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3R Antagonism for Neurodegenerative Diseases</span></div><div class="casAuthors">Bautista-Aguilera, Oscar M.; Hagenow, Stefanie; Palomino-Antolin, Alejandra; Farre-Alins, Victor; Ismaili, Lhassane; Joffrin, Pierre-Louis; Jimeno, Maria L.; Soukup, Ondrej; Janockova, Jana; Kalinowsky, Lena; Proschak, Ewgenij; Iriepa, Isabel; Moraleda, Ignacio; Schwed, Johannes S.; Romero Martinez, Alejandro; Lopez-Munoz, Francisco; Chioua, Mourad; Egea, Javier; Ramsay, Rona R.; Marco-Contelles, Jose; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">12765-12769</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The therapy of complex neurodegenerative diseases requires the development of multitarget-directed drugs (MTDs).  Novel indole derivs. with inhibitory activity towards acetyl/butyrylcholinesterases and monoamine oxidases A/B as well as the histamine H3 receptor (H3R) were obtained by optimization of the neuroprotectant ASS234 by incorporating generally accepted H3R pharmacophore motifs.  These small-mol. hits demonstrated balanced activities at the targets, mostly in the nanomolar concn. range.  Addnl. in vitro studies showed antioxidative neuroprotective effects as well as the ability to penetrate the blood-brain barrier.  With this promising in vitro profile, contilisant (at 1 mg kg-1 i.p.) also significantly improved lipopolysaccharide-induced cognitive deficits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2wNLAClUFULVg90H21EOLACvtfcHk0lhru__SjldIyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVekt73L&md5=4a962ad1ada3f5b8e8102add09cd4e60</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1002%2Fanie.201706072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201706072%26sid%3Dliteratum%253Aachs%26aulast%3DBautista-Aguilera%26aufirst%3D%25C3%2593.%2BM.%26aulast%3DHagenow%26aufirst%3DS.%26aulast%3DPalomino-Antolin%26aufirst%3DA.%26aulast%3DFarr%25C3%25A9-Alins%26aufirst%3DV.%26aulast%3DIsmaili%26aufirst%3DL.%26aulast%3DJoffrin%26aufirst%3DP.%2BL.%26aulast%3DJimeno%26aufirst%3DM.%2BL.%26aulast%3DSoukup%26aufirst%3DO.%26aulast%3DJano%25C4%258Dkov%25C3%25A1%26aufirst%3DJ.%26aulast%3DKalinowsky%26aufirst%3DL.%26atitle%3DMultitarget-directed%2520ligands%2520combining%2520cholinesterase%2520and%2520monoamine%2520oxidase%2520inhibition%2520with%2520histamine%2520H3R%2520antagonism%2520for%2520neurodegenerative%2520diseases%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D12765%26epage%3D12769%26doi%3D10.1002%2Fanie.201706072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryoo, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dylan, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bs, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. N.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson’s disease</span>. <i>Isis</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">788</span>– <span class="NLM_lpage">797</span>, <span class="refDoi"> DOI: 10.1002/mds.870130506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2Fmds.870130506" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1998&pages=788-797&author=H.+L.+Ryooauthor=B.+S.+Dylanauthor=P.+Bsauthor=J.+N.+Joyce&title=Dopamine+D3+receptor+is+decreased+and+D2+receptor+is+elevated+in+the+striatum+of+Parkinson%E2%80%99s+disease&doi=10.1002%2Fmds.870130506"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fmds.870130506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.870130506%26sid%3Dliteratum%253Aachs%26aulast%3DRyoo%26aufirst%3DH.%2BL.%26aulast%3DDylan%26aufirst%3DB.%2BS.%26aulast%3DBs%26aufirst%3DP.%26aulast%3DJoyce%26aufirst%3DJ.%2BN.%26atitle%3DDopamine%2520D3%2520receptor%2520is%2520decreased%2520and%2520D2%2520receptor%2520is%2520elevated%2520in%2520the%2520striatum%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DIsis%26date%3D1998%26volume%3D13%26spage%3D788%26epage%3D797%26doi%3D10.1002%2Fmds.870130506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 agonists in the treatment of Parkinson’s disease</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">908</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.2174/156802661510150328223428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.2174%2F156802661510150328223428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=25832718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1akt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=908-926&author=B.+Dasauthor=G.+Modiauthor=A.+Dutta&title=Dopamine+D3+agonists+in+the+treatment+of+Parkinson%E2%80%99s+disease&doi=10.2174%2F156802661510150328223428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 Agonists in the Treatment of Parkinson's Disease</span></div><div class="casAuthors">Das, Banibrata; Modi, Gyan; Dutta, Aloke</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">908-926</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) is t he second most common form of neurodegenerative disorders that results from the progressive loss of dopaminergic neurons in the midbrain substantia nigra pars compacta (SNpc) triggering profound motor perturbation, as well as cognitive, sensory and mood deficits.  Although these symptoms can be improved using currently available dopamine replacement strategies, they are not able to slow the neurodegenerative process that underlies PD progression.  Following the discovery of the D3 receptor from mol. cloning, it has gained much attention as a potential therapeutic target for the treatment of PD due to their localization in the limbic regions of the brain as well as pharmacol. similarity to the D2 receptor subtype.  Of particular interest, D3 receptor- selective agonists appear to have neuroprotective effects apart from their ability to relieve PD symptoms.  Owing to the distinct significance of D3 receptor in mediating diverse neurol. effects, it represents a unique target for therapeutic intervention in PD with much less undesirable side effects.  Herein, we review progress in the development of D3 receptor selective agonist mols. having a broad spectrum of affinities, selectivities as well as unique pharmacol. properties directed at slowing the neurodegeneration process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1vO7t50SK9rVg90H21EOLACvtfcHk0lgpExiYQxxZ7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1akt7w%253D&md5=46885592d050d099cbad73ba7ef8e61b</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.2174%2F156802661510150328223428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802661510150328223428%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DB.%26aulast%3DModi%26aufirst%3DG.%26aulast%3DDutta%26aufirst%3DA.%26atitle%3DDopamine%2520D3%2520agonists%2520in%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2015%26volume%3D15%26spage%3D908%26epage%3D926%26doi%3D10.2174%2F156802661510150328223428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kassel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwed, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 receptor agonists as pharmacological tools</span>. <i>Eur. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1480</span>– <span class="NLM_lpage">1499</span>, <span class="refDoi"> DOI: 10.1016/j.euroneuro.2014.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.euroneuro.2014.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=25498414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFCrtrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1480-1499&author=S.+Kasselauthor=J.+S.+Schwedauthor=H.+Stark&title=Dopamine+D3+receptor+agonists+as+pharmacological+tools&doi=10.1016%2Fj.euroneuro.2014.11.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 receptor agonists as pharmacological tools</span></div><div class="casAuthors">Kassel, S.; Schwed, J. S.; Stark, H.</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1480-1499</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dysregulation of the dopaminergic innervation in the central nervous system plays a key role in different neurol. disorders like Parkinson's disease, restless legs syndrome, schizophrenia etc.  Although dopamine D3 receptors have been recognized as an important target in these diseases, their full pharmacol. properties need further investigations.  With focus on dopamine D3 receptor full agonists, this review has divided the ergoline and non-ergoline ligands in dissimilar chem. subclasses describing their pharmacodynamic properties on different related receptors, on species differences and their functional properties on different signaling mechanism.  This is combined with a short description of structure-activity relationships for each class.  Therefore, this overview should support the rational choice for the optimal compd. selection based on affinity, selectivity and efficacy data in biochem. and pharmacol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUbHeDU9BILrVg90H21EOLACvtfcHk0lgpExiYQxxZ7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFCrtrrE&md5=ad73384987fecd0b4b795c771270eefb</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.euroneuro.2014.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euroneuro.2014.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DKassel%26aufirst%3DS.%26aulast%3DSchwed%26aufirst%3DJ.%2BS.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DDopamine%2520D3%2520receptor%2520agonists%2520as%2520pharmacological%2520tools%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2015%26volume%3D25%26spage%3D1480%26epage%3D1499%26doi%3D10.1016%2Fj.euroneuro.2014.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hackling, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 receptor ligands with antagonist properties</span>. <i>Chembiochem</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">946</span>– <span class="NLM_lpage">961</span>, <span class="refDoi"> DOI: 10.1002/1439-7633(20021004)3:10<946::aid-cbic946>3.0.co;2-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2F1439-7633%2820021004%293%3A10%3C946%3A%3Aaid-cbic946%3E3.0.co%3B2-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=12362359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD38XnvFGgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=946-961&author=A.+E.+Hacklingauthor=H.+Stark&title=Dopamine+D3+receptor+ligands+with+antagonist+properties&doi=10.1002%2F1439-7633%2820021004%293%3A10%3C946%3A%3Aaid-cbic946%3E3.0.co%3B2-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 receptor ligands with antagonist properties</span></div><div class="casAuthors">Hackling, Anneke E.; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">946-961</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The dopamine D3 receptor was recognized to play an important role in the mol. mechanisms of various neuropsychiatric disorders.  The development of new dopamine D3 receptor selective antagonists is premised on the potentially improved therapeutic treatment of psychosis like schizophrenia.  Partial agonists at dopamine D3 receptors are supposed to be beneficial when administered to drug abusers or in Parkinson's disease.  The structural basis for most compds. is at least a basic, aryl-substituted alkanamine part with an alkyl moiety, which in many compds. forms a spacer to another aryl residue.  Structural variety among the amine moiety includes aminotetralins, tetrahydroisoquinolines, isoindoles, benzazepines, and amino-indans, as well as pyrrolidines, pyrroles, and 4-phenylpiperazines.  Various ways for lead optimization are shown in different classes of compds.  Promising ligands with high D3 receptor affinity often lack sufficient selectivity or display deficits in the required in vivo parameters.  Structure-activity relationships for dopamine D3 receptor antagonists and partial agonists are discussed here, along with the outlook for their potential therapeutic application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7h56q6SPZN7Vg90H21EOLACvtfcHk0lgpExiYQxxZ7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnvFGgu7c%253D&md5=ba9cd2302ced89619ae5d1d82e7d08e4</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1002%2F1439-7633%2820021004%293%3A10%3C946%3A%3Aaid-cbic946%3E3.0.co%3B2-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1439-7633%252820021004%25293%253A10%253C946%253A%253Aaid-cbic946%253E3.0.co%253B2-5%26sid%3Dliteratum%253Aachs%26aulast%3DHackling%26aufirst%3DA.%2BE.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DDopamine%2520D3%2520receptor%2520ligands%2520with%2520antagonist%2520properties%26jtitle%3DChembiochem%26date%3D2002%26volume%3D3%26spage%3D946%26epage%3D961%26doi%3D10.1002%2F1439-7633%2820021004%293%3A10%3C946%3A%3Aaid-cbic946%3E3.0.co%3B2-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahlholm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacome, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Highly selective dopamine D3 receptor antagonists with arylated diazaspiro alkane cores</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9905</span>– <span class="NLM_lpage">9910</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01248</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01248" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2gsbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9905-9910&author=S.+W.+Reillyauthor=S.+Griffinauthor=M.+Taylorauthor=K.+Sahlholmauthor=C.-C.+Wengauthor=K.+Xuauthor=D.+A.+Jacomeauthor=R.+R.+Luedtkeauthor=R.+H.+Mach&title=Highly+selective+dopamine+D3+receptor+antagonists+with+arylated+diazaspiro+alkane+cores&doi=10.1021%2Facs.jmedchem.7b01248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Dopamine D3 Receptor Antagonists with Arylated Diazaspiro Alkane Cores</span></div><div class="casAuthors">Reilly, Sean W.; Griffin, Suzy; Taylor, Michelle; Sahlholm, Kristoffer; Weng, Chi-Chang; Xu, Kuiying; Jacome, Daniel A.; Luedtke, Robert R.; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9905-9910</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aryldiazaspirocyclylpropyl phenyltriazolyl thioethers such as I (R = 2-MeOC6H4, 4-FC6H4, 4-MeOC6H4, 2-pyridinyl, 3-NCC6H4, 2,3-Cl2C6H3) were prepd. as selective dopamine D3 receptor (D3R) antagonists; their selectivities for D3R over D2R and for selected compds. over 5-HT1a, 5-HT2a, and 5-HT2c receptors and adenylyl cyclase were detd.  I (R = 2-MeOC6H4, 4-FC6H4) showed favorable D3R affinities (Ki = 12-25.6 nM) and were 264- to 905-fold selective for D3R vs D2R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHLC1nn5_14LVg90H21EOLACvtfcHk0lgpExiYQxxZ7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2gsbjL&md5=a60ed8b0524189901b7155e11025d3c6</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01248%26sid%3Dliteratum%253Aachs%26aulast%3DReilly%26aufirst%3DS.%2BW.%26aulast%3DGriffin%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DSahlholm%26aufirst%3DK.%26aulast%3DWeng%26aufirst%3DC.-C.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DJacome%26aufirst%3DD.%2BA.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DHighly%2520selective%2520dopamine%2520D3%2520receptor%2520antagonists%2520with%2520arylated%2520diazaspiro%2520alkane%2520cores%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9905%26epage%3D9910%26doi%3D10.1021%2Facs.jmedchem.7b01248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maramai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 receptor antagonists as potential therapeutics for the treatment of neurological diseases</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">451</span>, <span class="refDoi"> DOI: 10.3389/fnins.2016.00451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.3389%2Ffnins.2016.00451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=27761108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BC2srktFCktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=451&author=S.+Maramaiauthor=S.+Gemmaauthor=S.+Brogiauthor=G.+Campianiauthor=S.+Butiniauthor=H.+Starkauthor=M.+Brindisi&title=Dopamine+D3+receptor+antagonists+as+potential+therapeutics+for+the+treatment+of+neurological+diseases&doi=10.3389%2Ffnins.2016.00451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases</span></div><div class="casAuthors">Maramai Samuele; Gemma Sandra; Brogi Simone; Campiani Giuseppe; Butini Stefania; Brindisi Margherita; Stark Holger</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">451</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">D3 receptors represent a major focus of current drug design and development of therapeutics for dopamine-related pathological states.  Their close homology with the D2 receptor subtype makes the development of D3 selective antagonists a challenging task.  In this review, we explore the relevance and therapeutic utility of D3 antagonists or partial agonists endowed with multireceptor affinity profile in the field of central nervous system disorders such as schizophrenia and drug abuse.  In fact, the peculiar distribution and low brain abundance of D3 receptors make them a valuable target for the development of drugs devoid of motor side effects classically elicited by D2 antagonists.  Recent research efforts were devoted to the conception of chemical templates possibly endowed with a multi-target profile, especially with regards to other G-protein-coupled receptors (GPCRs).  A comprehensive overview of the recent literature in the field is herein provided.  In particular, the evolution of the chemical templates has been tracked, according to the growing advancements in both the structural information and the refinement of the key pharmacophoric elements.  The receptor/multireceptor affinity and functional profiles for the examined compounds have been covered, together with their most significant pharmacological applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdsZ2fFId2JDslzEEsg76ufW6udTcc2eb7ngehjLlIw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srktFCktA%253D%253D&md5=03b1e02b49ea48ab9331f5c9d38dfaf1</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2016.00451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2016.00451%26sid%3Dliteratum%253Aachs%26aulast%3DMaramai%26aufirst%3DS.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DBrogi%26aufirst%3DS.%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DBrindisi%26aufirst%3DM.%26atitle%3DDopamine%2520D3%2520receptor%2520antagonists%2520as%2520potential%2520therapeutics%2520for%2520the%2520treatment%2520of%2520neurological%2520diseases%26jtitle%3DFront.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D451%26doi%3D10.3389%2Ffnins.2016.00451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Micheli, F.</span></span> <span> </span><span class="NLM_article-title">Novel, Selective, and developable dopamine D3 antagonists with a modified “amino” region</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1254</span>– <span class="NLM_lpage">1260</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2Fcmdc.201700148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=28426179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntVyrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1254-1260&author=F.+Micheli&title=Novel%2C+Selective%2C+and+developable+dopamine+D3+antagonists+with+a+modified+%E2%80%9Camino%E2%80%9D+region&doi=10.1002%2Fcmdc.201700148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Novel, Selective, and Developable Dopamine D3 Antagonists with a Modified "Amino" Region</span></div><div class="casAuthors">Micheli, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1254-1260</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">This Minireview describes a presentation made at the XXIV National Meeting in Medicinal Chem. (NMMC) held in Perugia (Italy), Sept. 11-14, 2016.  It relates to the discovery of novel templates of the so-called "amino" region of dopamine D3 receptor antagonists.  Moving from the early scaffolds, which were modified in the amine portion, this review discusses the variations that led to the discovery of new systems published in 2016, which allowed the identification of compds. endowed with great selectivity over the dopamine D2 receptor and the human ether-a-go-go-related gene (hERG) ion channel.  The main efforts in characterizing these compds. were devoted not only to detg. their potency and selectivity relative to closely assocd. targets (e.g., the dopamine D2 receptor), but to ensure a large therapeutic window vs. liability points such as hERG.  In particular, we present examples of derivs. with selectivities greater than 2000-fold.  Furthermore, much focus is devoted to the overall developability of the scaffolds, ensuring that appropriate physicochem. and pharmacokinetic parameters are present in all compds. progressing through the screening cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3T2_i9pQBx7Vg90H21EOLACvtfcHk0lhHcPpHj2JC5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntVyrtL8%253D&md5=14ae39f7601c0bc971d1e637722c090c</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700148%26sid%3Dliteratum%253Aachs%26aulast%3DMicheli%26aufirst%3DF.%26atitle%3DNovel%252C%2520Selective%252C%2520and%2520developable%2520dopamine%2520D3%2520antagonists%2520with%2520a%2520modified%2520%25E2%2580%259Camino%25E2%2580%259D%2520region%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D1254%26epage%3D1260%26doi%3D10.1002%2Fcmdc.201700148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span> <span> </span><span class="NLM_article-title">Monoamine oxidases: The biochemistry of the proteins as targets in medicinal chemistry and drug discovery</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2189</span>– <span class="NLM_lpage">2209</span>, <span class="refDoi"> DOI: 10.2174/156802612805219978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.2174%2F156802612805219978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=23231396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1Gmsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=2189-2209&author=R.+R.+Ramsay&title=Monoamine+oxidases%3A+The+biochemistry+of+the+proteins+as+targets+in+medicinal+chemistry+and+drug+discovery&doi=10.2174%2F156802612805219978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine oxidases: the biochemistry of the proteins as targets in medicinal chemistry and drug discovery</span></div><div class="casAuthors">Ramsay, Rona R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2189-2209</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Monoamine oxidase (MAO, EC.1.4.3.4) has been a drug target for 60 years, with the primary rationale of developing drugs to treat neuropsychiatric disorders.  The biol. importance of MAO is to regulate amine levels is the brain and to metabolize amines and drugs in the periphery.  This review of the biochem. of MAO A and MAO B describes the functional properties of the two enzymes integrated with knowledge of the structures of the many MAO-inhibitor complexes published in the last 10 years.  The anal. of activity, and the chem. and kinetic mechanisms are discussed.  Inhibition studies on human MAO in vitro are now facilitated by assays using readily available materials but the kinetics of MAO involving alternative oxidative pathways and sensitivity to the oxygen concn. mean that careful anal. of the data is required as well as the good practice of detg. mechanism of inhibition and kinetic consts.  Kinetic consts. can then be compared with thermodn. calcns.  Inhibitors bind to both the oxidized and reduced forms of MAO present during turnover so both forms should be considered when using mol. dynamics to facilitate drug design.  Interaction of inhibitors with the active site can be detected as changes in the visible spectrum and these changes can provide clues about the flavin adduct formed for irreversible inhibitors or about the proximity to the flavin for reversible inhibitors.  Developing areas (knock-out mice for behavior, the imidazoline binding site, and imaging to monitor the activity and the inhibition of MAO in the patient) are mentioned.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjlHIBsEIrCLVg90H21EOLACvtfcHk0lhHcPpHj2JC5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1Gmsrk%253D&md5=bf68e400bf04c0b556a56e69d3393252</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.2174%2F156802612805219978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802612805219978%26sid%3Dliteratum%253Aachs%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26atitle%3DMonoamine%2520oxidases%253A%2520The%2520biochemistry%2520of%2520the%2520proteins%2520as%2520targets%2520in%2520medicinal%2520chemistry%2520and%2520drug%2520discovery%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2012%26volume%3D12%26spage%3D2189%26epage%3D2209%26doi%3D10.2174%2F156802612805219978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tipton, K. F.</span></span> <span> </span><span class="NLM_article-title">90 Years of monoamine oxidase: Some progress and some confusion</span>. <i>J. Neural. Transm.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1519</span>– <span class="NLM_lpage">1551</span>, <span class="refDoi"> DOI: 10.1007/s00702-018-1881-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1007%2Fs00702-018-1881-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=29637260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsVaqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2018&pages=1519-1551&author=K.+F.+Tipton&title=90+Years+of+monoamine+oxidase%3A+Some+progress+and+some+confusion&doi=10.1007%2Fs00702-018-1881-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">90 years of monoamine oxidase: some progress and some confusion</span></div><div class="casAuthors">Tipton, Keith F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neural Transmission</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1519-1551</span>CODEN:
                <span class="NLM_cas:coden">JNTRF3</span>;
        ISSN:<span class="NLM_cas:issn">0300-9564</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag GmbH</span>)
        </div><div class="casAbstract">A review.  It would not be practical to attempt to deal with all the advances that have informed our understanding of the behavior and functions of this enzyme over the past 90 years.  This account concs. key advances that explain why the monoamine oxidases remain of pharmacol. and biochem. interest and on some areas of continuing uncertainty.  Some issues that remain to be understood or are in need of further clarification are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwU8LnCd8YNLVg90H21EOLACvtfcHk0liMJ0ikBT4eHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsVaqsLg%253D&md5=73d9c86f3b2990977537cb5eca3561de</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1007%2Fs00702-018-1881-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00702-018-1881-5%26sid%3Dliteratum%253Aachs%26aulast%3DTipton%26aufirst%3DK.%2BF.%26atitle%3D90%2520Years%2520of%2520monoamine%2520oxidase%253A%2520Some%2520progress%2520and%2520some%2520confusion%26jtitle%3DJ.%2520Neural.%2520Transm.%26date%3D2018%26volume%3D125%26spage%3D1519%26epage%3D1551%26doi%3D10.1007%2Fs00702-018-1881-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riederer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laux, G.</span></span> <span> </span><span class="NLM_article-title">MAO-inhibitors in Parkinson’s disease</span>. <i>Exp. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.5607/en.2011.20.1.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.5607%2Fen.2011.20.1.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=22110357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FlsFGlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=1-17&author=P.+Riedererauthor=G.+Laux&title=MAO-inhibitors+in+Parkinson%E2%80%99s+disease&doi=10.5607%2Fen.2011.20.1.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">MAO-inhibitors in Parkinson's Disease</span></div><div class="casAuthors">Riederer Peter; Laux Gerd</div><div class="citationInfo"><span class="NLM_cas:title">Experimental neurobiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-17</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Monoamine oxidase inhibitors (MAO-I) belong to the earliest drugs tried in Parkinson's disease (PD).  They have been used with or without levodopa (L-DOPA).  Non-selective MAO-I due to their side-effect/adverse reaction profile, like tranylcypromine have limited use in the treatment of depression in PD, while selective, reversible MAO-A inhibitors are recommended due to their easier clinical handling.  For the treatment of akinesia and motor fluctuations selective irreversible MAO-B inhibitors selegiline and rasagiline are recommended.  They are safe and well tolerated at the recommended daily doses.  Their main differences are related to (1) metabolism, (2) interaction with CYP-enzymes and (3) quantitative properties at the molecular biological/genetic level.  Rasagiline is more potent in clinical practise and has a hypothesis driven more favourable side effect/adverse reaction profile due to its metabolism to aminoindan.  Both selegiline and rasagiline have a neuroprotective and neurorestaurative potential.  A head-to head clinical trial would be of utmost interest from both the clinical outcome and a hypothesis-driven point of view.  Selegiline is available as tablet and melting tablet for PD and as transdermal selegiline for depression, while rasagiline is marketed as tablet for PD.  In general, the clinical use of MAO-I nowadays is underestimated.  There should be more efforts to evaluate their clinical potency as antidepressants and antidementive drugs in addition to the final proof of their disease-modifying potential.  In line with this are recent innovative developments of MAO-I plus inhibition of acetylcholine esterase for Alzheimer's disease as well as combined MAO-I and iron chelation for PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLFR15fhEdC_csfMJQC1ZdfW6udTcc2eYewojkSR0zhLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FlsFGlsw%253D%253D&md5=83bd71bf598fe9e625291fa7c98ac0fd</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.5607%2Fen.2011.20.1.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5607%252Fen.2011.20.1.1%26sid%3Dliteratum%253Aachs%26aulast%3DRiederer%26aufirst%3DP.%26aulast%3DLaux%26aufirst%3DG.%26atitle%3DMAO-inhibitors%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DExp.%2520Neurobiol.%26date%3D2011%26volume%3D20%26spage%3D1%26epage%3D17%26doi%3D10.5607%2Fen.2011.20.1.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeMaagd, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philip, A.</span></span> <span> </span><span class="NLM_article-title">Parkinson’s disease and its management: Part 5: Treatment of nonmotor complications</span>. <i>P T</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">838</span>– <span class="NLM_lpage">846</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=26681906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BC28rislyrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2015&pages=838-846&author=G.+DeMaagdauthor=A.+Philip&title=Parkinson%E2%80%99s+disease+and+its+management%3A+Part+5%3A+Treatment+of+nonmotor+complications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Parkinson's Disease and Its Management: Part 5: Treatment of Nonmotor Complications</span></div><div class="casAuthors">DeMaagd George; Philip Ashok</div><div class="citationInfo"><span class="NLM_cas:title">P & T : a peer-reviewed journal for formulary management</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">838-46</span>
        ISSN:<span class="NLM_cas:issn">1052-1372</span>.
    </div><div class="casAbstract">Most patients with Parkinson's disease experience nonmotor complications, broadly classified as either neuropsychiatric presentations or autonomic disorders.  Despite the prevalence of these nonmotor features, treatment options for them are limited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyYNpHHtF1I_h3YQQtAhNufW6udTcc2eYewojkSR0zhLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rislyrsQ%253D%253D&md5=e528716cab59f2a74968b3ebb4643b81</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDeMaagd%26aufirst%3DG.%26aulast%3DPhilip%26aufirst%3DA.%26atitle%3DParkinson%25E2%2580%2599s%2520disease%2520and%2520its%2520management%253A%2520Part%25205%253A%2520Treatment%2520of%2520nonmotor%2520complications%26jtitle%3DP%2520T%26date%3D2015%26volume%3D40%26spage%3D838%26epage%3D846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of phenylxanthine derivatives as potential dual A2AR antagonists/MAO-B inhibitors for Parkinson’s disease</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1010</span>, <span class="refDoi"> DOI: 10.3390/molecules22061010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.3390%2Fmolecules22061010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVGgtLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1010&author=X.+Wangauthor=C.+Hanauthor=Y.+Xuauthor=K.+Wuauthor=S.+Chenauthor=M.+Huauthor=L.+Wangauthor=Y.+Ye&title=Synthesis+and+evaluation+of+phenylxanthine+derivatives+as+potential+dual+A2AR+antagonists%2FMAO-B+inhibitors+for+Parkinson%E2%80%99s+disease&doi=10.3390%2Fmolecules22061010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of phenylxanthine derivatives as potential dual A2AR antagonists/MAO-B inhibitors for Parkinson's disease</span></div><div class="casAuthors">Wang, Xuebao; Han, Chao; Xu, Yong; Wu, Kaiqi; Chen, Shuangya; Hu, Mangsha; Wang, Luyao; Ye, Yun; Ye, Faqing</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1010/1-1010/13</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The aim of this research was to prove the speculation that phenylxanthine (PX) derivs. possess adenosine A2A receptor (A2AR)-blocking properties and to screening and evaluate these PX derivs. as dual A2AR antagonists/MAO-B inhibitors for Parkinson0s disease.  To explore this hypothesis, two series of PX derivs. were prepd. and their antagonism against A2AR and inhibition against MAO-B were detd. in vitro.  In order to evaluate further the antiparkinsonian properties, pharmacokinetic and haloperidol-induced catalepsy expts. were carried out in vivo.  The PX-D and PX-E analogs acted as potent A2AR antagonists with Ki values ranging from 0.27 to 10 μM, and these analogs displayed relatively mild MAO-B inhibition potencies, with inhibitor dissocn. consts. (Ki values) ranging from 0.25 to 10 μM.  Further, the compds. PX-D-P6 and PX-E-P8 displayed efficacious antiparkinsonian properties in haloperidol-induced catalepsy expts., verifying that these two compds. were potent A2AR antagonists and MAO-B inhibitors.  We conclude that PX-D and PX-E analogs are a promising candidate class of dual-acting compds. for treating Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpkdoiOmu87rVg90H21EOLACvtfcHk0liMJ0ikBT4eHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVGgtLbJ&md5=9804c51e9ea8302927601323590b65fb</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22061010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22061010%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520phenylxanthine%2520derivatives%2520as%2520potential%2520dual%2520A2AR%2520antagonists%252FMAO-B%2520inhibitors%2520for%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26spage%3D1010%26doi%3D10.3390%2Fmolecules22061010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagenow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasiak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Ciproxifan, a histamine H3 receptor antagonist, reversibly inhibits monoamine oxidase A and B</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">40541</span>, <span class="refDoi"> DOI: 10.1038/srep40541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1038%2Fsrep40541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=28084411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvVSitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=40541&author=S.+Hagenowauthor=A.+Stasiakauthor=R.+R.+Ramsayauthor=H.+Stark&title=Ciproxifan%2C+a+histamine+H3+receptor+antagonist%2C+reversibly+inhibits+monoamine+oxidase+A+and+B&doi=10.1038%2Fsrep40541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Ciproxifan, a histamine H3 receptor antagonist, reversibly inhibits monoamine oxidase A and B</span></div><div class="casAuthors">Hagenow, S.; Stasiak, A.; Ramsay, R. R.; Stark, H.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40541</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ciproxifan is a well-investigated histamine H3 receptor (H3R) inverse agonist/antagonist, showing an exclusively high species-specific affinity at rodent compared to human H3R.  It is well studied as ref. compd. for H3R in rodent models for neurol. diseases connected with neurotransmitter dysregulation, e.g. attention deficit hyperactivity disorder or Alzheimer's disease.  In a screening for potential monoamine oxidase A and B inhibition ciproxifan showed efficacy on both enzyme isoforms.  Further characterization of ciproxifan revealed IC50 values in a micromolar concn. range for human and rat monoamine oxidases with slight preference for monoamine oxidase B in both species.  The inhibition by ciproxifan was reversible for both human isoforms.  Regarding inhibitory potency of ciproxifan on rat brain MAO, these findings should be considered, when using high doses in rat models for neurol. diseases.  As the H3R and monoamine oxidases are all capable of affecting neurotransmitter modulation in brain, we consider dual targeting ligands as interesting approach for treatment of neurol. disorders.  Since ciproxifan shows only moderate activity at human targets, further investigations in animals are not of primary interest.  On the other hand, it may serve as starting point for the development of dual targeting ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3NWO3L7ij4bVg90H21EOLACvtfcHk0lgEg5DT5pylKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvVSitw%253D%253D&md5=b75d06386aed46be0cd50a2a333247bb</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1038%2Fsrep40541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep40541%26sid%3Dliteratum%253Aachs%26aulast%3DHagenow%26aufirst%3DS.%26aulast%3DStasiak%26aufirst%3DA.%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DCiproxifan%252C%2520a%2520histamine%2520H3%2520receptor%2520antagonist%252C%2520reversibly%2520inhibits%2520monoamine%2520oxidase%2520A%2520and%2520B%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D40541%26doi%3D10.1038%2Fsrep40541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fredholm, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klotz, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span> <span> </span><span class="NLM_article-title">International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">552</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1211%2F0022357011775631" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=11734617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVOltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2001&pages=527-552&author=B.+B.+Fredholmauthor=A.+P.+IJzermanauthor=K.+A.+Jacobsonauthor=K.+N.+Klotzauthor=J.+Linden&title=International+Union+of+Pharmacology.+XXV.+Nomenclature+and+classification+of+adenosine+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85aR"><div class="casContent"><span class="casTitleNuber">85a</span><div class="casTitle"><span class="NLM_cas:atitle">International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors</span></div><div class="casAuthors">Fredholm, Bertil B.; IJzerman, Adriaan P.; Jacobson, Kenneth A.; Klotz, Karl-Norbert; Linden, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">527-552</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Four adenosine receptors have been cloned and characterized from several mammalian species.  The receptors are named adenosine A1, A2A, A2B, and A3.  The A2A and A2B receptors preferably interact with members of the Gs family of G proteins and the A1 and A3 receptors with Gi/o proteins.  However, other G protein interactions have also been described.  Adenosine is the preferred endogenous agonist at all these receptors, but inosine can also activate the A3 receptor.  The levels of adenosine seen under basal conditions are sufficient to cause some activation of all the receptors, at least where they are abundantly expressed.  Adenosine levels during, e.g., ischemia can activate all receptors even when expressed in low abundance.  Accordingly, expts. with receptor antagonists and mice with targeted disruption of adenosine A1, A2A, and A3 expression reveal roles for these receptors under physiol. and particularly pathophysiol. conditions.  There are pharmacol. tools that can be used to classify A1, A2A, and A3 receptors but few drugs that interact selectively with A2B receptors.  Testable models of the interaction of these drugs with their receptors have been generated by site-directed mutagenesis and homol.-based modeling.  Both agonists and antagonists are being developed as potential drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJOCrJphTwDrVg90H21EOLACvtfcHk0lgEg5DT5pylKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVOltQ%253D%253D&md5=060ea8a3d7b07fdc4b2c8acc3b4d4745</span></div><a href="/servlet/linkout?suffix=cit85a&amp;dbid=16384&amp;doi=10.1211%2F0022357011775631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1211%252F0022357011775631%26sid%3Dliteratum%253Aachs%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DKlotz%26aufirst%3DK.%2BN.%26aulast%3DLinden%26aufirst%3DJ.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology.%2520XXV.%2520Nomenclature%2520and%2520classification%2520of%2520adenosine%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2001%26volume%3D53%26spage%3D527%26epage%3D552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit85b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robeva, A. S.</span></span> <span> </span><span class="NLM_article-title">Characterization of human A<sub>2B</sub> adenosine receptors: Radioligand binding, western blotting, and coupling to G<sub>q</sub> in human embryonic kidney 293 cells and HMC-1 mast cells</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">705</span>– <span class="NLM_lpage">713</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10496952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADyaK1MXmsVCmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1999&pages=705-713&author=J.+Lindenauthor=T.+Thaiauthor=H.+Figlerauthor=X.+Jinauthor=A.+S.+Robeva&title=Characterization+of+human+A2B+adenosine+receptors%3A+Radioligand+binding%2C+western+blotting%2C+and+coupling+to+Gq+in+human+embryonic+kidney+293+cells+and+HMC-1+mast+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85bR"><div class="casContent"><span class="casTitleNuber">85b</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of human A2B adenosine receptors: radioligand binding, Western blotting, and coupling to Gq in human embryonic kidney 293 cells and HMC-1 mast cells</span></div><div class="casAuthors">Linden, Joel; Thai, Tami; Figler, Heidi; Jin, Xiaowei; Robeva, Anna S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">705-713</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Recombinant human A2B adenosine receptors (A2BARs) and receptors extended on the N-terminus with hexahistidine and the FLAG epitope, DYKDDDDK (H/F-A2B) were stably over-expressed (to > 20,000 fmol/mg protein) in human embryonic kidney 293 cells (HEK-A2B).  By Western blotting, the H/F-A2B receptor runs as a 34.8-kDa glycoprotein.  Pharmacol. properties of A2BARs were characterized with 1251-3-aminobenzyl-8-phenyl-(4-oxyacetic acid)-1-propylxanthine (KD, 36 nM).  In competition binding assays, the affinity of agonists is reduced by substitution on either the N6- or the C-2 position of the adenine ring, whereas 5'-substitutions increase affinity, resulting in the potency order: 5'-N-ethylcarboxamidoadenosine (NECA) » N6-aminobenzyl-NECA ≈2-chloroadenosine > 2-[4-(2-carboxy-ethyl)phenethylamino]-NECA (CGS21680) > N6-aminobenzyladenosine.  The A2BAR is potently blocked by the A2A-selective antagonist 4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo-[2,3-a][1,3,5]triazin-5-yl-amino]ethyl)phenol (ZM241385; KI, 32 nM for A2B, 1,4 nM for A2A) and the A1 selective antagonist 8-cyclopentyl-1,3-dipropylxanthine (KI, 50.5 nM for A2B; 2.5 nM for A1).  The KI values for the antiasthmatic xanthines, theophylline (7.8 μM) and enprofylline (6.4 μM), are below their therapeutic plasma concns. (20 to 50 μM), and agree with KI detns. for inhibition of NECA-stimulated cAMP accumulation in HEK-A2B cells.  NECA or N6-(2-iodo)benzyl-5'-N-methylcarboxamidodoadenosine (IB-MECA) stimulate inositol trisphosphates and calcium accumulation in HEK-A2B or HEK-A3 cells, resp., but only the A3 response is prevented by pertussis toxin.  In human HMC-1 mast cells, A2BAR activation stimulates calcium mobilization and cAMP accumulation.  The authors conclude that HEK-A2B cells and HMC-1 mast cells possess A2BAR glycoproteins that are coupled to both Gq/11 and Gs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJqtHvYLzxoLVg90H21EOLACvtfcHk0lgEg5DT5pylKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsVCmtLY%253D&md5=dc4aa0211ecd1d0f865b1f5f98ed1f30</span></div><a href="/servlet/linkout?suffix=cit85b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLinden%26aufirst%3DJ.%26aulast%3DThai%26aufirst%3DT.%26aulast%3DFigler%26aufirst%3DH.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DRobeva%26aufirst%3DA.%2BS.%26atitle%3DCharacterization%2520of%2520human%2520A2B%2520adenosine%2520receptors%253A%2520Radioligand%2520binding%252C%2520western%2520blotting%252C%2520and%2520coupling%2520to%2520Gq%2520in%2520human%2520embryonic%2520kidney%2520293%2520cells%2520and%2520HMC-1%2520mast%2520cells%26jtitle%3DMol.%2520Pharmacol.%26date%3D1999%26volume%3D56%26spage%3D705%26epage%3D713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bastide, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Crompe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doudnikoff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernagut, P.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boraud, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bézard, E.</span></span> <span> </span><span class="NLM_article-title">Inhibiting lateral habenula improves L-DOPA-induced Dyskinesia</span>. <i>Biol. Psychiatr.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2014.08.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.biopsych.2014.08.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=25442003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOgsbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2016&pages=345-353&author=M.+F.+Bastideauthor=B.+de+la+Crompeauthor=E.+Doudnikoffauthor=P.-O.+Fernagutauthor=C.+E.+Grossauthor=N.+Malletauthor=T.+Boraudauthor=E.+B%C3%A9zard&title=Inhibiting+lateral+habenula+improves+L-DOPA-induced+Dyskinesia&doi=10.1016%2Fj.biopsych.2014.08.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86aR"><div class="casContent"><span class="casTitleNuber">86a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting Lateral Habenula Improves L-DOPA-induced Dyskinesia</span></div><div class="casAuthors">Bastide, Matthieu F.; de la Crompe, Brice; Doudnikoff, Evelyne; Fernagut, Pierre-Olivier; Gross, Christian E.; Mallet, Nicolas; Boraud, Thomas; Bezard, Erwan</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">345-353</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A systematic search of brain nuclei putatively involved in L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID) in Parkinson's disease shed light, notably, upon the lateral habenula (LHb), which displayed an overexpression of the ΔFosB, ARC, and Zif268 immediate-early genes only in rats experiencing abnormal involuntary movements (AIMs).  We thus hypothesized that LHb might play a role in LID.ΔFosB immunoreactivity, 2-deoxyglucose uptake, and firing activity of LHb were studied in exptl. models of Parkinson's disease and LID. ΔFosB-expressing LHb neurons were then targeted using the Daun02-inactivation method.  A total of 18 monkeys and 55 rats were used.  LHb was found to be metabolically modified in dyskinetic monkeys and its neuronal firing frequency significantly increased in ON L-DOPA dyskinetic 6-hydroxydopamine-lesioned rats, suggesting that increased LHb neuronal activity in response to L-DOPA is related to AIM manifestation.  Therefore, to mechanistically test if LHb neuronal activity might affect AIM severity, following induction of AIMs, 6-hydroxydopamine rats were injected with Daun02 in the LHb previously transfected with ss-galactosidase under control of the FosB promoter.  Three days after Daun02 administration, animals were tested daily with L-DOPA to assess LID and L-DOPA-induced rotations.  Inactivation of ΔFosB-expressing neurons significantly reduced AIM severity and also increased rotations.  Interestingly, the dopaminergic D1 receptor was overexpressed only on the lesioned side of dyskinetic rats in LHb and co-localized with ΔFosB, suggesting a D1 receptor-mediated mechanism supporting the LHb involvement in AIMs.  This study highlights the role of LHb in LID, offering a new target to innovative treatments of LID.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow3av5XOgESLVg90H21EOLACvtfcHk0ljIkoyNmgvnfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOgsbnL&md5=bf2d6976c807284963d414b42c540fb4</span></div><a href="/servlet/linkout?suffix=cit86a&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2014.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2014.08.022%26sid%3Dliteratum%253Aachs%26aulast%3DBastide%26aufirst%3DM.%2BF.%26aulast%3Dde%2Bla%2BCrompe%26aufirst%3DB.%26aulast%3DDoudnikoff%26aufirst%3DE.%26aulast%3DFernagut%26aufirst%3DP.-O.%26aulast%3DGross%26aufirst%3DC.%2BE.%26aulast%3DMallet%26aufirst%3DN.%26aulast%3DBoraud%26aufirst%3DT.%26aulast%3DB%25C3%25A9zard%26aufirst%3DE.%26atitle%3DInhibiting%2520lateral%2520habenula%2520improves%2520L-DOPA-induced%2520Dyskinesia%26jtitle%3DBiol.%2520Psychiatr.%26date%3D2016%26volume%3D79%26spage%3D345%26epage%3D353%26doi%3D10.1016%2Fj.biopsych.2014.08.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit86b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Porras, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berthet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehay, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladepeche, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normand, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dovero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doudnikoff, E.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">PSD-95 expression controls L-DOPA dyskinesia through dopamine D<sub>1</sub> receptor trafficking</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">3977</span>– <span class="NLM_lpage">3989</span>, <span class="refDoi"> DOI: 10.1172/jci59426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1172%2Fjci59426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=23041629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1CisL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2012&pages=3977-3989&author=G.+Porrasauthor=A.+Berthetauthor=B.+Dehayauthor=Q.+Liauthor=L.+Ladepecheauthor=E.+Normandauthor=S.+Doveroauthor=A.+Martinezauthor=E.+Doudnikoff&title=PSD-95+expression+controls+L-DOPA+dyskinesia+through+dopamine+D1+receptor+trafficking&doi=10.1172%2Fjci59426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86bR"><div class="casContent"><span class="casTitleNuber">86b</span><div class="casTitle"><span class="NLM_cas:atitle">PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking</span></div><div class="casAuthors">Porras, Gregory; Berthet, Amandine; Dehay, Benjamin; Li, Qin; Ladepeche, Laurent; Normand, Elisabeth; Dovero, Sandra; Martinez, Audrey; Doudnikoff, Evelyne; Martin-Negrier, Marie-Laure; Chuan, Qin; Bloch, Bertrand; Choquet, Daniel; Boue-Grabot, Eric; Groc, Laurent; Bezard, Erwan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3977-3989</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">L-DOPA-induced dyskinesia (LID), a detrimental consequence of dopamine replacement therapy for Parkinson's disease, is assocd. with an alteration in dopamine D1 receptor (D1R) and glutamate receptor interactions.  We hypothesized that the synaptic scaffolding protein PSD-95 plays a pivotal role in this process, as it interacts with D1R, regulates its trafficking and function, and is overexpressed in LID.  Here, we demonstrate in rat and macaque models that disrupting the interaction between D1R and PSD-95 in the striatum reduces LID development and severity.  Single quantum dot imaging revealed that this benefit was achieved primarily by destabilizing D1R localization, via increased lateral diffusion followed by increased internalization and diminished surface expression.  These findings indicate that altering D1R trafficking via synapse-assocd. scaffolding proteins may be useful in the treatment of dyskinesia in Parkinson's patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYoh_pGqyGuLVg90H21EOLACvtfcHk0ljIkoyNmgvnfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1CisL7I&md5=a16335d2b21baf5bd7eabfb78238ee57</span></div><a href="/servlet/linkout?suffix=cit86b&amp;dbid=16384&amp;doi=10.1172%2Fjci59426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci59426%26sid%3Dliteratum%253Aachs%26aulast%3DPorras%26aufirst%3DG.%26aulast%3DBerthet%26aufirst%3DA.%26aulast%3DDehay%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLadepeche%26aufirst%3DL.%26aulast%3DNormand%26aufirst%3DE.%26aulast%3DDovero%26aufirst%3DS.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DDoudnikoff%26aufirst%3DE.%26atitle%3DPSD-95%2520expression%2520controls%2520L-DOPA%2520dyskinesia%2520through%2520dopamine%2520D1%2520receptor%2520trafficking%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2012%26volume%3D122%26spage%3D3977%26epage%3D3989%26doi%3D10.1172%2Fjci59426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, W. K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tronci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidalgo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simola, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabrizi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carta, M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Antidyskinetic effect of A2Aand 5HT1A/1B receptor ligands in two animal models of Parkinson’s disease</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1002/mds.26475</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2Fmds.26475" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=26871939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVeitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2016&pages=501-511&author=A.+Pinnaauthor=W.+K.+D.+Koauthor=G.+Costaauthor=E.+Tronciauthor=C.+Fidalgoauthor=N.+Simolaauthor=Q.+Liauthor=M.+A.+Tabriziauthor=E.+Bezardauthor=M.+Carta&title=Antidyskinetic+effect+of+A2Aand+5HT1A%2F1B+receptor+ligands+in+two+animal+models+of+Parkinson%E2%80%99s+disease&doi=10.1002%2Fmds.26475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease</span></div><div class="casAuthors">Pinna, Annalisa; Ko, Wai Kin D.; Costa, Giulia; Tronci, Elisabetta; Fidalgo, Camino; Simola, Nicola; Li, Qin; Tabrizi, Mojgan Aghazadeh; Bezard, Erwan; Carta, Manolo; Morelli, Micaela</div><div class="citationInfo"><span class="NLM_cas:title">Movement Disorders</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">501-511</span>CODEN:
                <span class="NLM_cas:coden">MOVDEA</span>;
        ISSN:<span class="NLM_cas:issn">0885-3185</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : The serotonin 5-HT1A/1B receptor agonist eltoprazine suppressed dyskinetic-like behavior in animal models of Parkinson's disease (PD) but simultaneously reduced levodopa (L-dopa)-induced motility.  Moreover, adenosine A2A receptor antagonists, such as preladenant, significantly increased L-dopa efficacy in PD without exacerbating dyskinetic-like behavior.  Objectives : We evaluated whether a combination of eltoprazine and preladenant may prevent or suppress L-dopa-induced dyskinesia, without impairing L-dopa's efficacy in relieving motor signs, in 2 PD models: unilateral 6-hydroxydopamine-lesioned rats and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys.  Methods : Rotational behavior and abnormal involuntary movements, or disability and L-dopa-induced dyskinesia were evaluated in 6-hydroxydopamine-lesioned rats and MPTP-treated monkeys, resp.  Moreover, in the rodent striatum, induction of immediate-early gene zif-268, an index of long-term changes, was correlated with dyskinesia.  Results : In 6-hydroxydopamine-lesioned rats, combined administration of L-dopa (4 mg/kg) plus eltoprazine (0.6 mg/kg) plus preladenant (0.3 mg/kg) significantly prevented or reduced dyskinetic-like behavior without impairing motor activity.  Zif-268 was increased in the striatum of rats treated with L-dopa and L-dopa plus preladenant compared with vehicle.  In contrast, rats treated with eltoprazine (with or without preladenant) had lower zif-268 activation after chronic treatment in both the dyskinetic and L-dopa-non-primed groups.  Moreover, acute L-dopa plus eltoprazine plus preladenant prevented worsening of motor performance (adjusting step) and sensorimotor integration deficit.  Similar results were obtained in MPTP-treated monkeys, where a combination of preladenant with eltoprazine was found to counteract dyskinesia and maintain the full therapeutic effects of a low dose of L-dopa.  Conclusions : Our results suggest a promising nondopaminergic pharmacol. strategy for the treatment of dyskinesia in PD. cpr 2016 International Parkinson and Movement Disorder Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNgI8GG4O9FbVg90H21EOLACvtfcHk0ljIkoyNmgvnfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVeitLY%253D&md5=74b3db2f5792e487ad53afac1706778c</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1002%2Fmds.26475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.26475%26sid%3Dliteratum%253Aachs%26aulast%3DPinna%26aufirst%3DA.%26aulast%3DKo%26aufirst%3DW.%2BK.%2BD.%26aulast%3DCosta%26aufirst%3DG.%26aulast%3DTronci%26aufirst%3DE.%26aulast%3DFidalgo%26aufirst%3DC.%26aulast%3DSimola%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DTabrizi%26aufirst%3DM.%2BA.%26aulast%3DBezard%26aufirst%3DE.%26aulast%3DCarta%26aufirst%3DM.%26atitle%3DAntidyskinetic%2520effect%2520of%2520A2Aand%25205HT1A%252F1B%2520receptor%2520ligands%2520in%2520two%2520animal%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DMov.%2520Disord.%26date%3D2016%26volume%3D31%26spage%3D501%26epage%3D511%26doi%3D10.1002%2Fmds.26475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, W. K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camus, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pioli, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezard, E.</span></span> <span> </span><span class="NLM_article-title">An evaluation of istradefylline treatment on parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2016.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.neuropharm.2016.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=27424102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1GgsrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2016&pages=48-58&author=W.+K.+D.+Koauthor=S.+M.+Camusauthor=Q.+Liauthor=J.+Yangauthor=S.+McGuireauthor=E.+Y.+Pioliauthor=E.+Bezard&title=An+evaluation+of+istradefylline+treatment+on+parkinsonian+motor+and+cognitive+deficits+in+1-methyl-4-phenyl-1%2C2%2C3%2C6-tetrahydropyridine+%28MPTP%29-treated+macaque+models&doi=10.1016%2Fj.neuropharm.2016.07.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88aR"><div class="casContent"><span class="casTitleNuber">88a</span><div class="casTitle"><span class="NLM_cas:atitle">An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models</span></div><div class="casAuthors">Ko, Wai Kin D.; Camus, Sandrine M.; Li, Qin; Yang, Jianzhong; McGuire, Steve; Pioli, Elsa Y.; Bezard, Erwan</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">Part_A</span>),
    <span class="NLM_cas:pages">48-58</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Istradefylline (KW-6002), an adenosine A2A receptor antagonist, is used adjunct with optimal doses of L-3,4-dihydroxyphenylalanine (L-DOPA) to extend on-time in Parkinson's disease (PD) patients experiencing motor fluctuations.  Clin. application of istradefylline for the management of other L-DOPA-induced complications, both motor and non-motor related (i.e. dyskinesia and cognitive impairments), remains to be detd.  In this study, acute effects of istradefylline (60-100 mg/kg) alone, or with optimal and sub-optimal doses of L-DOPA, were evaluated in two monkey models of PD (i) the gold-std. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of parkinsonian and dyskinetic motor symptoms and (ii) the chronic low dose (CLD) MPTP-treated macaque model of cognitive (working memory and attentional) deficits.  Behavioral analyses in L-DOPA-primed MPTP-treated macaques showed that istradefylline alone specifically alleviated postural deficits.  When combined with an optimal L-DOPA treatment dose, istradefylline increased on-time, enhanced therapeutic effects on bradykinesia and locomotion, but exacerbated dyskinesia.  Istradefylline treatment at specific doses with sub-optimal L-DOPA specifically alleviated bradykinesia.  Cognitive assessments in CLD MPTP-treated macaques showed that the attentional and working memory deficits caused by L-DOPA were lowered after istradefylline administration.  Taken together, these data support a broader clin. use of istradefylline as an adjunct treatment in PD, where specific treatment combinations can be utilized to manage various L-DOPA-induced complications, which importantly, maintain a desired anti-parkinsonian response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYuv1lfhLsH7Vg90H21EOLACvtfcHk0ljZftGaJV9UFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1GgsrbP&md5=614d0aa4aa0b83c2272685f4ef6feaa6</span></div><a href="/servlet/linkout?suffix=cit88a&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2016.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2016.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DKo%26aufirst%3DW.%2BK.%2BD.%26aulast%3DCamus%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DMcGuire%26aufirst%3DS.%26aulast%3DPioli%26aufirst%3DE.%2BY.%26aulast%3DBezard%26aufirst%3DE.%26atitle%3DAn%2520evaluation%2520of%2520istradefylline%2520treatment%2520on%2520parkinsonian%2520motor%2520and%2520cognitive%2520deficits%2520in%25201-methyl-4-phenyl-1%252C2%252C3%252C6-tetrahydropyridine%2520%2528MPTP%2529-treated%2520macaque%2520models%26jtitle%3DNeuropharmacology%26date%3D2016%26volume%3D110%26spage%3D48%26epage%3D58%26doi%3D10.1016%2Fj.neuropharm.2016.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit88b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kanda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, R. K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kase, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwana, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenner, P.</span></span> <span> </span><span class="NLM_article-title">Combined Use of the Adenosine A2A Antagonist KW-6002 with l-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">327</span>, <span class="refDoi"> DOI: 10.1006/exnr.2000.7350</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1006%2Fexnr.2000.7350" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10739638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD3cXitVWqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2000&pages=321-327&author=T.+Kandaauthor=M.+J.+Jacksonauthor=L.+A.+Smithauthor=R.+K.+B.+Pearceauthor=J.+Nakamuraauthor=H.+Kaseauthor=Y.+Kuwanaauthor=P.+Jenner&title=Combined+Use+of+the+Adenosine+A2A+Antagonist+KW-6002+with+l-DOPA+or+with+Selective+D1+or+D2+Dopamine+Agonists+Increases+Antiparkinsonian+Activity+but+Not+Dyskinesia+in+MPTP-Treated+Monkeys&doi=10.1006%2Fexnr.2000.7350"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88bR"><div class="casContent"><span class="casTitleNuber">88b</span><div class="casTitle"><span class="NLM_cas:atitle">Combined Use of the Adenosine A2A Antagonist KW-6002 with l-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys</span></div><div class="casAuthors">Kanda, Tomoyuki; Jackson, Michael J.; Smith, Lance A.; Pearce, Ronald K. B.; Nakamura, Joji; Kase, Hiroshi; Kuwana, Yoshihisa; Jenner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">321-327</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The novel selective adenosine A2A receptor antagonist KW-6002 improves motor disability in MPTP-treated parkinsonian marmosets without provoking dyskinesia.  In this study we have investigated whether KW-6002 in combination with l-DOPA or selective D1 or D2 dopamine receptor agonists enhances antiparkinsonian activity in MPTP-treated common marmosets.  Combination of KW-6002 with the selective dopamine D2 receptor agonist quinpirole or the D1 receptor agonist SKF80723 produced an additive improvement in motor disability.  Coadministration of KW-6002 with a low dose of l-DOPA also produced an additive improvement in motor disability, and increased locomotor activity.  The ability of KW-6002 to enhance antiparkinsonian activity was more marked with l-DOPA and quinpirole than with the D1 agonist.  However, despite producing an enhanced antiparkinsonian response KW-6002 did not exacerbate l-DOPA-induced dyskinesia in MPTP-treated common marmosets previously primed to exhibit dyskinesia by prior exposure to l-DOPA.  Selective adenosine A2A receptor antagonists, such as KW-6002, may be one means of reducing the dosage of l-DOPA used in treating Parkinson's disease and are potentially a novel approach to treating the illness both as monotherapy and in combination with dopaminergic drugs.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsA7cu-aJS8rVg90H21EOLACvtfcHk0ljZftGaJV9UFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXitVWqsLY%253D&md5=28db343f66ae2a8179d7113246f39ae7</span></div><a href="/servlet/linkout?suffix=cit88b&amp;dbid=16384&amp;doi=10.1006%2Fexnr.2000.7350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fexnr.2000.7350%26sid%3Dliteratum%253Aachs%26aulast%3DKanda%26aufirst%3DT.%26aulast%3DJackson%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DL.%2BA.%26aulast%3DPearce%26aufirst%3DR.%2BK.%2BB.%26aulast%3DNakamura%26aufirst%3DJ.%26aulast%3DKase%26aufirst%3DH.%26aulast%3DKuwana%26aufirst%3DY.%26aulast%3DJenner%26aufirst%3DP.%26atitle%3DCombined%2520Use%2520of%2520the%2520Adenosine%2520A2A%2520Antagonist%2520KW-6002%2520with%2520l-DOPA%2520or%2520with%2520Selective%2520D1%2520or%2520D2%2520Dopamine%2520Agonists%2520Increases%2520Antiparkinsonian%2520Activity%2520but%2520Not%2520Dyskinesia%2520in%2520MPTP-Treated%2520Monkeys%26jtitle%3DExp.%2520Neurol.%26date%3D2000%26volume%3D162%26spage%3D321%26epage%3D327%26doi%3D10.1006%2Fexnr.2000.7350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdett, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredholm, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarzschild, M. A.</span></span> <span> </span><span class="NLM_article-title">Deletion of adenosine A1 or A2A receptors reduces L-3,4- dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson’s disease</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1367</i></span>,  <span class="NLM_fpage">310</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2010.08.099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.brainres.2010.08.099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=20828543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFyltbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1367&publication_year=2011&pages=310-318&author=D.+Xiaoauthor=J.+J.+Cassinauthor=B.+Healyauthor=T.+C.+Burdettauthor=J.-F.+Chenauthor=B.+B.+Fredholmauthor=M.+A.+Schwarzschild&title=Deletion+of+adenosine+A1+or+A2A+receptors+reduces+L-3%2C4-+dihydroxyphenylalanine-induced+dyskinesia+in+a+model+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.brainres.2010.08.099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Deletion of adenosine A1 or A2A receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease</span></div><div class="casAuthors">Xiao, Danqing; Cassin, Jared J.; Healy, Brian; Burdett, Thomas C.; Chen, Jiang-Fan; Fredholm, Bertil B.; Schwarzschild, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1367</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">310-318</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Adenosine A2A receptor antagonism provides a promising approach to developing nondopaminergic therapy for Parkinson's disease (PD).  Clin. trials of A2A antagonists have targeted PD patients with L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID) in an effort to improve parkinsonian symptoms.  The role of adenosine in the development of LID is little known, esp. regarding its actions via A1 receptors.  We aimed to examine the effects of genetic deletion and pharmacol. blockade of A1 and/or A2A receptors on the development of LID, on the induction of mol. markers of LID including striatal preprodynorphin and preproenkephalin (PPE), and on the integrity of dopaminergic nigrostriatal neurons in hemiparkinsonian mice.  Following a unilateral 6-hydroxydopamine lesion A1, A2A and double A1-A2A knockout (KO) and wild-type littermate mice, and mice pretreated with caffeine (an antagonist of both A1 and A2A receptors) or saline were treated daily for 18-21 days with a low dose of L-DOPA.  Total abnormal involuntary movements (AIMs, a measure of LID) were significantly attenuated (p < 0.05) in A1 and A2A KOs, but not in A1-A2A KOs and caffeine-pretreated mice.  An elevation of PPE mRNA ipsilateral to the lesion in WT mice was reduced in all KO mice.  In addn., neuronal integrity assessed by striatal dopamine content was similar in all KOs and caffeine-pretreated mice following 6-hydroxydopamine lesioning.  Our findings raise the possibility that A1 or A2A receptors blockade might also confer a disease-modifying benefit of reduced risk of disabling LID, whereas the effect of their combined inactivation is less clear.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLksjL5wTtsbVg90H21EOLACvtfcHk0ljZftGaJV9UFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFyltbvJ&md5=a9ba0c6e7d1f9b4f07f5cd5e48827663</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2010.08.099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2010.08.099%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DD.%26aulast%3DCassin%26aufirst%3DJ.%2BJ.%26aulast%3DHealy%26aufirst%3DB.%26aulast%3DBurdett%26aufirst%3DT.%2BC.%26aulast%3DChen%26aufirst%3DJ.-F.%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26aulast%3DSchwarzschild%26aufirst%3DM.%2BA.%26atitle%3DDeletion%2520of%2520adenosine%2520A1%2520or%2520A2A%2520receptors%2520reduces%2520L-3%252C4-%2520dihydroxyphenylalanine-induced%2520dyskinesia%2520in%2520a%2520model%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DBrain%2520Res.%26date%3D2011%26volume%3D1367%26spage%3D310%26epage%3D318%26doi%3D10.1016%2Fj.brainres.2010.08.099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C.-L.</span></span> <span> </span><span class="NLM_article-title">A Meta-analysis of adenosine A2A receptor antagonists on levodopa-induced dyskinesia in vivo</span>. <i>Front. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">702</span>, <span class="refDoi"> DOI: 10.3389/fneur.2017.00702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.3389%2Ffneur.2017.00702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=29375464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BC1MvkvVGlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=702&author=W.-W.+Wangauthor=M.-M.+Zhangauthor=X.-R.+Zhangauthor=Z.-R.+Zhangauthor=J.+Chenauthor=L.+Fengauthor=C.-L.+Xie&title=A+Meta-analysis+of+adenosine+A2A+receptor+antagonists+on+levodopa-induced+dyskinesia+in+vivo&doi=10.3389%2Ffneur.2017.00702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">A Meta-Analysis of Adenosine A2A Receptor Antagonists on Levodopa-Induced Dyskinesia In Vivo</span></div><div class="casAuthors">Wang Wen-Wen; Zhang Man-Man; Zhang Xing-Ru; Zhang Zeng-Rui; Chen Jie; Feng Liang; Xie Cheng-Long</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neurology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">702</span>
        ISSN:<span class="NLM_cas:issn">1664-2295</span>.
    </div><div class="casAbstract">Background:  Long-term use of levodopa (l-dopa) is inevitably complicated with highly disabling fluctuations and drug-induced dyskinesias, which pose major challenges to the existing drug therapy of Parkinson's disease.  Methods:  In this study, we conducted a systematic review and meta-analysis to assess the efficacy of A2A receptor antagonists on reducing l-dopa-induced dyskinesias (LID).  Results:  Nine studies with a total of 152 animals were included in this meta-analysis.  Total abnormal involuntary movements (AIM) score, locomotor activity, and motor disability were reported as outcome measures in 5, 5, and 3 studies, respectively.  Combined standardized mean difference (SMD) estimates were calculated using a random-effects model.  We pooled the whole data and found that, when compared to l-dopa alone, A2A receptor antagonists plus l-dopa treatment showed no effect on locomotor activity (SMD -0.00, 95% confidence interval (CI): -2.52 to 2.52, p = 1.0), superiority in improvement of motor disability (SMD -5.06, 95% CI: -9.25 to -0.87, p = 0.02) and more effective in control of AIM (SMD -1.82, 95% CI: -3.38 to -0.25, p = 0.02).  Conclusion:  To sum up, these results demonstrated that A2A receptor antagonists appear to have efficacy in animal models of LID.  However, large randomized clinical trials testing the effects of A2A receptor antagonists in LID patients are always warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAOyr9pbMx6rxanA7vODO6fW6udTcc2eZplbP1f1R9gLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvkvVGlsg%253D%253D&md5=640ce9dbcc9b42a8b133e9c981b5fe27</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.3389%2Ffneur.2017.00702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffneur.2017.00702%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.-W.%26aulast%3DZhang%26aufirst%3DM.-M.%26aulast%3DZhang%26aufirst%3DX.-R.%26aulast%3DZhang%26aufirst%3DZ.-R.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DXie%26aufirst%3DC.-L.%26atitle%3DA%2520Meta-analysis%2520of%2520adenosine%2520A2A%2520receptor%2520antagonists%2520on%2520levodopa-induced%2520dyskinesia%2520in%2520vivo%26jtitle%3DFront.%2520Neurol.%26date%3D2017%26volume%3D8%26spage%3D702%26doi%3D10.3389%2Ffneur.2017.00702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lundblad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirik, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierup, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenci, M. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson’s disease</span>. <i>Eur. J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1046/j.0953-816x.2001.01843.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1046%2Fj.0953-816x.2001.01843.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=11860512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BD387ktFynug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2002&pages=120-132&author=M.+Lundbladauthor=M.+Anderssonauthor=C.+Winklerauthor=D.+Kirikauthor=N.+Wierupauthor=M.+A.+Cenci&title=Pharmacological+validation+of+behavioural+measures+of+akinesia+and+dyskinesia+in+a+rat+model+of+Parkinson%E2%80%99s+disease&doi=10.1046%2Fj.0953-816x.2001.01843.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease</span></div><div class="casAuthors">Lundblad M; Andersson M; Winkler C; Kirik D; Wierup N; Cenci M Angela</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-32</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">In an attempt to define clinically relevant models of akinesia and dyskinesia in 6-hydroxydopamine (6-OHDA)-lesioned rats, we have examined the effects of drugs with high (L-DOPA) vs. low (bromocriptine) dyskinesiogenic potential in Parkinson's disease on three types of motor performance, namely: (i) abnormal involuntary movements (AIMs) (ii) rotational behaviour, and (iii) spontaneous forelimb use (cylinder test).  Rats with unilateral 6-OHDA lesions received single daily i.p. injections of L-DOPA or bromocriptine at therapeutic doses.  During 3 weeks of treatment, L-DOPA but not bromocriptine induced increasingly severe AIMs affecting the limb, trunk and orofacial region.  Rotational behaviour was induced to a much higher extent by bromocriptine than L-DOPA.  In the cylinder test, the two drugs initially improved the performance of the parkinsonian limb to a similar extent.  However, L-DOPA-treated animals showed declining levels of performance in this test because the drug-induced AIMs interfered with physiological limb use, and gradually replaced all normal motor activities.  L-DOPA-induced axial, limb and orolingual AIM scores were significantly reduced by the acute administration of compounds that have antidyskinetic efficacy in parkinsonian patients and/or nonhuman primates (-91%, yohimbine 10 mg/kg; -19%, naloxone 4-8 mg/kg; -37%, 5-methoxy 5-N,N-dimethyl-tryptamine 2 mg/kg; -30%, clozapine 8 mg/kg; -50%, amantadine 40 mg/kg).  L-DOPA-induced rotation was, however, not affected.  The present results demonstrate that 6-OHDA-lesioned rats do exhibit motor deficits that share essential functional similarities with parkinsonian akinesia or dyskinesia.  Such deficits can be quantified using novel and relatively simple testing procedures, whereas rotometry cannot discriminate between dyskinetic and antiakinetic effects of antiparkinsonian treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2N4CuMIbAh5I8NvIb08rbfW6udTcc2eZplbP1f1R9gLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387ktFynug%253D%253D&md5=264e2ded8dc58459f2c82754c5455be1</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1046%2Fj.0953-816x.2001.01843.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.0953-816x.2001.01843.x%26sid%3Dliteratum%253Aachs%26aulast%3DLundblad%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DM.%26aulast%3DWinkler%26aufirst%3DC.%26aulast%3DKirik%26aufirst%3DD.%26aulast%3DWierup%26aufirst%3DN.%26aulast%3DCenci%26aufirst%3DM.%2BA.%26atitle%3DPharmacological%2520validation%2520of%2520behavioural%2520measures%2520of%2520akinesia%2520and%2520dyskinesia%2520in%2520a%2520rat%2520model%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D2002%26volume%3D15%26spage%3D120%26epage%3D132%26doi%3D10.1046%2Fj.0953-816x.2001.01843.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ko, W. K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezard, E.</span></span> <span> </span><span class="NLM_article-title">A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson’s disease</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>813</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2017.07.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.ejphar.2017.07.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=28739086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1equ7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=813&publication_year=2017&pages=10-16&author=W.+K.+D.+Koauthor=Q.+Liauthor=L.+Y.+Chengauthor=M.+Morelliauthor=M.+Cartaauthor=E.+Bezard&title=A+preclinical+study+on+the+combined+effects+of+repeated+eltoprazine+and+preladenant+treatment+for+alleviating+L-DOPA-induced+dyskinesia+in+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.ejphar.2017.07.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease</span></div><div class="casAuthors">Ko, Wai Kin D.; Li, Qin; Cheng, Long Yun; Morelli, Micaela; Carta, Manolo; Bezard, Erwan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">813</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10-16</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Eltoprazine, a serotonergic (5-HT)1A/B receptor agonist, is a potential treatment for L-DOPA-induced dyskinesia (LID) in Parkinson's disease (PD) but notably compromises the anti-parkinsonian effects of L-DOPA, as seen in rodent and monkey models of PD.  Preladenant, a selective adenosine A2a receptor antagonist, mediates modest anti-parkinsonian effects in parkinsonian monkeys.  In a recent investigation, combined eltoprazine and preladenant treatment with a sub-threshold dose of L-DOPA acutely attenuated dyskinesia without exacerbating PD disability in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaques.  The aim of this study was to investigate the daily repeated treatment effects of eltoprazine (1 mg/kg) alone, and in combination with preladenant (5 mg/kg), on the motor symptoms of PD and LID in MPTP-treated macaques.  The anti-dyskinetic and -parkinsonian effects of combinative drug administration with a sub-threshold dose of L-DOPA were measured over 14 days.  Eltoprazine treatment alone produced a near-complete suppression of dyskinesia but consistently increased parkinsonism.  The administration of preladenant with eltoprazine prevented the increased severity of parkinsonian motor symptoms but was unable to maintain a reduced expression of dyskinesia with repeated administration.  These data demonstrate the clin. utility of the modulation of the serotonergic and adenosine neurotransmitter systems with selective pharmacol. agents for only acute treatment of LID.  This multi-targeted approach is unsuitable as a long-term treatment regimen due to unsustainable therapeutic effects on dyskinesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaOU-f4zjeMrVg90H21EOLACvtfcHk0lhh-vXLjr4N_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1equ7bF&md5=3bff68d15cae0212ac2dbb381987d518</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2017.07.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2017.07.030%26sid%3Dliteratum%253Aachs%26aulast%3DKo%26aufirst%3DW.%2BK.%2BD.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DCheng%26aufirst%3DL.%2BY.%26aulast%3DMorelli%26aufirst%3DM.%26aulast%3DCarta%26aufirst%3DM.%26aulast%3DBezard%26aufirst%3DE.%26atitle%3DA%2520preclinical%2520study%2520on%2520the%2520combined%2520effects%2520of%2520repeated%2520eltoprazine%2520and%2520preladenant%2520treatment%2520for%2520alleviating%2520L-DOPA-induced%2520dyskinesia%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2017%26volume%3D813%26spage%3D10%26epage%3D16%26doi%3D10.1016%2Fj.ejphar.2017.07.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solís, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Montes, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Granillo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moratalla, R.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 receptor modulates L-DOPA-induced dyskinesia by targeting D1 receptor-mediated striatal signaling</span>. <i>Cereb. Cortex</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">446</span>, <span class="refDoi"> DOI: 10.1093/cercor/bhv231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1093%2Fcercor%2Fbhv231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=26483399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BC28zjtlGmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=435-446&author=O.+Sol%C3%ADsauthor=J.+R.+Garcia-Montesauthor=A.+Gonz%C3%A1lez-Granilloauthor=M.+Xuauthor=R.+Moratalla&title=Dopamine+D3+receptor+modulates+L-DOPA-induced+dyskinesia+by+targeting+D1+receptor-mediated+striatal+signaling&doi=10.1093%2Fcercor%2Fbhv231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 Receptor Modulates l-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling</span></div><div class="casAuthors">Solis Oscar; Garcia-Montes Jose Ruben; Gonzalez-Granillo Aldo; Moratalla Rosario; Solis Oscar; Garcia-Montes Jose Ruben; Moratalla Rosario; Xu Ming</div><div class="citationInfo"><span class="NLM_cas:title">Cerebral cortex (New York, N.Y. : 1991)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">435-446</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The dopamine D3 receptor (D3R) belongs to the dopamine D2-like receptor family and is principally located in the ventral striatum.  However, previous studies reported D3R overexpression in the dorsal striatum following l-DOPA treatment in parkinsonian animals.  This fact has drawn attention in the importance of D3R in l-DOPA-induced dyskinesia (LID).  Here, we used D3R knockout mice to assess the role of D3R in LID and rotational sensitization in the hemiparkinsonian model.  Mice lacking D3R presented a reduction in dyskinesia without interfering with the antiparkinsonian l-DOPA effect and were accompanied by a reduction in the l-DOPA-induced rotations.  Interestingly, deleting D3R attenuated important molecular markers in the D1R-neurons such as FosB, extracellular signal-regulated kinase, and histone-3 (H3)-activation.  Colocalization studies in D1R-tomato and D2R-green fluorescent protein BAC-transgenic mice indicated that l-DOPA-induced D3R overexpression principally occurs in D1R-containing neurons although it is also present in the D2R-neurons.  Moreover, D3R pharmacological blockade with PG01037 reduced dyskinesia and the molecular markers expressed in D1R-neurons.  In addition, this antagonist further reduced dyskinetic symptoms in D1R heterozygous mice, indicating a direct interaction between D1R and D3R.  Together, our results demonstrate that D3R modulates the development of dyskinesia by targeting D1R-mediated intracellular signaling and suggest that decreasing D3R activity may help to ameliorate LID.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZlMHmvTSGI8-crCu0nI_sfW6udTcc2eY0vVYtRAJqfbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zjtlGmsQ%253D%253D&md5=8335e5d55089b38756146b45db4befe5</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1093%2Fcercor%2Fbhv231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcercor%252Fbhv231%26sid%3Dliteratum%253Aachs%26aulast%3DSol%25C3%25ADs%26aufirst%3DO.%26aulast%3DGarcia-Montes%26aufirst%3DJ.%2BR.%26aulast%3DGonz%25C3%25A1lez-Granillo%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DMoratalla%26aufirst%3DR.%26atitle%3DDopamine%2520D3%2520receptor%2520modulates%2520L-DOPA-induced%2520dyskinesia%2520by%2520targeting%2520D1%2520receptor-mediated%2520striatal%2520signaling%26jtitle%3DCereb.%2520Cortex%26date%3D2017%26volume%3D27%26spage%3D435%26epage%3D446%26doi%3D10.1093%2Fcercor%2Fbhv231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bézard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leriche, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boraud, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokoloff, P.</span></span> <span> </span><span class="NLM_article-title">Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">762</span>– <span class="NLM_lpage">767</span>, <span class="refDoi"> DOI: 10.1038/nm875</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1038%2Fnm875" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=12740572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktFOnu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=762-767&author=E.+B%C3%A9zardauthor=S.+Ferryauthor=U.+Machauthor=H.+Starkauthor=L.+Lericheauthor=T.+Boraudauthor=C.+Grossauthor=P.+Sokoloff&title=Attenuation+of+levodopa-induced+dyskinesia+by+normalizing+dopamine+D3+receptor+function&doi=10.1038%2Fnm875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function</span></div><div class="casAuthors">Bezard, Erwan; Ferry, Sandrine; Mach, Ulrich; Stark, Holger; Leriche, Ludovic; Boraud, Thomas; Gross, Christian; Sokoloff, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">762-767</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In monkeys rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), expression of the nigrostriatal dopamine D3 receptors was decreased.  However, levodopa-induced dyskinesia (LID), similar to the debilitating and drug-resistant involuntary movements elicited after long-term treatment with levodopa in patients with Parkinson's disease (PD), was assocd. with overexpression of this receptor.  Administration of a D3 receptor-selective partial agonist, BP 897, strongly attenuated the levodopa-induced dyskinesia but left unaffected the therapeutic effect of levodopa.  In contrast, attenuation of dyskinesia by D3 receptor antagonists was accompanied by the reappearance of PD-like symptoms.  These results indicated that the D3 receptor participates in both the dyskinesia and the therapeutic action of levodopa, and that partial agonists may normalize D3 receptor function and correct side effects of levodopa therapy in patients with PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPT5KLDLoCCLVg90H21EOLACvtfcHk0lhE0R5Ax5yeIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktFOnu7w%253D&md5=eb546a54dce74d4b5f08f85432221dee</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fnm875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm875%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25A9zard%26aufirst%3DE.%26aulast%3DFerry%26aufirst%3DS.%26aulast%3DMach%26aufirst%3DU.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DLeriche%26aufirst%3DL.%26aulast%3DBoraud%26aufirst%3DT.%26aulast%3DGross%26aufirst%3DC.%26aulast%3DSokoloff%26aufirst%3DP.%26atitle%3DAttenuation%2520of%2520levodopa-induced%2520dyskinesia%2520by%2520normalizing%2520dopamine%2520D3%2520receptor%2520function%26jtitle%3DNat.%2520Med.%26date%3D2003%26volume%3D9%26spage%3D762%26epage%3D767%26doi%3D10.1038%2Fnm875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Visanji, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brotchie, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brotchiea, J. M.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson’s disease</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">184</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2008.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.nbd.2008.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=19118628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFCgt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2009&pages=184-192&author=N.+P.+Visanjiauthor=S.+H.+Foxauthor=T.+Johnstonauthor=G.+Reyesauthor=M.+J.+Millanauthor=J.+M.+Brotchieauthor=J.+M.+Brotchiea&title=Dopamine+D3+receptor+stimulation+underlies+the+development+of+L-DOPA-induced+dyskinesia+in+animal+models+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.nbd.2008.11.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease</span></div><div class="casAuthors">Visanji, Naomi P.; Fox, Susan H.; Johnston, Tom; Reyes, Gabriela; Millan, Mark J.; Brotchie, Jonathan M.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-192</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Development of L-DOPA-induced dyskinesia (LID) remains a major problem in the long-term treatment of Parkinson's disease (PD).  Sensitization to L-DOPA correlates with ectopic expression of D3 dopamine receptors in the striatum, implicating D3 receptors in development of LID.  We demonstrate that the selective D3 antagonist S33084 abolishes development of LID over 30 days in MPTP-lesioned marmosets without effecting the anti-parkinsonian actions of L-DOPA.  Furthermore, following a 14 day washout, when challenged with L-DOPA in the absence of S33084, these animals continued to exhibit reduced LID.  In the 6-OHDA-lesioned rat, S33084 similarly attenuated development of behavioral sensitization to L-DOPA.  Addnl., L-DOPA-induced elevations in striatal pre-proenkephalin-A (PPE-A) (but not PPE-B, phospho[Thr34]DARPP-32, D1, and D2 receptor mRNA or D3 receptor levels) were reduced in S33084 treated animals.  Our data suggest a role for D3 receptors in the development of LID and suggest that initiating L-DOPA treatment with a D3 antagonist may reduce the development of LID in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokMZS17qgpkLVg90H21EOLACvtfcHk0lhE0R5Ax5yeIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFCgt74%253D&md5=e11479639deb283424a1a680fc98ffee</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2008.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2008.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DVisanji%26aufirst%3DN.%2BP.%26aulast%3DFox%26aufirst%3DS.%2BH.%26aulast%3DJohnston%26aufirst%3DT.%26aulast%3DReyes%26aufirst%3DG.%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26aulast%3DBrotchie%26aufirst%3DJ.%2BM.%26aulast%3DBrotchiea%26aufirst%3DJ.%2BM.%26atitle%3DDopamine%2520D3%2520receptor%2520stimulation%2520underlies%2520the%2520development%2520of%2520L-DOPA-induced%2520dyskinesia%2520in%2520animal%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2009%26volume%3D35%26spage%3D184%26epage%3D192%26doi%3D10.1016%2Fj.nbd.2008.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bibbiani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petzer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagnoli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarzschild, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chase, T. N.</span></span> <span> </span><span class="NLM_article-title">A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1016/s0014-4886(03)00250-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fs0014-4886%2803%2900250-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=14637099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptVektrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2003&pages=285-294&author=F.+Bibbianiauthor=J.+D.+Ohauthor=J.+P.+Petzerauthor=N.+Castagnoliauthor=J.-F.+Chenauthor=M.+A.+Schwarzschildauthor=T.+N.+Chase&title=A2A+antagonist+prevents+dopamine+agonist-induced+motor+complications+in+animal+models+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fs0014-4886%2803%2900250-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease</span></div><div class="casAuthors">Bibbiani, F.; Oh, J. D.; Petzer, J. P.; Castagnoli, N.; Chen, J.-F.; Schwarzschild, M. A.; Chase, T. N.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">285-294</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">Adenosine A2A receptors, abundantly expressed on striatal medium spiny neurons, appear to activate signaling cascades implicated in the regulation of coexpressed ionotropic glutamatergic receptors.  To evaluate the contribution of adenosinergic mechanisms to the pathogenesis of the response alterations induced by dopaminergic treatment, we studied the ability of the selective adenosine A2A receptor antagonist KW-6002 to prevent as well as palliate these syndromes in rodent and primate models of Parkinson's disease.  In rats, KW-6002 reversed the shortened motor response produced by chronic levodopa treatment while reducing levodopa-induced hyperphosphorylation at S845 residues on AMPA receptor GluR1 subunits.  In primates, KW-6002 evidenced modest antiparkinsonian activity when given alone.  Once-daily coadministration of KW-6002 with apomorphine prevented the development of dyskinesias, which appeared in control animals 7-10 days after initiating apomorphine treatment.  Animals initially given apomorphine plus KW-6002 for 3 wk did not begin to manifest apomorphine-induced dyskinesias until 10-12 days after discontinuing the A2A antagonist.  These results suggest that KW-6002 can attenuate the induction as well as the expression of motor response alterations to chronic dopaminergic stimulation in parkinsonian animals, possibly by blocking A2A receptor-stimulated signaling pathways.  Our findings strengthen the rationale for developing A2A antagonists as an early treatment strategy for Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSAWSN7Mb2t7Vg90H21EOLACvtfcHk0lgHWPGt2ceQiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptVektrw%253D&md5=081b90c918741d254ff011951ef7bb5e</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fs0014-4886%2803%2900250-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0014-4886%252803%252900250-4%26sid%3Dliteratum%253Aachs%26aulast%3DBibbiani%26aufirst%3DF.%26aulast%3DOh%26aufirst%3DJ.%2BD.%26aulast%3DPetzer%26aufirst%3DJ.%2BP.%26aulast%3DCastagnoli%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DJ.-F.%26aulast%3DSchwarzschild%26aufirst%3DM.%2BA.%26aulast%3DChase%26aufirst%3DT.%2BN.%26atitle%3DA2A%2520antagonist%2520prevents%2520dopamine%2520agonist-induced%2520motor%2520complications%2520in%2520animal%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DExp.%2520Neurol.%26date%3D2003%26volume%3D184%26spage%3D285%26epage%3D294%26doi%3D10.1016%2Fs0014-4886%2803%2900250-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarzschild, M. A.</span></span> <span> </span><span class="NLM_article-title">Role of adenosine A2A receptors in parkinsonian motor impairment and L-DOPA-induced motor complications</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1016/j.pneurobio.2007.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.pneurobio.2007.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=17826884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlags7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2007&pages=293-309&author=M.+Morelliauthor=T.+Di+Paoloauthor=J.+Wardasauthor=F.+Calonauthor=D.+Xiaoauthor=M.+A.+Schwarzschild&title=Role+of+adenosine+A2A+receptors+in+parkinsonian+motor+impairment+and+L-DOPA-induced+motor+complications&doi=10.1016%2Fj.pneurobio.2007.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Role of adenosine A2A receptors in parkinsonian motor impairment and L-DOPA-induced motor complications</span></div><div class="casAuthors">Morelli, Micaela; Di Paolo, Therese; Wardas, Jadwiga; Calon, Frederic; Xiao, Danqing; Schwarzschild, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">293-309</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Adenosine A2A receptors have a unique cellular and regional distribution in the basal ganglia, being particularly concd. in areas richly innervated by dopamine such as the caudate-putamen and the globus pallidus.  Adenosine A2A receptors are selectively located on striatopallidal neurons and are capable of forming functional heteromeric complexes with dopamine D2 and metabotropic glutamate mGlu5 receptors.  Based on the unique cellular and regional distribution of this receptor and in line with data showing that A2A receptor antagonists improve motor symptoms in animal models of Parkinson's disease (PD) and in initial clin. trials, A2A receptor antagonists have emerged as an attractive non-dopaminergic target to improve the motor deficits that characterize PD.  Exptl. data have also shown that A2A receptor antagonists do not induce neuroplasticity phenomena that complicate long-term dopaminergic treatments.  The present review provides an updated summary of results reported in the literature concerning the biochem. characteristics and basal ganglia distribution of A2A receptors.  We subsequently aim to examine the effects of adenosine A2A antagonists in rodent and primate models of PD and of -DOPA-induced dyskinesia.  Finally, concluding remarks are made on post-mortem human brains and on the translation of adenosine A2A receptor antagonists in the treatment of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsCzoxtvHY_LVg90H21EOLACvtfcHk0lgHWPGt2ceQiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlags7zM&md5=c5a9a8210856a487ee6ee7d5c3784379</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2007.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2007.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DMorelli%26aufirst%3DM.%26aulast%3DDi%2BPaolo%26aufirst%3DT.%26aulast%3DWardas%26aufirst%3DJ.%26aulast%3DCalon%26aufirst%3DF.%26aulast%3DXiao%26aufirst%3DD.%26aulast%3DSchwarzschild%26aufirst%3DM.%2BA.%26atitle%3DRole%2520of%2520adenosine%2520A2A%2520receptors%2520in%2520parkinsonian%2520motor%2520impairment%2520and%2520L-DOPA-induced%2520motor%2520complications%26jtitle%3DProg.%2520Neurobiol.%26date%3D2007%26volume%3D83%26spage%3D293%26epage%3D309%26doi%3D10.1016%2Fj.pneurobio.2007.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertorelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varty, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachowicz, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forlani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredduzzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen-williams, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Impagnatiello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolussi, E.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Characterization of the potent and highly selective A2A receptor antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">294</span>– <span class="NLM_lpage">303</span>, <span class="refDoi"> DOI: 10.1124/jpet.108.149617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1124%2Fjpet.108.149617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=19332567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFeluro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2009&pages=294-303&author=R.+A.+Hodgsonauthor=R.+Bertorelliauthor=G.+B.+Vartyauthor=J.+E.+Lachowiczauthor=A.+Forlaniauthor=S.+Fredduzziauthor=M.+E.+Cohen-williamsauthor=G.+A.+Higginsauthor=F.+Impagnatielloauthor=E.+Nicolussi&title=Characterization+of+the+potent+and+highly+selective+A2A+receptor+antagonists+Preladenant+and+SCH+412348+%5B7-%5B2-%5B4-2%2C4-difluorophenyl%5D-1-piperazinyl%5Dethyl%5D-2-%282-furanyl%29-7H-pyrazolo%5B4%2C3-e%5D%5B1%2C2%2C4%5Dtriazolo%5B1%2C5-c%5Dpyrimidin-5-amine%5D+in+rodent+models+of+movement+disorders+and+depression&doi=10.1124%2Fjpet.108.149617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression</span></div><div class="casAuthors">Hodgson, Robert A.; Bertorelli, Rosalia; Varty, Geoffrey B.; Lachowicz, Jean E.; Forlani, Angelo; Fredduzzi, Silva; Cohen-Williams, Mary E.; Higgins, Guy A.; Impagnatiello, Francesco; Nicolussi, Elisa; Parra, Leonard E.; Foster, Carolyn; Zhai, Ying; Neustadt, Bernie R.; Stamford, Andrew W.; Parker, Eric M.; Reggiani, Angelo; Hunter, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">294-303</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The adenosine A2A receptor has been implicated in the underlying biol. of various neurol. and psychiatric disorders, including Parkinson's disease (PD) and depression.  Preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] are potent competitive antagonists of the human A2A receptor (Ki = 1.1 and 0.6 nM, resp.) and have > 1000-fold selectivity over all other adenosine receptors, making these compds. the most selective A2A receptor antagonists reported to date.  Both compds. attenuate hypolocomotion induced by the A2A receptor agonist CGS-21680 [2-[p-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamidoadenosine], suggesting that they inhibit A2A receptor activity in vivo.  Their high degree of selectivity and robust in vivo activity make preladenant and SCH 412348 useful tools to investigate the role of the A2A receptor system in animal models of PD and depression.  Oral administration of preladenant and SCH 412348 (0.1-1 mg/kg) to rats potentiated 3,4-dihydroxy-L-phenylalanine (L-Dopa)-induced contralateral rotations after 6-hydroxydopamine lesions in the medial forebrain bundle and potently attenuated the cataleptic effects of haloperidol.  Preladenant (1 mg/kg) inhibited L-Dopa-induced behavioral sensitization after repeated daily administration, which suggests a reduced risk of the development of dyskinesias.  Finally, preladenant and SCH 412348 exhibited antidepressant-like profiles in models of behavioral despair, namely the mouse tail suspension test and the mouse and rat forced swim test.  These studies demonstrate that preladenant and SCH 412348 are potent and selective A2A receptor antagonists and provide further evidence of the potential therapeutic benefits of A2A receptor inhibition in PD (with reduced risk of dyskinesias) and depression (one of the primary nonmotor symptoms of PD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNkJMOfNlLc7Vg90H21EOLACvtfcHk0lgHWPGt2ceQiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFeluro%253D&md5=b8ce809c2d57a994d201ecca4daa39a3</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.149617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.149617%26sid%3Dliteratum%253Aachs%26aulast%3DHodgson%26aufirst%3DR.%2BA.%26aulast%3DBertorelli%26aufirst%3DR.%26aulast%3DVarty%26aufirst%3DG.%2BB.%26aulast%3DLachowicz%26aufirst%3DJ.%2BE.%26aulast%3DForlani%26aufirst%3DA.%26aulast%3DFredduzzi%26aufirst%3DS.%26aulast%3DCohen-williams%26aufirst%3DM.%2BE.%26aulast%3DHiggins%26aufirst%3DG.%2BA.%26aulast%3DImpagnatiello%26aufirst%3DF.%26aulast%3DNicolussi%26aufirst%3DE.%26atitle%3DCharacterization%2520of%2520the%2520potent%2520and%2520highly%2520selective%2520A2A%2520receptor%2520antagonists%2520Preladenant%2520and%2520SCH%2520412348%2520%255B7-%255B2-%255B4-2%252C4-difluorophenyl%255D-1-piperazinyl%255Dethyl%255D-2-%25282-furanyl%2529-7H-pyrazolo%255B4%252C3-e%255D%255B1%252C2%252C4%255Dtriazolo%255B1%252C5-c%255Dpyrimidin-5-amine%255D%2520in%2520rodent%2520models%2520of%2520movement%2520disorders%2520and%2520depression%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D330%26spage%3D294%26epage%3D303%26doi%3D10.1124%2Fjpet.108.149617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urade, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayaishi, O.</span></span> <span> </span><span class="NLM_article-title">The role of adenosine in the regulation of sleep</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1047</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.2174/156802611795347654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.2174%2F156802611795347654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=21401496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvFyktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1047-1057&author=Z.-L.+Huangauthor=Y.+Uradeauthor=O.+Hayaishi&title=The+role+of+adenosine+in+the+regulation+of+sleep&doi=10.2174%2F156802611795347654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">The role of adenosine in the regulation of sleep</span></div><div class="casAuthors">Huang, Zhi-Li; Urade, Yoshihiro; Hayaishi, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1047-1057</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  This paper presents an overview of the current knowledge about the role of adenosine in the sleep-wake regulation with a focus on adenosine in the central nervous system, regulation of adenosine levels, adenosine receptors, and manipulations of the adenosine system by the use of pharmacol. and mol. biol. tools.  The endogenous somnogen prostaglandin (PG) D2 increases the extracellular level of adenosine under the subarachnoid space of the basal forebrain and promotes physiol. sleep.  Adenosine is neither stored nor released as a classical neurotransmitter and is thought to be formed inside cells or on their surface, mostly by breakdown of adenine nucleotides.  The extracellular concn. of adenosine increases in the cortex and basal forebrain during prolonged wakefulness and decreases during the sleep recovery period.  Therefore, adenosine is proposed to act as a homeostatic regulator of sleep and to be a link between the humoral and neural mechanisms of sleep-wake regulation.  Both the adenosine A1 receptor (A1R) and A2AR are involved in sleep induction.  The A2AR plays a predominant role in the somnogenic effects of PGD2.  By use of gene-manipulated mice, the arousal effect of caffeine was shown to be dependent on the A2AR.  On the other hand, inhibition of wake-promoting neurons via the A1R also mediates the sleep-inducing effects of adenosine, whereas activation of A1R in the lateral preoptic area induces wakefulness, suggesting that A1R regulates the sleep-wake cycle in a site-dependent manner.  The potential therapeutic applications of agonists and antagonists of these receptors in sleep disorders are briefly discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg7NbK0sc9MLVg90H21EOLACvtfcHk0lify3xlda_ggQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvFyktLc%253D&md5=7b79c819a52140a0bd4eb775642eafce</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.2174%2F156802611795347654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611795347654%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DZ.-L.%26aulast%3DUrade%26aufirst%3DY.%26aulast%3DHayaishi%26aufirst%3DO.%26atitle%3DThe%2520role%2520of%2520adenosine%2520in%2520the%2520regulation%2520of%2520sleep%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D1047%26epage%3D1057%26doi%3D10.2174%2F156802611795347654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherasse, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, W.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bass, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winsky-Sommerer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredholm, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boison, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayaishi, O.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">10067</span>– <span class="NLM_lpage">10075</span>, <span class="refDoi"> DOI: 10.1523/jneurosci.6730-10.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1523%2Fjneurosci.6730-10.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=21734299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptFWqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=10067-10075&author=M.+Lazarusauthor=H.-Y.+Shenauthor=Y.+Cherasseauthor=W.-M.+Quauthor=Z.-L.+Huangauthor=C.+E.+Bassauthor=R.+Winsky-Sommererauthor=K.+Sembaauthor=B.+B.+Fredholmauthor=D.+Boisonauthor=O.+Hayaishi&title=Arousal+effect+of+caffeine+depends+on+adenosine+A2A+receptors+in+the+shell+of+the+nucleus+accumbens&doi=10.1523%2Fjneurosci.6730-10.2011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens</span></div><div class="casAuthors">Lazarus, Michael; Shen, Hai-Ying; Cherasse, Yoan; Qu, Wei-Min; Huang, Zhi-Li; Bass, Caroline E.; Winsky-Sommerer, Raphaelle; Semba, Kazue; Fredholm, Bertil B.; Boison, Detlev; Hayaishi, Osamu; Urade, Yoshihiro; Chen, Jiang-Fan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">10067-10075</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Caffeine, the most widely used psychoactive compd., is an adenosine receptor antagonist.  It promotes wakefulness by blocking adenosine A2A receptors (A2ARs) in the brain, but the specific neurons on which caffeine acts to produce arousal have not been identified.  Using selective gene deletion strategies based on the Cre/loxP technol. in mice and focal RNA interference to silence the expression of A2ARs in rats by local infection with adeno-assocd. virus carrying short-hairpin RNA, we report that the A2ARs in the shell region of the nucleus accumbens (NAc) are responsible for the effect of caffeine on wakefulness.  Caffeine-induced arousal was not affected in rats when A2ARs were focally removed from the NAc core or other A2AR-pos. areas of the basal ganglia.  Our observations suggest that caffeine promotes arousal by activating pathways that traditionally have been assocd. with motivational and motor responses in the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGW5Fzs9wilbVg90H21EOLACvtfcHk0lify3xlda_ggQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptFWqsrg%253D&md5=2400a4ba6e294e343814eaf87d4cb5f7</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1523%2Fjneurosci.6730-10.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252Fjneurosci.6730-10.2011%26sid%3Dliteratum%253Aachs%26aulast%3DLazarus%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.-Y.%26aulast%3DCherasse%26aufirst%3DY.%26aulast%3DQu%26aufirst%3DW.-M.%26aulast%3DHuang%26aufirst%3DZ.-L.%26aulast%3DBass%26aufirst%3DC.%2BE.%26aulast%3DWinsky-Sommerer%26aufirst%3DR.%26aulast%3DSemba%26aufirst%3DK.%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26aulast%3DBoison%26aufirst%3DD.%26aulast%3DHayaishi%26aufirst%3DO.%26atitle%3DArousal%2520effect%2520of%2520caffeine%2520depends%2520on%2520adenosine%2520A2A%2520receptors%2520in%2520the%2520shell%2520of%2520the%2520nucleus%2520accumbens%26jtitle%3DJ.%2520Neurosci.%26date%3D2011%26volume%3D31%26spage%3D10067%26epage%3D10075%26doi%3D10.1523%2Fjneurosci.6730-10.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, W.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eguchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarzschild, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredholm, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urade, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayaishi, O.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">858</span>– <span class="NLM_lpage">859</span>, <span class="refDoi"> DOI: 10.1038/nn1491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1038%2Fnn1491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=15965471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvFWjs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2005&pages=858-859&author=Z.-L.+Huangauthor=W.-M.+Quauthor=N.+Eguchiauthor=J.-F.+Chenauthor=M.+A.+Schwarzschildauthor=B.+B.+Fredholmauthor=Y.+Uradeauthor=O.+Hayaishi&title=Adenosine+A2A%2C+but+not+A1%2C+receptors+mediate+the+arousal+effect+of+caffeine&doi=10.1038%2Fnn1491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine</span></div><div class="casAuthors">Huang, Zhi-Li; Qu, Wei-Min; Eguchi, Naomi; Chen, Jiang-Fan; Schwarzschild, Michael A.; Fredholm, Bertil B.; Urade, Yoshihiro; Hayaishi, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">858-859</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Caffeine, a component of tea, coffee and cola, induces wakefulness.  It binds to adenosine A1 and A2A receptors as an antagonist, but the receptor subtype mediating caffeine-induced wakefulness remains unclear.  Here we report that caffeine at 5, 10 and 15 mg kg-1 increased wakefulness in both wild-type mice and A1 receptor knockout mice, but not in A2A receptor knockout mice.  Thus, caffeine-induced wakefulness depends on adenosine A2A receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO2QOYwdslRbVg90H21EOLACvtfcHk0lify3xlda_ggQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvFWjs74%253D&md5=9f2d012c7d8f106b354bf64ac5e7ea8c</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fnn1491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn1491%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DZ.-L.%26aulast%3DQu%26aufirst%3DW.-M.%26aulast%3DEguchi%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DJ.-F.%26aulast%3DSchwarzschild%26aufirst%3DM.%2BA.%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26aulast%3DUrade%26aufirst%3DY.%26aulast%3DHayaishi%26aufirst%3DO.%26atitle%3DAdenosine%2520A2A%252C%2520but%2520not%2520A1%252C%2520receptors%2520mediate%2520the%2520arousal%2520effect%2520of%2520caffeine%26jtitle%3DNat.%2520Neurosci.%26date%3D2005%26volume%3D8%26spage%3D858%26epage%3D859%26doi%3D10.1038%2Fnn1491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Postuma, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munhoz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charland, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moscovich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanatta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rios Romenets, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, R.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Caffeine for treatment of Parkinson disease: A randomized controlled trial</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">658</span>, <span class="refDoi"> DOI: 10.1212/wnl.0b013e318263570d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1212%2Fwnl.0b013e318263570d" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=22855866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ajs7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2012&pages=651-658&author=R.+B.+Postumaauthor=A.+E.+Langauthor=R.+P.+Munhozauthor=K.+Charlandauthor=A.+Pelletierauthor=M.+Moscovichauthor=L.+Fillaauthor=D.+Zanattaauthor=S.+Rios+Romenetsauthor=R.+Altman&title=Caffeine+for+treatment+of+Parkinson+disease%3A+A+randomized+controlled+trial&doi=10.1212%2Fwnl.0b013e318263570d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Caffeine for treatment of Parkinson disease: A randomized controlled trial</span></div><div class="casAuthors">Postuma, Ronald B.; Lang, Anthony E.; Munhoz, Renato P.; Charland, Katia; Pelletier, Amelie; Moscovich, Mariana; Filla, Luciane; Zanatta, Debora; Rios Romenets, Silvia; Altman, Robert; Chuang, Rosa; Shah, Binit</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">651-658</span>CODEN:
                <span class="NLM_cas:coden">NEURAI</span>;
        ISSN:<span class="NLM_cas:issn">0028-3878</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Epidemiol. studies consistently link caffeine, a nonselective adenosine antagonist, to lower risk of Parkinson disease (PD).  However, the symptomatic effects of caffeine in PD have not been adequately evaluated.  We conducted a 6-wk randomized controlled trial of caffeine in PD to assess effects upon daytime somnolence, motor severity, and other nonmotor features.  Patients with PD with daytime somnolence (Epworth >10) were given caffeine 100 mg twice daily ×3 wk, then 200 mg twice daily ×3 wk, or matching placebo.  The primary outcome was the Epworth Sleepiness Scale score.  Secondary outcomes included motor severity, sleep markers, fatigue, depression, and quality of life.  Effects of caffeine were analyzed with Bayesian hierarchical models, adjusting for study site, baseline scores, age, and sex.  Of 61 patients, 31 were randomized to placebo and 30 to caffeine.  On the primary intention-to-treat anal., caffeine resulted in a nonsignificant redn. in Epworth Sleepiness Scale score (-1.71 points; 95% confidence interval [CI] -3.57, 0.13).  However, somnolence improved on the Clin. Global Impression of Change (+0.64; 0.16, 1.13, intention-to-treat), with significant redn. in Epworth Sleepiness Scale score on per-protocol anal. (-1.97; -3.87, -0.05).  Caffeine reduced the total Unified Parkinson's Disease Rating Scale score (-4.69 points; -7.7, -1.6) and the objective motor component (-3.15 points; -5.50, -0.83).  Other than modest improvement in global health measures, there were no changes in quality of life, depression, or sleep quality.  Adverse events were comparable in caffeine and placebo groups.  Caffeine provided only equivocal borderline improvement in excessive somnolence in PD, but improved objective motor measures.  These potential motor benefits suggest that a larger long-term trial of caffeine is warranted.  Classification of evidence: This study provides Class I evidence that caffeine, up to 200 mg BID for 6 wk, had no significant benefit on excessive daytime sleepiness in patients with PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoofrMikXYL27Vg90H21EOLACvtfcHk0lhj5If3dW4NpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ajs7vI&md5=9c675d983bfddd1f3bf81f2d7d6e5155</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1212%2Fwnl.0b013e318263570d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252Fwnl.0b013e318263570d%26sid%3Dliteratum%253Aachs%26aulast%3DPostuma%26aufirst%3DR.%2BB.%26aulast%3DLang%26aufirst%3DA.%2BE.%26aulast%3DMunhoz%26aufirst%3DR.%2BP.%26aulast%3DCharland%26aufirst%3DK.%26aulast%3DPelletier%26aufirst%3DA.%26aulast%3DMoscovich%26aufirst%3DM.%26aulast%3DFilla%26aufirst%3DL.%26aulast%3DZanatta%26aufirst%3DD.%26aulast%3DRios%2BRomenets%26aufirst%3DS.%26aulast%3DAltman%26aufirst%3DR.%26atitle%3DCaffeine%2520for%2520treatment%2520of%2520Parkinson%2520disease%253A%2520A%2520randomized%2520controlled%2520trial%26jtitle%3DNeurology%26date%3D2012%26volume%3D79%26spage%3D651%26epage%3D658%26doi%3D10.1212%2Fwnl.0b013e318263570d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chubukov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structural basis for allosteric regulation of GPCRs by sodium ions</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>337</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1126/science.1219218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1126%2Fscience.1219218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=22798613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVKqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2012&pages=232-236&author=W.+Liuauthor=E.+Chunauthor=A.+A.+Thompsonauthor=P.+Chubukovauthor=F.+Xuauthor=V.+Katritchauthor=G.+W.+Hanauthor=C.+B.+Rothauthor=L.+H.+Heitmanauthor=A.+P.+IJzermanauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structural+basis+for+allosteric+regulation+of+GPCRs+by+sodium+ions&doi=10.1126%2Fscience.1219218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions</span></div><div class="casAuthors">Liu, Wei; Chun, Eugene; Thompson, Aaron A.; Chubukov, Pavel; Xu, Fei; Katritch, Vsevolod; Han, Gye Won; Roth, Christopher B.; Heitman, Laura H.; IJzerman, Adriaan P.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">6091</span>),
    <span class="NLM_cas:pages">232-236</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Pharmacol. responses of G protein-coupled receptors (GPCRs) can be fine-tuned by allosteric modulators.  Structural studies of such effects have been limited due to the medium resoln. of GPCR structures.  We reengineered the human A2A adenosine receptor by replacing its third intracellular loop with apocytochrome b562RIL and solved the structure at 1.8 angstrom resoln.  The high-resoln. structure allowed us to identify 57 ordered water mols. inside the receptor comprising three major clusters.  The central cluster harbors a putative sodium ion bound to the highly conserved aspartate residue Asp2.50.  Addnl., two cholesterols stabilize the conformation of helix VI, and one of 23 ordered lipids intercalates inside the ligand-binding pocket.  These high-resoln. details shed light on the potential role of structured water mols., sodium ions, and lipids/cholesterol in GPCR stabilization and function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvcjQimGnIMLVg90H21EOLACvtfcHk0lhj5If3dW4NpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVKqtbs%253D&md5=782b2235b76ef77b11b6456f8e4485e1</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1126%2Fscience.1219218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1219218%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DChun%26aufirst%3DE.%26aulast%3DThompson%26aufirst%3DA.%2BA.%26aulast%3DChubukov%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DRoth%26aufirst%3DC.%2BB.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructural%2520basis%2520for%2520allosteric%2520regulation%2520of%2520GPCRs%2520by%2520sodium%2520ions%26jtitle%3DScience%26date%3D2012%26volume%3D337%26spage%3D232%26epage%3D236%26doi%3D10.1126%2Fscience.1219218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">MOE</span>.  <i>Molecular operating environment (MOE 2014.09)</i>; <span class="NLM_publisher-name">Chemical Computing Group: Montreal</span>: <span class="NLM_publisher-loc">Quebec: Canada</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=MOE&title=Molecular+operating+environment+%28MOE+2014.09%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26btitle%3DMolecular%2520operating%2520environment%2520%2528MOE%25202014.09%2529%26pub%3DChemical%2520Computing%2520Group%253A%2520Montreal%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isberg, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolajsen, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bibbe, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flock, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deupi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloriam, D. E.</span></span> <span> </span><span class="NLM_article-title">An online resource for GPCR structure determination and analysis</span>. <i>Nat. Methods</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1038/s41592-018-0302-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1038%2Fs41592-018-0302-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=30664776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtFGru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=151-162&author=C.+Munkauthor=E.+Muttauthor=V.+Isbergauthor=L.+F.+Nikolajsenauthor=J.+M.+Bibbeauthor=T.+Flockauthor=M.+A.+Hansonauthor=R.+C.+Stevensauthor=X.+Deupiauthor=D.+E.+Gloriam&title=An+online+resource+for+GPCR+structure+determination+and+analysis&doi=10.1038%2Fs41592-018-0302-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">An online resource for GPCR structure determination and analysis</span></div><div class="casAuthors">Munk, Christian; Mutt, Eshita; Isberg, Vignir; Nikolajsen, Louise F.; Bibbe, Janne M.; Flock, Tilman; Hanson, Michael A.; Stevens, Raymond C.; Deupi, Xavier; Gloriam, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Methods</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-162</span>CODEN:
                <span class="NLM_cas:coden">NMAEA3</span>;
        ISSN:<span class="NLM_cas:issn">1548-7091</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) transduce physiol. and sensory stimuli into appropriate cellular responses and mediate the actions of one-third of drugs.  GPCR structural studies have revealed the general bases of receptor activation, signaling, drug action and allosteric modulation, but so far cover only 13% of nonolfactory receptors.  We broadly surveyed the receptor modifications/engineering and methods used to produce all available GPCR crystal and cryo-electron microscopy (cryo-EM) structures, and present an interactive resource integrated in GPCRdb (http://www.gpcrdb.org) to assist users in designing constructs and browsing appropriate exptl. conditions for structure studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnhlg2FyHfTLVg90H21EOLACvtfcHk0lhj5If3dW4NpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtFGru74%253D&md5=a0e1ffb48671b58a63764ed4cff86901</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1038%2Fs41592-018-0302-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41592-018-0302-x%26sid%3Dliteratum%253Aachs%26aulast%3DMunk%26aufirst%3DC.%26aulast%3DMutt%26aufirst%3DE.%26aulast%3DIsberg%26aufirst%3DV.%26aulast%3DNikolajsen%26aufirst%3DL.%2BF.%26aulast%3DBibbe%26aufirst%3DJ.%2BM.%26aulast%3DFlock%26aufirst%3DT.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DDeupi%26aufirst%3DX.%26aulast%3DGloriam%26aufirst%3DD.%2BE.%26atitle%3DAn%2520online%2520resource%2520for%2520GPCR%2520structure%2520determination%2520and%2520analysis%26jtitle%3DNat.%2520Methods%26date%3D2019%26volume%3D16%26spage%3D151%26epage%3D162%26doi%3D10.1038%2Fs41592-018-0302-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belew, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodsell, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. J.</span></span> <span> </span><span class="NLM_article-title">AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2785</span>– <span class="NLM_lpage">2791</span>, <span class="refDoi"> DOI: 10.1002/jcc.21256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2Fjcc.21256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=19399780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=2785-2791&author=G.+M.+Morrisauthor=R.+Hueyauthor=W.+Lindstromauthor=M.+F.+Sannerauthor=R.+K.+Belewauthor=D.+S.+Goodsellauthor=A.+J.+Olson&title=AutoDock4+and+AutoDockTools4%3A+Automated+docking+with+selective+receptor+flexibility&doi=10.1002%2Fjcc.21256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock and AutoDockTools: Automated docking with selective receptor flexibility</span></div><div class="casAuthors">Morris, Garrett M.; Huey, Ruth; Lindstrom, William; Sanner, Michel F.; Belew, Richard K.; Goodsell, David S.; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2785-2791</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">We describe the testing and release of AutoDock4 and the accompanying graphical user interface AutoDockTools.  AutoDock4 incorporates limited flexibility in the receptor.  Several tests are reported here, including a redocking expt. with 188 diverse ligand-protein complexes and a cross-docking expt. using flexible sidechains in 87 HIV protease complexes.  We also report its utility in anal. of covalently bound ligands, using both a grid-based docking method and a modification of the flexible sidechain technique. © 2009 Wiley Periodicals, Inc.  J Comput Chem, 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqktE6WAo4GEbVg90H21EOLACvtfcHk0ljDxi2oroa40Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK&md5=679ce22fc50e9291c9aa16e7a1855845</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21256%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DG.%2BM.%26aulast%3DHuey%26aufirst%3DR.%26aulast%3DLindstrom%26aufirst%3DW.%26aulast%3DSanner%26aufirst%3DM.%2BF.%26aulast%3DBelew%26aufirst%3DR.%2BK.%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutoDock4%2520and%2520AutoDockTools4%253A%2520Automated%2520docking%2520with%2520selective%2520receptor%2520flexibility%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2009%26volume%3D30%26spage%3D2785%26epage%3D2791%26doi%3D10.1002%2Fjcc.21256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanner, M. F.</span></span> <span> </span><span class="NLM_article-title">Python: a programming language for software integration and development</span>. <i>J. Mol. Graph. Model.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">61</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10660911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtV2rsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=57-61&author=M.+F.+Sanner&title=Python%3A+a+programming+language+for+software+integration+and+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Python: a programming language for software integration and development</span></div><div class="casAuthors">Sanner, M. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Graphics & Modelling</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-61</span>CODEN:
                <span class="NLM_cas:coden">JMGMFI</span>;
        ISSN:<span class="NLM_cas:issn">1093-3263</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The use of interpreted languages in biocomputing has been investigated to create a programmable, dynamic environment in which components can be tied together at a high level.  This work has demonstrated the benefits of such an approach and the features of the interpreted language that are key to successful component integration.  This involved Python, an interpreted, interactive, object-oriented programming language.  It provides high-level data structures such as list and associative arrays, dynamic typing and dynamic binding, modules, classes, exceptions, automatic memory management and others.  Python has been found to be instrumental in the mol. modeling research environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaCFXA1JC8X7Vg90H21EOLACvtfcHk0ljDxi2oroa40Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtV2rsA%253D%253D&md5=3bf94934548080055dda54f68468c656</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSanner%26aufirst%3DM.%2BF.%26atitle%3DPython%253A%2520a%2520programming%2520language%2520for%2520software%2520integration%2520and%2520development%26jtitle%3DJ.%2520Mol.%2520Graph.%2520Model.%26date%3D1999%26volume%3D17%26spage%3D57%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Namasivayam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Günther, R.</span></span> <span> </span><span class="NLM_article-title"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="e191928ea18094958e858e828a">[email protected]</a>: A fast flexible molecular docking program based on swarm intelligence</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.1111/j.1747-0285.2007.00588.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1111%2Fj.1747-0285.2007.00588.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=17986206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2007&pages=475-484&author=V.+Namasivayamauthor=R.+G%C3%BCnther&title=pso%40autodock%3A+A+fast+flexible+molecular+docking+program+based+on+swarm+intelligence&doi=10.1111%2Fj.1747-0285.2007.00588.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="f1a1a2beb1b0a4a5beb5beb2ba">[email protected]</a>: a fast flexible molecular docking program based on Swarm intelligence</span></div><div class="casAuthors">Namasivayam, Vigneshwaran; Guenther, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">475-484</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">On the quest of novel therapeutics, mol. docking methods have proven to be valuable tools for screening large libraries of compds. detg. the interactions of potential drugs with the target proteins.  A widely used docking approach is the simulation of the docking process guided by a binding energy function.  On the basis of the mol. docking program AUTODOCK, we present <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="bceceff3fcfde9e8f3f8f3fff7">[email protected]</a> as a tool for fast flexible mol. docking.  Our novel Particle Swarm Optimization (PSO) algorithms varCPSO and varCPSO-Is are suited for rapid docking of highly flexible ligands.  Thus, a ligand with 23 rotatable bonds was successfully docked within as few as 100 000 computing steps (rmsd = 0.87 Å), which corresponds to only 10% of the computing time demanded by AUTODOCK.  In comparison to other docking techniques as GOLD 3.0, DOCK 6.0, FLEXX 2.2.0, AUTODOCK 3.05, and SODOCK, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="ca9a99858a8b9f9e858e858981">[email protected]</a> provides the smallest rmsd values for 12 in 37 protein-ligand complexes.  The av. rmsd value of 1.4 Å is significantly lower then those obtained with the other docking programs, which are all above 2.0 Å.  Thus, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="baeae9f5fafbefeef5fef5f9f1">[email protected]</a> is suggested as a highly efficient docking program in terms of speed and quality for flexible peptide-protein docking and virtual screening studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryKHisUEtA_LVg90H21EOLACvtfcHk0ljDxi2oroa40Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsb3E&md5=a8e0f99d7a51e3b62e42900c05a92b7f</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00588.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00588.x%26sid%3Dliteratum%253Aachs%26aulast%3DNamasivayam%26aufirst%3DV.%26aulast%3DG%25C3%25BCnther%26aufirst%3DR.%26atitle%3Dpso%2540autodock%253A%2520A%2520fast%2520flexible%2520molecular%2520docking%2520program%2520based%2520on%2520swarm%2520intelligence%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2007%26volume%3D70%26spage%3D475%26epage%3D484%26doi%3D10.1111%2Fj.1747-0285.2007.00588.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Filippo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellizzari, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deganutti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Tayeb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiedel, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span> <span> </span><span class="NLM_article-title">A2A and A2B adenosine receptors: The extracellular loop 2 determines high (A2A) or low affinity (A2B) for adenosine</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">113718</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2019.113718</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.bcp.2019.113718" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=31751537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlGitbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2020&pages=113718&author=E.+De+Filippoauthor=S.+Hinzauthor=V.+Pellizzariauthor=G.+Deganuttiauthor=A.+El-Tayebauthor=G.+Navarroauthor=R.+Francoauthor=S.+Moroauthor=A.+C.+Schiedelauthor=C.+E.+M%C3%BCller&title=A2A+and+A2B+adenosine+receptors%3A+The+extracellular+loop+2+determines+high+%28A2A%29+or+low+affinity+%28A2B%29+for+adenosine&doi=10.1016%2Fj.bcp.2019.113718"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">A2A and A2B adenosine receptors: The extracellular loop 2 determines high (A2A) or low affinity (A2B) for adenosine</span></div><div class="casAuthors">De Filippo, Elisabetta; Hinz, Sonja; Pellizzari, Veronica; Deganutti, Giuseppe; El-Tayeb, Ali; Navarro, Gemma; Franco, Rafael; Moro, Stefano; Schiedel, Anke C.; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113718</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A2A and A2B adenosine receptors (ARs) are closely related G protein-coupled receptor subtypes, which represent important (potential) drug targets.  Despite their almost identical binding sites for adenosine, A2AARs are activated by low (nanomolar) adenosine concns., while A2BARs require micromolar concns.  In the present study, we exchanged the extracellular loop 2 (ECL2) of the human A2AAR for that of the A2BAR.  The resulting chimeric A2A(ECL2-A2B)AR was investigated in radioligand binding and cAMP accumulation assays in comparison to the wildtype A2AAR.  While the ribose-modified adenosine analog N-ethylcarboxamidoadenosine (NECA) and its 2-substituted deriv. CGS-21680 did not exhibit significant changes, adenosine showed dramatically reduced potency and affinity for the A2A(ECL2-A2B)AR mutant displaying similarly low potency as for the wt A2BAR.  Supervised mol. dynamics simulation studies predicted a meta-binding site with high affinity for adenosine, but not for NECA, which may contribute to the obsd. effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2YSz82BRuI7Vg90H21EOLACvtfcHk0liUDc41n6UhdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlGitbbN&md5=60982342c717b305861e31d07b5673ee</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2019.113718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2019.113718%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BFilippo%26aufirst%3DE.%26aulast%3DHinz%26aufirst%3DS.%26aulast%3DPellizzari%26aufirst%3DV.%26aulast%3DDeganutti%26aufirst%3DG.%26aulast%3DEl-Tayeb%26aufirst%3DA.%26aulast%3DNavarro%26aufirst%3DG.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DMoro%26aufirst%3DS.%26aulast%3DSchiedel%26aufirst%3DA.%2BC.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DA2A%2520and%2520A2B%2520adenosine%2520receptors%253A%2520The%2520extracellular%2520loop%25202%2520determines%2520high%2520%2528A2A%2529%2520or%2520low%2520affinity%2520%2528A2B%2529%2520for%2520adenosine%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2020%26volume%3D172%26spage%3D113718%26doi%3D10.1016%2Fj.bcp.2019.113718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gondard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anaclet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akaoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.-S.</span></span> <span> </span><span class="NLM_article-title">Enhanced histaminergic neurotransmission and sleep-wake alterations, a study in histamine H3-receptor knock-out mice</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1015</span>– <span class="NLM_lpage">1031</span>, <span class="refDoi"> DOI: 10.1038/npp.2012.266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1038%2Fnpp.2012.266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=23303066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt1Shtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=1015-1031&author=E.+Gondardauthor=C.+Anacletauthor=H.+Akaokaauthor=R.-X.+Guoauthor=M.+Zhangauthor=C.+Budaauthor=P.+Francoauthor=H.+Kotaniauthor=J.-S.+Lin&title=Enhanced+histaminergic+neurotransmission+and+sleep-wake+alterations%2C+a+study+in+histamine+H3-receptor+knock-out+mice&doi=10.1038%2Fnpp.2012.266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced Histaminergic Neurotransmission and Sleep-Wake Alterations, a Study in Histamine H3-Receptor Knock-Out Mice</span></div><div class="casAuthors">Gondard, Elise; Anaclet, Christelle; Akaoka, Hideo; Guo, Rui-Xian; Zhang, Mei; Buda, Colette; Franco, Patricia; Kotani, Hidehito; Lin, Jian-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1015-1031</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Long-term abolition of a brain arousal system impairs wakefulness (W), but little is known about the consequences of long-term enhancement.  The brain histaminergic arousal system is under the neg. control of H3-autoreceptors whose deletion results in permanent enhancement of histamine (HA) turnover.  In order to det. the consequences of enhancement of the histaminergic system, we compared the cortical EEG and sleep-wake states of H3-receptor knockout (H3R-/-) and wild-type mouse littermates.  We found that H3R-/-mice had rich phenotypes.  On the one hand, they showed clear signs of enhanced HA neurotransmission and vigilance, i.e., a higher EEG θ power during spontaneous W and a greater extent of W or sleep restriction during behavioral tasks, including environmental change, locomotion, and motivation tests.  On the other hand, during the baseline dark period, they displayed deficient W and signs of sleep deterioration, such as pronounced sleep fragmentation and reduced cortical slow activity during slow wave sleep (SWS), most likely due to a desensitization of postsynaptic histaminergic receptors as a result of const. HA release.  Ciproxifan (H3-receptor inverse agonist) enhanced W in wild-type mice, but not in H3R-/-mice, indicating a functional deletion of H3-receptors, whereas triprolidine (postsynaptic H1-receptor antagonist) or α-fluoromethylhistidine (HA-synthesis inhibitor) caused a greater SWS increase in H3R-/- than in wild-type mice, consistent with enhanced HA neurotransmission.  These sleep-wake characteristics and the obesity phenotypes previously reported in this animal model suggest that chronic enhancement of histaminergic neurotransmission eventually compromises the arousal system, leading to sleep-wake, behavioral, and metabolic disorders similar to those caused by voluntary sleep restriction in humans.  Neuropsychopharmacol. (2013) 38, 1015-1031; doi:10.1038/npp.2012.266; published online 13 Feb. 2013.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplyX0giHLDrbVg90H21EOLACvtfcHk0liUDc41n6UhdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmt1Shtbk%253D&md5=1aecabe87c066f33ec172580658a07e5</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2012.266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2012.266%26sid%3Dliteratum%253Aachs%26aulast%3DGondard%26aufirst%3DE.%26aulast%3DAnaclet%26aufirst%3DC.%26aulast%3DAkaoka%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DR.-X.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DBuda%26aufirst%3DC.%26aulast%3DFranco%26aufirst%3DP.%26aulast%3DKotani%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DJ.-S.%26atitle%3DEnhanced%2520histaminergic%2520neurotransmission%2520and%2520sleep-wake%2520alterations%252C%2520a%2520study%2520in%2520histamine%2520H3-receptor%2520knock-out%2520mice%26jtitle%3DNeuropsychopharmacology%26date%3D2013%26volume%3D38%26spage%3D1015%26epage%3D1031%26doi%3D10.1038%2Fnpp.2012.266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duchêne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomasson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauveau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piérard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagarde, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picoli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeanson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouthon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dauvilliers, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaume, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charvériat, M.</span></span> <span> </span><span class="NLM_article-title">Impact of astroglial connexins on modafinil pharmacological properties</span>. <i>Sleep</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1283</span>– <span class="NLM_lpage">1292</span>, <span class="refDoi"> DOI: 10.5665/sleep.5854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.5665%2Fsleep.5854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=27091533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BC28bhtFCluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2016&pages=1283-1292&author=A.+Duch%C3%AAneauthor=M.+Perierauthor=Y.+Zhaoauthor=X.+Liuauthor=J.+Thomassonauthor=F.+Chauveauauthor=C.+Pi%C3%A9rardauthor=D.+Lagardeauthor=C.+Picoliauthor=T.+Jeansonauthor=F.+Mouthonauthor=Y.+Dauvilliersauthor=C.+Giaumeauthor=J.-S.+Linauthor=M.+Charv%C3%A9riat&title=Impact+of+astroglial+connexins+on+modafinil+pharmacological+properties&doi=10.5665%2Fsleep.5854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Astroglial Connexins on Modafinil Pharmacological Properties</span></div><div class="casAuthors">Duchene Adeline; Picoli Christele; Jeanson Tiffany; Mouthon Franck; Charveriat Mathieu; Perier Magali; Zhao Yan; Lin Jian-Sheng; Liu Xinhe; Jeanson Tiffany; Giaume Christian; Thomasson Julien; Chauveau Frederic; Pierard Christophe; Lagarde Didier; Picoli Christele; Dauvilliers Yves</div><div class="citationInfo"><span class="NLM_cas:title">Sleep</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1283-92</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">STUDY OBJECTIVES:  Modafinil is a non-amphetaminic wake-promoting compound used as therapy against sleepiness and narcolepsy.  Its mode of action is complex, but modafinil has been recently proposed to act as a cellular-coupling enhancer in glial cells, through modulation of gap junctions constituted by connexins.  The present study investigated in mice the impact of connexins on the effects of modafinil using connexin inhibitors.  METHODS:  Modafinil was administered alone or combined with inhibitors of astrocyte connexin, meclofenamic acid, or flecainide, respectively, acting on Cx30 and Cx43.  Sleep-wake states were monitored in wild-type and narcoleptic orexin knockout mice.  A spontaneous alternation task was used to evaluate working memory in wild-type mice.  The effects of the compounds on astroglial intercellular coupling were determined using dye transfer in acute cortical slices.  RESULTS:  Meclofenamic acid had little modulation on the effects of modafinil, but flecainide enhanced the wake-promoting and pro-cognitive effects of modafinil.  Co-administration of modafinil/flecainide resulted in a marked decrease in the number and duration of direct transitions to rapid eye movement sleep, which are characteristic of narcoleptic episodes in orexin knockout mice.  Furthermore, modafinil enhanced the connexin-mediated astroglial cell coupling, whereas flecainide reduced it.  Finally, this modafinil-induced effect was reversed by co-administration with flecainide.  CONCLUSIONS:  Our study indicates that flecainide impacts the pharmacological effects of modafinil, likely through the normalization of Cx30-dependent gap junctional coupling in astroglial networks.  The enhancement of the wake-promoting, behavioral, and cognitive outcomes of modafinil demonstrated here with flecainide would open new perspectives in the management of sleep disorders such as narcolepsy.  COMMENTARY:  A commentary on this article appears in this issue on page 1175.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS239Z5xsJnGysZ1x6zOs0vfW6udTcc2eb5Uqgq4wMQ6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bhtFCluw%253D%253D&md5=33c14356ff136c4d23db1c20e3920dd0</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.5665%2Fsleep.5854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5665%252Fsleep.5854%26sid%3Dliteratum%253Aachs%26aulast%3DDuch%25C3%25AAne%26aufirst%3DA.%26aulast%3DPerier%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DThomasson%26aufirst%3DJ.%26aulast%3DChauveau%26aufirst%3DF.%26aulast%3DPi%25C3%25A9rard%26aufirst%3DC.%26aulast%3DLagarde%26aufirst%3DD.%26aulast%3DPicoli%26aufirst%3DC.%26aulast%3DJeanson%26aufirst%3DT.%26aulast%3DMouthon%26aufirst%3DF.%26aulast%3DDauvilliers%26aufirst%3DY.%26aulast%3DGiaume%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.-S.%26aulast%3DCharv%25C3%25A9riat%26aufirst%3DM.%26atitle%3DImpact%2520of%2520astroglial%2520connexins%2520on%2520modafinil%2520pharmacological%2520properties%26jtitle%3DSleep%26date%3D2016%26volume%3D39%26spage%3D1283%26epage%3D1292%26doi%3D10.5665%2Fsleep.5854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akaoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lintunen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panula, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.-S.</span></span> <span> </span><span class="NLM_article-title">Role of histamine H1-receptor on behavioral states and wake maintenance during deficiency of a brain activating system: A study using a knockout mouse model</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2015.12.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.neuropharm.2015.12.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=26723880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtFCmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2016&pages=20-34&author=R.+Parmentierauthor=Y.+Zhaoauthor=M.+Perierauthor=H.+Akaokaauthor=M.+Lintunenauthor=Y.+Houauthor=P.+Panulaauthor=T.+Watanabeauthor=P.+Francoauthor=J.-S.+Lin&title=Role+of+histamine+H1-receptor+on+behavioral+states+and+wake+maintenance+during+deficiency+of+a+brain+activating+system%3A+A+study+using+a+knockout+mouse+model&doi=10.1016%2Fj.neuropharm.2015.12.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Role of histamine H1-receptor on behavioral states and wake maintenance during deficiency of a brain activating system: A study using a knockout mouse model</span></div><div class="casAuthors">Parmentier, Regis; Zhao, Yan; Perier, Magali; Akaoka, Hideo; Lintunen, Minnamaija; Hou, Yiping; Panula, Pertti; Watanabe, Takeshi; Franco, Patricia; Lin, Jian-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20-34</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Using knockout KO mice lacking the histamine HA-synthesizing enzyme histidine decarboxylase, HDC, we have previously shown the importance of histaminergic neurons in maintaining wakefulness W under behavioral challenges.  Since the central actions of HA are mediated by several receptor subtypes, it remains to be detd. which one s could be responsible for such a role.  We have therefore compared the cortical-EEG, sleep and W under baseline conditions or behavioral/pharmacol. stimuli in littermate wild-type WT and H1-receptor KO H1-/- mice.  We found that H1-/- mice shared several characteristics with HDC KO mice, i.e. (1) a decrease in W after lights-off despite its normal baseline daily amt.; (2) a decreased EEG slow wave sleep SWS/W power ratio; (3) inability to maintain W in response to behavioral challenges demonstrated by a decreased sleep latency when facing various stimuli.  These effects were mediated by central H1-receptors.  Indeed, in WT mice, injection of triprolidine, a brain-penetrating H1-receptor antagonist increased SWS, whereas ciproxifan H3-receptor antagonist/inverse agonist elicited W; all these injections had no effect in H1-/- mice.  Finally, H1-/- mice showed markedly greater changes in EEG power notably in the 0.8-5 Hz band and sleep-wake cycle than in WT mice after application of a cholinergic antagonist or an indirect agonist, i.e., scopolamine or physostigmine.  Hence, the role of HA in wake-promotion is largely ensured by H1-receptors.  An upregulated cholinergic system may account for a quasi-normal daily amt. of W in HDC or H1-receptor KO mice and likely constitutes a major compensatory mechanism when the brain is facing deficiency of an activating system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaqEix_Ri7zrVg90H21EOLACvtfcHk0ljKHOtpgIbppw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtFCmtg%253D%253D&md5=6132521779b508023a09f3ffeffd5eff</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2015.12.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2015.12.014%26sid%3Dliteratum%253Aachs%26aulast%3DParmentier%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DPerier%26aufirst%3DM.%26aulast%3DAkaoka%26aufirst%3DH.%26aulast%3DLintunen%26aufirst%3DM.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DPanula%26aufirst%3DP.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DFranco%26aufirst%3DP.%26aulast%3DLin%26aufirst%3DJ.-S.%26atitle%3DRole%2520of%2520histamine%2520H1-receptor%2520on%2520behavioral%2520states%2520and%2520wake%2520maintenance%2520during%2520deficiency%2520of%2520a%2520brain%2520activating%2520system%253A%2520A%2520study%2520using%2520a%2520knockout%2520mouse%2520model%26jtitle%3DNeuropharmacology%26date%3D2016%26volume%3D106%26spage%3D20%26epage%3D34%26doi%3D10.1016%2Fj.neuropharm.2015.12.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34a','cit34b'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85a','cit85b'],'ref86':['cit86a','cit86b'],'ref87':['cit87'],'ref88':['cit88a','cit88b'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/medium/jm0c00914_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00914&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/medium/jm0c00914_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. H<sub>3</sub>R ligands UCL2190 (hH<sub>3</sub>R <i>K</i><sub>i</sub> = 1.6 nM)<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> and <b>I</b>,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> as well as potent adenosine antagonists (preladenant and JNJ-40255293)<a onclick="showRef(event, 'ref45 ref50'); return false;" href="javascript:void(0);" class="ref ref45 ref50">(45,50)</a> taken as lead structures for the synthesis of MTLs (<b>1–12</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00914&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/medium/jm0c00914_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route for the Design of MTLs <b>1–12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00914&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(I) Benzyl bromide, K<sub>2</sub>CO<sub>3</sub>, dimethylformamide, r.t., 15 h; (II) 1-(3-chloropropyl)piperidine, K<sub>2</sub>CO<sub>3</sub>, KI, acetone, reflux, 15–24 h; (III) appropriate benzaldehyde, NaOH, ethanol, r.t., 30 min; (IV) guanidine hydrochloride, NaOH, ethanol or methanol, N<sub>2</sub>, reflux, 18–24 h; (V) Pd/C (wt 10%), ethanol, H<sub>2</sub>, r.t., 18 h; (VI) 1-(3-chloropropyl)piperidine or 1-(3-chloropropyl)pyrrolidine, K<sub>2</sub>CO<sub>3</sub>, dimethylformamide, N<sub>2</sub>, 80 °C, 4 h; (VII) NaOH, dimethylformamide, O<sub>2</sub>, 80 °C, 2 h; Bn = benzyl; Y<sup>1</sup> = 3-piperidinopropyloxy; Y<sup>2</sup> = 3-pyrrolidinopropyloxy; <b>4</b> (<b>ST-2001</b>), <b>12</b> (<b>ST-1992</b>).</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/medium/jm0c00914_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. cAMP accumulation experiments. Stimulation of cAMP accumulation in CHO cells expressing the human adenosine A<sub>2A</sub>R was induced by 0.3 μM of the agonist NECA (set at 100%). The one-way ANOVA with Dunnett’s posthoc test indicated significant differences (***<i>p</i> < 0.001, ****<i>p</i> < 0.0001) between the effect of NECA in the absence and in the presence of A<sub>2A</sub>R antagonists (<b>4</b>, <b>12</b>, and for comparison MSX-2 [3-(3-hydroxypropyl)-8-(<i>m</i>-methoxystyryl)-7-methyl-1-propargylxanthine)].</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00914&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/medium/jm0c00914_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A–C) 3D docking model and (D–F) 2D schematic diagram of the docking model of ZM241385 (colored in green, A), preladenant (colored in magenta, B) and compound <b>ST-1992</b> (colored in cyan, C) with the human A<sub>2A</sub>R. For modeling studies, the structure of the A<sub>2A</sub>R cocrystallized with ZM241385 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EIY">4EIY</a>) was used, displayed in a cartoon representation (gray). Oxygen atoms are colored in red, nitrogen atoms in blue, and hydrogen atoms in silver white.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00914&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/medium/jm0c00914_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) 3D docking model and (B) 2D schematic diagram of compound <b>ST-1992</b> using a homology model of the human H<sub>3</sub>R (based on the X-ray structure of the human H<sub>1</sub>R, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RZE">3RZE</a>). The homology model of the H<sub>3</sub>R is displayed in a cartoon representation (light brown). Carbon atoms are colored in cyan, oxygen atoms in red, nitrogen atoms in blue, and hydrogen atoms on the amino group are shown in silver white.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00914&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/medium/jm0c00914_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Time-course panels reporting the effect of best MTLs <b>ST-2001</b> (<b>4</b>) (A–C) and <b>ST-1992</b> (<b>12</b>) (D–F) and amantadine on either overall ALO or axial AIM scores induced by <span class="smallcaps smallerCapital">l</span>-DOPA (6 mg/kg, i.p.). AIM scores are expressed as individual data and median. Control (★), amantadine (●) 40 mg/kg (i.p.), <span class="smallcaps smallerCapital">l</span>-DOPA + <b>4</b> (*) 0.1 mg/kg (i.p.), <span class="smallcaps smallerCapital">l</span>-DOPA + <b>4</b> (☆) 1 mg/kg (i.p.), <span class="smallcaps smallerCapital">l</span>-DOPA + <b>12</b> (▲) 0.1 mg/kg (i.p.), and <span class="smallcaps smallerCapital">l</span>-DOPA + <b>12</b> (▼) 1 mg/kg (i.p.). ST-2001 and ST-1992 testing followed a within-subject escalation dose design (5 male rats per compound). The data were analyzed by the Friedman test, followed by Dunn’s multiple comparison test; *<i>p</i> < 0.05 and **<i>p</i> < 0.01 <i>vs</i> control (0 mg/kg).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00914&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/medium/jm0c00914_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Sleep–wake patterns following p.o. administration of compound <b>ST-1992</b> (<b>12</b>) at 1 mg/kg (A) and 2 mg/kg (B) showing cumulative indices after 4 h (a) and time-dependent effects on wake (W) (b), SWS (c), and PS phases (d) (*<i>p</i> < 0.05 <i>vs</i>. control (black bar, 0 mg/kg); Dunnett’s <i>t</i>-test after significant ANOVA; <i>n</i> = 5).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c00914/20210616/images/large/jm0c00914_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00914&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i47">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78540" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78540" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 112 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiffmann, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumont, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderhaeghen, J.-J.</span></span> <span> </span><span class="NLM_article-title">A cloned G protein-coupled protein with a distribution restricted to striatal medium-sized neurons. Possible relationship with D1 dopamine receptor</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>519</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1016/0006-8993(90)90097-u</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2F0006-8993%2890%2990097-u" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=2168785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADyaK3cXkvFWrsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=519&publication_year=1990&pages=333-337&author=S.+N.+Schiffmannauthor=F.+Libertauthor=G.+Vassartauthor=J.+E.+Dumontauthor=J.-J.+Vanderhaeghen&title=A+cloned+G+protein-coupled+protein+with+a+distribution+restricted+to+striatal+medium-sized+neurons.+Possible+relationship+with+D1+dopamine+receptor&doi=10.1016%2F0006-8993%2890%2990097-u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">A cloned G protein-coupled protein with a distribution restricted to striatal medium-sized neurons.  Possible relationship with D1 dopamine receptor</span></div><div class="casAuthors">Schiffmann, S. N.; Libert, F.; Vassart, G.; Dumont, J. E.; Vanderhaeghen, J. J.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">519</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">333-7</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    </div><div class="casAbstract">RDC8, a recently cloned new putative member of the G protein-coupled receptor family, is exclusively present in the medium-sized neurons of the dorsal and ventral striatum in the rat and dog brains.  The existence of a striatum-restricted putative G protein-coupled receptor is of major importance for the understanding of basal ganglia physiol. and degenerative diseases pathogeny such as Huntington's and Parkinson's disease.  This striatal restricted localization mimics the major striatal dopamine D1 receptor localization.  RDC7, another putative G protein-coupled receptor presenting a close sequence similarity with RDC8, is mainly distributed in the cerebral cortex, the amygdala, the hippocampus, and the claustrum.  This localization is also compatible with that expected from a subtype of dopamine D1 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV1UB3cVbAMLVg90H21EOLACvtfcHk0lhpIdopf9t7bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXkvFWrsb8%253D&md5=13aba0568740042cea1918a5b1b7da5e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2890%2990097-u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252890%252990097-u%26sid%3Dliteratum%253Aachs%26aulast%3DSchiffmann%26aufirst%3DS.%2BN.%26aulast%3DLibert%26aufirst%3DF.%26aulast%3DVassart%26aufirst%3DG.%26aulast%3DDumont%26aufirst%3DJ.%2BE.%26aulast%3DVanderhaeghen%26aufirst%3DJ.-J.%26atitle%3DA%2520cloned%2520G%2520protein-coupled%2520protein%2520with%2520a%2520distribution%2520restricted%2520to%2520striatal%2520medium-sized%2520neurons.%2520Possible%2520relationship%2520with%2520D1%2520dopamine%2520receptor%26jtitle%3DBrain%2520Res.%26date%3D1990%26volume%3D519%26spage%3D333%26epage%3D337%26doi%3D10.1016%2F0006-8993%2890%2990097-u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiffmann, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moresco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunha, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferré, S.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptors and basal ganglia physiology</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1016/j.pneurobio.2007.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.pneurobio.2007.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=17646043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlags7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2007&pages=277-292&author=S.+N.+Schiffmannauthor=G.+Fisoneauthor=R.+Morescoauthor=R.+A.+Cunhaauthor=S.+Ferr%C3%A9&title=Adenosine+A2A+receptors+and+basal+ganglia+physiology&doi=10.1016%2Fj.pneurobio.2007.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A receptors and basal ganglia physiology</span></div><div class="casAuthors">Schiffmann, S. N.; Fisone, G.; Moresco, R.; Cunha, R. A.; Ferre, S.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">277-292</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Adenosine A2A receptors are highly enriched in the basal ganglia system.  They are predominantly expressed in enkephalin-expressing GABAergic striatopallidal neurons and therefore are highly relevant to the function of the indirect efferent pathway of the basal ganglia system.  In these GABAergic enkephalinergic neurons, the A2A receptor tightly interacts structurally and functionally with the dopamine D2 receptor.  Both by forming receptor heteromers and by targeting common intracellular signaling cascades, A2A and D2 receptors exhibit reciprocal antagonistic interactions that are central to the function of the indirect pathway and hence to basal ganglia control of movement, motor learning, motivation and reward.  Consequently, this A2A/D2 receptors antagonistic interaction is also central to basal ganglia dysfunction in Parkinson's disease.  However, recent evidence demonstrates that, in addn. to this post-synaptic site of action, striatal A2A receptors are also expressed and have physiol. relevance on pre-synaptic glutamatergic terminals of the cortico-limbic-striatal and thalamo-striatal pathways, where they form heteromeric receptor complexes with adenosine A1 receptors.  Therefore, A2A receptors play an important fine-tuning role, boosting the efficiency of glutamatergic information flow in the indirect pathway by exerting control, either pre- and/or post-synaptically, over other key modulators of glutamatergic synapses, including D2 receptors, group I metabotropic mGlu5 glutamate receptors and cannabinoid CB1 receptors, and by triggering the cAMP-protein kinase A signaling cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUH2pJWR7dD7Vg90H21EOLACvtfcHk0lhpIdopf9t7bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlags7%252FE&md5=6257d9a3d3b5d581ae1ce8b894a04e1e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2007.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2007.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DSchiffmann%26aufirst%3DS.%2BN.%26aulast%3DFisone%26aufirst%3DG.%26aulast%3DMoresco%26aufirst%3DR.%26aulast%3DCunha%26aufirst%3DR.%2BA.%26aulast%3DFerr%25C3%25A9%26aufirst%3DS.%26atitle%3DAdenosine%2520A2A%2520receptors%2520and%2520basal%2520ganglia%2520physiology%26jtitle%3DProg.%2520Neurobiol.%26date%3D2007%26volume%3D83%26spage%3D277%26epage%3D292%26doi%3D10.1016%2Fj.pneurobio.2007.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kase, H.</span></span> <span> </span><span class="NLM_article-title">The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">605</span>– <span class="NLM_lpage">611</span>, <span class="refDoi"> DOI: 10.1523/jneurosci.16-02-00605.1996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1523%2Fjneurosci.16-02-00605.1996" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1996&pages=605-611&author=A.+Moriauthor=T.+Shindouauthor=M.+Ichimuraauthor=H.+Nonakaauthor=H.+Kase&title=The+role+of+adenosine+A2a+receptors+in+regulating+GABAergic+synaptic+transmission+in+striatal+medium+spiny+neurons&doi=10.1523%2Fjneurosci.16-02-00605.1996"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1523%2Fjneurosci.16-02-00605.1996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252Fjneurosci.16-02-00605.1996%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DA.%26aulast%3DShindou%26aufirst%3DT.%26aulast%3DIchimura%26aufirst%3DM.%26aulast%3DNonaka%26aufirst%3DH.%26aulast%3DKase%26aufirst%3DH.%26atitle%3DThe%2520role%2520of%2520adenosine%2520A2a%2520receptors%2520in%2520regulating%2520GABAergic%2520synaptic%2520transmission%2520in%2520striatal%2520medium%2520spiny%2520neurons%26jtitle%3DProg.%2520Neurobiol.%26date%3D1996%26volume%3D16%26spage%3D605%26epage%3D611%26doi%3D10.1523%2Fjneurosci.16-02-00605.1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. J.</span></span> <span> </span><span class="NLM_article-title">The adenosine A2A receptor of the basal ganglia</span>. <i>J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>532</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1111/j.1469-7793.2001.0284f.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1111%2Fj.1469-7793.2001.0284f.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=11306648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjtFOntro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=532&publication_year=2001&pages=284-286&author=P.+J.+Richardson&title=The+adenosine+A2A+receptor+of+the+basal+ganglia&doi=10.1111%2Fj.1469-7793.2001.0284f.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The adenosine A2A receptor of the basal ganglia</span></div><div class="casAuthors">Richardson, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">532</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">284</span>CODEN:
                <span class="NLM_cas:coden">JPHYA7</span>;
        ISSN:<span class="NLM_cas:issn">0022-3751</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">A review with 6 refs.  It is widely recognized that Parkinson's disease (PD) is caused by the deterioration of the dopaminergic neurons of the nigro-striatal pathway, resulting in abnormal neural processing in the basal ganglia and consequent motor abnormalities.  The current mainstay of therapy for this disease is dopamine replacement using the precursor L-DOPA.  However, the duration of L-DOPA therapy is severely limited, and it is assocd. with the development of incapacitating side-effects such as dyskinesias, on/off episodes and hallucinations.  It was therefore of considerable interest when two groups in the late 1980s and early 1990s suggested that the adenosine A2A receptor could be a suitable target for novel anti-PD drugs.  It was hoped that such agents would exhibit fewer side effects than the current dopamine-based therapies.  Indeed it appears that in primate and rodent models of PD, A2A receptor antagonists do not cause dyskinesias, unlike L-DOPA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdtiILzYnV8rVg90H21EOLACvtfcHk0libbT1Th-Ivpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjtFOntro%253D&md5=75e36241290039c25fc50fc7e365d5bf</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fj.1469-7793.2001.0284f.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1469-7793.2001.0284f.x%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BJ.%26atitle%3DThe%2520adenosine%2520A2A%2520receptor%2520of%2520the%2520basal%2520ganglia%26jtitle%3DJ.%2520Physiol.%26date%3D2001%26volume%3D532%26spage%3D284%26epage%3D286%26doi%3D10.1111%2Fj.1469-7793.2001.0284f.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacey, M. G.</span></span> <span> </span><span class="NLM_article-title">A Postsynaptic Interaction between dopamine D1and NMDA receptors promotes presynaptic inhibition in the rat nucleus accumbens via adenosine release</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">5271</span>– <span class="NLM_lpage">5280</span>, <span class="refDoi"> DOI: 10.1523/jneurosci.17-14-05271.1997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1523%2Fjneurosci.17-14-05271.1997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=9204911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADyaK2sXksVSgtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1997&pages=5271-5280&author=J.+Harveyauthor=M.+G.+Lacey&title=A+Postsynaptic+Interaction+between+dopamine+D1and+NMDA+receptors+promotes+presynaptic+inhibition+in+the+rat+nucleus+accumbens+via+adenosine+release&doi=10.1523%2Fjneurosci.17-14-05271.1997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A postsynaptic interaction between dopamine D1 and NMDA receptors promotes presynaptic inhibition in the rat nucleus accumbens via adenosine release</span></div><div class="casAuthors">Harvey, Jenni; Lacey, Michael G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5271-5280</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The mechanism underlying dopamine D1 receptor-mediated attenuation of glutamatergic synaptic input to nucleus accumbens (NAcc) neurons was investigated in slices of rat forebrain, using whole-cell patch-clamp recording.  The depression by dopamine of EPSCs evoked by single-shock cortical stimulation was stimulus-dependent.  Synaptic activation of NMDA-type glutamate receptors was crit. for this effect, because dopamine-induced EPSC depressions were blocked by the competitive NMDA receptor antagonist D/L-2-amino-5-phosphonopentanoate (AP5).  Application of NMDA also depressed the EPSC, and both this effect and the dopamine depressions were blocked by the A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), implicating adenosine release in the EPSC depression.  A1 receptor agonists also depressed EPSCs by a presynaptic action, causing increased paired-pulse facilitation, but this was insensitive to AP5.  Activation of D1 receptors enhanced both postsynaptic inward currents evoked by NMDA application and the isolated NMDA receptor-mediated component of synaptic transmission.  The biochem. processes underlying the dopamine-induced EPSC depression did not involve either protein kinase A or the prodn. of cAMP and its metabolites, because this effect was resistant to the protein kinase inhibitors H89 and H7 and the cAMP-specific phosphodiesterase inhibitor rolipram.  We conclude that activation of postsynaptic D1 receptors enhances the synaptic activation of NMDA receptors in nucleus accumbens neurons, thereby promoting a transsynaptic feedback inhibition of glutamatergic synaptic transmission via release of adenosine.  Unusually for D1 receptors, this phenomenon occurs independently of adenylyl cyclase stimulation.  This process may contribute to the locomotor stimulant action of dopaminergic agents in the NAcc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod_Wz6t-JNQrVg90H21EOLACvtfcHk0lgf7YZouPP2rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXksVSgtrc%253D&md5=578a0472a5475d5de5656b479ac8b846</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1523%2Fjneurosci.17-14-05271.1997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252Fjneurosci.17-14-05271.1997%26sid%3Dliteratum%253Aachs%26aulast%3DHarvey%26aufirst%3DJ.%26aulast%3DLacey%26aufirst%3DM.%2BG.%26atitle%3DA%2520Postsynaptic%2520Interaction%2520between%2520dopamine%2520D1and%2520NMDA%2520receptors%2520promotes%2520presynaptic%2520inhibition%2520in%2520the%2520rat%2520nucleus%2520accumbens%2520via%2520adenosine%2520release%26jtitle%3DJ.%2520Neurosci.%26date%3D1997%26volume%3D17%26spage%3D5271%26epage%3D5280%26doi%3D10.1523%2Fjneurosci.17-14-05271.1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciruela, F.</span></span> <span> </span><span class="NLM_article-title">Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2080</span>– <span class="NLM_lpage">2087</span>, <span class="refDoi"> DOI: 10.1523/jneurosci.3574-05.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1523%2Fjneurosci.3574-05.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=16481441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD28XitVansbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=2080-2087&author=F.+Ciruela&title=Presynaptic+control+of+striatal+glutamatergic+neurotransmission+by+adenosine+A1-A2A+receptor+heteromers&doi=10.1523%2Fjneurosci.3574-05.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers</span></div><div class="casAuthors">Ciruela, Francisco; Casado, Vicent; Rodrigues, Ricardo J.; Lujan, Rafael; Burgueno, Javier; Canals, Meritxell; Borycz, Janusz; Rebola, Nelson; Goldberg, Steven R.; Mallol, Josefa; Cortes, Antonio; Canela, Enric I.; Lopez-Gimenez, Juan F.; Milligan, Graeme; Lluis, Carme; Cunha, Rodrigo A.; Ferre, Sergi; Franco, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2080-2087</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The functional role of heteromers of G-protein-coupled receptors is a matter of debate.  In the present study, we demonstrate that heteromerization of adenosine A1 receptors (A1Rs) and A2A receptors (A2ARs) allows adenosine to exert a fine-tuning modulation of glutamatergic neurotransmission.  By means of coimmunopptn., bioluminescence and time-resolved fluorescence resonance energy transfer techniques, we showed the existence of A1R-A2AR heteromers in the cell surface of cotransfected cells.  Immunogold detection and coimmunopptn. expts. indicated that A1R and A2AR are colocalized in the same striatal glutamatergic nerve terminals.  Radioligand-binding expts. in cotransfected cells and rat striatum showed that a main biochem. characteristic of the A1R-A2AR heteromer is the ability of A2AR activation to reduce the affinity of the A1R for agonists.  This provides a switch mechanism by which low and high concns. of adenosine inhibit and stimulate, resp., glutamate release.  Furthermore, it is also shown that A1R-A2AR heteromers constitute a unique target for caffeine and that chronic caffeine treatment leads to modifications in the function of the A1R-A2AR heteromer that could underlie the strong tolerance to the psychomotor effects of caffeine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdjtEghr6th7Vg90H21EOLACvtfcHk0lgf7YZouPP2rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitVansbo%253D&md5=0821e06c0c2f5880614e7f39963974d4</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1523%2Fjneurosci.3574-05.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252Fjneurosci.3574-05.2006%26sid%3Dliteratum%253Aachs%26aulast%3DCiruela%26aufirst%3DF.%26atitle%3DPresynaptic%2520control%2520of%2520striatal%2520glutamatergic%2520neurotransmission%2520by%2520adenosine%2520A1-A2A%2520receptor%2520heteromers%26jtitle%3DJ.%2520Neurosci.%26date%3D2006%26volume%3D26%26spage%3D2080%26epage%3D2087%26doi%3D10.1523%2Fjneurosci.3574-05.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soliman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fathalla, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moustafa, A. A.</span></span> <span> </span><span class="NLM_article-title">Adenosine role in brain functions: Pathophysiological influence on Parkinson’s disease and other brain disorders</span>. <i>Pharmacol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">661</span>– <span class="NLM_lpage">667</span>, <span class="refDoi"> DOI: 10.1016/j.pharep.2018.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.pharep.2018.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=29909246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFKlsbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2018&pages=661-667&author=A.+M.+Solimanauthor=A.+M.+Fathallaauthor=A.+A.+Moustafa&title=Adenosine+role+in+brain+functions%3A+Pathophysiological+influence+on+Parkinson%E2%80%99s+disease+and+other+brain+disorders&doi=10.1016%2Fj.pharep.2018.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine role in brain functions: Pathophysiological influence on Parkinson's disease and other brain disorders</span></div><div class="casAuthors">Soliman, Amira M.; Fathalla, Ahmed M.; Moustafa, Ahmed A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">661-667</span>CODEN:
                <span class="NLM_cas:coden">PRHEDU</span>;
        ISSN:<span class="NLM_cas:issn">2299-5684</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Although adenosine plays a key role in multiple motor, affective, and cognitive processes, it has received less attention in the neuroscience field compared to other neurotransmitters (e.g., dopamine).  In this review, we highlight the role of adenosine in behavior as well as its interaction with other neurotransmitters, such as dopamine.  We also discuss brain disorders impacted by alterations to adenosine, and how targeting adenosine can ameliorate Parkinson's disease motor symptoms.  We also discuss the role of caffeine (as an adenosine antagonist) on cognition as well as a neuroprotective agent against Parkinson's disease (PD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7_4b-G0k3RbVg90H21EOLACvtfcHk0lizu4bxbEnu1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFKlsbrK&md5=eb5e4a41ab87c49926b3b624dad7fa2c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.pharep.2018.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharep.2018.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DSoliman%26aufirst%3DA.%2BM.%26aulast%3DFathalla%26aufirst%3DA.%2BM.%26aulast%3DMoustafa%26aufirst%3DA.%2BA.%26atitle%3DAdenosine%2520role%2520in%2520brain%2520functions%253A%2520Pathophysiological%2520influence%2520on%2520Parkinson%25E2%2580%2599s%2520disease%2520and%2520other%2520brain%2520disorders%26jtitle%3DPharmacol.%2520Rep.%26date%3D2018%26volume%3D70%26spage%3D661%26epage%3D667%26doi%3D10.1016%2Fj.pharep.2018.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simola, N.</span></span> <span> </span><span class="NLM_article-title">Role of adenosine A2A receptors in motor control: Relevance to Parkinson’s disease and dyskinesia</span>. <i>J. Neural. Transm.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1273</span>– <span class="NLM_lpage">1286</span>, <span class="refDoi"> DOI: 10.1007/s00702-018-1848-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1007%2Fs00702-018-1848-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=29396609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit12hsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2018&pages=1273-1286&author=A.+Pinnaauthor=M.+Serraauthor=M.+Morelliauthor=N.+Simola&title=Role+of+adenosine+A2A+receptors+in+motor+control%3A+Relevance+to+Parkinson%E2%80%99s+disease+and+dyskinesia&doi=10.1007%2Fs00702-018-1848-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Role of adenosine A2A receptors in motor control: relevance to Parkinson's disease and dyskinesia</span></div><div class="casAuthors">Pinna, Annalisa; Serra, Marcello; Morelli, Micaela; Simola, Nicola</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neural Transmission</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1273-1286</span>CODEN:
                <span class="NLM_cas:coden">JNTRF3</span>;
        ISSN:<span class="NLM_cas:issn">0300-9564</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag GmbH</span>)
        </div><div class="casAbstract">A review.  Adenosine is an endogenous purine nucleoside that regulates several physiol. functions, at the central and peripheral levels.  Besides, adenosine has emerged as a major player in the regulation of motor behavior.  In fact, adenosine receptors of the A2A subtype are highly enriched in the caudate-putamen, which is richly innervated by dopamine.  Moreover, several studies in exptl. animals have consistently demonstrated that the pharmacol. antagonism of A2A receptors has a facilitatory influence on motor behavior.  Taken together, these findings have envisaged A2A receptors as a promising target for symptomatic therapies aimed at ameliorating motor deficits.  Accordingly, A2A receptor antagonists have been extensively studied as new agents for the treatment of Parkinson's disease (PD), the epitome of motor disorders.  In this review, we provide an overview of the effects that adenosine A2A receptor antagonists elicit in rodent and primate exptl. models of PD, with regard to the counteraction of motor deficits as well as to manifestation of dyskinesia and motor fluctuations.  Moreover, we briefly present the results of clin. trials of A2A receptor antagonists in PD patients experiencing motor fluctuations, with particular regard to dyskinesia.  Finally, we discuss the interaction between A2A receptor antagonists and serotonin receptor agonists, since combined administration of these drugs has recently emerged as a new potential therapeutic strategy in the treatment of dyskinesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCLiOGmgbfiLVg90H21EOLACvtfcHk0lizu4bxbEnu1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit12hsLw%253D&md5=865076b4e6d3843701fbcda45af0e565</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs00702-018-1848-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00702-018-1848-6%26sid%3Dliteratum%253Aachs%26aulast%3DPinna%26aufirst%3DA.%26aulast%3DSerra%26aufirst%3DM.%26aulast%3DMorelli%26aufirst%3DM.%26aulast%3DSimola%26aufirst%3DN.%26atitle%3DRole%2520of%2520adenosine%2520A2A%2520receptors%2520in%2520motor%2520control%253A%2520Relevance%2520to%2520Parkinson%25E2%2580%2599s%2520disease%2520and%2520dyskinesia%26jtitle%3DJ.%2520Neural.%2520Transm.%26date%3D2018%26volume%3D125%26spage%3D1273%26epage%3D1286%26doi%3D10.1007%2Fs00702-018-1848-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burnstock, G.</span></span> <span> </span><span class="NLM_article-title">Purinergic signalling: From discovery to current developments</span>. <i>Exp. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1113/expphysiol.2013.071951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1113%2Fexpphysiol.2013.071951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=24078669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotFWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2014&pages=16-34&author=G.+Burnstock&title=Purinergic+signalling%3A+From+discovery+to+current+developments&doi=10.1113%2Fexpphysiol.2013.071951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Purinergic signalling: from discovery to current developments</span></div><div class="casAuthors">Burnstock, Geoffrey</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Physiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-34</span>CODEN:
                <span class="NLM_cas:coden">EXPHEZ</span>;
        ISSN:<span class="NLM_cas:issn">1469-445X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  New Findings : What is the topic of this review This is a personal historical review about the discovery and the main conceptual advances leading to our current understanding of purinergic signalling.  The contributions of leading figures in the field are acknowledged.  It includes the discovery of purinergic neuromuscular and synaptic transmission, cotransmission, the identification of P1 (adenosine), P2X nucleotide ion channel and P2Y nucleotide G protein-coupled receptors, the identity of ectonucleotidases and release of ATP from cells by mech. stimulation and mechanosensory transduction.  What advances does it highlight It highlights the pathophysiol. of purinergic signalling and recent therapeutic developments.  This lecture is about the history of the purinergic signalling concept.  It begins with ref. to the paper by Paton & Vane published in 1963, which identified non-cholinergic relaxation in response to vagal nerve stimulation in several species, although they suggested that it might be due to sympathetic adrenergic nerves in the vagal nerve trunk.  Using the sucrose gap technique for simultaneous mech. and elec. recordings in smooth muscle (developed while in Feldberg's department in the National Institute for Medical Research) of the guinea-pig taenia coli prepn. (learned when working in Edith Buelbring's smooth muscle lab. in Oxford Pharmacol.), we showed that the hyperpolarizations recorded in the presence of antagonists to the classical autonomic neurotransmitters, acetylcholine and noradrenaline, were inhibitory junction potentials in response to non-adrenergic, non-cholinergic neurotransmission, mediated by intrinsic enteric nerves controlled by vagal and sacral parasympathetic nerves.  We then showed that ATP satisfied the criteria needed to identify a neurotransmitter released by these nerves.  Subsequently, it was shown that ATP is a cotransmitter in all nerves in the peripheral and central nervous systems.  The receptors for purines and pyrimidines were cloned and characterized in the early 1990s, and immunostaining showed that most non-neuronal cells as well as nerve cells expressed these receptors.  The physiol. and pathophysiol. of purinergic signalling is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFkHtMEJezobVg90H21EOLACvtfcHk0liJWer9c8h4eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotFWgug%253D%253D&md5=98641f7884ee39473288dc5c1d264f7a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1113%2Fexpphysiol.2013.071951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1113%252Fexpphysiol.2013.071951%26sid%3Dliteratum%253Aachs%26aulast%3DBurnstock%26aufirst%3DG.%26atitle%3DPurinergic%2520signalling%253A%2520From%2520discovery%2520to%2520current%2520developments%26jtitle%3DExp.%2520Physiol.%26date%3D2014%26volume%3D99%26spage%3D16%26epage%3D34%26doi%3D10.1113%2Fexpphysiol.2013.071951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrejew, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira-Giacomelli, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonfim
Marques, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semyanov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, H.</span></span> <span> </span><span class="NLM_article-title">Purinergic receptors in basal ganglia diseases: Shared molecular mechanisms between Huntington’s and Parkinson’s disease</span>. <i>Neurosci. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1299</span>– <span class="NLM_lpage">1314</span>, <span class="refDoi"> DOI: 10.1007/s12264-020-00582-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1007%2Fs12264-020-00582-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=33026587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BB3s%252FosV2gtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2020&pages=1299-1314&author=T.+Glaserauthor=R.+Andrejewauthor=%C3%81.+Oliveira-Giacomelliauthor=D.+E.+Ribeiroauthor=L.+Bonfim%0AMarquesauthor=Q.+Yeauthor=W.-J.+Renauthor=A.+Semyanovauthor=P.+Illesauthor=Y.+Tangauthor=H.+Ulrich&title=Purinergic+receptors+in+basal+ganglia+diseases%3A+Shared+molecular+mechanisms+between+Huntington%E2%80%99s+and+Parkinson%E2%80%99s+disease&doi=10.1007%2Fs12264-020-00582-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Purinergic Receptors in Basal Ganglia Diseases: Shared Molecular Mechanisms between Huntington's and Parkinson's Disease</span></div><div class="casAuthors">Glaser Talita; Andrejew Roberta; Oliveira-Giacomelli Agatha; Ribeiro Deidiane Elisa; Bonfim Marques Lucas; Ye Qing; Ulrich Henning; Ye Qing; Ren Wen-Jing; Tang Yong; Ren Wen-Jing; Illes Peter; Semyanov Alexey; Semyanov Alexey; Illes Peter; Tang Yong</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience bulletin</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1299-1314</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Huntington's (HD) and Parkinson's diseases (PD) are neurodegenerative disorders caused by the death of GABAergic and dopaminergic neurons in the basal ganglia leading to hyperkinetic and hypokinetic symptoms, respectively.  We review here the participation of purinergic receptors through intracellular Ca(2+) signaling in these neurodegenerative diseases.  The adenosine A2A receptor stimulates striatopallidal GABAergic neurons, resulting in inhibitory actions on GABAergic neurons of the globus pallidus.  A2A and dopamine D2 receptors form functional heteromeric complexes inducing allosteric inhibition, and A2A receptor activation results in motor inhibition.  Furthermore, the A2A receptor physically and functionally interacts with glutamate receptors, mainly with the mGlu5 receptor subtype.  This interaction facilitates glutamate release, resulting in NMDA glutamate receptor activation and an increase of Ca(2+) influx.  P2X7 receptor activation also promotes glutamate release and neuronal damage.  Thus, modulation of purinergic receptor activity, such as A2A and P2X7 receptors, and subsequent aberrant Ca(2+) signaling, might present interesting therapeutic potential for HD and PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSMij9artkVcZagfuraLLzSfW6udTcc2eZ5zQ0ww7iQ57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3s%252FosV2gtQ%253D%253D&md5=2f47937d51c70ee9f0e8747b8b475f43</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs12264-020-00582-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12264-020-00582-8%26sid%3Dliteratum%253Aachs%26aulast%3DGlaser%26aufirst%3DT.%26aulast%3DAndrejew%26aufirst%3DR.%26aulast%3DOliveira-Giacomelli%26aufirst%3D%25C3%2581.%26aulast%3DRibeiro%26aufirst%3DD.%2BE.%26aulast%3DBonfim%2BMarques%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DRen%26aufirst%3DW.-J.%26aulast%3DSemyanov%26aufirst%3DA.%26aulast%3DIlles%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DUlrich%26aufirst%3DH.%26atitle%3DPurinergic%2520receptors%2520in%2520basal%2520ganglia%2520diseases%253A%2520Shared%2520molecular%2520mechanisms%2520between%2520Huntington%25E2%2580%2599s%2520and%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurosci.%2520Bull.%26date%3D2020%26volume%3D36%26spage%3D1299%26epage%3D1314%26doi%3D10.1007%2Fs12264-020-00582-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wichmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Factor, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLong, M. R.</span></span> <span> </span><span class="NLM_article-title">Parkinson’s disease therapeutics: New developments and challenges since the introduction of Levodopa</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.1038/npp.2011.212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1038%2Fnpp.2011.212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=21956442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ejsrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2012&pages=213-246&author=Y.+Smithauthor=T.+Wichmannauthor=S.+A.+Factorauthor=M.+R.+DeLong&title=Parkinson%E2%80%99s+disease+therapeutics%3A+New+developments+and+challenges+since+the+introduction+of+Levodopa&doi=10.1038%2Fnpp.2011.212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa</span></div><div class="casAuthors">Smith, Yoland; Wichmann, Thomas; Factor, Stewart A.; DeLong, Mahlon R.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">213-246</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The demonstration that dopamine loss is the key pathol. feature of Parkinson's disease (PD), and the subsequent introduction of levodopa have revolutionalized the field of PD therapeutics.  This review will discuss the significant progress that has been made in the development of new pharmacol. and surgical tools to treat PD motor symptoms since this major breakthrough in the 1960s.  However, we will also highlight some of the challenges the field of PD therapeutics has been struggling with during the past decades.  The lack of neuroprotective therapies and the limited treatment strategies for the nonmotor symptoms of the disease (ie, cognitive impairments, autonomic dysfunctions, psychiatric disorders, etc.) are among the most pressing issues to be addressed in the years to come.  It appears that the combination of early PD nonmotor symptoms with imaging of the nigrostriatal dopaminergic system offers a promising path toward the identification of PD biomarkers, which, once characterized, will set the stage for efficient use of neuroprotective agents that could slow down and alter the course of the disease.  Neuropsychopharmacol. Reviews (2012) 37, 213-246; doi:10.1038/npp.2011.212; published online 28 Sept. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKGa2hNY5gcbVg90H21EOLACvtfcHk0liS1_yTn--V-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ejsrbF&md5=d1e259530039c7e35aae30f77a939fe6</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2011.212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2011.212%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DY.%26aulast%3DWichmann%26aufirst%3DT.%26aulast%3DFactor%26aufirst%3DS.%2BA.%26aulast%3DDeLong%26aufirst%3DM.%2BR.%26atitle%3DParkinson%25E2%2580%2599s%2520disease%2520therapeutics%253A%2520New%2520developments%2520and%2520challenges%2520since%2520the%2520introduction%2520of%2520Levodopa%26jtitle%3DNeuropsychopharmacology%26date%3D2012%26volume%3D37%26spage%3D213%26epage%3D246%26doi%3D10.1038%2Fnpp.2011.212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blesa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trigo-Damas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dileone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">del Rey, N. L.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeso, J. A.</span></span> <span> </span><span class="NLM_article-title">Compensatory mechanisms in Parkinson’s disease: Circuits adaptations and role in disease modification</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>298</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1016/j.expneurol.2017.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.expneurol.2017.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=28987461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1aisLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2017&pages=148-161&author=J.+Blesaauthor=I.+Trigo-Damasauthor=M.+Dileoneauthor=N.+L.-G.+del+Reyauthor=L.+F.+Hernandezauthor=J.+A.+Obeso&title=Compensatory+mechanisms+in+Parkinson%E2%80%99s+disease%3A+Circuits+adaptations+and+role+in+disease+modification&doi=10.1016%2Fj.expneurol.2017.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Compensatory mechanisms in Parkinson's disease: Circuits adaptations and role in disease modification</span></div><div class="casAuthors">Blesa, Javier; Trigo-Damas, Ines; Dileone, Michele; Lopez-Gonzalez el Rey, Natalia; Hernandez, Ledia F.; Obeso, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">Part_B</span>),
    <span class="NLM_cas:pages">148-161</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The motor features of Parkinson's disease (PD) are well known to manifest only when striatal dopaminergic deficit reaches 60-70%.  Thus, PD has a long pre-symptomatic and pre-motor evolution during which compensatory mechanisms take place to delay the clin. onset of disabling manifestations.  Classic compensatory mechanisms have been attributed to changes and adjustments in the nigro-striatal system, such as increased neuronal activity in the substantia nigra pars compacta and enhanced dopamine synthesis and release in the striatum.  However, it is not so clear currently that such changes occur early enough to account for the pre-symptomatic period.  Other possible mechanisms relate to changes in basal ganglia and motor cortical circuits including the cerebellum.  However, data from early PD patients are difficult to obtain as most studies have been carried out once the diagnosis and treatments have been established.  Likewise, putative compensatory mechanisms taking place throughout disease evolution are nearly impossible to distinguish by themselves.  Here, we review the evidence for the role of the best known and other possible compensatory mechanisms in PD.  We also discuss the possibility that, although beneficial in practical terms, compensation could also play a deleterious role in disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE1Vg834LycrVg90H21EOLACvtfcHk0ljkcVwZZKHKug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1aisLnI&md5=ae8f6cf84c0ab502194f7c9e817f0c88</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.expneurol.2017.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.expneurol.2017.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DBlesa%26aufirst%3DJ.%26aulast%3DTrigo-Damas%26aufirst%3DI.%26aulast%3DDileone%26aufirst%3DM.%26aulast%3Ddel%2BRey%26aufirst%3DN.%2BL.-G.%26aulast%3DHernandez%26aufirst%3DL.%2BF.%26aulast%3DObeso%26aufirst%3DJ.%2BA.%26atitle%3DCompensatory%2520mechanisms%2520in%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520Circuits%2520adaptations%2520and%2520role%2520in%2520disease%2520modification%26jtitle%3DExp.%2520Neurol.%26date%3D2017%26volume%3D298%26spage%3D148%26epage%3D161%26doi%3D10.1016%2Fj.expneurol.2017.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferré, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuxe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">B. Fredholm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popoli, P.</span></span> <span> </span><span class="NLM_article-title">Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia</span>. <i>Trends Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">482</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1016/s0166-2236(97)01096-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fs0166-2236%2897%2901096-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=9347617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADyaK2sXmsFKisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1997&pages=482-487&author=S.+Ferr%C3%A9author=K.+Fuxeauthor=B.+B.+Fredholmauthor=M.+Morelliauthor=P.+Popoli&title=Adenosine-dopamine+receptor-receptor+interactions+as+an+integrative+mechanism+in+the+basal+ganglia&doi=10.1016%2Fs0166-2236%2897%2901096-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia</span></div><div class="casAuthors">Ferre, Sergi; Fredholm, Bertil B.; Morelli, Micaela; Popoli, Patrizia; Fuxe, Kjell</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Neurosciences</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">482-487</span>CODEN:
                <span class="NLM_cas:coden">TNSCDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-2236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review, with 48 refs.  Increasing evidence suggests that antagonistic interactions between specific subtypes of adenosine and dopamine receptors in the basal ganglia are involved in the motor depressant effects of adenosine receptor agonists and the motor stimulant effects of adenosine receptor antagonists, such as caffeine.  The GABAergic striatopallidal neurons are regulated by interacting adenosine A2A and dopamine D2 receptors.  The GABAergic striatonigral and striatoentopeduncular neurons seem to be regulated by interacting adenosine A1 and dopamine D1 receptors.  Furthermore, behavioral studies have revealed interactions between adenosine A2A and dopamine D1 receptors that occur at the network level.  These adenosine-dopamine receptor-receptor interactions might offer new therapeutic leads for basal ganglia disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq79FXLvi2_orVg90H21EOLACvtfcHk0ljkcVwZZKHKug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsFKisr4%253D&md5=986e1e4f2207c6844f000db83557cca8</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fs0166-2236%2897%2901096-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0166-2236%252897%252901096-5%26sid%3Dliteratum%253Aachs%26aulast%3DFerr%25C3%25A9%26aufirst%3DS.%26aulast%3DFuxe%26aufirst%3DK.%26aulast%3DB.%2BFredholm%26aufirst%3DB.%26aulast%3DMorelli%26aufirst%3DM.%26aulast%3DPopoli%26aufirst%3DP.%26atitle%3DAdenosine-dopamine%2520receptor-receptor%2520interactions%2520as%2520an%2520integrative%2520mechanism%2520in%2520the%2520basal%2520ganglia%26jtitle%3DTrends%2520Neurosci.%26date%3D1997%26volume%3D20%26spage%3D482%26epage%3D487%26doi%3D10.1016%2Fs0166-2236%2897%2901096-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fuxe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcellino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genedani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agnati, L.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptors, dopamine D2 receptors and their interactions in Parkinson’s disease</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1990</span>– <span class="NLM_lpage">2017</span>, <span class="refDoi"> DOI: 10.1002/mds.21440</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2Fmds.21440" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=17618524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BD2snlt1ehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2007&pages=1990-2017&author=K.+Fuxeauthor=D.+Marcellinoauthor=S.+Genedaniauthor=L.+Agnati&title=Adenosine+A2A+receptors%2C+dopamine+D2+receptors+and+their+interactions+in+Parkinson%E2%80%99s+disease&doi=10.1002%2Fmds.21440"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease</span></div><div class="casAuthors">Fuxe Kjell; Marcellino Daniel; Genedani Susanna; Agnati Luigi</div><div class="citationInfo"><span class="NLM_cas:title">Movement disorders : official journal of the Movement Disorder Society</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1990-2017</span>
        ISSN:<span class="NLM_cas:issn">0885-3185</span>.
    </div><div class="casAbstract">Future therapies in Parkinson's disease may substantially build on the existence of intra-membrane receptor-receptor interactions in DA receptor containing heteromeric receptor complexes.  The A(2A)/D(2) heteromer is of substantial interest in view of its specific location in cortico-striatal glutamate terminals and in striato-pallidal GABA neurons.  Antagonistic A(2A)/D(2) receptor interactions in this heteromer demonstrated at the cellular level, and at the level of the striato-pallidal GABA neuron and at the network level made it possible to suggest A(2A) antagonists as anti-parkinsonian drugs.  The major mechanism is an enhancement of D(2) signaling leading to attenuation of hypokinesia, tremor, and rigidity in models of Parkinson's disease with inspiring results in two clinical trials.  Other interactions are antagonism at the level of the adenylyl cyclase; heterologous sensitization at the A(2A) activated adenylyl cyclase by persistent D(2) activation and a compensatory up-regulation of A(2A) receptors in response to intermittent Levodopa treatment.  An increased dominance of A(2A) homomers over D(2) homomers and A(2A)/D(2) heteromers after intermittent Levodopa treatment may therefore contribute to development of Levodopa induced dyskinesias and to the wearing off of the therapeutic actions of Levodopa giving additional therapeutic roles of A(2A) antagonists.  Their neuroprotective actions may involve an increase in the retrograde trophic signaling in the nigro-striatal DA system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8MLoYMOhuTUewzGPswiWOfW6udTcc2ebgRcPxBrrxWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2snlt1ehug%253D%253D&md5=ef97216335cccae8e8c87baa7ff2fe8e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fmds.21440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.21440%26sid%3Dliteratum%253Aachs%26aulast%3DFuxe%26aufirst%3DK.%26aulast%3DMarcellino%26aufirst%3DD.%26aulast%3DGenedani%26aufirst%3DS.%26aulast%3DAgnati%26aufirst%3DL.%26atitle%3DAdenosine%2520A2A%2520receptors%252C%2520dopamine%2520D2%2520receptors%2520and%2520their%2520interactions%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DMov.%2520Disord.%26date%3D2007%26volume%3D22%26spage%3D1990%26epage%3D2017%26doi%3D10.1002%2Fmds.21440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarzschild, M.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential of adenosine A2A receptor antagonists in Parkinson’s disease</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">310</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2004.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.pharmthera.2004.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=15737407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhvVCjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=267-310&author=K.+Xuauthor=E.+Bastiaauthor=M.+Schwarzschild&title=Therapeutic+potential+of+adenosine+A2A+receptor+antagonists+in+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.pharmthera.2004.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease</span></div><div class="casAuthors">Xu, Kui; Bastia, Elena; Schwarzschild, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">267-310</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In the pursuit of improved treatments for Parkinson's disease (PD), the adenosine A2A receptor has emerged as an attractive nondopaminergic target.  Based on the compelling behavioral pharmacol. and selective basal ganglia expression of this G-protein-coupled receptor, its antagonists are now crossing the threshold of clin. development as adjunctive symptomatic treatment for relatively advanced PD.  The antiparkinsonian potential of A2A antagonism has been boosted further by recent preclin. evidence that A2A antagonists might favorably alter the course as well as the symptoms of the disease.  Convergent epidemiol. and lab. data have suggested that A2A blockade may confer neuroprotection against the underlying dopaminergic neuron degeneration.  In addn., rodent and nonhuman primate studies have raised the possibility that A2A receptor activation contributes to the pathophysiol. of dyskinesias-problematic motor complications of std. PD therapy-and that A2A antagonism might help prevent them.  Realistically, despite being targeted to basal ganglia pathophysiol., A2A antagonists may be expected to have other beneficial and adverse effects elsewhere in the central nervous system (e.g., on mood and sleep) and in the periphery (e.g., on immune and inflammatory processes).  The thoughtful design of new clin. trials of A2A antagonists should take into consideration these counterbalancing hopes and concerns and may do well to shift toward a broader set of disease-modifying as well as symptomatic indications in early PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3HbF9ZxHP3bVg90H21EOLACvtfcHk0lhLSsNbjaMjQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhvVCjt7s%253D&md5=ca493d29bdda09382108c0566a3a0877</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2004.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2004.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DK.%26aulast%3DBastia%26aufirst%3DE.%26aulast%3DSchwarzschild%26aufirst%3DM.%26atitle%3DTherapeutic%2520potential%2520of%2520adenosine%2520A2A%2520receptor%2520antagonists%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DPharmacol.%2520Ther.%26date%3D2005%26volume%3D105%26spage%3D267%26epage%3D310%26doi%3D10.1016%2Fj.pharmthera.2004.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Armentero, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferré, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanciego, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, R.</span></span> <span> </span><span class="NLM_article-title">Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson’s disease</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">280</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2011.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.pharmthera.2011.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=21810444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2ntrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2011&pages=280-299&author=M.+T.+Armenteroauthor=A.+Pinnaauthor=S.+Ferr%C3%A9author=J.+L.+Lanciegoauthor=C.+E.+M%C3%BCllerauthor=R.+Franco&title=Past%2C+present+and+future+of+A2A+adenosine+receptor+antagonists+in+the+therapy+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.pharmthera.2011.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease</span></div><div class="casAuthors">Armentero, Marie Therese; Pinna, Annalisa; Ferre, Sergi; Lanciego, Jose Luis; Mueller, Christa E.; Franco, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">280-299</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Several selective antagonists for adenosine A2A receptors (A2AR) are currently under evaluation in clin. trials (phases I to III) to treat Parkinson's disease, and they will probably soon reach the market.  The usefulness of these antagonists has been deduced from studies demonstrating functional interactions between dopamine D2 and adenosine A2A receptors in the basal ganglia.  At present it is believed that A2AR antagonists can be used in combination with the dopamine precursor L-DOPA to minimize the motor symptoms of Parkinson's patients.  However, a considerable body of data indicates that in addn. to ameliorating motor symptoms, adenosine A2AR antagonists may also prevent neurodegeneration.  Despite these promising indications, one further issue must be considered in order to develop fully optimized antiparkinsonian drug therapy, namely the existence of (hetero)dimers/oligomers of G protein-coupled receptors, a topic that is currently the focus of intense debate within the scientific community.  Dopamine D2 receptors (D2Rs) expressed in the striatum are known to form heteromers with A2A adenosine receptors.  Thus, the development of heteromer-specific A2A receptor antagonists represents a promising strategy for the identification of more selective and safer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2pOYdmdfQMLVg90H21EOLACvtfcHk0liRbEtQNezU2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2ntrzP&md5=39fa871338516f7574deb7845029e624</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2011.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2011.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DArmentero%26aufirst%3DM.%2BT.%26aulast%3DPinna%26aufirst%3DA.%26aulast%3DFerr%25C3%25A9%26aufirst%3DS.%26aulast%3DLanciego%26aufirst%3DJ.%2BL.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DFranco%26aufirst%3DR.%26atitle%3DPast%252C%2520present%2520and%2520future%2520of%2520A2A%2520adenosine%2520receptor%2520antagonists%2520in%2520the%2520therapy%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DPharmacol.%2520Ther.%26date%3D2011%26volume%3D132%26spage%3D280%26epage%3D299%26doi%3D10.1016%2Fj.pharmthera.2011.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Waarde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dierckx, R. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanapur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishiwata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luurtsema, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, E. F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsinga, P. H.</span></span> <span> </span><span class="NLM_article-title">Potential therapeutic applications of adenosine A2A receptor ligands and opportunities for A2A receptor imaging</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1002/med.21432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2Fmed.21432" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2017&pages=5-53&author=A.+Van%0AWaardeauthor=R.+A.+J.+Dierckxauthor=X.+Zhouauthor=S.+Khanapurauthor=H.+Tsukadaauthor=K.+Ishiwataauthor=G.+Luurtsemaauthor=E.+F.+J.+de+Vriesauthor=P.+H.+Elsinga&title=Potential+therapeutic+applications+of+adenosine+A2A+receptor+ligands+and+opportunities+for+A2A+receptor+imaging&doi=10.1002%2Fmed.21432"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fmed.21432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21432%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BWaarde%26aufirst%3DA.%26aulast%3DDierckx%26aufirst%3DR.%2BA.%2BJ.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DKhanapur%26aufirst%3DS.%26aulast%3DTsukada%26aufirst%3DH.%26aulast%3DIshiwata%26aufirst%3DK.%26aulast%3DLuurtsema%26aufirst%3DG.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BF.%2BJ.%26aulast%3DElsinga%26aufirst%3DP.%2BH.%26atitle%3DPotential%2520therapeutic%2520applications%2520of%2520adenosine%2520A2A%2520receptor%2520ligands%2520and%2520opportunities%2520for%2520A2A%2520receptor%2520imaging%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2017%26volume%3D1%26spage%3D5%26epage%3D53%26doi%3D10.1002%2Fmed.21432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelsey, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langelier, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oriel, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reedy, C.</span></span> <span> </span><span class="NLM_article-title">The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>201</i></span>,  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">539</span>, <span class="refDoi"> DOI: 10.1007/s00213-008-1319-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1007%2Fs00213-008-1319-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=18791705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1OntLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=2009&pages=529-539&author=J.+E.+Kelseyauthor=N.+A.+Langelierauthor=B.+S.+Orielauthor=C.+Reedy&title=The+effects+of+systemic%2C+intrastriatal%2C+and+intrapallidal+injections+of+caffeine+and+systemic+injections+of+A2A+and+A1+antagonists+on+forepaw+stepping+in+the+unilateral+6-OHDA-lesioned+rat&doi=10.1007%2Fs00213-008-1319-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat</span></div><div class="casAuthors">Kelsey, John E.; Langelier, Nicole A.; Oriel, Brad S.; Reedy, Catherine</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">201</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">529-539</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Rationale and objectives: Given that adenosine A2A antagonists appear to be therapeutic in several animal models of Parkinson's disease (PD), we examd. the extent to which caffeine and selective A2A and A1 antagonists could enhance contralateral forepaw stepping in the unilateral 6-OHDA-lesioned rat.  Materials and methods: Following unilateral injections of 12 μg 6-OHDA into the medial forebrain bundle (MFB), frequency of stepping with both front paws was counted sep. as the paws were dragged anteriorally and laterally by a treadmill.  Results: The MFB lesions decreased contralateral stepping by 74-83%, and 8 mg/kg 3,4-dihydroxy-L-phenylalanine (L-DOPA) increased contralateral stepping by 25-26%.  Caffeine given systemically (15 mg/kg) or into the dorsal striatum or external globus pallidus (GPE; 20-40 μg) increased contralateral forepaw stepping by 14%, 27%, and 26%, resp., and enhanced the effect of 8 mg/kg L-DOPA on stepping.  The selective A2A antagonist SCH-58261 (2 mg/kg) also increased stepping by 13% and enhanced the therapeutic effect of L-DOPA, whereas the selective A2A antagonist 8-cyclopentyltheophylline (3-7 mg/kg) and A1 agonist N6-cyclopentyladenosine (0.03-0.2 mg/kg) had no effect.  None of these drugs appeared to produce dyskinesic effects.  Conclusions: In this well-validated animal model of the akinesic effects of PD, caffeine and a selective A2A, but not an A1, antagonist were able to provide both monotherapeutic and adjunctive therapeutic effects.  These data are consistent with the hypothesis that A2A antagonists may be therapeutic in human PD patients and indicate that the dorsal striatum and GPE are crit. sites of therapeutic action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqITkClJvQ1rVg90H21EOLACvtfcHk0liRbEtQNezU2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1OntLzN&md5=407f6d6693949eea54c8c6110e44ce1f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs00213-008-1319-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-008-1319-0%26sid%3Dliteratum%253Aachs%26aulast%3DKelsey%26aufirst%3DJ.%2BE.%26aulast%3DLangelier%26aufirst%3DN.%2BA.%26aulast%3DOriel%26aufirst%3DB.%2BS.%26aulast%3DReedy%26aufirst%3DC.%26atitle%3DThe%2520effects%2520of%2520systemic%252C%2520intrastriatal%252C%2520and%2520intrapallidal%2520injections%2520of%2520caffeine%2520and%2520systemic%2520injections%2520of%2520A2A%2520and%2520A1%2520antagonists%2520on%2520forepaw%2520stepping%2520in%2520the%2520unilateral%25206-OHDA-lesioned%2520rat%26jtitle%3DPsychopharmacology%26date%3D2009%26volume%3D201%26spage%3D529%26epage%3D539%26doi%3D10.1007%2Fs00213-008-1319-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takuma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyoshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizoguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, S.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-parkinsonian mouse model</span>. <i>J. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1254/jphs.scz070058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1254%2Fjphs.scz070058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=17341841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1KltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2007&pages=329-332&author=T.+Matsuyaauthor=K.+Takumaauthor=K.+Satoauthor=M.+Asaiauthor=Y.+Murakamiauthor=S.+Miyoshiauthor=A.+Nodaauthor=T.+Nagaiauthor=H.+Mizoguchiauthor=S.+Nishimura&title=Synergistic+effects+of+adenosine+A2A+antagonist+and+L-DOPA+on+rotational+behaviors+in+6-hydroxydopamine-induced+hemi-parkinsonian+mouse+model&doi=10.1254%2Fjphs.scz070058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model</span></div><div class="casAuthors">Matsuya, Takahiro; Takuma, Kazuhiro; Sato, Kosuke; Asai, Makoto; Murakami, Yoshihiro; Miyoshi, Sosuke; Noda, Akihiro; Nagai, Taku; Mizoguchi, Hiroyuki; Nishimura, Shintaro; Yamada, Kiyofumi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-332</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">In this study, we examd. the combination effects of L-DOPA and adenosine receptor antagonists on rotational behaviors in a hemi-Parkinsonian mouse model induced by unilateral 6-hydroxydopamine (6-OHDA) injection.  The adenosine A2A antagonist SCH-58261, but not the A1-receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine or A2B-receptor antagonist alloxazine, synergistically potentiated the L-DOPA-induced rotational behaviors in the 6-OHDA-lesioned mice.  In addn., the 6-OHDA-induced lesions of the dopaminergic system did not affect the in vivo binding of an adenosine A2A-receptor tracer [11C]SCH-442416 in the striatum.  These findings suggest that adenosine A2A antagonists are extremely useful for pharmacotherapy of L-DOPA in Parkinson's disease patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzL_z0WuyimLVg90H21EOLACvtfcHk0liRbEtQNezU2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1KltLk%253D&md5=76b850e339b9af4668ca4c177ef34825</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1254%2Fjphs.scz070058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjphs.scz070058%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuya%26aufirst%3DT.%26aulast%3DTakuma%26aufirst%3DK.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DAsai%26aufirst%3DM.%26aulast%3DMurakami%26aufirst%3DY.%26aulast%3DMiyoshi%26aufirst%3DS.%26aulast%3DNoda%26aufirst%3DA.%26aulast%3DNagai%26aufirst%3DT.%26aulast%3DMizoguchi%26aufirst%3DH.%26aulast%3DNishimura%26aufirst%3DS.%26atitle%3DSynergistic%2520effects%2520of%2520adenosine%2520A2A%2520antagonist%2520and%2520L-DOPA%2520on%2520rotational%2520behaviors%2520in%25206-hydroxydopamine-induced%2520hemi-parkinsonian%2520mouse%2520model%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2007%26volume%3D103%26spage%3D329%26epage%3D332%26doi%3D10.1254%2Fjphs.scz070058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collins, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galtieri, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennum, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sager, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hockemeyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrobak, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salamone, J. D.</span></span> <span> </span><span class="NLM_article-title">Oral tremor induced by the muscarinic agonist pilocarpine is suppressed by the adenosine A2A antagonists MSX-3 and SCH58261, but not the adenosine A1 antagonist DPCPX</span>. <i>Pharmacol. Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">569</span>, <span class="refDoi"> DOI: 10.1016/j.pbb.2009.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.pbb.2009.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=19958787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVans7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2010&pages=561-569&author=L.+E.+Collinsauthor=D.+J.+Galtieriauthor=L.+T.+Brennumauthor=T.+N.+Sagerauthor=J.+Hockemeyerauthor=C.+E.+M%C3%BCllerauthor=J.+R.+Hinmanauthor=J.+J.+Chrobakauthor=J.+D.+Salamone&title=Oral+tremor+induced+by+the+muscarinic+agonist+pilocarpine+is+suppressed+by+the+adenosine+A2A+antagonists+MSX-3+and+SCH58261%2C+but+not+the+adenosine+A1+antagonist+DPCPX&doi=10.1016%2Fj.pbb.2009.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Oral tremor induced by the muscarinic agonist pilocarpine is suppressed by the adenosine A2A antagonists MSX-3 and SCH58261, but not the adenosine A1 antagonist DPCPX</span></div><div class="casAuthors">Collins, Lyndsey E.; Galtieri, Daniel J.; Brennum, Lise T.; Sager, Thomas N.; Hockemeyer, Joerg; Mueller, Christa E.; Hinman, James R.; Chrobak, James J.; Salamone, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">561-569</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Tremulous jaw movements in rats, which can be induced by dopamine (DA) antagonists, DA depletion, and cholinomimetics, have served as a useful model for studies of tremor.  Although adenosine A2A antagonists can reduce the tremulous jaw movements induced by DA antagonists and DA depletion, there are conflicting reports about the interaction between adenosine antagonists and cholinomimetic drugs.  The present studies investigated the ability of adenosine antagonists to reverse the tremorogenic effect of the muscarinic agonist pilocarpine.  While the adenosine A2A antagonist MSX-3 was incapable of reversing the tremulous jaw movements induced by the 4.0 mg/kg dose of pilocarpine, both MSX-3 and the adenosine A2A antagonist SCH58261 reversed the tremulous jaw movements elicited by 0.5 mg/kg pilocarpine.  Systemic administration of the adenosine A1 antagonist DPCPX failed to reverse the tremulous jaw movements induced by either an acute 0.5 mg/kg dose of the cholinomimetic pilocarpine or the DA D2 antagonist pimozide, indicating that the tremorolytic effects of adenosine antagonists may be receptor subtype specific.  Behaviorally active doses of MSX-3 and SCH 58261 showed substantial in vivo occupancy of A2A receptors, but DPCPX did not.  The results of these studies support the use of adenosine A2A antagonists for the treatment of tremor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLbdsk5B8vnLVg90H21EOLACvtfcHk0lhxWKM0ICiHzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVans7w%253D&md5=e406879131384ba96eeb14f8458257b4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2009.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2009.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DCollins%26aufirst%3DL.%2BE.%26aulast%3DGaltieri%26aufirst%3DD.%2BJ.%26aulast%3DBrennum%26aufirst%3DL.%2BT.%26aulast%3DSager%26aufirst%3DT.%2BN.%26aulast%3DHockemeyer%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DHinman%26aufirst%3DJ.%2BR.%26aulast%3DChrobak%26aufirst%3DJ.%2BJ.%26aulast%3DSalamone%26aufirst%3DJ.%2BD.%26atitle%3DOral%2520tremor%2520induced%2520by%2520the%2520muscarinic%2520agonist%2520pilocarpine%2520is%2520suppressed%2520by%2520the%2520adenosine%2520A2A%2520antagonists%2520MSX-3%2520and%2520SCH58261%252C%2520but%2520not%2520the%2520adenosine%2520A1%2520antagonist%2520DPCPX%26jtitle%3DPharmacol.%2520Biochem.%2520Behav.%26date%3D2010%26volume%3D94%26spage%3D561%26epage%3D569%26doi%3D10.1016%2Fj.pbb.2009.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mihara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarimizu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akahane, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwashita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, N.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1<i>H</i>)-one (ASP5854), in models of Parkinson’s disease and cognition</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>323</i></span>,  <span class="NLM_fpage">708</span>– <span class="NLM_lpage">719</span>, <span class="refDoi"> DOI: 10.1124/jpet.107.121962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1124%2Fjpet.107.121962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=17684118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1ynsb%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2007&pages=708-719&author=T.+Miharaauthor=K.+Miharaauthor=J.+Yarimizuauthor=Y.+Mitaniauthor=R.+Matsudaauthor=H.+Yamamotoauthor=S.+Aokiauthor=A.+Akahaneauthor=A.+Iwashitaauthor=N.+Matsuoka&title=Pharmacological+characterization+of+a+novel%2C+potent+adenosine+A1+and+A2A+receptor+dual+antagonist%2C+5-%5B5-amino-3-%284-fluorophenyl%29pyrazin-2-yl%5D-1-isopropylpyridine-2%281H%29-one+%28ASP5854%29%2C+in+models+of+Parkinson%E2%80%99s+disease+and+cognition&doi=10.1124%2Fjpet.107.121962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition</span></div><div class="casAuthors">Mihara, Takuma; Mihara, Kayoko; Yarimizu, Junko; Mitani, Yasuyuki; Matsuda, Ritsuko; Yamamoto, Hiroko; Aoki, Satoshi; Akahane, Atsushi; Iwashita, Akinori; Matsuoka, Nobuya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">708-719</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Central adenosine A2A receptor is a promising target for drugs to treat Parkinson's disease (PD), and the central blockade of adenosine A1 receptor improves cognitive function.  In the present study, we investigated the effect of a novel adenosine A1 and A2A dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one(ASP5854),in animal models of PD and cognition.  The binding affinities of ASP5854 for human A1 and A2A receptors were 9.03 and 1.76 nM, resp., with higher specificity and no species differences.  ASP5854 also showed antagonistic action on A1 and A2A agonist-induced increases of intracellular Ca2+ concn.  ASP5854 ameliorated A2A agonist 2-[p-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamidoadenosine (CGS21680)- and haloperidol-induced catalepsy in mice, with the min. EDs of 0.32 and 0.1 mg/kg, resp., and it also improved haloperidol-induced catalepsy in rats at doses higher than 0.1 mg/kg.  In unilateral 6-hydroxydopamine-lesioned rats, ASP5854 significantly potentiated 7-dihydroxyphenylalanine (L-DOPA)-induced rotational behavior at doses higher than 0.032 mg/kg.  ASP5854 also significantly restored the striatal dopamine content reduced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment in mice at doses higher than 0.1 mg/kg.  Furthermore, in the rat passive avoidance test, ASP5854 significantly reversed the scopolamine-induced memory deficits, whereas the specific adenosine A2A antagonist 8-((E)-2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione (KW-6002; istradefylline) did not.  Scopolamine- or 5H-dibenzo[a,d]cyclohepten-5,10-imine (dizocilpine maleate) (MK-801)-induced impairment of spontaneous alternation in the mouse Y-maze test was ameliorated by ASP5854, whereas KW-6002 did not exert improvement at therapeutically relevant dosages.  These results demonstrate that the novel, selective, and orally active dual adenosine A1 and A2A receptors antagonist ASP5854 improves motor impairments, is neuroprotective via A2A antagonism, and also enhances cognitive function through A1 antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKhOITDQ8dxrVg90H21EOLACvtfcHk0lhxWKM0ICiHzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1ynsb%252FF&md5=2d9770179a47a228d825a49feab70ef2</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.121962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.121962%26sid%3Dliteratum%253Aachs%26aulast%3DMihara%26aufirst%3DT.%26aulast%3DMihara%26aufirst%3DK.%26aulast%3DYarimizu%26aufirst%3DJ.%26aulast%3DMitani%26aufirst%3DY.%26aulast%3DMatsuda%26aufirst%3DR.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DAoki%26aufirst%3DS.%26aulast%3DAkahane%26aufirst%3DA.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DMatsuoka%26aufirst%3DN.%26atitle%3DPharmacological%2520characterization%2520of%2520a%2520novel%252C%2520potent%2520adenosine%2520A1%2520and%2520A2A%2520receptor%2520dual%2520antagonist%252C%25205-%255B5-amino-3-%25284-fluorophenyl%2529pyrazin-2-yl%255D-1-isopropylpyridine-2%25281H%2529-one%2520%2528ASP5854%2529%252C%2520in%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%2520and%2520cognition%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D323%26spage%3D708%26epage%3D719%26doi%3D10.1124%2Fjpet.107.121962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Essawy, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawfik, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korayem, H. E.</span></span> <span> </span><span class="NLM_article-title">Effects of adenosine receptor antagonists in MPTP mouse model of Parkinson’s disease: mitochondrial DNA integrity</span>. <i>Arch. Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">659</span>– <span class="NLM_lpage">669</span>, <span class="refDoi"> DOI: 10.5114/aoms.2017.67284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.5114%2Faoms.2017.67284" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=659-669&author=S.+S.+Essawyauthor=M.+K.+Tawfikauthor=H.+E.+Korayem&title=Effects+of+adenosine+receptor+antagonists+in+MPTP+mouse+model+of+Parkinson%E2%80%99s+disease%3A+mitochondrial+DNA+integrity&doi=10.5114%2Faoms.2017.67284"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.5114%2Faoms.2017.67284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5114%252Faoms.2017.67284%26sid%3Dliteratum%253Aachs%26aulast%3DEssawy%26aufirst%3DS.%2BS.%26aulast%3DTawfik%26aufirst%3DM.%2BK.%26aulast%3DKorayem%26aufirst%3DH.%2BE.%26atitle%3DEffects%2520of%2520adenosine%2520receptor%2520antagonists%2520in%2520MPTP%2520mouse%2520model%2520of%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520mitochondrial%2520DNA%2520integrity%26jtitle%3DArch.%2520Med.%2520Sci.%26date%3D2017%26volume%3D3%26spage%3D659%26epage%3D669%26doi%3D10.5114%2Faoms.2017.67284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, A.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptor antagonists in Parkinson’s disease: Progress in clinical trials from the newly approved Istradefylline to drugs in early development and those already discontinued</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1007/s40263-014-0161-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1007%2Fs40263-014-0161-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=24687255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVWhtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=455-474&author=A.+Pinna&title=Adenosine+A2A+receptor+antagonists+in+Parkinson%E2%80%99s+disease%3A+Progress+in+clinical+trials+from+the+newly+approved+Istradefylline+to+drugs+in+early+development+and+those+already+discontinued&doi=10.1007%2Fs40263-014-0161-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A Receptor Antagonists in Parkinson's Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued</span></div><div class="casAuthors">Pinna, Annalisa</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">455-474</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Neurotransmitters other than dopamine, such as norepinephrine, 5-hydroxytryptamine, glutamate, adenosine and acetylcholine, are involved in Parkinson's disease (PD) and contribute to its symptomatol.  Thus, the progress of non-dopaminergic therapies for PD has attracted much interest in recent years.  Among new classes of drugs, adenosine A2A antagonists have emerged as promising candidates.  The development of new highly selective adenosine A2A receptor antagonists, and their encouraging anti-parkinsonian responses in animal models of PD, has provided a rationale for clin. trials to evaluate the therapeutic potential and the safety of these agents in patients with PD.  To date, the clin. research regarding A2A antagonists and their potential utilization in PD therapy continues to evolve between drugs just or previously discontinued (preladenant and vipadenant), new derivs. in development (tozadenant, PBF-509, ST1535, ST4206 and V81444) and the relatively old drug istradefylline, which has finally been licensed as an anti-parkinsonian drug in Japan.  All these compds. have been shown to have a good safety profile and be well tolerated.  Moreover, results from phase II and III trials also demonstrate that A2A antagonists are effective in reducing off-time, without worsening troublesome dyskinesia, and in increasing on-time with a mild increase of non-troublesome dyskinesia, in patients at an advanced stage of PD treated with L-DOPA.  In addn., early findings suggest that A2A antagonists might also be efficacious as monotherapy in patients at an early stage of PD.  This review summarizes pharmacol. and clin. data available on istradefylline, tozadenant, PBF-509, ST1535, ST4206, V81444, preladenant and vipadenant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9RSy9sahNnbVg90H21EOLACvtfcHk0ljx41zS1Ef3SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVWhtLc%253D&md5=1c12ad215ddb2384ec190027d23a3216</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs40263-014-0161-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-014-0161-7%26sid%3Dliteratum%253Aachs%26aulast%3DPinna%26aufirst%3DA.%26atitle%3DAdenosine%2520A2A%2520receptor%2520antagonists%2520in%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520Progress%2520in%2520clinical%2520trials%2520from%2520the%2520newly%2520approved%2520Istradefylline%2520to%2520drugs%2520in%2520early%2520development%2520and%2520those%2520already%2520discontinued%26jtitle%3DCNS%2520Drugs%26date%3D2014%26volume%3D28%26spage%3D455%26epage%3D474%26doi%3D10.1007%2Fs40263-014-0161-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pourcher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huot, P.</span></span> <span> </span><span class="NLM_article-title">Adenosine 2A receptor antagonists for the treatment of motor symptoms in Parkinson’s disease</span>. <i>Mov. Disord. Clin. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1002/mdc3.12187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2Fmdc3.12187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=30363540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BB3cvjsFGntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2015&pages=331-340&author=E.+Pourcherauthor=P.+Huot&title=Adenosine+2A+receptor+antagonists+for+the+treatment+of+motor+symptoms+in+Parkinson%E2%80%99s+disease&doi=10.1002%2Fmdc3.12187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson's Disease</span></div><div class="casAuthors">Pourcher Emmanuelle; Pourcher Emmanuelle; Huot Philippe; Huot Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Movement disorders clinical practice</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">331-340</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Treatment of motor fluctuations in Parkinson's disease (PD) remains an unmet challenge.  Adenosine 2A (A2A) receptors are located along the indirect pathway and represent a potential target to enhance l-3,4-dihydroxyphenylalanine (l-DOPA) antiparkinsonian action.  Methods:  This article summarizes the preclinical and clinical literature on A2A antagonists in PD, with a specific focus on their effect on off time, on time, and dyskinesia.  Findings:  Several A2A receptor antagonists have been tested in preclinical studies and clinical trials.  In preclinical studies, A2A antagonists enhanced l-DOPA antiparkinsonian action without exacerbating dyskinesia, but A2A antagonists were generally administered in combination with a subthreshold dose of l-DOPA, which is different to the paradigms used in clinical trials, where A2A antagonists were usually added to an optimal antiparkinsonian regimen.  In clinical settings, A2A antagonists generally reduced duration of off time, by as much as 25% in some studies.  The effect of on time duration is less clear, and in a few studies an exacerbation of dyskinesia was reported.  Two A2A antagonists have been tested in phase III settings: istradefylline and preladenant.  Istradefylline was effective in two phase III trials, but ineffective in another; the drug has been commercially available in Japan since 2013.  In contrast, preladenant was ineffective in a phase III trial and the drug was discontinued.  A phase III study with tozadenant will begin in 2015; the drug was effective at reducing off time in a phase IIb study.  Other A2A antagonists are in development at the preclinical and early clinical levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSejnAfV_exrv69nzq6467DfW6udTcc2ebPVneeCQYD8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvjsFGntA%253D%253D&md5=636bce3f59f3480abaaecb0f65a8f5fa</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fmdc3.12187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmdc3.12187%26sid%3Dliteratum%253Aachs%26aulast%3DPourcher%26aufirst%3DE.%26aulast%3DHuot%26aufirst%3DP.%26atitle%3DAdenosine%25202A%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520motor%2520symptoms%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DMov.%2520Disord.%2520Clin.%2520Pract.%26date%3D2015%26volume%3D2%26spage%3D331%26epage%3D340%26doi%3D10.1002%2Fmdc3.12187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchiyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadowaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsubara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakuramoto, H.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Istradefylline improves daytime sleepiness in patients with Parkinson’s disease: An open-label, 3-month study</span>. <i>J. Neurol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">230</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1016/j.jns.2017.07.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.jns.2017.07.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=28870576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1ynsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2017&pages=230-233&author=K.+Suzukiauthor=M.+Miyamotoauthor=T.+Miyamotoauthor=T.+Uchiyamaauthor=Y.+Watanabeauthor=S.+Suzukiauthor=T.+Kadowakiauthor=H.+Fujitaauthor=T.+Matsubaraauthor=H.+Sakuramoto&title=Istradefylline+improves+daytime+sleepiness+in+patients+with+Parkinson%E2%80%99s+disease%3A+An+open-label%2C+3-month+study&doi=10.1016%2Fj.jns.2017.07.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Istradefylline improves daytime sleepiness in patients with Parkinson's disease: An open-label, 3-month study</span></div><div class="casAuthors">Suzuki, Keisuke; Miyamoto, Masayuki; Miyamoto, Tomoyuki; Uchiyama, Tomoyuki; Watanabe, Yuka; Suzuki, Shiho; Kadowaki, Taro; Fujita, Hiroaki; Matsubara, Takeo; Sakuramoto, Hirotaka; Hirata, Koichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Neurological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">230-233</span>CODEN:
                <span class="NLM_cas:coden">JNSCAG</span>;
        ISSN:<span class="NLM_cas:issn">0022-510X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Istradefylline, a selective adenosine A2A receptor antagonist, has been reported to improve daily "off time" and motor symptoms in patients with Parkinson's disease (PD).  However, the effect of istradefylline on sleep problems has not been thoroughly investigated.  We evaluated the effect of istradefylline on daytime sleepiness, sleep disturbances, and motor symptoms in 22 PD patients who were affected by the wearing off phenomenon in an open-label, 3-mo study.  Participants received 20-40 mg/day istradefylline once daily (morning) over a 3-mo period.  The Epworth Sleepiness Scale (ESS), PD sleep scale (PDSS)-2 and PD Questionnaire (PDQ-8) were administered at baseline, 2 wk, 1 mo, 2 mo and 3 mo.  At baseline and 3 mo, patients were evaluated on the Movement Disorder Society Revision of the Unified PD Rating Scale (MDS-UPDRS) parts III and IV.  Twenty-one patients (95.5%) completed the study.  At 3 mo, MDS-UPDRS part III (- 5.3, p = 0.0002) and part IV (- 2.5, p = 0.001) scores improved and off time decreased significantly (- 50.1 min, p = 0.0004).  PDQ-8 scores were unchanged at 3 mo.  ESS scores decreased significantly at 2 mo and 3 mo (- 2.4 and - 3.3, resp., p < 0.0001), but the total PDSS-2 scores did not change.  Istradefylline improved daytime sleepiness in PD patients, possibly through its effect on enhancing alertness.  In addn., the lack of significant changes in the total PDSS-2 scores over the study period suggests istradefylline had no neg. impact on sleep.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgYau0p08DE7Vg90H21EOLACvtfcHk0ljx41zS1Ef3SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1ynsb3F&md5=9e6a88c0d11632d07c7f3dbb9371564c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.jns.2017.07.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jns.2017.07.045%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DK.%26aulast%3DMiyamoto%26aufirst%3DM.%26aulast%3DMiyamoto%26aufirst%3DT.%26aulast%3DUchiyama%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DKadowaki%26aufirst%3DT.%26aulast%3DFujita%26aufirst%3DH.%26aulast%3DMatsubara%26aufirst%3DT.%26aulast%3DSakuramoto%26aufirst%3DH.%26atitle%3DIstradefylline%2520improves%2520daytime%2520sleepiness%2520in%2520patients%2520with%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520An%2520open-label%252C%25203-month%2520study%26jtitle%3DJ.%2520Neurol.%2520Sci.%26date%3D2017%26volume%3D380%26spage%3D230%26epage%3D233%26doi%3D10.1016%2Fj.jns.2017.07.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stockwell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cayabyab, F. S.</span></span> <span> </span><span class="NLM_article-title">Adenosine A1 and A2A receptors in the brain: Current research and their role in neurodegeneration</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">676</span>, <span class="refDoi"> DOI: 10.3390/molecules22040676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.3390%2Fmolecules22040676" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFert7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=676&author=J.+Stockwellauthor=E.+Jakovaauthor=F.+S.+Cayabyab&title=Adenosine+A1+and+A2A+receptors+in+the+brain%3A+Current+research+and+their+role+in+neurodegeneration&doi=10.3390%2Fmolecules22040676"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A1 and A2A receptors in the brain: current research and their role in neurodegeneration</span></div><div class="casAuthors">Stockwell, Jocelyn; Jakova, Elisabet; Cayabyab, Francisco S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">676/1-676/18</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The inhibitory adenosine A1 receptor (A1R) and excitatory A2A receptor (A2AR) are predominantly expressed in the brain.  Whereas the A2AR has been implicated in normal aging and enhancing neurotoxicity in multiple neurodegenerative diseases, the inhibitory A1R has traditionally been ascribed to have a neuroprotective function in various brain insults.  This review provides a summary of the emerging role of prolonged A1R signaling and its potential cross-talk with A2AR in the cellular basis for increased neurotoxicity in neurodegenerative disorders.  This A1R signaling enhances A2AR-mediated neurodegeneration, and provides a platform for future development of neuroprotective agents in stroke, Parkinson's disease and epilepsy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohCTsmNnKJvLVg90H21EOLACvtfcHk0lgy6OU2YCok4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFert7jJ&md5=1e1223b43bc5dd1ec982b1805c1667e7</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22040676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22040676%26sid%3Dliteratum%253Aachs%26aulast%3DStockwell%26aufirst%3DJ.%26aulast%3DJakova%26aufirst%3DE.%26aulast%3DCayabyab%26aufirst%3DF.%2BS.%26atitle%3DAdenosine%2520A1%2520and%2520A2A%2520receptors%2520in%2520the%2520brain%253A%2520Current%2520research%2520and%2520their%2520role%2520in%2520neurodegeneration%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26spage%3D676%26doi%3D10.3390%2Fmolecules22040676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delamarre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meissner, W. G.</span></span> <span> </span><span class="NLM_article-title">Epidemiology, environmental risk factors and genetics of Parkinson’s disease</span>. <i>Presse Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1016/j.lpm.2017.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.lpm.2017.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=28189372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BC1c3lvFWrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2017&pages=175-181&author=A.+Delamarreauthor=W.+G.+Meissner&title=Epidemiology%2C+environmental+risk+factors+and+genetics+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.lpm.2017.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology, environmental risk factors and genetics of Parkinson's disease</span></div><div class="casAuthors">Delamarre Anna; Meissner Wassilios G</div><div class="citationInfo"><span class="NLM_cas:title">Presse medicale (Paris, France : 1983)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">2 Pt 1</span>),
    <span class="NLM_cas:pages">175-181</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Parkinson's disease (PD) is a frequent neurodegenerative disease with a premotor phase that lasts several years.  Risk factors that have been linked to PD are tobacco, caffeine, black tea, pesticides and calcium channel blockers.  Some risk factors may be due to inverse causality (e.g. changes in personality during the premotor phase).  The genetics of PD are complex with a contribution of Mendelian (e.g.  SNCA, LRRK2, Parkin, Pink1,...) and non-Mendelian factors (e.g. single nucleotide polymorphisms).  Glucocerebrosidase gene mutations (Gaucher disease) are currently the strongest genetic risk factor for PD.  Studying risk factors will help to better understand the pathogenesis of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKqImwQhsvv-Lt9HypzAgQfW6udTcc2eaEa2H93YBJ5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3lvFWrsw%253D%253D&md5=f2178a9d5543ec897690613d450e4939</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.lpm.2017.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lpm.2017.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DDelamarre%26aufirst%3DA.%26aulast%3DMeissner%26aufirst%3DW.%2BG.%26atitle%3DEpidemiology%252C%2520environmental%2520risk%2520factors%2520and%2520genetics%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DPresse%2520Med.%26date%3D2017%26volume%3D46%26spage%3D175%26epage%3D181%26doi%3D10.1016%2Fj.lpm.2017.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bastide, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meissner, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picconi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernagut, P.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feyder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francardo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcacer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brambilla, R.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1016/j.pneurobio.2015.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.pneurobio.2015.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=26209473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Crsr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2015&pages=96-168&author=M.+F.+Bastideauthor=W.+G.+Meissnerauthor=B.+Picconiauthor=S.+Fasanoauthor=P.-O.+Fernagutauthor=M.+Feyderauthor=V.+Francardoauthor=C.+Alcacerauthor=Y.+Dingauthor=R.+Brambilla&title=Pathophysiology+of+L-dopa-induced+motor+and+non-motor+complications+in+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.pneurobio.2015.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease</span></div><div class="casAuthors">Bastide, Matthieu F.; Meissner, Wassilios G.; Picconi, Barbara; Fasano, Stefania; Fernagut, Pierre-Olivier; Feyder, Michael; Francardo, Veronica; Alcacer, Cristina; Ding, Yunmin; Brambilla, Riccardo; Fisone, Gilberto; Jon Stoessl, A.; Bourdenx, Mathieu; Engeln, Michel; Navailles, Sylvia; De Deurwaerdere, Philippe; Ko, Wai Kin D.; Simola, Nicola; Morelli, Micaela; Groc, Laurent; Rodriguez, Maria-Cruz; Gurevich, Eugenia V.; Quik, Maryka; Morari, Michele; Mellone, Manuela; Gardoni, Fabrizio; Tronci, Elisabetta; Guehl, Dominique; Tison, Francois; Crossman, Alan R.; Kang, Un Jung; Steece-Collier, Kathy; Fox, Susan; Carta, Manolo; Angela Cenci, M.; Bezard, Erwan</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">96-168</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) therapy for Parkinson's disease (PD).  L-dopa-induced dyskinesia (LID) are ultimately experienced by the vast majority of patients.  In addn., psychiatric conditions often manifested as compulsive behaviors, are emerging as a serious problem in the management of L-dopa therapy.  The present review attempts to provide an overview of our current understanding of dyskinesia and other L-dopa-induced dysfunctions, a field that dramatically evolved in the past twenty years.  In view of the extensive literature on LID, there appeared a crit. need to re-frame the concepts, to highlight the most suitable models, to review the central nervous system (CNS) circuitry that may be involved, and to propose a pathophysiol. framework was timely and necessary.  An updated review to clarify our understanding of LID and other L-dopa-related side effects was therefore timely and necessary.  This review should help in the development of novel therapeutic strategies aimed at preventing the generation of dyskinetic symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbmGOnBY16j7Vg90H21EOLACvtfcHk0lgy6OU2YCok4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Crsr3I&md5=3fa026d75e85fc6a595a8c59148787d9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2015.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2015.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DBastide%26aufirst%3DM.%2BF.%26aulast%3DMeissner%26aufirst%3DW.%2BG.%26aulast%3DPicconi%26aufirst%3DB.%26aulast%3DFasano%26aufirst%3DS.%26aulast%3DFernagut%26aufirst%3DP.-O.%26aulast%3DFeyder%26aufirst%3DM.%26aulast%3DFrancardo%26aufirst%3DV.%26aulast%3DAlcacer%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DBrambilla%26aufirst%3DR.%26atitle%3DPathophysiology%2520of%2520L-dopa-induced%2520motor%2520and%2520non-motor%2520complications%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DProg.%2520Neurobiol.%26date%3D2015%26volume%3D132%26spage%3D96%26epage%3D168%26doi%3D10.1016%2Fj.pneurobio.2015.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, D. J.</span></span> <span> </span><span class="NLM_article-title">Sleep disorders in Parkinson’s disease: Many causes, few therapeutic options</span>. <i>J. Neurol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>314</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1016/j.jns.2011.10.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.jns.2011.10.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=22118862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BC383it12hug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=2012&pages=12-19&author=N.+J.+Diederichauthor=D.+J.+McIntyre&title=Sleep+disorders+in+Parkinson%E2%80%99s+disease%3A+Many+causes%2C+few+therapeutic+options&doi=10.1016%2Fj.jns.2011.10.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Sleep disorders in Parkinson's disease: many causes, few therapeutic options</span></div><div class="casAuthors">Diederich Nico J; McIntyre Deborah J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the neurological sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">314</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">12-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sleep symptoms in Parkinson's disease (PD) are frequent and have multifactorial and multilayered causes.  Primary involvement of sleep/wake regulating centers in the brainstem, sleep problems caused by the nocturnal manifestation of motor and dysautonomic signs and medication-induced sleep problems are often impossible to disentangle in the individual patient.  Two syndromes, hypersomnia and REM sleep behavior disorder (RBD), are increasingly recognized as harbingers of the core PD motor syndrome.  RBD, associated with a panoply of other nonmotor symptoms, may predispose to a specific PD phenotype.  Long-acting dopaminergic stimulation, when abating nocturnal akinesia, also improves subjective sleep quantity.  While this strategy is backed up by several randomized controlled trials (RCT), other treatment recommendations are mostly based on case series or expert opinion.  Thus we identified only two other RCT, one treating insomnia with eszopiclone, the other nocturnal behavioral abnormalities in demented PD patients with memantine.  While the causal complexity of sleep problems in PD certainly hampers the design of therapeutic studies, multiple general treatment strategies against sleep disorders can however be applied efficiently in PD patients as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQA5xSdihpBVi86Js-BCLiifW6udTcc2ebL0NS_CuF1sbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383it12hug%253D%253D&md5=83306c5e161906ce2cd081b52c5edfd2</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.jns.2011.10.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jns.2011.10.025%26sid%3Dliteratum%253Aachs%26aulast%3DDiederich%26aufirst%3DN.%2BJ.%26aulast%3DMcIntyre%26aufirst%3DD.%2BJ.%26atitle%3DSleep%2520disorders%2520in%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520Many%2520causes%252C%2520few%2520therapeutic%2520options%26jtitle%3DJ.%2520Neurol.%2520Sci.%26date%3D2012%26volume%3D314%26spage%3D12%26epage%3D19%26doi%3D10.1016%2Fj.jns.2011.10.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: Challenges and opportunities in drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7874</span>– <span class="NLM_lpage">7887</span>, <span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+Challenges+and+opportunities+in+drug+discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0ljCaf-0l7a9ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520Challenges%2520and%2520opportunities%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J.-U.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology - foe or friend?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8955</span>– <span class="NLM_lpage">8971</span>, <span class="refDoi"> DOI: 10.1021/jm400856t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-8971&author=J.-U.+Peters&title=Polypharmacology+-+foe+or+friend%3F&doi=10.1021%2Fjm400856t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology - Foe or Friend?</span></div><div class="casAuthors">Peters, Jens-Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8955-8971</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. describes the activity of compds. at multiple targets.  Current research focuses on two aspects of polypharmacol.: (1) unintended polypharmacol. can lead to adverse effects; (2) polypharmacol. across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects.  This perspective reviews these interconnected aspects of polypharmacol.  The first part discusses the relevance of polypharmacol. for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacol. compds. early in the drug discovery process.  The second part discusses the advantages of polypharmacol. in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing.  This perspective aims to provide a balanced view on polypharmacol., which can compromise the safety of drugs, but can also confer superior efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vnFGPfTnGLVg90H21EOLACvtfcHk0ljCaf-0l7a9ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO&md5=f4aeb6efddd4bfdf4e94656303323cba</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.-U.%26atitle%3DPolypharmacology%2520-%2520foe%2520or%2520friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8955%26epage%3D8971%26doi%3D10.1021%2Fjm400856t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brückmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agbaba, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Polypharmacology of dopamine receptor ligands</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1016/j.pneurobio.2016.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.pneurobio.2016.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=27234980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVCmsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2016&pages=68-103&author=S.+Butiniauthor=K.+Nikolicauthor=S.+Kasselauthor=H.+Br%C3%BCckmannauthor=S.+Filipicauthor=D.+Agbabaauthor=S.+Gemmaauthor=S.+Brogiauthor=M.+Brindisiauthor=G.+Campiani&title=Polypharmacology+of+dopamine+receptor+ligands&doi=10.1016%2Fj.pneurobio.2016.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology of dopamine receptor ligands</span></div><div class="casAuthors">Butini, S.; Nikolic, K.; Kassel, S.; Bruckmann, H.; Filipic, S.; Agbaba, D.; Gemma, S.; Brogi, S.; Brindisi, M.; Campiani, G.; Stark, H.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">68-103</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Most neurol. diseases have a multifactorial nature and the no. of mol. mechanisms discovered as underpinning these diseases is continuously evolving.  The old concept of developing selective agents for a single target does not fit with the medical need of most neurol. diseases.  The development of designed multiple ligands holds great promises and appears as the next step in drug development for the treatment of these multifactorial diseases.  Dopamine and its five receptor subtypes are intimately involved in numerous neurol. disorders.  Dopamine receptor ligands display a high degree of cross interactions with many other targets including G-protein coupled receptors, transporters, enzymes and ion channels.  For brain disorders like Parkinsons disease, schizophrenia and depression the dopaminergic system, being intertwined with many other signaling systems, plays a key role in pathogenesis and therapy.  The concept of designed multiple ligands and polypharmacol., which perfectly meets the therapeutic needs for these brain disorders, is herein discussed as a general ligand-based concept while focusing on dopaminergic agents and receptor subtypes in particular.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroyjxwUVpuobVg90H21EOLACvtfcHk0lhIup0esW-_cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVCmsLk%253D&md5=4e518d55c2b25e20b56a0ac4c5ff117c</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2016.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2016.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DButini%26aufirst%3DS.%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DKassel%26aufirst%3DS.%26aulast%3DBr%25C3%25BCckmann%26aufirst%3DH.%26aulast%3DFilipic%26aufirst%3DS.%26aulast%3DAgbaba%26aufirst%3DD.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DBrogi%26aufirst%3DS.%26aulast%3DBrindisi%26aufirst%3DM.%26aulast%3DCampiani%26aufirst%3DG.%26atitle%3DPolypharmacology%2520of%2520dopamine%2520receptor%2520ligands%26jtitle%3DProg.%2520Neurobiol.%26date%3D2016%26volume%3D142%26spage%3D68%26epage%3D103%26doi%3D10.1016%2Fj.pneurobio.2016.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khanfar, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Affini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutsenko, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Multiple targeting approaches on histamine H3 receptor antagonists</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">201</span>, <span class="refDoi"> DOI: 10.3389/fnins.2016.00201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.3389%2Ffnins.2016.00201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=27303254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BC2s7gtlGluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=201&author=M.+A.+Khanfarauthor=A.+Affiniauthor=K.+Lutsenkoauthor=K.+Nikolicauthor=S.+Butiniauthor=H.+Stark&title=Multiple+targeting+approaches+on+histamine+H3+receptor+antagonists&doi=10.3389%2Ffnins.2016.00201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple Targeting Approaches on Histamine H3 Receptor Antagonists</span></div><div class="casAuthors">Khanfar Mohammad A; Affini Anna; Lutsenko Kiril; Stark Holger; Nikolic Katarina; Butini Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">201</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">With the very recent market approval of pitolisant (Wakix®), the interest in clinical applications of novel multifunctional histamine H3 receptor antagonists has clearly increased.  Since histamine H3 receptor antagonists in clinical development have been tested for a variety of different indications, the combination of pharmacological properties in one molecule for improved pharmacological effects and reduced unwanted side-effects is rationally based on the increasing knowledge on the complex neurotransmitter regulations.  The polypharmacological approaches on histamine H3 receptor antagonists on different G-protein coupled receptors, transporters, enzymes as well as on NO-signaling mechanism are described, supported with some lead structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFAQnNocm8nhOk4JA3soTqfW6udTcc2eZGHd8CHejlR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7gtlGluw%253D%253D&md5=f9063905722db37fa039898d9874e00a</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2016.00201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2016.00201%26sid%3Dliteratum%253Aachs%26aulast%3DKhanfar%26aufirst%3DM.%2BA.%26aulast%3DAffini%26aufirst%3DA.%26aulast%3DLutsenko%26aufirst%3DK.%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DMultiple%2520targeting%2520approaches%2520on%2520histamine%2520H3%2520receptor%2520antagonists%26jtitle%3DFront.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D201%26doi%3D10.3389%2Ffnins.2016.00201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majekova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valoti, M.</span></span> <span> </span><span class="NLM_article-title">Key targets for multi-target ligands designed to combat neurodegeneration</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">375</span>, <span class="refDoi"> DOI: 10.3389/fnins.2016.00375</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.3389%2Ffnins.2016.00375" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=27597816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BC2sznvFKhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=375&author=R.+R.+Ramsayauthor=M.+Majekovaauthor=M.+Medinaauthor=M.+Valoti&title=Key+targets+for+multi-target+ligands+designed+to+combat+neurodegeneration&doi=10.3389%2Ffnins.2016.00375"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34aR"><div class="casContent"><span class="casTitleNuber">34a</span><div class="casTitle"><span class="NLM_cas:atitle">Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration</span></div><div class="casAuthors">Ramsay Rona R; Majekova Magdalena; Medina Milagros; Valoti Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">375</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">HIGHLIGHTS Compounds that interact with multiple targets but minimally with the cytochrome P450 system (CYP) address the many factors leading to neurodegeneration.Acetyl- and Butyryl-cholineEsterases (AChE, BChE) and Monoamine Oxidases A/B (MAO A, MAO B) are targets for Multi-Target Designed Ligands (MTDL).ASS234 is an irreversible inhibitor of MAO A >MAO B and has micromolar potency against the cholinesterases.ASS234 is a poor CYP substrate in human liver, yielding the depropargylated metabolite.SMe1EC2, a stobadine derivative, showed high radical scavenging property, in vitro and in vivo giving protection in head trauma and diabetic damage of endothelium.Control of mitochondrial function and morphology by manipulating fission and fusion is emerging as a target area for therapeutic strategies to decrease the pathological outcome of neurodegenerative diseases.  Growing evidence supports the view that neurodegenerative diseases have multiple and common mechanisms in their aetiologies.  These multifactorial aspects have changed the broadly common assumption that selective drugs are superior to "dirty drugs" for use in therapy.  This drives the research in studies of novel compounds that might have multiple action mechanisms.  In neurodegeneration, loss of neuronal signaling is a major cause of the symptoms, so preservation of neurotransmitters by inhibiting the breakdown enzymes is a first approach.  Acetylcholinesterase (AChE) inhibitors are the drugs preferentially used in AD and that one of these, rivastigmine, is licensed also for PD.  Several studies have shown that monoamine oxidase (MAO) B, located mainly in glial cells, increases with age and is elevated in Alzheimer (AD) and Parkinson's Disease's (PD).  Deprenyl, a MAO B inhibitor, significantly delays the initiation of levodopa treatment in PD patients.  These indications underline that AChE and MAO are considered a necessary part of multi-target designed ligands (MTDL).  However, both of these targets are simply symptomatic treatment so if new drugs are to prevent degeneration rather than compensate for loss of neurotransmitters, then oxidative stress and mitochondrial events must also be targeted.  MAO inhibitors can protect neurons from apoptosis by mechanisms unrelated to enzyme inhibition.  Understanding the involvement of MAO and other proteins in the induction and regulation of the apoptosis in mitochondria will aid progress toward strategies to prevent the loss of neurons.  In general, the oxidative stress observed both in PD and AD indicate that antioxidant properties are a desirable part of MTDL molecules.  After two or more properties are incorporated into one molecule, the passage from a lead compound to a therapeutic tool is strictly linked to its pharmacokinetic and toxicity.  In this context the interaction of any new molecules with cytochrome P450 and other xenobiotic metabolic processes is a crucial point.  The present review covers the biochemistry of enzymes targeted in the design of drugs against neurodegeneration and the cytochrome P450-dependent metabolism of MTDLs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQjOr1PdgGetEwlCcfExbvbfW6udTcc2eZGHd8CHejlR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sznvFKhsA%253D%253D&md5=d4262692b6fbea1a58815dca979f2c69</span></div><a href="/servlet/linkout?suffix=cit34a&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2016.00375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2016.00375%26sid%3Dliteratum%253Aachs%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DMajekova%26aufirst%3DM.%26aulast%3DMedina%26aufirst%3DM.%26aulast%3DValoti%26aufirst%3DM.%26atitle%3DKey%2520targets%2520for%2520multi-target%2520ligands%2520designed%2520to%2520combat%2520neurodegeneration%26jtitle%3DFront.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D375%26doi%3D10.3389%2Ffnins.2016.00375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit34b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaspar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouvet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouvet, M.</span></span> <span> </span><span class="NLM_article-title">The unfinished journey with modafinil and discovery of a novel population of modafinil-immunoreactive neurons</span>. <i>Sleep Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1016/j.sleep.2018.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.sleep.2018.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=30172629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BB3c3ksFKlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2018&pages=40-52&author=J.-S.+Linauthor=B.+Rousselauthor=A.+Gasparauthor=Y.+Zhaoauthor=Y.+Houauthor=M.+Schmidtauthor=A.+Jouvetauthor=M.+Jouvet&title=The+unfinished+journey+with+modafinil+and+discovery+of+a+novel+population+of+modafinil-immunoreactive+neurons&doi=10.1016%2Fj.sleep.2018.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34bR"><div class="casContent"><span class="casTitleNuber">34b</span><div class="casTitle"><span class="NLM_cas:atitle">The unfinished journey with modafinil and discovery of a novel population of modafinil-immunoreactive neurons</span></div><div class="casAuthors">Lin Jian-Sheng; Roussel Bernard; Hou Yiping; Schmidt Markus; Jouvet Michel; Gaspar Alexandre; Zhao Yan; Jouvet Anne</div><div class="citationInfo"><span class="NLM_cas:title">Sleep medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Modafinil, a wake-promoting compound now used worldwide in sleep medicine, was initially regarded as a sedative compound because mice were so quiet with respect to locomotion after receiving it that this behavioral state was qualified as sedation.  In the early 1980's when modafinil was first assessed by polysomnography in a cat in our laboratory, surprisingly, the cat spent the whole night awake without even one minute of sleep! This initial observation resulted subsequently in a series of basic and clinical studies in order to define the pharmacological profile of modafinil and its mode of action and, notably, to identify the brain targets by which modafinil acts to promote wakefulness.  These studies were undertaken using pharmacologic approach coupled with the Cerveau isole (brain transection) preparation, c-fos labelling and knockout mouse models.  It was also in this context that we have developed a purified polyclonal antibody against modafinil.  We expected that using immunohistochemistry with this antibody would allow us to localize the brain distribution of modafinil dosing.  Surprisingly, we found discrete modafinil immunoreactive neuronal populations in several brain areas of modafinil-naive cats, rodents and humans.  The most numerous and intensely labeled modafinil-immunoreactive neurons characterized by granular staining were found in the basal forebrain.  They shared the regional location with cholinergic and aspartate-containing neurons but did not colocalize with them.  In summary, we here present a newly identified neuronal population located in the basal forebrain that has never previously been published and suggests that these modafinil-immunoreactive neurons might be involved in forebrain functions such as sleep-wake control and cognition.  This paper briefly reviews our journey with modafinil research and presents new unpublished experimental data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQODDxLan-ZZ3tlzo9xastyfW6udTcc2eZGHd8CHejlR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3ksFKlsA%253D%253D&md5=93eb8593689267536fa3aec4d2f7fad1</span></div><a href="/servlet/linkout?suffix=cit34b&amp;dbid=16384&amp;doi=10.1016%2Fj.sleep.2018.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sleep.2018.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.-S.%26aulast%3DRoussel%26aufirst%3DB.%26aulast%3DGaspar%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DSchmidt%26aufirst%3DM.%26aulast%3DJouvet%26aufirst%3DA.%26aulast%3DJouvet%26aufirst%3DM.%26atitle%3DThe%2520unfinished%2520journey%2520with%2520modafinil%2520and%2520discovery%2520of%2520a%2520novel%2520population%2520of%2520modafinil-immunoreactive%2520neurons%26jtitle%3DSleep%2520Med.%26date%3D2018%26volume%3D49%26spage%3D40%26epage%3D52%26doi%3D10.1016%2Fj.sleep.2018.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeq, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>312</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2016.06.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.bbr.2016.06.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=27363923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ekurjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2016&pages=415-430&author=B.+Sadekauthor=A.+Saadauthor=A.+Sadeqauthor=F.+Jalalauthor=H.+Stark&title=Histamine+H3+receptor+as+a+potential+target+for+cognitive+symptoms+in+neuropsychiatric+diseases&doi=10.1016%2Fj.bbr.2016.06.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases</span></div><div class="casAuthors">Sadek, Bassem; Saad, Ali; Sadeq, Adel; Jalal, Fakhreya; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">415-430</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The potential contributions of the brain histaminergic system in neurodegenerative diseases, and the possiblity of histamine-targeting treatments is attracting considerable interests.  The histamine H3 receptor (H3R) is expressed mainly in the central nervous system, and is, consequently, an attractive pharmacol. target.  Although recently described clin. trials have been disappointing in attention deficit hyperactivity disorder (ADHD) and schizophrenia (SCH), numerous H3R antagonists, including pitolisant, demonstrate potential in the treatment of narcolepsy, excessive daytime sleepiness assocd. with cognitive impairment, epilepsy, and Alzheimer's disease (AD).  This review focuses on the recent preclin. as well as clin. results that support the relevance of H3R antagonists for the treatment of cognitive symptoms in neuropsychiatric diseases, namely AD, epilepsy and SCH.  The review summarizes the role of histaminergic neurotransmission with focus on these brain disorders, as well as the effects of numerous H3R antagonists on animal models and humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu0qvZ7tUjyrVg90H21EOLACvtfcHk0lj7T4sySf7ykQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ekurjN&md5=f7a95fe5f633779a98ad5968c4b714a2</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2016.06.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2016.06.051%26sid%3Dliteratum%253Aachs%26aulast%3DSadek%26aufirst%3DB.%26aulast%3DSaad%26aufirst%3DA.%26aulast%3DSadeq%26aufirst%3DA.%26aulast%3DJalal%26aufirst%3DF.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DHistamine%2520H3%2520receptor%2520as%2520a%2520potential%2520target%2520for%2520cognitive%2520symptoms%2520in%2520neuropsychiatric%2520diseases%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2016%26volume%3D312%26spage%3D415%26epage%3D430%26doi%3D10.1016%2Fj.bbr.2016.06.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghamari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarei, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arias-Montano, J.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dastmalchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamzeh-Mivehroud, M.</span></span> <span> </span><span class="NLM_article-title">Histamine H3 receptor antagonists/inverse agonists: Where do they go?</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>200</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2019.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.pharmthera.2019.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=31028835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovVOmtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=200&publication_year=2019&pages=69-84&author=N.+Ghamariauthor=O.+Zareiauthor=J.-A.+Arias-Montanoauthor=D.+Reinerauthor=S.+Dastmalchiauthor=H.+Starkauthor=M.+Hamzeh-Mivehroud&title=Histamine+H3+receptor+antagonists%2Finverse+agonists%3A+Where+do+they+go%3F&doi=10.1016%2Fj.pharmthera.2019.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Histamine H3 receptor antagonists/inverse agonists: Where do they go?</span></div><div class="casAuthors">Ghamari, Nakisa; Zarei, Omid; Arias-Montano, Jose-Antonio; Reiner, David; Dastmalchi, Siavoush; Stark, Holger; Hamzeh-Mivehroud, Maryam</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">200</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">69-84</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Since the discovery of the histamine H3 receptor in 1983, tremendous advances in the pharmacol. aspects of H3 receptor antagonists/inverse agonists have been accomplished in preclin. studies.  At present, there are several drug candidates that reached clin. trial studies for various indications.  However, entrance of these candidates to the pharmaceutical market is not free from challenges, and a variety of difficulties is engaged with their developmental process.  In this review, the potential role of H3 receptors in the pathophysiol. of various central nervous system, metabolic and allergic diseases is discussed.  Thereafter, the current status for H3 receptor antagonists/inverse agonists in ongoing clin. trial studies is reviewed and obstacles in developing these agents are emphasized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IbgM1GUg97Vg90H21EOLACvtfcHk0lj7T4sySf7ykQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovVOmtrs%253D&md5=7129bc498b85275ffa09f839ddeb04a9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2019.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2019.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DGhamari%26aufirst%3DN.%26aulast%3DZarei%26aufirst%3DO.%26aulast%3DArias-Montano%26aufirst%3DJ.-A.%26aulast%3DReiner%26aufirst%3DD.%26aulast%3DDastmalchi%26aufirst%3DS.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DHamzeh-Mivehroud%26aufirst%3DM.%26atitle%3DHistamine%2520H3%2520receptor%2520antagonists%252Finverse%2520agonists%253A%2520Where%2520do%2520they%2520go%253F%26jtitle%3DPharmacol.%2520Ther.%26date%3D2019%26volume%3D200%26spage%3D69%26epage%3D84%26doi%3D10.1016%2Fj.pharmthera.2019.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellenbroek, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiabi, B.</span></span> <span> </span><span class="NLM_article-title">The other side of the histamine H3 receptor</span>. <i>Trends Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.1016/j.tins.2014.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.tins.2014.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=24636456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1Sgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2014&pages=191-199&author=B.+A.+Ellenbroekauthor=B.+Ghiabi&title=The+other+side+of+the+histamine+H3+receptor&doi=10.1016%2Fj.tins.2014.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The other side of the histamine H3 receptor</span></div><div class="casAuthors">Ellenbroek, Bart A.; Ghiabi, Bibinaz</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Neurosciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">191-199</span>CODEN:
                <span class="NLM_cas:coden">TNSCDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-2236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Although histamine H3 receptors are predominantly known as presynaptic receptors, regulating the release of neurotransmitters such as dopamine, acetylcholine, and histamine, in the striatal complex the vast majority of these receptors are actually located on the other side, in other words postsynaptically.  Given their strategic location, they can crucially affect signaling throughout the basal ganglia.  We describe the anatomy and function of H3 receptors within the basal ganglia with a specific focus on their colocalization with dopamine D1 and D2 receptors.  Because the basal ganglia are centrally involved in several major neurol. and psychiatric disorders, we also discuss the therapeutic potential of drugs targeting H3 receptors in the treatment of Parkinson disease (PD), schizophrenia, and addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCTyvYOgmdA7Vg90H21EOLACvtfcHk0lj7T4sySf7ykQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1Sgtbk%253D&md5=a70fb6db22985403ec87e2fef7199a5b</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.tins.2014.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tins.2014.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DEllenbroek%26aufirst%3DB.%2BA.%26aulast%3DGhiabi%26aufirst%3DB.%26atitle%3DThe%2520other%2520side%2520of%2520the%2520histamine%2520H3%2520receptor%26jtitle%3DTrends%2520Neurosci.%26date%3D2014%26volume%3D37%26spage%3D191%26epage%3D199%26doi%3D10.1016%2Fj.tins.2014.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panula, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chazot, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutzmer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W. L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurmond, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, H. L.</span></span> <span> </span><span class="NLM_article-title">International Union of Basic and Clinical Pharmacology. XCVIII. Histamine receptors</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">655</span>, <span class="refDoi"> DOI: 10.1124/pr.114.010249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1124%2Fpr.114.010249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=26084539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCmurnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=601-655&author=P.+Panulaauthor=P.+L.+Chazotauthor=M.+Cowartauthor=R.+Gutzmerauthor=R.+Leursauthor=W.+L.+S.+Liuauthor=H.+Starkauthor=R.+L.+Thurmondauthor=H.+L.+Haas&title=International+Union+of+Basic+and+Clinical+Pharmacology.+XCVIII.+Histamine+receptors&doi=10.1124%2Fpr.114.010249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">International union of basic and clinical pharmacology. XCVIII. histamine receptors</span></div><div class="casAuthors">Panula, Pertti; Chazot, Paul L.; Cowart, Marlon; Gutzmer, Ralf; Leurs, Rob; Liu, Wai L. S.; Stark, Holger; Thurmond, Robin L.; Haas, Helmut L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">601-655</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Histamine is a developmentally highly conserved autacoid found in most vertebrate tissues.  Its physiol. functions are mediated by four 7- transmembrane G protein-coupled receptors (H1R, H2R, H3R, H4R) that are all targets of pharmacol. intervention.  The receptors displaymol. heterogeneity and constitutive activity.  H1R antagonists are long known antiallergic and sedating drugs, whereas the H2R was identified in the 1970s and led to the development of H2R-antagonists that revolutionized stomach ulcer treatment.  The crystal structure of ligand-bound H1R has rendered it possible to design new ligands with novel properties.  The H3R is an autoreceptor and heteroreceptor providing neg. feedback on histaminergic and inhibition on other neurons.  A block of these actions promotes waking.  The H4R occurs on immunocompetent cells and the development of anti-inflammatory drugs is anticipated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg14M2S2Ip6bVg90H21EOLACvtfcHk0ljO87pWKZ5h2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCmurnF&md5=11a54133a707bab57dfb74eb54157f4f</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1124%2Fpr.114.010249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.114.010249%26sid%3Dliteratum%253Aachs%26aulast%3DPanula%26aufirst%3DP.%26aulast%3DChazot%26aufirst%3DP.%2BL.%26aulast%3DCowart%26aufirst%3DM.%26aulast%3DGutzmer%26aufirst%3DR.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DW.%2BL.%2BS.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DThurmond%26aufirst%3DR.%2BL.%26aulast%3DHaas%26aufirst%3DH.%2BL.%26atitle%3DInternational%2520Union%2520of%2520Basic%2520and%2520Clinical%2520Pharmacology.%2520XCVIII.%2520Histamine%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2015%26volume%3D67%26spage%3D601%26epage%3D655%26doi%3D10.1124%2Fpr.114.010249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morales-Figueroa, G.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera-Ramírez, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Pantoja, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escamilla-Sánchez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Hernández, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galván, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arias-Montaño, J.-A.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A and histamine H3 receptors interact at the CAMP/PKA pathway to modulate depolarization-evoked [<sup>3</sup>H]-GABA release from rat striato-pallidal terminals</span>. <i>Purinergic Signal.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1007/s11302-018-9638-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1007%2Fs11302-018-9638-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=30565027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFChsrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=85-93&author=G.-E.+Morales-Figueroaauthor=N.+Rivera-Ram%C3%ADrezauthor=R.+Gonz%C3%A1lez-Pantojaauthor=J.+Escamilla-S%C3%A1nchezauthor=U.+Garc%C3%ADa-Hern%C3%A1ndezauthor=E.+J.+Galv%C3%A1nauthor=J.-A.+Arias-Monta%C3%B1o&title=Adenosine+A2A+and+histamine+H3+receptors+interact+at+the+CAMP%2FPKA+pathway+to+modulate+depolarization-evoked+%5B3H%5D-GABA+release+from+rat+striato-pallidal+terminals&doi=10.1007%2Fs11302-018-9638-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A and histamine H3 receptors interact at the cAMP/PKA pathway to modulate depolarization-evoked [3H]-GABA release from rat striato-pallidal terminals</span></div><div class="casAuthors">Morales-Figueroa, Guadalupe-Elide; Rivera-Ramirez, Nayeli; Gonzalez-Pantoja, Raul; Escamilla-Sanchez, Juan; Garcia-Hernandez, Ubaldo; Galvan, Emilio J.; Arias-Montano, Jose-Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Purinergic Signalling</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-93</span>CODEN:
                <span class="NLM_cas:coden">PSUIA9</span>;
        ISSN:<span class="NLM_cas:issn">1573-9538</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">We previously reported that the activation of histamine H3 receptors (H3Rs) selectively counteracts the facilitatory action of adenosine A2A receptors (A2ARs) on GABA release from rat globus pallidus (GP) isolated nerve terminals (synaptosomes).  In this work, we examd. the mechanisms likely to underlie this functional interaction.  Three possibilities were explored: (a) changes in receptor affinity for agonists induced by phys. A2AR/H3R interaction, (b) opposite actions of A2ARs and H3Rs on depolarization-induced Ca2+ entry, and (c) an A2AR/H3R interaction at the level of adenosine 3',5'-cyclic monophosphate (cAMP) formation.  In GP synaptosomal membranes, H3R activation with immepip reduced A2AR affinity for the agonist 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine hydrochloride hydrate (CGS-21680) (Ki control 4.53 nM; + immepip 9.32 nM), whereas A2AR activation increased H3R affinity for immepip (Ki control 0.63 nM; + CGS-21680 0.26 nM).  Neither A2AR activation nor H3R stimulation modified calcium entry through voltage-gated calcium channels in GP synaptosomes, as evaluated by microfluorometry.  A2AR-mediated facilitation of depolarization-evoked [2,3-3H]-γ-aminobutyric acid ([3H]-GABA) release from GP synaptosomes (130.4 ± 3.6% of control values) was prevented by the PKA inhibitor H-89 and mimicked by the adenylyl cyclase activator forskolin or by 8-Bromo-cAMP, a membrane permeant cAMP analog (169.5 ± 17.3 and 149.5 ± 14.5% of controls).  H3R activation failed to reduce the facilitation of [3H]-GABA release induced by 8-Bromo-cAMP.  In GP slices, A2AR activation stimulated cAMP accumulation (290% of basal) and this effect was reduced (- 75%) by H3R activation.  These results indicate that in striato-pallidal nerve terminals, A2ARs and H3Rs interact at the level of cAMP formation to modulate PKA activity and thus GABA release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofoo4bOHwjQrVg90H21EOLACvtfcHk0ljO87pWKZ5h2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFChsrfE&md5=2309822165d722a471c7dec75486b34c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1007%2Fs11302-018-9638-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11302-018-9638-z%26sid%3Dliteratum%253Aachs%26aulast%3DMorales-Figueroa%26aufirst%3DG.-E.%26aulast%3DRivera-Ram%25C3%25ADrez%26aufirst%3DN.%26aulast%3DGonz%25C3%25A1lez-Pantoja%26aufirst%3DR.%26aulast%3DEscamilla-S%25C3%25A1nchez%26aufirst%3DJ.%26aulast%3DGarc%25C3%25ADa-Hern%25C3%25A1ndez%26aufirst%3DU.%26aulast%3DGalv%25C3%25A1n%26aufirst%3DE.%2BJ.%26aulast%3DArias-Monta%25C3%25B1o%26aufirst%3DJ.-A.%26atitle%3DAdenosine%2520A2A%2520and%2520histamine%2520H3%2520receptors%2520interact%2520at%2520the%2520CAMP%252FPKA%2520pathway%2520to%2520modulate%2520depolarization-evoked%2520%255B3H%255D-GABA%2520release%2520from%2520rat%2520striato-pallidal%2520terminals%26jtitle%3DPurinergic%2520Signal.%26date%3D2019%26volume%3D15%26spage%3D85%26epage%3D93%26doi%3D10.1007%2Fs11302-018-9638-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Márquez-Gómez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutiérrez-Rodelo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arias, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivares-Reyes, J.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Rijn, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arias-Montaño, J.-A.</span></span> <span> </span><span class="NLM_article-title">Functional histamine H3 and adenosine A2A receptor heteromers in recombinant cells and rat striatum</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">525</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2017.11.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.phrs.2017.11.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=29217157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFKhur3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2018&pages=515-525&author=R.+M%C3%A1rquez-G%C3%B3mezauthor=M.+T.+Robinsauthor=C.+Guti%C3%A9rrez-Rodeloauthor=J.-M.+Ariasauthor=J.-A.+Olivares-Reyesauthor=R.+M.+van+Rijnauthor=J.-A.+Arias-Monta%C3%B1o&title=Functional+histamine+H3+and+adenosine+A2A+receptor+heteromers+in+recombinant+cells+and+rat+striatum&doi=10.1016%2Fj.phrs.2017.11.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Functional histamine H3 and adenosine A2A receptor heteromers in recombinant cells and rat striatum</span></div><div class="casAuthors">Marquez-Gomez, Ricardo; Robins, Meridith T.; Gutierrez-Rodelo, Citlaly; Arias, Juan-Manuel; Olivares-Reyes, Jesus-Alberto; Rijn, Richard M. van; Arias-Montano, Jose-Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">515-525</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In the striatum, histamine H3 receptors (H3Rs) are co-expressed with adenosine A2A receptors (A2ARs) in the cortico-striatal glutamatergic afferents and the GABAergic medium-sized spiny neurons that originate the indirect pathway of the basal ganglia.  This location allows H3Rs and A2ARs to regulate the striatal GABAergic and glutamatergic transmission.  However, whether these receptors can phys. interact has not yet been assessed.  To test this hypothesis, a heteromer-selective in vitro assay was used to detect functional complementation between a chimeric A2AR302-Gαqi4 and wild-type H3Rs in transfected HEK-293T cells.  H3R activation with the agonist RAMH resulted in Ca2+ mobilization (pEC50 7.31 ± 0.23; maximal stimulation, Emax 449 ± 25% of basal) indicative of receptor heterodimerization.  Functional H3R-A2AR heteromers were confirmed by co-immunopptn. and observations of differential cAMP signaling when both receptors were co-expressed in the same cells.  In membranes from rat striatal synaptosomes, H3R activation decreased A2AR affinity for the agonist CGS-21680 (pKi values 8.10 ± 0.04 and 7.70 ± 0.04).  Moreover, H3Rs and A2ARs co-immunopptd. in protein exts. from striatal synaptosomes.  These results support the existence of a H3R-A2AR heteromer with possible physiol. implications for the modulation of the intra-striatal transmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM061OOBTBDbVg90H21EOLACvtfcHk0ljO87pWKZ5h2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFKhur3M&md5=beb1748c853d2b65722867ea18d1cb04</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2017.11.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2017.11.036%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A1rquez-G%25C3%25B3mez%26aufirst%3DR.%26aulast%3DRobins%26aufirst%3DM.%2BT.%26aulast%3DGuti%25C3%25A9rrez-Rodelo%26aufirst%3DC.%26aulast%3DArias%26aufirst%3DJ.-M.%26aulast%3DOlivares-Reyes%26aufirst%3DJ.-A.%26aulast%3Dvan%2BRijn%26aufirst%3DR.%2BM.%26aulast%3DArias-Monta%25C3%25B1o%26aufirst%3DJ.-A.%26atitle%3DFunctional%2520histamine%2520H3%2520and%2520adenosine%2520A2A%2520receptor%2520heteromers%2520in%2520recombinant%2520cells%2520and%2520rat%2520striatum%26jtitle%3DPharmacol.%2520Res.%26date%3D2018%26volume%3D129%26spage%3D515%26epage%3D525%26doi%3D10.1016%2Fj.phrs.2017.11.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morales-Figueroa, G.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Márquez-Gómez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Pantoja, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escamilla-Sánchez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arias-Montaño, J.-A.</span></span> <span> </span><span class="NLM_article-title">Histamine H3 receptor activation counteracts adenosine A2A receptor-mediated enhancement of depolarization-evoked [<sup>3</sup>H]-GABA release from rat globus pallidus synaptosomes</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">645</span>, <span class="refDoi"> DOI: 10.1021/cn500001m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn500001m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptVajsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=637-645&author=G.-E.+Morales-Figueroaauthor=R.+M%C3%A1rquez-G%C3%B3mezauthor=R.+Gonz%C3%A1lez-Pantojaauthor=J.+Escamilla-S%C3%A1nchezauthor=J.-A.+Arias-Monta%C3%B1o&title=Histamine+H3+receptor+activation+counteracts+adenosine+A2A+receptor-mediated+enhancement+of+depolarization-evoked+%5B3H%5D-GABA+release+from+rat+globus+pallidus+synaptosomes&doi=10.1021%2Fcn500001m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Histamine H3 Receptor Activation Counteracts Adenosine A2A Receptor-Mediated Enhancement of Depolarization-Evoked [3H]-GABA Release from Rat Globus Pallidus Synaptosomes</span></div><div class="casAuthors">Morales-Figueroa, Guadalupe-Elide; Marquez-Gomez, Ricardo; Gonzalez-Pantoja, Raul; Escamilla-Sanchez, Juan; Arias-Montano, Jose-Antonio</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">637-645</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">High levels of histamine H3 receptors (H3Rs) are found in the globus pallidus (GP), a neuronal nucleus in the basal ganglia involved in the control of motor behavior.  By using rat GP isolated nerve terminals (synaptosomes), we studied whether H3R activation modified the previously reported enhancing action of adenosine A2A receptor (A2AR) stimulation on depolarization-evoked [3H]-GABA release.  At 3 and 10 nM, the A2AR agonist CGS-21680 enhanced [3H]-GABA release induced by high K+ (20 mM) and the effect of 3 nM CGS-21680 was prevented by the A2AR antagonist ZM-241385 (100 nM).  The presence of presynaptic H3Rs was confirmed by the specific binding of N-α-[methyl-3H]-histamine to membranes from GP synaptosomes (max. binding, Bmax, 1327 ± 79 fmol/mg protein; dissocn. const., Kd, 0.74 nM), which was inhibited by the H3R ligands immepip, clobenpropit, and A-331440 (inhibition consts., Ki, 0.28, 8.53, and 316 nM, resp.).  Perfusion of synaptosomes with the H3R agonist immepip (100 nM) had no effect on K+-evoked [3H]-GABA release, but inhibited the stimulatory action of A2AR activation.  In turn, the effect of immepip was blocked by the H3R antagonist clobenpropit, which had no significant effect of its own on K+-induced [3H]-GABA release.  These data indicate that H3R activation selectively counteracts the facilitatory action of A2AR stimulation on GABA release from striato-pallidal projections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzGRDLA1e7j7Vg90H21EOLACvtfcHk0lhBO3Sn8QZhLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptVajsb8%253D&md5=8ff84f4aeaecb9ce668bc8a8f9adb9a4</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fcn500001m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn500001m%26sid%3Dliteratum%253Aachs%26aulast%3DMorales-Figueroa%26aufirst%3DG.-E.%26aulast%3DM%25C3%25A1rquez-G%25C3%25B3mez%26aufirst%3DR.%26aulast%3DGonz%25C3%25A1lez-Pantoja%26aufirst%3DR.%26aulast%3DEscamilla-S%25C3%25A1nchez%26aufirst%3DJ.%26aulast%3DArias-Monta%25C3%25B1o%26aufirst%3DJ.-A.%26atitle%3DHistamine%2520H3%2520receptor%2520activation%2520counteracts%2520adenosine%2520A2A%2520receptor-mediated%2520enhancement%2520of%2520depolarization-evoked%2520%255B3H%255D-GABA%2520release%2520from%2520rat%2520globus%2520pallidus%2520synaptosomes%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2014%26volume%3D5%26spage%3D637%26epage%3D645%26doi%3D10.1021%2Fcn500001m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wingen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Scaffold variations in amine warhead of histamine H3 receptor antagonists</span>. <i>Drug Discov. Today Technol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e483</span>– <span class="NLM_lpage">e489</span>, <span class="refDoi"> DOI: 10.1016/j.ddtec.2013.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.ddtec.2013.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=24451638" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=e483-e489&author=K.+Wingenauthor=H.+Stark&title=Scaffold+variations+in+amine+warhead+of+histamine+H3+receptor+antagonists&doi=10.1016%2Fj.ddtec.2013.07.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2013.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2013.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DWingen%26aufirst%3DK.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DScaffold%2520variations%2520in%2520amine%2520warhead%2520of%2520histamine%2520H3%2520receptor%2520antagonists%26jtitle%3DDrug%2520Discov.%2520Today%2520Technol.%26date%3D2013%26volume%3D10%26spage%3De483%26epage%3De489%26doi%3D10.1016%2Fj.ddtec.2013.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Affini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagenow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zivkovic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson’s disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">487</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.ejmech.2018.02.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=29477889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsF2msbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2018&pages=487-497&author=A.+Affiniauthor=S.+Hagenowauthor=A.+Zivkovicauthor=J.+Marco-Contellesauthor=H.+Stark&title=Novel+indanone+derivatives+as+MAO+B%2FH3R+dual-targeting+ligands+for+treatment+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.ejmech.2018.02.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease</span></div><div class="casAuthors">Affini, Anna; Hagenow, Stefanie; Zivkovic, Aleksandra; Marco-Contelles, Jose; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">487-497</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders.  As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, the authors synthesized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the treatment of PD.  Three series of compds. were developed by attaching the H3R pharmacophore to indanone-related MAO B motifs, leading to development of MAO B/H3R DTLs.  Among synthesized indanone DTLs, compds. bearing the 2-benzylidene-1-indanone core structure showed MAO B preferring inhibition capabilities along with nanomolar hH3R affinity.  Substitution of C5 and C6 position of the 2-benzylidene-1-indanones with lipophilic substituents revealed three promising candidates exhibiting inhibitory potencies for MAO B with IC50 values ranging from 1931 nM to 276 nM and high affinities at hH3R (Ki < 50 nM).  Compd. 3f ((E)-5-((4-bromobenzyl)oxy)-2-(4-(3-(piperidin-1-yl)propoxy)benzylidene)-2,3-dihydro-1H-inden-1-one, MAO B IC50 = 276 nM, hH3R Ki = 6.5 nM) showed highest preference for MAO B over MAO A (SI > 36).  Interestingly, IC50 detns. after preincubation of enzyme and DTLs revealed also nanomolar MAO B potency for 3e (MAO B IC50 = 232 nM), a structural isomer of 3f, and 3d ((E)-5-fluoro-2-[4-[3-(piperidin-1-yl)propoxy]benzylidene]-2,3-dihydro-1H-inden-1-one) (MAO B IC50 = 541 nM), suggesting time-dependent inhibition modes.  Reversibility of inhibition for all three compds. were confirmed by diln. studies in excess of substrate.  Thus, indanone-substituted derivs. are promising lead structures for the design of MAO B/hH3R DTLs as novel therapeutic approach of PD therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozgPusP5M44bVg90H21EOLACvtfcHk0lhBO3Sn8QZhLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsF2msbY%253D&md5=9b915ce055294d79bfa8e585a19e6466</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DAffini%26aufirst%3DA.%26aulast%3DHagenow%26aufirst%3DS.%26aulast%3DZivkovic%26aufirst%3DA.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DNovel%2520indanone%2520derivatives%2520as%2520MAO%2520B%252FH3R%2520dual-targeting%2520ligands%2520for%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D148%26spage%3D487%26epage%3D497%26doi%3D10.1016%2Fj.ejmech.2018.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matasi, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neustadt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arik, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulshian, D. B.</span></span> <span> </span><span class="NLM_article-title">The discovery and synthesis of novel adenosine receptor (A2A) antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1333</span>– <span class="NLM_lpage">1336</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.01.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.bmcl.2005.01.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=15713381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlShuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=1333-1336&author=J.+J.+Matasiauthor=J.+P.+Caldwellauthor=J.+Haoauthor=B.+Neustadtauthor=L.+Arikauthor=C.+J.+Fosterauthor=J.+Lachowiczauthor=D.+B.+Tulshian&title=The+discovery+and+synthesis+of+novel+adenosine+receptor+%28A2A%29+antagonists&doi=10.1016%2Fj.bmcl.2005.01.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery and synthesis of novel adenosine receptor (A2A) antagonists</span></div><div class="casAuthors">Matasi, Julius J.; Caldwell, John P.; Hao, Jinsong; Neustadt, Bernard; Arik, Leyla; Foster, Carolyn J.; Lachowicz, Jean; Tulshian, Deen B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1333-1336</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In high throughput screening of our file compds., a novel structure I was identified as a potent A2A receptor antagonist with no selectivity over the A1 adenosine receptor.  The structure-activity relationship investigation using I as a template lead to identification of a novel class of compds. as potent and selective antagonists of A2A adenosine receptor.  One compd., identified to be the most potent A2A receptor antagonist (Ki = 0.8 nM) showed 100-fold selectivity over the A1 adenosine receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgJZio7c8kKbVg90H21EOLACvtfcHk0lj6Z29WiH1EUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlShuro%253D&md5=e5f2ff6291e06df09dc58098f1dbfe0e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.01.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.01.019%26sid%3Dliteratum%253Aachs%26aulast%3DMatasi%26aufirst%3DJ.%2BJ.%26aulast%3DCaldwell%26aufirst%3DJ.%2BP.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DNeustadt%26aufirst%3DB.%26aulast%3DArik%26aufirst%3DL.%26aulast%3DFoster%26aufirst%3DC.%2BJ.%26aulast%3DLachowicz%26aufirst%3DJ.%26aulast%3DTulshian%26aufirst%3DD.%2BB.%26atitle%3DThe%2520discovery%2520and%2520synthesis%2520of%2520novel%2520adenosine%2520receptor%2520%2528A2A%2529%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D1333%26epage%3D1336%26doi%3D10.1016%2Fj.bmcl.2005.01.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shook, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. F.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A receptor antagonists and Parkinson’s disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">555</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1021/cn2000537</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn2000537" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVSrsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=555-567&author=B.+C.+Shookauthor=P.+F.+Jackson&title=Adenosine+A2A+receptor+antagonists+and+Parkinson%E2%80%99s+disease&doi=10.1021%2Fcn2000537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A Receptor Antagonists and Parkinson's Disease</span></div><div class="casAuthors">Shook, Brian C.; Jackson, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">555-567</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This Review summarizes and updates the work on adenosine A2A receptor antagonists for Parkinson's disease from 2006 to the present.  There have been numerous publications, patent applications, and press releases within this time frame that highlight new medicinal chem. approaches to this attractive and promising target to treat Parkinson's disease.  The Review is broken down by scaffold type and will discuss the efforts to optimize particular scaffolds for activity, pharmacokinetics, and other drug discovery parameters.  The majority of approaches focus on prepg. selective A2A antagonists, but a few approaches to dual A2A/A1 antagonists will also be highlighted.  The in vivo profiles of compds. will be highlighted and discussed to compare activities across different chem. series.  A clin. report and update will be given on compds. that have entered clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9jbqVC-a6P7Vg90H21EOLACvtfcHk0lj6Z29WiH1EUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVSrsrc%253D&md5=81746259f96dd1a270f12c3cb2dbe1d3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fcn2000537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn2000537%26sid%3Dliteratum%253Aachs%26aulast%3DShook%26aufirst%3DB.%2BC.%26aulast%3DJackson%26aufirst%3DP.%2BF.%26atitle%3DAdenosine%2520A2A%2520receptor%2520antagonists%2520and%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2011%26volume%3D2%26spage%3D555%26epage%3D567%26doi%3D10.1021%2Fcn2000537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensenhauser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shook, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassnick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, K.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Overcoming the genotoxicity of a pyrrolidine substituted arylindenopyrimidine as a potent dual adenosine A2A/A1 antagonist by minimizing bioactivation to an iminium ion reactive intermediate</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1012</span>– <span class="NLM_lpage">1030</span>, <span class="refDoi"> DOI: 10.1021/tx1004437</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx1004437" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVGjsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1012-1030&author=H.-K.+Limauthor=J.+Chenauthor=C.+Sensenhauserauthor=K.+Cookauthor=R.+Prestonauthor=T.+Thomasauthor=B.+Shookauthor=P.+F.+Jacksonauthor=S.+Rassnickauthor=K.+Rhodes&title=Overcoming+the+genotoxicity+of+a+pyrrolidine+substituted+arylindenopyrimidine+as+a+potent+dual+adenosine+A2A%2FA1+antagonist+by+minimizing+bioactivation+to+an+iminium+ion+reactive+intermediate&doi=10.1021%2Ftx1004437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming the Genotoxicity of a Pyrrolidine Substituted Arylindenopyrimidine As a Potent Dual Adenosine A2A/A1 Antagonist by Minimizing Bioactivation to an Iminium Ion Reactive Intermediate</span></div><div class="casAuthors">Lim, Heng-Keang; Chen, Jie; Sensenhauser, Carlo; Cook, Kevin; Preston, Robert; Thomas, Tynisha; Shook, Brian; Jackson, Paul F.; Rassnick, Stefanie; Rhodes, Kenneth; Gopaul, Vedwatee; Salter, Rhys; Silva, Jose; Evans, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1012-1030</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">2-Amino-4-phenyl-8-pyrrolidin-1-ylmethyl-indeno[1,2-d]pyrimidin-5-one (1) is a novel and potent selective dual A2A/A1 adenosine receptor antagonist from the arylindenopyrimidine series that was detd. to be genotoxic in both the Ames and Mouse Lymphoma L5178Y assays only following metabolic activation.  Compd. 1 was identified as a frame-shift mutagen in Salmonella typhimurium tester strain TA1537 as indicated by a significant dose-dependent increase in revertant colonies as compared to the vehicle control.  The metabolic activation-dependent irreversible covalent binding of radioactivity to DNA, recovery of 1 and its enamine metabolite from acid hydrolysis of covalently modified DNA, and protection of covalent binding to DNA by both cyanide ion and methoxylamine suggest that the frame-shift mutation in TA1537 strain involved covalent binding instead of simple intercalation to DNA.  Compd. 1 was bioactivated to endocyclic iminium ion, aldehyde, epoxide, and α,β-unsatd. keto reactive intermediates from the detection of cyano, oxime, and glutathione conjugates by data-dependent high resoln. accurate mass measurements.  Collision-induced dissocn. of these conjugates provided evidence for bioactivation of the pyrrolidine ring of 1.  The epoxide and α,β-unsatd. keto reactive intermediates were unlikely to cause the genotoxicity of 1 because the formation of their glutathione adducts did not ameliorate the binding of compd. related material to DNA.  Instead, the endocyclic iminium ions and amino aldehydes were likely candidates responsible for genotoxicity based on, first, the protection afforded by both cyanide ion and methoxylamine, which reduced the potential to form covalent adducts with DNA, and, second, analogs of 1 designed with low probability to form these reactive intermediates were not genotoxic.  It was concluded that 1 also had the potential to be mutagenic in humans based on observing the endocyclic iminium ion following incubation with a human liver S9 prepn. and the commensurate detection of DNA adducts.  An understanding of this genotoxicity mechanism supported an evidence-based approach to selectively modify the structure of 1 which resulted in analogs being synthesized that were devoid of a genotoxic liability.  In addn., potency and selectivity against both adenosine A2A and A1 receptors were maintained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9N__9056Cr7Vg90H21EOLACvtfcHk0lj6Z29WiH1EUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVGjsLc%253D&md5=ef0a49a0c0889517eb37018fe808367f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Ftx1004437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx1004437%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DH.-K.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSensenhauser%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DK.%26aulast%3DPreston%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DT.%26aulast%3DShook%26aufirst%3DB.%26aulast%3DJackson%26aufirst%3DP.%2BF.%26aulast%3DRassnick%26aufirst%3DS.%26aulast%3DRhodes%26aufirst%3DK.%26atitle%3DOvercoming%2520the%2520genotoxicity%2520of%2520a%2520pyrrolidine%2520substituted%2520arylindenopyrimidine%2520as%2520a%2520potent%2520dual%2520adenosine%2520A2A%252FA1%2520antagonist%2520by%2520minimizing%2520bioactivation%2520to%2520an%2520iminium%2520ion%2520reactive%2520intermediate%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1012%26epage%3D1030%26doi%3D10.1021%2Ftx1004437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shook, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassnick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crooke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ault, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbay, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, K.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Design and characterization of optimized adenosine A2A/A1 receptor antagonists for the treatment of Parkinson’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1402</span>– <span class="NLM_lpage">1417</span>, <span class="refDoi"> DOI: 10.1021/jm201640m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201640m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFWqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1402-1417&author=B.+C.+Shookauthor=S.+Rassnickauthor=N.+Wallaceauthor=J.+Crookeauthor=M.+Aultauthor=D.+Chakravartyauthor=J.+K.+Barbayauthor=A.+Wangauthor=M.+T.+Powellauthor=K.+Leonard&title=Design+and+characterization+of+optimized+adenosine+A2A%2FA1+receptor+antagonists+for+the+treatment+of+Parkinson%E2%80%99s+disease&doi=10.1021%2Fjm201640m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Characterization of Optimized Adenosine A2A/A1 Receptor Antagonists for the Treatment of Parkinson's Disease</span></div><div class="casAuthors">Shook, Brian C.; Rassnick, Stefanie; Wallace, Nathaniel; Crooke, Jeffrey; Ault, Mark; Chakravarty, Devraj; Barbay, J. Kent; Wang, Aihua; Powell, Mark T.; Leonard, Kristi; Alford, Vernon; Scannevin, Robert H.; Carroll, Karen; Lampron, Lisa; Westover, Lori; Lim, Heng-Keang; Russell, Ronald; Branum, Shawn; Wells, Kenneth M.; Damon, Sandra; Youells, Scott; Li, Xun; Beauchamp, Derek A.; Rhodes, Kenneth; Jackson, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1402-1417</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design and characterization of two, dual adenosine A2A/A1 receptor antagonists in several animal models of Parkinson's disease is described.  A pyrrolidinylmethyl aminoindenopyrimidinone (I) was previously reported as a potential treatment for Parkinson's disease.  Further characterization of I revealed that it was metabolized to reactive intermediates that caused its genotoxicity in the Ames and mouse lymphoma L51784 assays.  The identification of the metabolites enabled the prepn. of two optimized compds., an aminooxoindenopyrimidinecarbonyl piperazine and a morpholinylethoxy aminoindenopyrimidinone that were devoid of the metabolic liabilities assocd. with I.  The aminooxoindenopyrimidinecarbonyl piperazine and the morpholinylethoxy aminoindenopyrimidinone are potent dual A2A/A1 receptor antagonists that have excellent activity, after oral administration, across a no. of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse and rat models of reserpine-induced akinesia, and the rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonnYVdjHJevrVg90H21EOLACvtfcHk0lgzu3rs1WIJvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFWqug%253D%253D&md5=987f8aed3e075d7caee66eb464fd94fb</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm201640m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201640m%26sid%3Dliteratum%253Aachs%26aulast%3DShook%26aufirst%3DB.%2BC.%26aulast%3DRassnick%26aufirst%3DS.%26aulast%3DWallace%26aufirst%3DN.%26aulast%3DCrooke%26aufirst%3DJ.%26aulast%3DAult%26aufirst%3DM.%26aulast%3DChakravarty%26aufirst%3DD.%26aulast%3DBarbay%26aufirst%3DJ.%2BK.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DPowell%26aufirst%3DM.%2BT.%26aulast%3DLeonard%26aufirst%3DK.%26atitle%3DDesign%2520and%2520characterization%2520of%2520optimized%2520adenosine%2520A2A%252FA1%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1402%26epage%3D1417%26doi%3D10.1021%2Fjm201640m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Atack, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shook, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassnick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drinkenburg, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahnaou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Te Riele, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrupka, B.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson’s disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1019</span>, <span class="refDoi"> DOI: 10.1021/cn5001606</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn5001606" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsV2qtr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1005-1019&author=J.+R.+Atackauthor=B.+C.+Shookauthor=S.+Rassnickauthor=P.+F.+Jacksonauthor=K.+Rhodesauthor=W.+H.+Drinkenburgauthor=A.+Ahnaouauthor=P.+Te+Rieleauthor=X.+Langloisauthor=B.+Hrupka&title=JNJ-40255293%2C+a+novel+adenosine+A2A%2FA1+antagonist+with+efficacy+in+preclinical+models+of+Parkinson%E2%80%99s+disease&doi=10.1021%2Fcn5001606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">JNJ-40255293, a Novel Adenosine A2A/A1 Antagonist with Efficacy in Preclinical Models of Parkinson's Disease</span></div><div class="casAuthors">Atack, John R.; Shook, Brian C.; Rassnick, Stefanie; Jackson, Paul F.; Rhodes, Kenneth; Drinkenburg, Wilhelmus H.; Ahnaou, Abdallah; te Riele, Paula; Langlois, Xavier; Hrupka, Brian; De Haes, Patrick; Hendrickx, Herman; Aerts, Nancy; Hens, Koen; Wellens, Annemie; Vermeire, Jef; Megens, Anton A. H. P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1005-1019</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Adenosine A2A antagonists are believed to have therapeutic potential in the treatment of Parkinson's disease (PD).  We have characterized the dual adenosine A2A/A1 receptor antagonist JNJ-40255293 (2-amino-8-[2-(4-morpholinyl)ethoxy]-4-phenyl-5H-indeno[1,2-d]pyrimidin-5-one).  JNJ-40255293 was a high-affinity (7.5 nM) antagonist at the human A2A receptor with 7-fold in vitro selectivity vs. the human A1 receptor.  A similar A2A:A1 selectivity was seen in vivo (ED50's of 0.21 and 2.1 mg/kg p.o. for occupancy of rat brain A2A and A1 receptors, resp.).  The plasma EC50 for occupancy of rat brain A2A receptors was 13 ng/mL.  In sleep-wake encephalog. (EEG) studies, JNJ-40255293 dose-dependently enhanced a consolidated waking assocd. with a subsequent delayed compensatory sleep (min. ED: 0.63 mg/kg p.o.).  As measured by microdialysis, JNJ-40255293 did not affect dopamine and noradrenaline release in the prefrontal cortex and the striatum.  However, it was able to reverse effects (catalepsy, hypolocomotion, and conditioned avoidance impairment in rats; hypolocomotion in mice) produced by the dopamine D2 antagonist haloperidol.  The compd. also potentiated the agitation induced by the dopamine agonist apomorphine.  JNJ-40255293 also reversed hypolocomotion produced by the dopamine-depleting agent reserpine and potentiated the effects of L-dihydroxyphenylalanine (L-DOPA) in rats with unilateral 6-hydroxydopamine-induced lesions of the nigro-striatal pathway, an animal model of Parkinson's disease.  Extrapolating from the rat receptor occupancy dose-response curve, the occupancy required to produce these various effects in rats was generally in the range of 60-90%.  The findings support the continued research and development of A2A antagonists as potential treatments for PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg4IuostoOT7Vg90H21EOLACvtfcHk0lgzu3rs1WIJvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsV2qtr3F&md5=fdad31db89148d0d2920afb8ca33788d</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fcn5001606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn5001606%26sid%3Dliteratum%253Aachs%26aulast%3DAtack%26aufirst%3DJ.%2BR.%26aulast%3DShook%26aufirst%3DB.%2BC.%26aulast%3DRassnick%26aufirst%3DS.%26aulast%3DJackson%26aufirst%3DP.%2BF.%26aulast%3DRhodes%26aufirst%3DK.%26aulast%3DDrinkenburg%26aufirst%3DW.%2BH.%26aulast%3DAhnaou%26aufirst%3DA.%26aulast%3DTe%2BRiele%26aufirst%3DP.%26aulast%3DLanglois%26aufirst%3DX.%26aulast%3DHrupka%26aufirst%3DB.%26atitle%3DJNJ-40255293%252C%2520a%2520novel%2520adenosine%2520A2A%252FA1%2520antagonist%2520with%2520efficacy%2520in%2520preclinical%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2014%26volume%3D5%26spage%3D1005%26epage%3D1019%26doi%3D10.1021%2Fcn5001606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mikó, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligneau, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertz, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrang, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robin
Ganellin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schunack, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Structural variations of 1-(4-(phenoxymethyl)benzyl)piperidines as nonimidazole histamine H3 receptor antagonists</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2727</span>– <span class="NLM_lpage">2736</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2004.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.bmc.2004.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=15110854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtl2nurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=2727-2736&author=T.+Mik%C3%B3author=X.+Ligneauauthor=H.+H.+Pertzauthor=J.-M.+Arrangauthor=C.+Robin%0AGanellinauthor=J.-C.+Schwartzauthor=W.+Schunackauthor=H.+Stark&title=Structural+variations+of+1-%284-%28phenoxymethyl%29benzyl%29piperidines+as+nonimidazole+histamine+H3+receptor+antagonists&doi=10.1016%2Fj.bmc.2004.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Structural variations of 1-(4-(phenoxymethyl)benzyl)piperidines as nonimidazole histamine H3 receptor antagonists</span></div><div class="casAuthors">Miko, Tibor; Ligneau, Xavier; Pertz, Heinz H.; Arrang, Jean-Michel; Ganellin, C. Robin; Schwartz, Jean-Charles; Schunack, Walter; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2727-2736</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Recent bioisoteric replacements in histamine H3 receptor ligands with an exchange of the imidazole moiety by a piperidino group as well as of the trimethylene chain in 4-((3-phenoxy)propyl)-1H-imidazole derivs. (proxifan class) by an α,α'-xylendiyl linker represents the starting point in the development of 1-(4-(phenoxymethyl)benzyl)piperidines as a new class of nonimidazole histamine H3 receptor antagonists.  According to different strategies in optimization of imidazole-contg. antagonists the central benzyl Ph ether moiety was replaced by numerous other polar functionalities.  Addnl., the ortho- and meta-analogs of the lead were synthesized to det. the influence of the position of the piperidinomethyl substituent.  The new compds. were tested in an in vitro binding assay for their affinities for cloned human H3 receptors stably expressed in CHO-K1 cells and for their oral in vivo potencies brain in a functional screening assay in the brain of mice.  Addnl., activities of selected compds. were detd. in the guinea-pig ileum functional test model.  In contrast to the analogs ortho-substituted compds. all other compds. maintained respectable affinities for the human H3 receptor (-logKi values 6.3-7.5).  Despite the results from other classes of compds. the 4-Me substituted derivs. generally displayed higher affinities than the corresponding 4-chloro substituted compds.  In vivo only the inverse Ph benzyl ether (3) showed worthwhile antagonist potencies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVX2atR-P62bVg90H21EOLACvtfcHk0lgzu3rs1WIJvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtl2nurg%253D&md5=9c7c3d41d97af2ce3d6de7d17c15df9f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2004.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2004.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DMik%25C3%25B3%26aufirst%3DT.%26aulast%3DLigneau%26aufirst%3DX.%26aulast%3DPertz%26aufirst%3DH.%2BH.%26aulast%3DArrang%26aufirst%3DJ.-M.%26aulast%3DRobin%2BGanellin%26aufirst%3DC.%26aulast%3DSchwartz%26aufirst%3DJ.-C.%26aulast%3DSchunack%26aufirst%3DW.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DStructural%2520variations%2520of%25201-%25284-%2528phenoxymethyl%2529benzyl%2529piperidines%2520as%2520nonimidazole%2520histamine%2520H3%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2004%26volume%3D12%26spage%3D2727%26epage%3D2736%26doi%3D10.1016%2Fj.bmc.2004.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span> <span> </span><span class="NLM_article-title">Recent developments in adenosine receptor ligands and their potential as novel drugs</span>. <i>Natl. Inst. Health</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1808</i></span>,  <span class="NLM_fpage">1290</span>– <span class="NLM_lpage">1308</span>, <span class="refDoi"> DOI: 10.1016/j.bbamem.2010.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.bbamem.2010.12.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1808&publication_year=2011&pages=1290-1308&author=C.+E.+M%C3%BCllerauthor=K.+A.+Jacobson&title=Recent+developments+in+adenosine+receptor+ligands+and+their+potential+as+novel+drugs&doi=10.1016%2Fj.bbamem.2010.12.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamem.2010.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamem.2010.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DRecent%2520developments%2520in%2520adenosine%2520receptor%2520ligands%2520and%2520their%2520potential%2520as%2520novel%2520drugs%26jtitle%3DNatl.%2520Inst.%2520Health%26date%3D2011%26volume%3D1808%26spage%3D1290%26epage%3D1308%26doi%3D10.1016%2Fj.bbamem.2010.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">The physicochemical challenges of designing multiple ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4961</span>– <span class="NLM_lpage">4970</span>, <span class="refDoi"> DOI: 10.1021/jm0603015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4961-4970&author=R.+Morphyauthor=Z.+Rankovic&title=The+physicochemical+challenges+of+designing+multiple+ligands&doi=10.1021%2Fjm0603015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The Physicochemical Challenges of Designing Multiple Ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4961-4970</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compds. designed to bind more than one target can provide a therapeutic benefit relative to highly target-selective ligands.  The physicochem. properties of designed multiple ligands were found to be less druglike than those for preclin. compds. in general.  These properties are controlled by the superfamily to which the targets belong and the lead discovery strategy that was followed.  The properties for peptide G-protein-coupled receptor (GPCR) ligands were the least favorable for oral delivery, whereas transporter, monoamine GPCR, and oxidase ligands were the most druglike.  The lead discovery strategy, framework combination or screening, exerts a profound influence on the property values.  Combining the frameworks from two selective ligands often results in large, complex dual ligands, but druglike ligands can be achieved if the degree of framework overlap is maximized and the size of the selective ligands minimized.  For some target combinations, a screening approach may provide a route to smaller, less complex leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonGHbXyxgv4LVg90H21EOLACvtfcHk0ljkHJ3OIoVs3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D&md5=c7a227848516d0aa58ed037a582943fe</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm0603015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603015%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DThe%2520physicochemical%2520challenges%2520of%2520designing%2520multiple%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4961%26epage%3D4970%26doi%3D10.1021%2Fjm0603015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zewge, D.</span></span> <span> </span><span class="NLM_article-title">Recent advances in ether dealkylation</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7833</span>– <span class="NLM_lpage">7863</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2005.05.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.tet.2005.05.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2005&pages=7833-7863&author=S.+A.+Weissmanauthor=D.+Zewge&title=Recent+advances+in+ether+dealkylation&doi=10.1016%2Fj.tet.2005.05.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in ether dealkylation</span></div><div class="casAuthors">Weissman, Steven A.; Zewge, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">7833-7863</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review on the developments from 1995 through the end of 2004 with focus on reagents of practical value and some level of generality.  The following topics are discussed: deprotection of aryl and alkyl ethers (including propargylic), allyl and related ethers (including isoprenyl), benzylic ethers (including trityl), and cyclic ethers.  Aspects of regio- and chemoselectivities are also mentioned.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHYugNUDxpjLVg90H21EOLACvtfcHk0lg7nVGLxWcLZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFCltro%253D&md5=41a698090e3cc03e616d3c972d52e788</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2005.05.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2005.05.041%26sid%3Dliteratum%253Aachs%26aulast%3DWeissman%26aufirst%3DS.%2BA.%26aulast%3DZewge%26aufirst%3DD.%26atitle%3DRecent%2520advances%2520in%2520ether%2520dealkylation%26jtitle%3DTetrahedron%26date%3D2005%26volume%3D61%26spage%3D7833%26epage%3D7863%26doi%3D10.1016%2Fj.tet.2005.05.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tomasch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwed, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Novel chalcone-based fluorescent human histamine H(3) receptor ligands as pharmacological tools</span>. <i>Front. Syst. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">14</span>, <span class="refDoi"> DOI: 10.3389/fnsys.2012.00014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.3389%2Ffnsys.2012.00014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=22470321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFGqtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=14&author=M.+Tomaschauthor=J.+S.+Schwedauthor=L.+Weizelauthor=H.+Stark&title=Novel+chalcone-based+fluorescent+human+histamine+H%283%29+receptor+ligands+as+pharmacological+tools&doi=10.3389%2Ffnsys.2012.00014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Novel chalcone-based fluorescent human histamine H3 receptor ligands as pharmacological tools</span></div><div class="casAuthors">Tomasch, Miriam; Schwed, J. Stephan; Weizel, Lilia; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Systems Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">March</span>),
    <span class="NLM_cas:pages">14</span>CODEN:
                <span class="NLM_cas:coden">FSNRAR</span>;
        ISSN:<span class="NLM_cas:issn">1662-5137</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Novel fluorescent chalcone-based ligands at human histamine H3 receptors (hH3R) have been designed, synthesized and characterized.  Compds. described are non-imidazole analogs of ciproxifan with a tetralone motif.  Tetralones as chem. precursors and related fluorescent chalcones exhibit affinities at hH3R in the same concn. range like the ref. antagonist ciproxifan (hH3R pKi value of 7.2).  Fluorescence characterization of our novel ligands shows emission maxima about 570 nm for yellow fluorescent chalcones and ≥600 nm for the red fluorescent derivs.  Interferences to cellular autofluorescence could be excluded.  All synthesized chalcone compds. could be used to visualize hH3R proteins in stably transfected HEK-293 cells using confocal laser scanning fluorescence microscopy.  These novel fluorescent ligands possess high potential to be used as pharmacol. tools for hH3R visualization in different tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdUye1majEG7Vg90H21EOLACvtfcHk0lg7nVGLxWcLZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFGqtLo%253D&md5=f5347376b0c63ee9b9bbbfe58a39596c</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.3389%2Ffnsys.2012.00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnsys.2012.00014%26sid%3Dliteratum%253Aachs%26aulast%3DTomasch%26aufirst%3DM.%26aulast%3DSchwed%26aufirst%3DJ.%2BS.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DNovel%2520chalcone-based%2520fluorescent%2520human%2520histamine%2520H%25283%2529%2520receptor%2520ligands%2520as%2520pharmacological%2520tools%26jtitle%3DFront.%2520Syst.%2520Neurosci.%26date%3D2012%26volume%3D6%26spage%3D14%26doi%3D10.3389%2Ffnsys.2012.00014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sander, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kottke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffend, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camelin, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligneau, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J.-C.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">First metal-containing histamine H3 receptor ligands</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2578</span>– <span class="NLM_lpage">2581</span>, <span class="refDoi"> DOI: 10.1021/ol100419y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol100419y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsleht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=2578-2581&author=K.+Sanderauthor=T.+Kottkeauthor=C.+Hoffendauthor=M.+Walterauthor=L.+Weizelauthor=J.-C.+Camelinauthor=X.+Ligneauauthor=E.+H.+Schneiderauthor=R.+Seifertauthor=J.-C.+Schwartz&title=First+metal-containing+histamine+H3+receptor+ligands&doi=10.1021%2Fol100419y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">First Metal-Containing Histamine H3 Receptor Ligands</span></div><div class="casAuthors">Sander, Kerstin; Kottke, Tim; Hoffend, Claas; Walter, Miriam; Weizel, Lilia; Camelin, Jean-Claude; Ligneau, Xavier; Schneider, Erich H.; Seifert, Roland; Schwartz, Jean-Charles; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2578-2581</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Iron-contg. ligands targeting the human histamine H3 receptor (hH3R) were prepd.  The compds. contain ferrocene sandwich complexes coupled via different linkers to a basic hH3R antagonist/inverse agonist pharmacophore.  In a click chem. approach, a triazole was successfully inserted as a new linking element.  Two ferrocenylmethylamines and a ferrocenyltriazole were the most affine hH3R ligands within this series, showing receptor binding in the nano- and subnanomolar concn. range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKo1tojdBi5rVg90H21EOLACvtfcHk0lhkLeapyrPXZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsleht7c%253D&md5=d35fed6a05a07ae59c87901147d3f987</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fol100419y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol100419y%26sid%3Dliteratum%253Aachs%26aulast%3DSander%26aufirst%3DK.%26aulast%3DKottke%26aufirst%3DT.%26aulast%3DHoffend%26aufirst%3DC.%26aulast%3DWalter%26aufirst%3DM.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DCamelin%26aufirst%3DJ.-C.%26aulast%3DLigneau%26aufirst%3DX.%26aulast%3DSchneider%26aufirst%3DE.%2BH.%26aulast%3DSeifert%26aufirst%3DR.%26aulast%3DSchwartz%26aufirst%3DJ.-C.%26atitle%3DFirst%2520metal-containing%2520histamine%2520H3%2520receptor%2520ligands%26jtitle%3DOrg.%2520Lett.%26date%3D2010%26volume%3D12%26spage%3D2578%26epage%3D2581%26doi%3D10.1021%2Fol100419y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwed, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adem, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.ejmech.2014.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=24650714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtVSitLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2014&pages=269-279&author=B.+Sadekauthor=J.+S.+Schwedauthor=D.+Subramanianauthor=L.+Weizelauthor=M.+Walterauthor=A.+Ademauthor=H.+Stark&title=Non-imidazole+histamine+H3+receptor+ligands+incorporating+antiepileptic+moieties&doi=10.1016%2Fj.ejmech.2014.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties</span></div><div class="casAuthors">Sadek, Bassem; Schwed, Johannes Stephan; Subramanian, Dhanasekaran; Weizel, Lilia; Walter, Miriam; Adem, Abdu; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">269-279</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A small series of histamine H3 receptor (H3R) ligands (1-5) incorporating different antiepileptic structural motifs has been newly synthesized.  All compds. exhibited moderate to high in vitro hH3R affinities up to a sub-nanomolar concn. range with pKi values in the range of 6.25-9.62 with varying preferences for this receptor subtype.  The compds. (1-5) were further investigated in vivo on anticonvulsant effects against max. electroshock (MES)-induced and pentylenetetrazole (PTZ)-kindled convulsions in rats having phenytoin (PHT) as the ref. antiepileptic drug (AED).  Surprisingly, animals pretreated with 1 mg/kg, i.p. of 5,5-diphenyl-3-(3-(piperidin-1-yl)propyl)imidazolidine-2,4-dione (4) were only moderately protected and no protection was obsd. for compds. 1-3 and 5 in three different doses (1 mg, 5 mg, and 10 mg/kg i.p.).  Compd. 4 (1 mg/kg, i.p.) failed to modify PTZ-kindled convulsion.  However, a dose of 10 mg/kg significantly reduced convulsions in both models.  In contrast, 5,5-diphenyl-3-(4-(3-(piperidin-1-yl)propoxy)benzyl)imidazolidine-2,4-dione (5) (1, 5, and 10 mg/kg, i.p.) showed proconvulsant effects in the MES model with further confirmation of these results in the PTZ model as no protection was obsd. against convulsion in the doses tested (1 and 10 mg/kg).  In addn., compd. 4 (10 mg/kg, i.p.) significantly prolonged myoclonic latency time and shortened total convulsion duration when compared to control, PHT or std. H3R inverse agonist/antagonist pitolisant (PIT).  Our results showed that H3R pharmacophores could successfully be structurally combined to antiepileptic moieties, esp. phenytoin partial structures, maintaining the H3R affinity.  However, the new derivs. for multiple-target approaches in epilepsy models are complex and show that pharmacophore elements are not easily pharmacol. combinable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCcEDmmdlPXrVg90H21EOLACvtfcHk0lhkLeapyrPXZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtVSitLc%253D&md5=4ca60e1ca75828355c78caf5e126fbba</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DSadek%26aufirst%3DB.%26aulast%3DSchwed%26aufirst%3DJ.%2BS.%26aulast%3DSubramanian%26aufirst%3DD.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DWalter%26aufirst%3DM.%26aulast%3DAdem%26aufirst%3DA.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DNon-imidazole%2520histamine%2520H3%2520receptor%2520ligands%2520incorporating%2520antiepileptic%2520moieties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D77%26spage%3D269%26epage%3D279%26doi%3D10.1016%2Fj.ejmech.2014.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patil, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bari, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firke, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donda, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, D. A.</span></span> <span> </span><span class="NLM_article-title">A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer’s disease</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2434</span>– <span class="NLM_lpage">2450</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.bmc.2013.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=23517722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktlSiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2434-2450&author=P.+O.+Patilauthor=S.+B.+Bariauthor=S.+D.+Firkeauthor=P.+K.+Deshmukhauthor=S.+T.+Dondaauthor=D.+A.+Patil&title=A+comprehensive+review+on+synthesis+and+designing+aspects+of+coumarin+derivatives+as+monoamine+oxidase+inhibitors+for+depression+and+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.bmc.2013.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease</span></div><div class="casAuthors">Patil, Pravin O.; Bari, Sanjay B.; Firke, Sandip D.; Deshmukh, Prashant K.; Donda, Shailesh T.; Patil, Dilip A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2434-2450</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Monoamine oxidase (MAO) enzyme inhibition is a crucial target for the management of depression and Alzheimer disease and inhibitors of MAO are the most important drugs for their management.  Coumarins are a large family of compds., of natural and synthetic origin, that exhibit a variety of pharmacol. activities, including MAO inhibition.  The current review highlights the design and synthetic methods of coumarin derivs. as well as coumarins obtained from plant source as MAO inhibitors for treatment of depression and Alzheimer disease with salient finding related to structure-activity relationship.  The aim of present review is to find out natural as well as synthetic coumarins as MAO inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBZYAH89AyobVg90H21EOLACvtfcHk0lgcfu0bIHdTNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktlSiuro%253D&md5=15c84861ae6fc00bcf9ffba764223694</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DP.%2BO.%26aulast%3DBari%26aufirst%3DS.%2BB.%26aulast%3DFirke%26aufirst%3DS.%2BD.%26aulast%3DDeshmukh%26aufirst%3DP.%2BK.%26aulast%3DDonda%26aufirst%3DS.%2BT.%26aulast%3DPatil%26aufirst%3DD.%2BA.%26atitle%3DA%2520comprehensive%2520review%2520on%2520synthesis%2520and%2520designing%2520aspects%2520of%2520coumarin%2520derivatives%2520as%2520monoamine%2520oxidase%2520inhibitors%2520for%2520depression%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2434%26epage%3D2450%26doi%3D10.1016%2Fj.bmc.2013.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Llàcer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romea, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urpí, F.</span></span> <span> </span><span class="NLM_article-title">Studies on the hydrogenolysis of benzyl ethers</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">5815</span>– <span class="NLM_lpage">5818</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2006.05.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.tetlet.2006.05.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFers7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=5815-5818&author=E.+Ll%C3%A0cerauthor=P.+Romeaauthor=F.+Urp%C3%AD&title=Studies+on+the+hydrogenolysis+of+benzyl+ethers&doi=10.1016%2Fj.tetlet.2006.05.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Studies on the hydrogenolysis of benzyl ethers</span></div><div class="casAuthors">Llacer, Enric; Romea, Pedro; Urpi, Felix</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">5815-5818</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Selective hydrogenolysis of arom. and aliph. benzyl ethers in the presence of benzylic Me ether can be achieved by the appropriate choice of the catalyst, solvent, and concn., which facilitates the design of O-benzyl-based protecting group strategies for the synthesis of natural products, such as debromoaplysiatoxin and oscillatoxin D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYW5eqs5y677Vg90H21EOLACvtfcHk0lgcfu0bIHdTNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFers7Y%253D&md5=fe0d822be716067fb885a61f6182b3a4</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2006.05.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2006.05.109%26sid%3Dliteratum%253Aachs%26aulast%3DLl%25C3%25A0cer%26aufirst%3DE.%26aulast%3DRomea%26aufirst%3DP.%26aulast%3DUrp%25C3%25AD%26aufirst%3DF.%26atitle%3DStudies%2520on%2520the%2520hydrogenolysis%2520of%2520benzyl%2520ethers%26jtitle%3DTetrahedron%2520Lett.%26date%3D2006%26volume%3D47%26spage%3D5815%26epage%3D5818%26doi%3D10.1016%2Fj.tetlet.2006.05.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bei, D.</span></span> <span> </span><span class="NLM_article-title">Lithium chloride-catalyzed selective demethylation of aryl methyl ethers under microwave irradiation</span>. <i>J. Mol. Catal.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1016/j.molcata.2007.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.molcata.2007.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2sXos1anu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=2007&pages=16-23&author=Z.+Fangauthor=G.-C.+Zhouauthor=S.-L.+Zhengauthor=G.-L.+Heauthor=J.-L.+Liauthor=L.+Heauthor=D.+Bei&title=Lithium+chloride-catalyzed+selective+demethylation+of+aryl+methyl+ethers+under+microwave+irradiation&doi=10.1016%2Fj.molcata.2007.04.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Lithium chloride-catalyzed selective demethylation of aryl methyl ethers under microwave irradiation</span></div><div class="casAuthors">Fang, Zhuan; Zhou, Guo-Chuan; Zheng, Shi-Long; He, Guang-Li; Li, Ju-Lian; He, Ling; Bei, Di</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Catalysis A: Chemical</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">16-23</span>CODEN:
                <span class="NLM_cas:coden">JMCCF2</span>;
        ISSN:<span class="NLM_cas:issn">1381-1169</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A rapid method for the selective cleavage of aryl Me ether was developed in the LiCl-DMF system under microwave irradn.  Effects of substituent, metal salt, and solvent on the activity and selectivity in the cleavage were investigated.  Microwave improves the reaction yield and the selectivity of demethylation for electron-deficient arom. Me ethers.  The catalytic mechanism of demethylation by LiCl salt is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbqALUc8Sp4rVg90H21EOLACvtfcHk0lgcfu0bIHdTNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXos1anu7k%253D&md5=1355452eb985f4c5f921ab5b228ec459</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.molcata.2007.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcata.2007.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DG.-C.%26aulast%3DZheng%26aufirst%3DS.-L.%26aulast%3DHe%26aufirst%3DG.-L.%26aulast%3DLi%26aufirst%3DJ.-L.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DBei%26aufirst%3DD.%26atitle%3DLithium%2520chloride-catalyzed%2520selective%2520demethylation%2520of%2520aryl%2520methyl%2520ethers%2520under%2520microwave%2520irradiation%26jtitle%3DJ.%2520Mol.%2520Catal.%26date%3D2007%26volume%3D274%26spage%3D16%26epage%3D23%26doi%3D10.1016%2Fj.molcata.2007.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettit, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herald, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNulty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgs, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumberg, P. M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Antineoplastic agents 491.1 Synthetic conversion of aaptamine to isoaaptamine, 9-demethylaaptamine, and 4-methylaaptamine</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">2251</span>– <span class="NLM_lpage">2256</span>, <span class="refDoi"> DOI: 10.1021/jo0300486</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0300486" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1CmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=2251-2256&author=G.+R.+Pettitauthor=H.+Hoffmannauthor=D.+L.+Heraldauthor=J.+McNultyauthor=A.+Murphyauthor=K.+C.+Higgsauthor=E.+Hamelauthor=N.+E.+Lewinauthor=L.+V.+Pearceauthor=P.+M.+Blumberg&title=Antineoplastic+agents+491.1+Synthetic+conversion+of+aaptamine+to+isoaaptamine%2C+9-demethylaaptamine%2C+and+4-methylaaptamine&doi=10.1021%2Fjo0300486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Antineoplastic Agents 491. Synthetic Conversion of Aaptamine to Isoaaptamine, 9-Demethylaaptamine, and 4-Methylaaptamine</span></div><div class="casAuthors">Pettit, George R.; Hoffmann, Holger; Herald, Delbert L.; McNulty, James; Murphy, Alison; Higgs, Kerianne C.; Hamel, Ernest; Lewin, Nancy E.; Pearce, Larry V.; Blumberg, Peter M.; Pettit, Robin K.; Knight, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2251-2256</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aaptamine [I; R1 = H, R2 = R3 = Me (II)] was used as starting material for synthetic transformation to isoaaptamine I [R1 = R3 = Me, R2 = H (III)], 9-demethylaaptamine I [R1 = R2 = H, R3 = Me (IV)], and 4-methylaaptamine (V).  A general method for the selective O-demethylation of such 1H-benzo[de][1,6]-naphthyridine II marine sponge constituents at position C-9 has been developed.  Selective O-demethylation of II and 1-methylaaptamine I (R1 = R2 = R3 = Me) with 48% hydrobromic acid led to IV and III, resp.  A selection of other aaptamine derivs. were synthesized, and their structures were unambiguously detd. by X-ray methods.  In addn., their cancer cell growth inhibitory properties were evaluated against the murine P388 lymphocytic cell line and a minipanel of human cancer cell lines.  Evaluation as inhibitors of the PKC signal transduction pathway and against a selection of microorganisms was also undertaken.  Aaptamine derivs. I (R1 = R2 = R3 = H).HBr and IV.HBr had broad-spectrum antimicrobial activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAlJE_3AUCCrVg90H21EOLACvtfcHk0ljSwP1aStVlGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1CmtLY%253D&md5=3da5c0dd56e23831b295376c3b098996</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjo0300486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0300486%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DHoffmann%26aufirst%3DH.%26aulast%3DHerald%26aufirst%3DD.%2BL.%26aulast%3DMcNulty%26aufirst%3DJ.%26aulast%3DMurphy%26aufirst%3DA.%26aulast%3DHiggs%26aufirst%3DK.%2BC.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DLewin%26aufirst%3DN.%2BE.%26aulast%3DPearce%26aufirst%3DL.%2BV.%26aulast%3DBlumberg%26aufirst%3DP.%2BM.%26atitle%3DAntineoplastic%2520agents%2520491.1%2520Synthetic%2520conversion%2520of%2520aaptamine%2520to%2520isoaaptamine%252C%25209-demethylaaptamine%252C%2520and%25204-methylaaptamine%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D2251%26epage%3D2256%26doi%3D10.1021%2Fjo0300486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, A.</span></span> <span> </span><span class="NLM_article-title">Ueber die Theorie der Aetherbildung</span>. <i>Ann. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1851</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1002/jlac.18510770104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2Fjlac.18510770104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADyaD28XkslY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1851&pages=37-49&author=A.+Williamson&title=Ueber+die+Theorie+der+Aetherbildung&doi=10.1002%2Fjlac.18510770104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Theory of ether formation</span></div><div class="casAuthors">Williamson, Al.</div><div class="citationInfo"><span class="NLM_cas:title">Justus Liebigs Annalen der Chemie</span>
        (<span class="NLM_cas:date">1851</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">37-49</span>CODEN:
                <span class="NLM_cas:coden">JLACBF</span>;
        ISSN:<span class="NLM_cas:issn">0075-4617</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoBsulJDxWmrVg90H21EOLACvtfcHk0ljSwP1aStVlGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaD28XkslY%253D&md5=1804f12d6796401fac1b63bcc3431a1e</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1002%2Fjlac.18510770104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlac.18510770104%26sid%3Dliteratum%253Aachs%26aulast%3DWilliamson%26aufirst%3DA.%26atitle%3DUeber%2520die%2520Theorie%2520der%2520Aetherbildung%26jtitle%3DAnn.%2520Chem.%26date%3D1851%26volume%3D77%26spage%3D37%26epage%3D49%26doi%3D10.1002%2Fjlac.18510770104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diveshkumar, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakrikar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harikrishna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhamodharan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradeepkumar, P. I.</span></span> <span> </span><span class="NLM_article-title">Targeting promoter G-quadruplex DNAs by indenopyrimidine-based ligands</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2754</span>– <span class="NLM_lpage">2765</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201402394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2Fcmdc.201402394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=25359695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVaksbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=2754-2765&author=K.+V.+Diveshkumarauthor=S.+Sakrikarauthor=S.+Harikrishnaauthor=V.+Dhamodharanauthor=P.+I.+Pradeepkumar&title=Targeting+promoter+G-quadruplex+DNAs+by+indenopyrimidine-based+ligands&doi=10.1002%2Fcmdc.201402394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Promoter G-Quadruplex DNAs by Indenopyrimidine-Based Ligands</span></div><div class="casAuthors">Diveshkumar, K. V.; Sakrikar, Saaz; Harikrishna, S.; Dhamodharan, V.; Pradeepkumar, P. I.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2754-2765</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The formation of G-quadruplex structures can regulate telomerase activity and the expression of oncogenes at the transcriptional and translational levels.  Therefore, stabilization of G-quadruplex DNA structures by small mols. has been recognized as a promising strategy for anticancer drug therapy.  One of the major challenges in this field is to impart stabilizing mols. with selectivity toward quadruplex structures over duplex DNAs, and to maintain specificity toward a particular quadruplex topol.  Herein we report the synthesis and binding interactions of indenopyrimidine derivs., endowed with drug-like properties, with oncogenic promoters of c-myc and c-kit, telomeric and duplex DNAs.  The results show specific stabilization of promoter over telomeric quadruplexes and duplex DNAs.  Mol. modeling studies support the exptl. observations by unraveling the dual binding mode of ligands by exploiting the top and bottom quartets of a G-quadruplex structure.  This study underscores the potential of the indenopyrimidine scaffold, which can be used to achieve specific G-quadruplex-mediated anticancer activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXUsrnuMBWCbVg90H21EOLACvtfcHk0ljSwP1aStVlGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVaksbfK&md5=09fcc4d763aede71428b9c107b148321</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402394%26sid%3Dliteratum%253Aachs%26aulast%3DDiveshkumar%26aufirst%3DK.%2BV.%26aulast%3DSakrikar%26aufirst%3DS.%26aulast%3DHarikrishna%26aufirst%3DS.%26aulast%3DDhamodharan%26aufirst%3DV.%26aulast%3DPradeepkumar%26aufirst%3DP.%2BI.%26atitle%3DTargeting%2520promoter%2520G-quadruplex%2520DNAs%2520by%2520indenopyrimidine-based%2520ligands%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D2754%26epage%3D2765%26doi%3D10.1002%2Fcmdc.201402394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Köse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gollos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karcz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiene, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heisig, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrenswerth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieć-Kononowicz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namasivayam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span> <span> </span><span class="NLM_article-title">Fluorescent-labeled selective adenosine A2B receptor antagonist enables competition binding assay by flow cytometry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4301</span>– <span class="NLM_lpage">4316</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01627</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01627" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BC1Mjlt1Onsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4301-4316&author=M.+K%C3%B6seauthor=S.+Gollosauthor=T.+Karczauthor=A.+Fieneauthor=F.+Heisigauthor=A.+Behrenswerthauthor=K.+Kie%C4%87-Kononowiczauthor=V.+Namasivayamauthor=C.+E.+M%C3%BCller&title=Fluorescent-labeled+selective+adenosine+A2B+receptor+antagonist+enables+competition+binding+assay+by+flow+cytometry&doi=10.1021%2Facs.jmedchem.7b01627"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorescent-Labeled Selective Adenosine A2B Receptor Antagonist Enables Competition Binding Assay by Flow Cytometry</span></div><div class="casAuthors">Kose Meryem; Gollos Sabrina; Fiene Amelie; Heisig Fabian; Behrenswerth Andrea; Namasivayam Vigneshwaran; Muller Christa E; Karcz Tadeusz; Kiec-Kononowicz Katarzyna</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4301-4316</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Fluorescent ligands represent powerful tools for biological studies and are considered attractive alternatives to radioligands.  In this study, we developed fluorescent antagonists for A2B adenosine receptors (A2BARs), which are targeted by antiasthmatic xanthines and were proposed as novel targets in immuno-oncology.  Our approach was to merge a small borondipyrromethene (BODIPY) derivative with the pharmacophore of 8-substituted xanthine derivatives.  On the basis of the design, synthesis, and evaluation of model compounds, several fluorescent ligands were synthesized.  Compound 29 (PSB-12105), which displayed high affinity for human, rat, and mouse A2BARs ( Ki = 0.2-2 nM) and high selectivity for this AR subtype, was selected for further studies.  A homology model of the human A2BAR was generated, and docking studies were performed.  Moreover, 29 allowed us to establish a homogeneous receptor-ligand binding assay using flow cytometry.  These compounds constitute the first potent, selective fluorescent A2BAR ligands and are anticipated to be useful for a variety of applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcShJSPcTqEx0ZVVjGoY74BafW6udTcc2eYG8bWdt7MI2rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mjlt1Onsg%253D%253D&md5=9d595306619272562da897096f630b92</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01627%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6se%26aufirst%3DM.%26aulast%3DGollos%26aufirst%3DS.%26aulast%3DKarcz%26aufirst%3DT.%26aulast%3DFiene%26aufirst%3DA.%26aulast%3DHeisig%26aufirst%3DF.%26aulast%3DBehrenswerth%26aufirst%3DA.%26aulast%3DKie%25C4%2587-Kononowicz%26aufirst%3DK.%26aulast%3DNamasivayam%26aufirst%3DV.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DFluorescent-labeled%2520selective%2520adenosine%2520A2B%2520receptor%2520antagonist%2520enables%2520competition%2520binding%2520assay%2520by%2520flow%2520cytometry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4301%26epage%3D4316%26doi%3D10.1021%2Facs.jmedchem.7b01627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burbiel, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghattas, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Küppers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzner, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kombu, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akkinepally, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hockemeyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span> <span> </span><span class="NLM_article-title">2-Amino[1,2,4]triazolo[1,5-c]quinazolines and derived novel heterocycles: Syntheses and structure-activity relationships of potent adenosine receptor antagonists</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2272</span>– <span class="NLM_lpage">2286</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2Fcmdc.201600255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=27531666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlCht7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2272-2286&author=J.+C.+Burbielauthor=W.+Ghattasauthor=P.+K%C3%BCppersauthor=M.+K%C3%B6seauthor=S.+Lacherauthor=A.-M.+Herznerauthor=R.+S.+Kombuauthor=R.+R.+Akkinepallyauthor=J.+Hockemeyerauthor=C.+E.+M%C3%BCller&title=2-Amino%5B1%2C2%2C4%5Dtriazolo%5B1%2C5-c%5Dquinazolines+and+derived+novel+heterocycles%3A+Syntheses+and+structure-activity+relationships+of+potent+adenosine+receptor+antagonists&doi=10.1002%2Fcmdc.201600255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">2-Amino[1,2,4]triazolo[1,5-c]quinazolines and Derived Novel Heterocycles: Syntheses and Structure-Activity Relationships of Potent Adenosine Receptor Antagonists</span></div><div class="casAuthors">Burbiel, Joachim C.; Ghattas, Wadih; Kueppers, Petra; Koese, Meryem; Lacher, Svenja; Herzner, Anna-Maria; Kombu, Rajan Subramanian; Akkinepally, Raghuram Rao; Hockemeyer, Joerg; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2272-2286</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">2-Amino[1,2,4]triazolo[1,5-c]quinazolines, e.g., I were identified as potent adenosine receptor (AR) antagonists.  Synthetic strategies were devised to gain access to a broad range of derivs. including novel polyheterocyclic compds.  Potent and selective A3AR antagonists were discovered, including 3,5-diphenyl[1,2,4]triazolo[4,3-c]quinazoline (Ki human A3AR 1.16 nM) and 5'-phenyl-1,2-dihydro-3'H-spiro[indole-3,2'-[1,2,4]triazolo[1,5-c]quinazolin]-2-one (Ki human A3AR 6.94 nM).  In addn., multitarget antagonists were obtained, such as the dual A1/A3 antagonist 2,5-diphenyl[1,2,4]triazolo[1,5-c]quinazoline (Ki human A1AR 51.6 nM, human A3AR 11.1 nM), and the balanced pan-AR antagonists 5-(2-thienyl)[1,2,4]triazolo[1,5-c]quinazolin-2-amine (Ki human A1AR 131 nM, A2AAR 32.7 nM, A2BAR 150 nM, A3AR 47.5 nM) and 9-bromo-5-phenyl[1,2,4]triazolo[1,5-c]quinazolin-2-amine (Ki human A1AR 67.7 nM, A2AAR 13.6 nM, A2BAR 75.0 nM, A3AR 703 nM).  In many cases, significantly different affinities for human and rat receptors were obsd., which emphasizes the need for caution in extrapolating conclusions between different species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFDHybKVAIpbVg90H21EOLACvtfcHk0lh9vfxJbCrVRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlCht7bE&md5=6cf719986efb0218f12f1fe3e265d45c</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600255%26sid%3Dliteratum%253Aachs%26aulast%3DBurbiel%26aufirst%3DJ.%2BC.%26aulast%3DGhattas%26aufirst%3DW.%26aulast%3DK%25C3%25BCppers%26aufirst%3DP.%26aulast%3DK%25C3%25B6se%26aufirst%3DM.%26aulast%3DLacher%26aufirst%3DS.%26aulast%3DHerzner%26aufirst%3DA.-M.%26aulast%3DKombu%26aufirst%3DR.%2BS.%26aulast%3DAkkinepally%26aufirst%3DR.%2BR.%26aulast%3DHockemeyer%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3D2-Amino%255B1%252C2%252C4%255Dtriazolo%255B1%252C5-c%255Dquinazolines%2520and%2520derived%2520novel%2520heterocycles%253A%2520Syntheses%2520and%2520structure-activity%2520relationships%2520of%2520potent%2520adenosine%2520receptor%2520antagonists%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D2272%26epage%3D2286%26doi%3D10.1002%2Fcmdc.201600255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurinsh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, R.</span></span> <span> </span><span class="NLM_article-title">Binding of [<sup>3</sup>H]MSX-2-(3-(3-hydroxypropyl)-7-methyl-8-(<i>m</i>-methoxystyryl)-1-propargylxanthine) to rat striatal membranes—a new, selective antagonist radioligand for A2A adenosine receptors</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1016/s0928-0987(00)00064-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fs0928-0987%2800%2900064-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10838015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjs1Cgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=259-265&author=C.+E.+M%C3%BCllerauthor=J.+Maurinshauthor=R.+Sauer&title=Binding+of+%5B3H%5DMSX-2-%283-%283-hydroxypropyl%29-7-methyl-8-%28m-methoxystyryl%29-1-propargylxanthine%29+to+rat+striatal+membranes%E2%80%94a+new%2C+selective+antagonist+radioligand+for+A2A+adenosine+receptors&doi=10.1016%2Fs0928-0987%2800%2900064-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Binding of [3H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes - a new, selective antagonist radioligand for A2A adenosine receptors</span></div><div class="casAuthors">Muller, C. E.; Maurinsh, J.; Sauer, R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">259-265</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">The present study describes the prepn. and binding properties of a new, potent, and selective A2A adenosine receptor (AR) antagonist radioligand, [3H]3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine ([3H]MSX-2).  [3H]MSX-2 binding to rat striatal membranes was saturable and reversible.  Satn. expts. showed that [3H]MSX-2 labeled a single class of binding sites with high affinity (Kd=8.0 nM) and limited capacity (Bmax=1.16 fmol·mg-1 of protein).  The presence of 100 μM GTP, or 10 mM magnesium chloride, resp., had no effect on [3H]MSX-2 binding.  AR agonists competed with the binding of 1 nM [3H]MSX-2 with the following order of potency: 5'-N-ethylcarboxamidoadenosine (NECA)°2-[4-(carboxyethyl)phenylethylamino]-5'-N-ethylcarboxamidoadenosine (CGS-21680)°2-chloroadenosine (2-CADO)°N6-cyclopentyladenosine (CPA).  AR antagonists showed the following order of potency: 8-(m-bromostyryl)-3,7-dimethyl-1-propargylxanthine (BS-DMPX)°1,3-dipropyl-8-cyclopentylxanthine (DPCPX)°(R)-5,6-dimethyl-7-(1-phenylethyl)-2-(4-pyridyl)-7H-pyrrolo[2,3-d]pyrimidine-4-amine (SH-128)°3,7-dimethyl-1-propargylxanthine (DMPX)°caffeine.  The Ki values for antagonists were in accordance with data from binding studies with the agonist radioligand [3H]CGS21680, while agonist affinities were 3-7-fold lower. [3H]MSX-2 is a highly selective A2A AR antagonist radioligand exhibiting a selectivity of at least two orders of magnitude vs. all other AR subtypes.  The new radioligand shows high specific radioactivity (85 Ci/mmol, 3150 GBq/mmol) and acceptable nonspecific binding at rat striatal membranes of 20-30%, at 1 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8VMEXXUj3RbVg90H21EOLACvtfcHk0lh9vfxJbCrVRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjs1Cgsrs%253D&md5=012d1ae18ba96e8768e7652b25308998</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fs0928-0987%2800%2900064-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0928-0987%252800%252900064-6%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DMaurinsh%26aufirst%3DJ.%26aulast%3DSauer%26aufirst%3DR.%26atitle%3DBinding%2520of%2520%255B3H%255DMSX-2-%25283-%25283-hydroxypropyl%2529-7-methyl-8-%2528m-methoxystyryl%2529-1-propargylxanthine%2529%2520to%2520rat%2520striatal%2520membranes%25E2%2580%2594a%2520new%252C%2520selective%2520antagonist%2520radioligand%2520for%2520A2A%2520adenosine%2520receptors%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2000%26volume%3D10%26spage%3D259%26epage%3D265%26doi%3D10.1016%2Fs0928-0987%2800%2900064-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diekmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozola, V.</span></span> <span> </span><span class="NLM_article-title">[<sup>3</sup>H]8-Ethyl-4-methyl-2-phenyl-(8<i>R</i>)-4,5,7,8-tetrahydro-1<i>H</i>-imidazo[2,1-<i>i</i>]-purin-5-one ([3H]PSB-11), a novel high-affinity antagonist radioligand for human A3 adenosine receptors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">503</span>, <span class="refDoi"> DOI: 10.1016/s0960-894x(01)00785-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fs0960-894x%2801%2900785-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=11814828" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=501-503&author=C.+E.+M%C3%BCllerauthor=M.+Diekmannauthor=M.+Thorandauthor=V.+Ozola&title=%5B3H%5D8-Ethyl-4-methyl-2-phenyl-%288R%29-4%2C5%2C7%2C8-tetrahydro-1H-imidazo%5B2%2C1-i%5D-purin-5-one+%28%5B3H%5DPSB-11%29%2C+a+novel+high-affinity+antagonist+radioligand+for+human+A3+adenosine+receptors&doi=10.1016%2Fs0960-894x%2801%2900785-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fs0960-894x%2801%2900785-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0960-894x%252801%252900785-5%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DDiekmann%26aufirst%3DM.%26aulast%3DThorand%26aufirst%3DM.%26aulast%3DOzola%26aufirst%3DV.%26atitle%3D%255B3H%255D8-Ethyl-4-methyl-2-phenyl-%25288R%2529-4%252C5%252C7%252C8-tetrahydro-1H-imidazo%255B2%252C1-i%255D-purin-5-one%2520%2528%255B3H%255DPSB-11%2529%252C%2520a%2520novel%2520high-affinity%2520antagonist%2520radioligand%2520for%2520human%2520A3%2520adenosine%2520receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D501%26epage%3D503%26doi%3D10.1016%2Fs0960-894x%2801%2900785-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klotz, K.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohse, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwabe, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristalli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vittori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grifantini, M.</span></span> <span> </span><span class="NLM_article-title">2-Chloro-N<sup>6</sup>-[<sup>3</sup>H]cyclopentyladenosine ([<sup>3</sup>H]CCPA) a high affinity agonist radioligand for A1 adenosine receptors</span>. <i>Naunyn-Schmiedeberg’s Arch. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>340</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">683</span>, <span class="refDoi"> DOI: 10.1007/bf00717744</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1007%2Fbf00717744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=2615857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADyaK3cXhtFGhsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=1989&pages=679-683&author=K.-N.+Klotzauthor=M.+J.+Lohseauthor=U.+Schwabeauthor=G.+Cristalliauthor=S.+Vittoriauthor=M.+Grifantini&title=2-Chloro-N6-%5B3H%5Dcyclopentyladenosine+%28%5B3H%5DCCPA%29+a+high+affinity+agonist+radioligand+for+A1+adenosine+receptors&doi=10.1007%2Fbf00717744"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">2-Chloro-N6-[3H]cyclopentyladenosine ([3H]CPPA) - a high affinity agonist radioligand for A1 adenosine receptors</span></div><div class="casAuthors">Klotz, Karl Norbert; Lohse, Martin J.; Schwabe, Ulrich; Cristalli, Gloria; Vittori, Sauro; Grifantini, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">679-83</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    </div><div class="casAbstract">The tritiated analog of 2-chloro-N6-cyclopentyladenosine (CCPA) (I), an adenosine deriv. with subnanomolar affinity and a 10,000-fold selectivity for A1 adenosine receptors, has been examd. as a new agonist radioligand.  [3H]CCPA was prepd. with a specific radioactivity of 1.58 TBq/mmol (43 Ci/mmol) and bound in a reversible manner to A1 receptors from rat brain membranes with a high affinity KD value of 0.2 nmol/L.  In the presence of GTP, a KDvalue of 13 nmol/L was detd. for the low affinity state for agonist binding.  Competition of several adenosine receptor agonists and antagonists for [3H]CCPA binding to rat brain membranes confirmed binding to an A1 receptor.  Solubilized A1 receptors bound [3H]CCPA with similar affinity for the high affinity state.  At solubilized receptors a reduced assocn. rate was obsd. in the presence of MgCl2, as has been shown for the agonist [3H]N6-phenylisopropyladenosine ([3H]PIA).  [3H]CCPA was also used for detection of A1 receptors in rat cardiomyocyte membranes, a tissue with a very low receptor d.  Kd-Value of 0.4 nmol-L and a Bmax-value of 16 fmol-platelet membranes, no specific binding of [3H]CCPA was measured at concns. up to 400 nmol/L, indicating that A2 receptors did not bind [3H]CCPA.  Based on the subnanomolar affinity and the high selectivity for A1 receptors, [3H]CCPA proved to be a useful agonist radioligand for characterization of A1 adenosine receptors also in tissues with very low receptor d.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquP1vlbGByYrVg90H21EOLACvtfcHk0lgrWGcvDmWL4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhtFGhsL8%253D&md5=d44acdedb7aa0c3b3c6f7d79666ae139</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1007%2Fbf00717744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fbf00717744%26sid%3Dliteratum%253Aachs%26aulast%3DKlotz%26aufirst%3DK.-N.%26aulast%3DLohse%26aufirst%3DM.%2BJ.%26aulast%3DSchwabe%26aufirst%3DU.%26aulast%3DCristalli%26aufirst%3DG.%26aulast%3DVittori%26aufirst%3DS.%26aulast%3DGrifantini%26aufirst%3DM.%26atitle%3D2-Chloro-N6-%255B3H%255Dcyclopentyladenosine%2520%2528%255B3H%255DCCPA%2529%2520a%2520high%2520affinity%2520agonist%2520radioligand%2520for%2520A1%2520adenosine%2520receptors%26jtitle%3DNaunyn-Schmiedeberg%25E2%2580%2599s%2520Arch.%2520Pharmacol.%26date%3D1989%26volume%3D340%26spage%3D679%26epage%3D683%26doi%3D10.1007%2Fbf00717744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borrmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertarelli, D. C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florin, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiff, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span> <span> </span><span class="NLM_article-title">1-Alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: Development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">3994</span>– <span class="NLM_lpage">4006</span>, <span class="refDoi"> DOI: 10.1021/jm900413e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900413e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsVOmtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3994-4006&author=T.+Borrmannauthor=S.+Hinzauthor=D.+C.+G.+Bertarelliauthor=W.+Liauthor=N.+C.+Florinauthor=A.+B.+Scheiffauthor=C.+E.+M%C3%BCller&title=1-Alkyl-8-%28piperazine-1-sulfonyl%29phenylxanthines%3A+Development+and+characterization+of+adenosine+A2B+receptor+antagonists+and+a+new+radioligand+with+subnanomolar+affinity+and+subtype+specificity&doi=10.1021%2Fjm900413e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">1-Alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: Development and Characterization of Adenosine A2B Receptor Antagonists and a New Radioligand with Subnanomolar Affinity and Subtype Specificity</span></div><div class="casAuthors">Borrmann, Thomas; Hinz, Sonja; Bertarelli, Daniela C. G.; Li, Wenjin; Florin, Nicole C.; Scheiff, Anja B.; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3994-4006</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new series of 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines was designed, synthesized, and characterized in radioligand binding and functional assays at A2B adenosine receptors.  A2B antagonists with subnanomolar affinity and high selectivity were discovered.  The most potent compds. were 1-ethyl-8-(4-(4-(4-trifluoromethylbenzyl)piperazine-1-sulfonyl)phenyl)xanthine (PSB-09120, Ki (human A2B) = 0.157 nM) and 8-(4-(4-(4-chlorobenzyl)piperazine-1-sulfonyl)phenyl)-1-propylxanthine (PSB-0788, Ki (human A2B) = 0.393 nM).  Moreover, 8-(4-(4-(4-chlorophenyl)piperazine-1-sulfonyl)phenyl)-1-propylxanthine ( PSB-603) was developed as an A2B-specific antagonist exhibiting a Ki value of 0.553 nM at the human A2B receptor and virtually no affinity for the human and rat A1 and A2A and the human A3 receptors up to a concn. of 10 μM.  A tritiated form of the compd. was prepd. as a new radioligand and characterized in kinetic, satn., and competition studies.  It was shown to be a useful pharmacol. tool for the selective labeling of human as well as rodent A2B receptors (KD human A2B 0.403 nM, mouse A2B 0.351 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWuka8J5BT1LVg90H21EOLACvtfcHk0lgrWGcvDmWL4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsVOmtLg%253D&md5=c32619fcbde66b6f4237b0467d9d2950</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fjm900413e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900413e%26sid%3Dliteratum%253Aachs%26aulast%3DBorrmann%26aufirst%3DT.%26aulast%3DHinz%26aufirst%3DS.%26aulast%3DBertarelli%26aufirst%3DD.%2BC.%2BG.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DFlorin%26aufirst%3DN.%2BC.%26aulast%3DScheiff%26aufirst%3DA.%2BB.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3D1-Alkyl-8-%2528piperazine-1-sulfonyl%2529phenylxanthines%253A%2520Development%2520and%2520characterization%2520of%2520adenosine%2520A2B%2520receptor%2520antagonists%2520and%2520a%2520new%2520radioligand%2520with%2520subnanomolar%2520affinity%2520and%2520subtype%2520specificity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3994%26epage%3D4006%26doi%3D10.1021%2Fjm900413e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span> <span> </span><span class="NLM_article-title">Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: Toward the development of sulfonic acid prodrugs with peroral bioavailability</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1031</span>– <span class="NLM_lpage">1043</span>, <span class="refDoi"> DOI: 10.1021/jm0310030</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0310030" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkvVKltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1031-1043&author=L.+Yanauthor=C.+E.+M%C3%BCller&title=Preparation%2C+properties%2C+reactions%2C+and+adenosine+receptor+affinities+of+sulfophenylxanthine+nitrophenyl+esters%3A+Toward+the+development+of+sulfonic+acid+prodrugs+with+peroral+bioavailability&doi=10.1021%2Fjm0310030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation, Properties, Reactions, and Adenosine Receptor Affinities of Sulfophenylxanthine Nitrophenyl Esters: Toward the Development of Sulfonic Acid Prodrugs with Peroral Bioavailability</span></div><div class="casAuthors">Yan, Luo; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1031-1043</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Many currently known antagonists for P2 purinergic receptors are anionic mols. bearing one or several phenylsulfonate groups.  Among the P1 (adenosine) receptor antagonists, the xanthine phenylsulfonates are a potent class of compds.  Due to their high acidity, phenylsulfonates are neg. charged at physiol. pH values and do not easily penetrate cell membranes.  The present study was aimed at developing lipophilic, perorally bioavailable prodrugs of sulfonates by converting them into chem. stable nitrophenyl esters.  Initial stability tests at different pH values using nitrophenyl tosylates as model compds. showed that m-nitrophenyl esters were stable over a wide pH range, while the ortho and para isomers were less stable under strongly acidic or basic conditions.  A series of m- and p-nitrophenyl esters of p-sulfophenylxanthine derivs., I (R1 = Me, n-Pr, n-Bu, R2 = Me, n-Pr, H, nitro position = 3, 4), were synthesized as model compds.  The target xanthine derivs. were obtained in high yields by condensation of the appropriate 5,6-diaminouracils with 4-(nitrophenoxysulfonyl)benzoic acids in the presence of a carbodiimide, followed by ring closure with polyphosphoric acid trimethylsilyl ester.  The chem. and enzymic stability of the m-nitrophenyl esters was investigated in vitro by means of capillary electrophoresis.  High stability in aq. soln., in artificial gastric acid, and in serum was obsd.  However, compd. I (R1 = n-Pr, R2 = H, nitro position = 3), used as a prototypic xanthine m-nitrophenylsulfonate, was hydrolyzed by rat liver homogenate indicating an enzymic pathway of hydrolysis.  Thus, nitrophenyl esters of sulfonic acids have a potential as peroral prodrugs of drugs bearing a sulfonate group.  The nitrophenyl esters of sulfophenylxanthines were addnl. investigated for their adenosine receptor affinities.  They showed high affinity at A1, A2A, and A2B, but not at A3 ARs.  One of the most potent compds. was 1-propyl-8-[4-[[p-nitrophenoxy]sulfonyl]phenyl]xanthine I (R1 = n-Pr, R2 = H, nitro position = 4), a mixed A1/A2B antagonist (KiA1 3.6 nM, KiA2B 5.4 nM) selective vs. the other subtypes.  As a further result of this study, the m-nitrophenoxy group was found to be a suitable protecting group for sulfonates in org. synthesis due to its high lipophilicity and stability; it can be split off under strongly basic conditions.  This new protection strategy allowed for the upscaling of the synthesis of 1-propyl-8-p-sulfophenylxanthine (PSB-1115), a selective A2B antagonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLwuTkcmC9DbVg90H21EOLACvtfcHk0lgrWGcvDmWL4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkvVKltQ%253D%253D&md5=9cfcfc3bee9c9ad1a9a3c1cdfd65baad</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm0310030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0310030%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DL.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DPreparation%252C%2520properties%252C%2520reactions%252C%2520and%2520adenosine%2520receptor%2520affinities%2520of%2520sulfophenylxanthine%2520nitrophenyl%2520esters%253A%2520Toward%2520the%2520development%2520of%2520sulfonic%2520acid%2520prodrugs%2520with%2520peroral%2520bioavailability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1031%26epage%3D1043%26doi%3D10.1021%2Fjm0310030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kottke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Receptor-specific functional efficacies of alkyl imidazoles as dual histamine H3/H4 receptor ligands</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>654</i></span>,  <span class="NLM_fpage">200</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2010.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.ejphar.2010.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=21237145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFeqt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=654&publication_year=2011&pages=200-208&author=T.+Kottkeauthor=K.+Sanderauthor=L.+Weizelauthor=E.+H.+Schneiderauthor=R.+Seifertauthor=H.+Stark&title=Receptor-specific+functional+efficacies+of+alkyl+imidazoles+as+dual+histamine+H3%2FH4+receptor+ligands&doi=10.1016%2Fj.ejphar.2010.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor-specific functional efficacies of alkyl imidazoles as dual histamine H3/H4 receptor ligands</span></div><div class="casAuthors">Kottke, Tim; Sander, Kerstin; Weizel, Lilia; Schneider, Erich H.; Seifert, Roland; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">654</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">200-208</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histamine H3 and H4 receptors are highly related G protein-coupled receptors.  Preclin. and clin. data strongly suggest the potential therapeutic application of selectively acting histamine H4 receptor ligands to inflammatory conditions but also hint at a certain interference of the two receptors in diseases attended with itch and pain.  The aim of this investigation was to identify dual acting ligands as pharmacol. tools.  Receptor binding profiles of ω-(1H-imidazol-4-yl)alkyl derivs. structurally defined as amides, carbamates, esters, ethers, ketones and ureas were evaluated with respect to their potencies at histamine H3 and H4 receptors.  A two-step screening method based on in vitro radioligand binding studies and functional [35S]GTPγS binding expts. was performed.  The examd. series of imidazole-contg. compds. displayed both, selective histamine H4 receptor and dual acting histamine H3/H4 receptor ligands.  Slight structural modifications caused major differences in selectivity profiles and on functional properties at the human histamine H4 receptor.  N-(3-(1H-Imidazol-4-yl)propyl)-2-cyclohexylacetamide 11 was identified as most potent and selective human histamine H4 receptor ligand in this series (K i = 45 nM).  Amide- and ether-contg. structures consistently exhibited partial agonist efficacies, whereas ureas, ketones, esters and carbamates mainly acted as antagonists and inverse agonists.  We identified novel dual acting histamine H3/H4 receptor ligands with varying efficacies at the histamine H4 receptor subtype, whereas histamine H3 receptor antagonism was kept const., e.g. 3-(1H-imidazol-4-yl)propyl (cyclohexylmethyl)carbamate 19 or 4-(3-(3-phenylpropylthio)propyl)-1H-imidazole 30.  These compds. state valuable pharmacol. tools in studies of diseases, in which histamine H3 and H4 receptor signalling contributes to pathophysiol. conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsv9f0qBmwObVg90H21EOLACvtfcHk0ljkfvGbFBfX9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFeqt7s%253D&md5=3adf59287c8109cd516eeeee25459c5a</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2010.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2010.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DKottke%26aufirst%3DT.%26aulast%3DSander%26aufirst%3DK.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DSchneider%26aufirst%3DE.%2BH.%26aulast%3DSeifert%26aufirst%3DR.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DReceptor-specific%2520functional%2520efficacies%2520of%2520alkyl%2520imidazoles%2520as%2520dual%2520histamine%2520H3%252FH4%2520receptor%2520ligands%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D654%26spage%3D200%26epage%3D208%26doi%3D10.1016%2Fj.ejphar.2010.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schübler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kottke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis, molecular properties estimations, and dual dopamine D2 and D3 receptor activities of benzothiazole-based ligands</span>. <i>Front. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.3389/fchem.2017.00064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.3389%2Ffchem.2017.00064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=28955709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVGms7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=64-19&author=M.+Sch%C3%BCblerauthor=B.+Sadekauthor=T.+Kottkeauthor=L.+Weizelauthor=H.+Stark&title=Synthesis%2C+molecular+properties+estimations%2C+and+dual+dopamine+D2+and+D3+receptor+activities+of+benzothiazole-based+ligands&doi=10.3389%2Ffchem.2017.00064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, molecular properties estimations, and dual dopamine D2 and D3 receptor activities of benzothiazole-based ligands</span></div><div class="casAuthors">Schuebler, Moritz; Sadek, Bassem; Kottke, Tim; Weizel, Lilia; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Chemistry (Lausanne, Switzerland)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">64/1-64/19</span>CODEN:
                <span class="NLM_cas:coden">FCLSAA</span>;
        ISSN:<span class="NLM_cas:issn">2296-2646</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Neurleptic drugs, e.g., aripiprazole, targeting the dopamine D2S and D3 receptors (D2SR and D3R) in the central nervous system are widely used in the treatment of several psychotic and neurodegenerative diseases.  Therefore, a new series of benzothiazole-based ligands (3-20) was synthesized by applying the bioisosteric approach derived from the selective D3Rs ligand BP-897 (1) and its structurally related benz[d]imidazole deriv. (2).  Herein, introduction of the benzothiazole moiety was well tolerated by D2SR and D3R binding sites leading to antagonist affinities in the low nanomolar concn. range at both receptor subtypes.  However, all novel compds. showed lower antagonist affinity to D3R when compared to that of 1.  Further exploration of different substitution patterns at the benzothiazole heterocycle and the basic 4-phenylpiperazine resulted in the discovery of high dually acting D2SR and D3R ligands.  Moreover, the methoxy substitution at 2-position of 4-phenylpiperazine resulted in significantly (22-fold) increased D2SR binding affinity as compared to the parent ligand 1, and improved physicochem. and drug-likeness properties of ligands 3-11.  However, the latter structural modifications failed to improve the drug-able properties in ligands having un-substituted 4-phenylpiperazine analogs (12-20).  Accordingly, compd. 9 showed in addn. to high dual affinity at the D2SR and D3R [Ki (hD2SR) = 2.8 ± 0.8 nM; Ki (hD3R) = 3.0 ± 1.6 nM], promising clogS, clogP, LE (hD2SR, hD3R), LipE (hD2SR, hD3R), and drug-likeness score values of -4.7, 4.2, (0.4, 0.4), (4.4, 4.3), and 0.7, resp.  Also, the deaminated analog 10 [Ki (hD2SR) = 3.2 ± 0.4 nM; Ki (hD3R) = 8.5 ± 2.2 nM] revealed clogS, clogP, LE (hD2SR, hD3R), LipE (hD2SR, hD3R) and drug-likeness score values of -4.7, 4.2, (0.4, 0.4), (3.9, 3.5), and 0.4, resp.  The results obsd. for the newly developed benzothiazole-based ligands 3-20 provide clues for the diversity in structure activity relationships (SARs) at the D2SR and D3R subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqglTMkwann9LVg90H21EOLACvtfcHk0ljkfvGbFBfX9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVGms7nE&md5=1331655955d94f33249ceb1156aa384b</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.3389%2Ffchem.2017.00064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffchem.2017.00064%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25BCbler%26aufirst%3DM.%26aulast%3DSadek%26aufirst%3DB.%26aulast%3DKottke%26aufirst%3DT.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DSynthesis%252C%2520molecular%2520properties%2520estimations%252C%2520and%2520dual%2520dopamine%2520D2%2520and%2520D3%2520receptor%2520activities%2520of%2520benzothiazole-based%2520ligands%26jtitle%3DFront.%2520Chem.%26date%3D2017%26volume%3D5%26spage%3D64%26epage%3D19%26doi%3D10.3389%2Ffchem.2017.00064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bautista-Aguilera, Ó. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagenow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palomino-Antolin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farré-Alins, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismaili, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joffrin, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soukup, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janočková, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinowsky, L.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Multitarget-directed ligands combining cholinesterase and monoamine oxidase inhibition with histamine H3R antagonism for neurodegenerative diseases</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">12765</span>– <span class="NLM_lpage">12769</span>, <span class="refDoi"> DOI: 10.1002/anie.201706072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2Fanie.201706072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVekt73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=12765-12769&author=%C3%93.+M.+Bautista-Aguileraauthor=S.+Hagenowauthor=A.+Palomino-Antolinauthor=V.+Farr%C3%A9-Alinsauthor=L.+Ismailiauthor=P.+L.+Joffrinauthor=M.+L.+Jimenoauthor=O.+Soukupauthor=J.+Jano%C4%8Dkov%C3%A1author=L.+Kalinowsky&title=Multitarget-directed+ligands+combining+cholinesterase+and+monoamine+oxidase+inhibition+with+histamine+H3R+antagonism+for+neurodegenerative+diseases&doi=10.1002%2Fanie.201706072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3R Antagonism for Neurodegenerative Diseases</span></div><div class="casAuthors">Bautista-Aguilera, Oscar M.; Hagenow, Stefanie; Palomino-Antolin, Alejandra; Farre-Alins, Victor; Ismaili, Lhassane; Joffrin, Pierre-Louis; Jimeno, Maria L.; Soukup, Ondrej; Janockova, Jana; Kalinowsky, Lena; Proschak, Ewgenij; Iriepa, Isabel; Moraleda, Ignacio; Schwed, Johannes S.; Romero Martinez, Alejandro; Lopez-Munoz, Francisco; Chioua, Mourad; Egea, Javier; Ramsay, Rona R.; Marco-Contelles, Jose; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">12765-12769</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The therapy of complex neurodegenerative diseases requires the development of multitarget-directed drugs (MTDs).  Novel indole derivs. with inhibitory activity towards acetyl/butyrylcholinesterases and monoamine oxidases A/B as well as the histamine H3 receptor (H3R) were obtained by optimization of the neuroprotectant ASS234 by incorporating generally accepted H3R pharmacophore motifs.  These small-mol. hits demonstrated balanced activities at the targets, mostly in the nanomolar concn. range.  Addnl. in vitro studies showed antioxidative neuroprotective effects as well as the ability to penetrate the blood-brain barrier.  With this promising in vitro profile, contilisant (at 1 mg kg-1 i.p.) also significantly improved lipopolysaccharide-induced cognitive deficits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2wNLAClUFULVg90H21EOLACvtfcHk0ljkfvGbFBfX9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVekt73L&md5=4a962ad1ada3f5b8e8102add09cd4e60</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1002%2Fanie.201706072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201706072%26sid%3Dliteratum%253Aachs%26aulast%3DBautista-Aguilera%26aufirst%3D%25C3%2593.%2BM.%26aulast%3DHagenow%26aufirst%3DS.%26aulast%3DPalomino-Antolin%26aufirst%3DA.%26aulast%3DFarr%25C3%25A9-Alins%26aufirst%3DV.%26aulast%3DIsmaili%26aufirst%3DL.%26aulast%3DJoffrin%26aufirst%3DP.%2BL.%26aulast%3DJimeno%26aufirst%3DM.%2BL.%26aulast%3DSoukup%26aufirst%3DO.%26aulast%3DJano%25C4%258Dkov%25C3%25A1%26aufirst%3DJ.%26aulast%3DKalinowsky%26aufirst%3DL.%26atitle%3DMultitarget-directed%2520ligands%2520combining%2520cholinesterase%2520and%2520monoamine%2520oxidase%2520inhibition%2520with%2520histamine%2520H3R%2520antagonism%2520for%2520neurodegenerative%2520diseases%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D12765%26epage%3D12769%26doi%3D10.1002%2Fanie.201706072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryoo, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dylan, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bs, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. N.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson’s disease</span>. <i>Isis</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">788</span>– <span class="NLM_lpage">797</span>, <span class="refDoi"> DOI: 10.1002/mds.870130506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2Fmds.870130506" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1998&pages=788-797&author=H.+L.+Ryooauthor=B.+S.+Dylanauthor=P.+Bsauthor=J.+N.+Joyce&title=Dopamine+D3+receptor+is+decreased+and+D2+receptor+is+elevated+in+the+striatum+of+Parkinson%E2%80%99s+disease&doi=10.1002%2Fmds.870130506"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fmds.870130506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.870130506%26sid%3Dliteratum%253Aachs%26aulast%3DRyoo%26aufirst%3DH.%2BL.%26aulast%3DDylan%26aufirst%3DB.%2BS.%26aulast%3DBs%26aufirst%3DP.%26aulast%3DJoyce%26aufirst%3DJ.%2BN.%26atitle%3DDopamine%2520D3%2520receptor%2520is%2520decreased%2520and%2520D2%2520receptor%2520is%2520elevated%2520in%2520the%2520striatum%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DIsis%26date%3D1998%26volume%3D13%26spage%3D788%26epage%3D797%26doi%3D10.1002%2Fmds.870130506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 agonists in the treatment of Parkinson’s disease</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">908</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.2174/156802661510150328223428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.2174%2F156802661510150328223428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=25832718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1akt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=908-926&author=B.+Dasauthor=G.+Modiauthor=A.+Dutta&title=Dopamine+D3+agonists+in+the+treatment+of+Parkinson%E2%80%99s+disease&doi=10.2174%2F156802661510150328223428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 Agonists in the Treatment of Parkinson's Disease</span></div><div class="casAuthors">Das, Banibrata; Modi, Gyan; Dutta, Aloke</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">908-926</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) is t he second most common form of neurodegenerative disorders that results from the progressive loss of dopaminergic neurons in the midbrain substantia nigra pars compacta (SNpc) triggering profound motor perturbation, as well as cognitive, sensory and mood deficits.  Although these symptoms can be improved using currently available dopamine replacement strategies, they are not able to slow the neurodegenerative process that underlies PD progression.  Following the discovery of the D3 receptor from mol. cloning, it has gained much attention as a potential therapeutic target for the treatment of PD due to their localization in the limbic regions of the brain as well as pharmacol. similarity to the D2 receptor subtype.  Of particular interest, D3 receptor- selective agonists appear to have neuroprotective effects apart from their ability to relieve PD symptoms.  Owing to the distinct significance of D3 receptor in mediating diverse neurol. effects, it represents a unique target for therapeutic intervention in PD with much less undesirable side effects.  Herein, we review progress in the development of D3 receptor selective agonist mols. having a broad spectrum of affinities, selectivities as well as unique pharmacol. properties directed at slowing the neurodegeneration process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1vO7t50SK9rVg90H21EOLACvtfcHk0lhaW1_u_-drcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1akt7w%253D&md5=46885592d050d099cbad73ba7ef8e61b</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.2174%2F156802661510150328223428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802661510150328223428%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DB.%26aulast%3DModi%26aufirst%3DG.%26aulast%3DDutta%26aufirst%3DA.%26atitle%3DDopamine%2520D3%2520agonists%2520in%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2015%26volume%3D15%26spage%3D908%26epage%3D926%26doi%3D10.2174%2F156802661510150328223428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kassel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwed, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 receptor agonists as pharmacological tools</span>. <i>Eur. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1480</span>– <span class="NLM_lpage">1499</span>, <span class="refDoi"> DOI: 10.1016/j.euroneuro.2014.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.euroneuro.2014.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=25498414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFCrtrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1480-1499&author=S.+Kasselauthor=J.+S.+Schwedauthor=H.+Stark&title=Dopamine+D3+receptor+agonists+as+pharmacological+tools&doi=10.1016%2Fj.euroneuro.2014.11.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 receptor agonists as pharmacological tools</span></div><div class="casAuthors">Kassel, S.; Schwed, J. S.; Stark, H.</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1480-1499</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dysregulation of the dopaminergic innervation in the central nervous system plays a key role in different neurol. disorders like Parkinson's disease, restless legs syndrome, schizophrenia etc.  Although dopamine D3 receptors have been recognized as an important target in these diseases, their full pharmacol. properties need further investigations.  With focus on dopamine D3 receptor full agonists, this review has divided the ergoline and non-ergoline ligands in dissimilar chem. subclasses describing their pharmacodynamic properties on different related receptors, on species differences and their functional properties on different signaling mechanism.  This is combined with a short description of structure-activity relationships for each class.  Therefore, this overview should support the rational choice for the optimal compd. selection based on affinity, selectivity and efficacy data in biochem. and pharmacol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUbHeDU9BILrVg90H21EOLACvtfcHk0lhaW1_u_-drcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFCrtrrE&md5=ad73384987fecd0b4b795c771270eefb</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.euroneuro.2014.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euroneuro.2014.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DKassel%26aufirst%3DS.%26aulast%3DSchwed%26aufirst%3DJ.%2BS.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DDopamine%2520D3%2520receptor%2520agonists%2520as%2520pharmacological%2520tools%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2015%26volume%3D25%26spage%3D1480%26epage%3D1499%26doi%3D10.1016%2Fj.euroneuro.2014.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hackling, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 receptor ligands with antagonist properties</span>. <i>Chembiochem</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">946</span>– <span class="NLM_lpage">961</span>, <span class="refDoi"> DOI: 10.1002/1439-7633(20021004)3:10<946::aid-cbic946>3.0.co;2-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2F1439-7633%2820021004%293%3A10%3C946%3A%3Aaid-cbic946%3E3.0.co%3B2-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=12362359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD38XnvFGgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=946-961&author=A.+E.+Hacklingauthor=H.+Stark&title=Dopamine+D3+receptor+ligands+with+antagonist+properties&doi=10.1002%2F1439-7633%2820021004%293%3A10%3C946%3A%3Aaid-cbic946%3E3.0.co%3B2-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 receptor ligands with antagonist properties</span></div><div class="casAuthors">Hackling, Anneke E.; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">946-961</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The dopamine D3 receptor was recognized to play an important role in the mol. mechanisms of various neuropsychiatric disorders.  The development of new dopamine D3 receptor selective antagonists is premised on the potentially improved therapeutic treatment of psychosis like schizophrenia.  Partial agonists at dopamine D3 receptors are supposed to be beneficial when administered to drug abusers or in Parkinson's disease.  The structural basis for most compds. is at least a basic, aryl-substituted alkanamine part with an alkyl moiety, which in many compds. forms a spacer to another aryl residue.  Structural variety among the amine moiety includes aminotetralins, tetrahydroisoquinolines, isoindoles, benzazepines, and amino-indans, as well as pyrrolidines, pyrroles, and 4-phenylpiperazines.  Various ways for lead optimization are shown in different classes of compds.  Promising ligands with high D3 receptor affinity often lack sufficient selectivity or display deficits in the required in vivo parameters.  Structure-activity relationships for dopamine D3 receptor antagonists and partial agonists are discussed here, along with the outlook for their potential therapeutic application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7h56q6SPZN7Vg90H21EOLACvtfcHk0lhaW1_u_-drcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnvFGgu7c%253D&md5=ba9cd2302ced89619ae5d1d82e7d08e4</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1002%2F1439-7633%2820021004%293%3A10%3C946%3A%3Aaid-cbic946%3E3.0.co%3B2-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1439-7633%252820021004%25293%253A10%253C946%253A%253Aaid-cbic946%253E3.0.co%253B2-5%26sid%3Dliteratum%253Aachs%26aulast%3DHackling%26aufirst%3DA.%2BE.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DDopamine%2520D3%2520receptor%2520ligands%2520with%2520antagonist%2520properties%26jtitle%3DChembiochem%26date%3D2002%26volume%3D3%26spage%3D946%26epage%3D961%26doi%3D10.1002%2F1439-7633%2820021004%293%3A10%3C946%3A%3Aaid-cbic946%3E3.0.co%3B2-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahlholm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacome, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Highly selective dopamine D3 receptor antagonists with arylated diazaspiro alkane cores</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9905</span>– <span class="NLM_lpage">9910</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01248</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01248" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2gsbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9905-9910&author=S.+W.+Reillyauthor=S.+Griffinauthor=M.+Taylorauthor=K.+Sahlholmauthor=C.-C.+Wengauthor=K.+Xuauthor=D.+A.+Jacomeauthor=R.+R.+Luedtkeauthor=R.+H.+Mach&title=Highly+selective+dopamine+D3+receptor+antagonists+with+arylated+diazaspiro+alkane+cores&doi=10.1021%2Facs.jmedchem.7b01248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Dopamine D3 Receptor Antagonists with Arylated Diazaspiro Alkane Cores</span></div><div class="casAuthors">Reilly, Sean W.; Griffin, Suzy; Taylor, Michelle; Sahlholm, Kristoffer; Weng, Chi-Chang; Xu, Kuiying; Jacome, Daniel A.; Luedtke, Robert R.; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9905-9910</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aryldiazaspirocyclylpropyl phenyltriazolyl thioethers such as I (R = 2-MeOC6H4, 4-FC6H4, 4-MeOC6H4, 2-pyridinyl, 3-NCC6H4, 2,3-Cl2C6H3) were prepd. as selective dopamine D3 receptor (D3R) antagonists; their selectivities for D3R over D2R and for selected compds. over 5-HT1a, 5-HT2a, and 5-HT2c receptors and adenylyl cyclase were detd.  I (R = 2-MeOC6H4, 4-FC6H4) showed favorable D3R affinities (Ki = 12-25.6 nM) and were 264- to 905-fold selective for D3R vs D2R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHLC1nn5_14LVg90H21EOLACvtfcHk0lifjyaorHaRdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2gsbjL&md5=a60ed8b0524189901b7155e11025d3c6</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01248%26sid%3Dliteratum%253Aachs%26aulast%3DReilly%26aufirst%3DS.%2BW.%26aulast%3DGriffin%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DSahlholm%26aufirst%3DK.%26aulast%3DWeng%26aufirst%3DC.-C.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DJacome%26aufirst%3DD.%2BA.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DHighly%2520selective%2520dopamine%2520D3%2520receptor%2520antagonists%2520with%2520arylated%2520diazaspiro%2520alkane%2520cores%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9905%26epage%3D9910%26doi%3D10.1021%2Facs.jmedchem.7b01248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maramai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 receptor antagonists as potential therapeutics for the treatment of neurological diseases</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">451</span>, <span class="refDoi"> DOI: 10.3389/fnins.2016.00451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.3389%2Ffnins.2016.00451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=27761108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BC2srktFCktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=451&author=S.+Maramaiauthor=S.+Gemmaauthor=S.+Brogiauthor=G.+Campianiauthor=S.+Butiniauthor=H.+Starkauthor=M.+Brindisi&title=Dopamine+D3+receptor+antagonists+as+potential+therapeutics+for+the+treatment+of+neurological+diseases&doi=10.3389%2Ffnins.2016.00451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases</span></div><div class="casAuthors">Maramai Samuele; Gemma Sandra; Brogi Simone; Campiani Giuseppe; Butini Stefania; Brindisi Margherita; Stark Holger</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">451</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">D3 receptors represent a major focus of current drug design and development of therapeutics for dopamine-related pathological states.  Their close homology with the D2 receptor subtype makes the development of D3 selective antagonists a challenging task.  In this review, we explore the relevance and therapeutic utility of D3 antagonists or partial agonists endowed with multireceptor affinity profile in the field of central nervous system disorders such as schizophrenia and drug abuse.  In fact, the peculiar distribution and low brain abundance of D3 receptors make them a valuable target for the development of drugs devoid of motor side effects classically elicited by D2 antagonists.  Recent research efforts were devoted to the conception of chemical templates possibly endowed with a multi-target profile, especially with regards to other G-protein-coupled receptors (GPCRs).  A comprehensive overview of the recent literature in the field is herein provided.  In particular, the evolution of the chemical templates has been tracked, according to the growing advancements in both the structural information and the refinement of the key pharmacophoric elements.  The receptor/multireceptor affinity and functional profiles for the examined compounds have been covered, together with their most significant pharmacological applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdsZ2fFId2JDslzEEsg76ufW6udTcc2eZf8eM656SXAbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srktFCktA%253D%253D&md5=03b1e02b49ea48ab9331f5c9d38dfaf1</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2016.00451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2016.00451%26sid%3Dliteratum%253Aachs%26aulast%3DMaramai%26aufirst%3DS.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DBrogi%26aufirst%3DS.%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DBrindisi%26aufirst%3DM.%26atitle%3DDopamine%2520D3%2520receptor%2520antagonists%2520as%2520potential%2520therapeutics%2520for%2520the%2520treatment%2520of%2520neurological%2520diseases%26jtitle%3DFront.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D451%26doi%3D10.3389%2Ffnins.2016.00451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Micheli, F.</span></span> <span> </span><span class="NLM_article-title">Novel, Selective, and developable dopamine D3 antagonists with a modified “amino” region</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1254</span>– <span class="NLM_lpage">1260</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2Fcmdc.201700148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=28426179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntVyrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1254-1260&author=F.+Micheli&title=Novel%2C+Selective%2C+and+developable+dopamine+D3+antagonists+with+a+modified+%E2%80%9Camino%E2%80%9D+region&doi=10.1002%2Fcmdc.201700148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Novel, Selective, and Developable Dopamine D3 Antagonists with a Modified "Amino" Region</span></div><div class="casAuthors">Micheli, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1254-1260</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">This Minireview describes a presentation made at the XXIV National Meeting in Medicinal Chem. (NMMC) held in Perugia (Italy), Sept. 11-14, 2016.  It relates to the discovery of novel templates of the so-called "amino" region of dopamine D3 receptor antagonists.  Moving from the early scaffolds, which were modified in the amine portion, this review discusses the variations that led to the discovery of new systems published in 2016, which allowed the identification of compds. endowed with great selectivity over the dopamine D2 receptor and the human ether-a-go-go-related gene (hERG) ion channel.  The main efforts in characterizing these compds. were devoted not only to detg. their potency and selectivity relative to closely assocd. targets (e.g., the dopamine D2 receptor), but to ensure a large therapeutic window vs. liability points such as hERG.  In particular, we present examples of derivs. with selectivities greater than 2000-fold.  Furthermore, much focus is devoted to the overall developability of the scaffolds, ensuring that appropriate physicochem. and pharmacokinetic parameters are present in all compds. progressing through the screening cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3T2_i9pQBx7Vg90H21EOLACvtfcHk0lifjyaorHaRdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntVyrtL8%253D&md5=14ae39f7601c0bc971d1e637722c090c</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700148%26sid%3Dliteratum%253Aachs%26aulast%3DMicheli%26aufirst%3DF.%26atitle%3DNovel%252C%2520Selective%252C%2520and%2520developable%2520dopamine%2520D3%2520antagonists%2520with%2520a%2520modified%2520%25E2%2580%259Camino%25E2%2580%259D%2520region%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D1254%26epage%3D1260%26doi%3D10.1002%2Fcmdc.201700148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span> <span> </span><span class="NLM_article-title">Monoamine oxidases: The biochemistry of the proteins as targets in medicinal chemistry and drug discovery</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2189</span>– <span class="NLM_lpage">2209</span>, <span class="refDoi"> DOI: 10.2174/156802612805219978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.2174%2F156802612805219978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=23231396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1Gmsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=2189-2209&author=R.+R.+Ramsay&title=Monoamine+oxidases%3A+The+biochemistry+of+the+proteins+as+targets+in+medicinal+chemistry+and+drug+discovery&doi=10.2174%2F156802612805219978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine oxidases: the biochemistry of the proteins as targets in medicinal chemistry and drug discovery</span></div><div class="casAuthors">Ramsay, Rona R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2189-2209</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Monoamine oxidase (MAO, EC.1.4.3.4) has been a drug target for 60 years, with the primary rationale of developing drugs to treat neuropsychiatric disorders.  The biol. importance of MAO is to regulate amine levels is the brain and to metabolize amines and drugs in the periphery.  This review of the biochem. of MAO A and MAO B describes the functional properties of the two enzymes integrated with knowledge of the structures of the many MAO-inhibitor complexes published in the last 10 years.  The anal. of activity, and the chem. and kinetic mechanisms are discussed.  Inhibition studies on human MAO in vitro are now facilitated by assays using readily available materials but the kinetics of MAO involving alternative oxidative pathways and sensitivity to the oxygen concn. mean that careful anal. of the data is required as well as the good practice of detg. mechanism of inhibition and kinetic consts.  Kinetic consts. can then be compared with thermodn. calcns.  Inhibitors bind to both the oxidized and reduced forms of MAO present during turnover so both forms should be considered when using mol. dynamics to facilitate drug design.  Interaction of inhibitors with the active site can be detected as changes in the visible spectrum and these changes can provide clues about the flavin adduct formed for irreversible inhibitors or about the proximity to the flavin for reversible inhibitors.  Developing areas (knock-out mice for behavior, the imidazoline binding site, and imaging to monitor the activity and the inhibition of MAO in the patient) are mentioned.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjlHIBsEIrCLVg90H21EOLACvtfcHk0lgAAIBoMqIVBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1Gmsrk%253D&md5=bf68e400bf04c0b556a56e69d3393252</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.2174%2F156802612805219978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802612805219978%26sid%3Dliteratum%253Aachs%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26atitle%3DMonoamine%2520oxidases%253A%2520The%2520biochemistry%2520of%2520the%2520proteins%2520as%2520targets%2520in%2520medicinal%2520chemistry%2520and%2520drug%2520discovery%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2012%26volume%3D12%26spage%3D2189%26epage%3D2209%26doi%3D10.2174%2F156802612805219978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tipton, K. F.</span></span> <span> </span><span class="NLM_article-title">90 Years of monoamine oxidase: Some progress and some confusion</span>. <i>J. Neural. Transm.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1519</span>– <span class="NLM_lpage">1551</span>, <span class="refDoi"> DOI: 10.1007/s00702-018-1881-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1007%2Fs00702-018-1881-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=29637260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsVaqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2018&pages=1519-1551&author=K.+F.+Tipton&title=90+Years+of+monoamine+oxidase%3A+Some+progress+and+some+confusion&doi=10.1007%2Fs00702-018-1881-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">90 years of monoamine oxidase: some progress and some confusion</span></div><div class="casAuthors">Tipton, Keith F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neural Transmission</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1519-1551</span>CODEN:
                <span class="NLM_cas:coden">JNTRF3</span>;
        ISSN:<span class="NLM_cas:issn">0300-9564</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag GmbH</span>)
        </div><div class="casAbstract">A review.  It would not be practical to attempt to deal with all the advances that have informed our understanding of the behavior and functions of this enzyme over the past 90 years.  This account concs. key advances that explain why the monoamine oxidases remain of pharmacol. and biochem. interest and on some areas of continuing uncertainty.  Some issues that remain to be understood or are in need of further clarification are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwU8LnCd8YNLVg90H21EOLACvtfcHk0lgAAIBoMqIVBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsVaqsLg%253D&md5=73d9c86f3b2990977537cb5eca3561de</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1007%2Fs00702-018-1881-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00702-018-1881-5%26sid%3Dliteratum%253Aachs%26aulast%3DTipton%26aufirst%3DK.%2BF.%26atitle%3D90%2520Years%2520of%2520monoamine%2520oxidase%253A%2520Some%2520progress%2520and%2520some%2520confusion%26jtitle%3DJ.%2520Neural.%2520Transm.%26date%3D2018%26volume%3D125%26spage%3D1519%26epage%3D1551%26doi%3D10.1007%2Fs00702-018-1881-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riederer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laux, G.</span></span> <span> </span><span class="NLM_article-title">MAO-inhibitors in Parkinson’s disease</span>. <i>Exp. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.5607/en.2011.20.1.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.5607%2Fen.2011.20.1.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=22110357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FlsFGlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=1-17&author=P.+Riedererauthor=G.+Laux&title=MAO-inhibitors+in+Parkinson%E2%80%99s+disease&doi=10.5607%2Fen.2011.20.1.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">MAO-inhibitors in Parkinson's Disease</span></div><div class="casAuthors">Riederer Peter; Laux Gerd</div><div class="citationInfo"><span class="NLM_cas:title">Experimental neurobiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-17</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Monoamine oxidase inhibitors (MAO-I) belong to the earliest drugs tried in Parkinson's disease (PD).  They have been used with or without levodopa (L-DOPA).  Non-selective MAO-I due to their side-effect/adverse reaction profile, like tranylcypromine have limited use in the treatment of depression in PD, while selective, reversible MAO-A inhibitors are recommended due to their easier clinical handling.  For the treatment of akinesia and motor fluctuations selective irreversible MAO-B inhibitors selegiline and rasagiline are recommended.  They are safe and well tolerated at the recommended daily doses.  Their main differences are related to (1) metabolism, (2) interaction with CYP-enzymes and (3) quantitative properties at the molecular biological/genetic level.  Rasagiline is more potent in clinical practise and has a hypothesis driven more favourable side effect/adverse reaction profile due to its metabolism to aminoindan.  Both selegiline and rasagiline have a neuroprotective and neurorestaurative potential.  A head-to head clinical trial would be of utmost interest from both the clinical outcome and a hypothesis-driven point of view.  Selegiline is available as tablet and melting tablet for PD and as transdermal selegiline for depression, while rasagiline is marketed as tablet for PD.  In general, the clinical use of MAO-I nowadays is underestimated.  There should be more efforts to evaluate their clinical potency as antidepressants and antidementive drugs in addition to the final proof of their disease-modifying potential.  In line with this are recent innovative developments of MAO-I plus inhibition of acetylcholine esterase for Alzheimer's disease as well as combined MAO-I and iron chelation for PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLFR15fhEdC_csfMJQC1ZdfW6udTcc2ea4-0fICTeBWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FlsFGlsw%253D%253D&md5=83bd71bf598fe9e625291fa7c98ac0fd</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.5607%2Fen.2011.20.1.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5607%252Fen.2011.20.1.1%26sid%3Dliteratum%253Aachs%26aulast%3DRiederer%26aufirst%3DP.%26aulast%3DLaux%26aufirst%3DG.%26atitle%3DMAO-inhibitors%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DExp.%2520Neurobiol.%26date%3D2011%26volume%3D20%26spage%3D1%26epage%3D17%26doi%3D10.5607%2Fen.2011.20.1.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeMaagd, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philip, A.</span></span> <span> </span><span class="NLM_article-title">Parkinson’s disease and its management: Part 5: Treatment of nonmotor complications</span>. <i>P T</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">838</span>– <span class="NLM_lpage">846</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=26681906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BC28rislyrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2015&pages=838-846&author=G.+DeMaagdauthor=A.+Philip&title=Parkinson%E2%80%99s+disease+and+its+management%3A+Part+5%3A+Treatment+of+nonmotor+complications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Parkinson's Disease and Its Management: Part 5: Treatment of Nonmotor Complications</span></div><div class="casAuthors">DeMaagd George; Philip Ashok</div><div class="citationInfo"><span class="NLM_cas:title">P & T : a peer-reviewed journal for formulary management</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">838-46</span>
        ISSN:<span class="NLM_cas:issn">1052-1372</span>.
    </div><div class="casAbstract">Most patients with Parkinson's disease experience nonmotor complications, broadly classified as either neuropsychiatric presentations or autonomic disorders.  Despite the prevalence of these nonmotor features, treatment options for them are limited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyYNpHHtF1I_h3YQQtAhNufW6udTcc2ea4-0fICTeBWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rislyrsQ%253D%253D&md5=e528716cab59f2a74968b3ebb4643b81</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDeMaagd%26aufirst%3DG.%26aulast%3DPhilip%26aufirst%3DA.%26atitle%3DParkinson%25E2%2580%2599s%2520disease%2520and%2520its%2520management%253A%2520Part%25205%253A%2520Treatment%2520of%2520nonmotor%2520complications%26jtitle%3DP%2520T%26date%3D2015%26volume%3D40%26spage%3D838%26epage%3D846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of phenylxanthine derivatives as potential dual A2AR antagonists/MAO-B inhibitors for Parkinson’s disease</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1010</span>, <span class="refDoi"> DOI: 10.3390/molecules22061010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.3390%2Fmolecules22061010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVGgtLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1010&author=X.+Wangauthor=C.+Hanauthor=Y.+Xuauthor=K.+Wuauthor=S.+Chenauthor=M.+Huauthor=L.+Wangauthor=Y.+Ye&title=Synthesis+and+evaluation+of+phenylxanthine+derivatives+as+potential+dual+A2AR+antagonists%2FMAO-B+inhibitors+for+Parkinson%E2%80%99s+disease&doi=10.3390%2Fmolecules22061010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of phenylxanthine derivatives as potential dual A2AR antagonists/MAO-B inhibitors for Parkinson's disease</span></div><div class="casAuthors">Wang, Xuebao; Han, Chao; Xu, Yong; Wu, Kaiqi; Chen, Shuangya; Hu, Mangsha; Wang, Luyao; Ye, Yun; Ye, Faqing</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1010/1-1010/13</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The aim of this research was to prove the speculation that phenylxanthine (PX) derivs. possess adenosine A2A receptor (A2AR)-blocking properties and to screening and evaluate these PX derivs. as dual A2AR antagonists/MAO-B inhibitors for Parkinson0s disease.  To explore this hypothesis, two series of PX derivs. were prepd. and their antagonism against A2AR and inhibition against MAO-B were detd. in vitro.  In order to evaluate further the antiparkinsonian properties, pharmacokinetic and haloperidol-induced catalepsy expts. were carried out in vivo.  The PX-D and PX-E analogs acted as potent A2AR antagonists with Ki values ranging from 0.27 to 10 μM, and these analogs displayed relatively mild MAO-B inhibition potencies, with inhibitor dissocn. consts. (Ki values) ranging from 0.25 to 10 μM.  Further, the compds. PX-D-P6 and PX-E-P8 displayed efficacious antiparkinsonian properties in haloperidol-induced catalepsy expts., verifying that these two compds. were potent A2AR antagonists and MAO-B inhibitors.  We conclude that PX-D and PX-E analogs are a promising candidate class of dual-acting compds. for treating Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpkdoiOmu87rVg90H21EOLACvtfcHk0ljWmdNGGsayIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVGgtLbJ&md5=9804c51e9ea8302927601323590b65fb</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22061010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22061010%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520phenylxanthine%2520derivatives%2520as%2520potential%2520dual%2520A2AR%2520antagonists%252FMAO-B%2520inhibitors%2520for%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26spage%3D1010%26doi%3D10.3390%2Fmolecules22061010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagenow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasiak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Ciproxifan, a histamine H3 receptor antagonist, reversibly inhibits monoamine oxidase A and B</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">40541</span>, <span class="refDoi"> DOI: 10.1038/srep40541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1038%2Fsrep40541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=28084411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvVSitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=40541&author=S.+Hagenowauthor=A.+Stasiakauthor=R.+R.+Ramsayauthor=H.+Stark&title=Ciproxifan%2C+a+histamine+H3+receptor+antagonist%2C+reversibly+inhibits+monoamine+oxidase+A+and+B&doi=10.1038%2Fsrep40541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Ciproxifan, a histamine H3 receptor antagonist, reversibly inhibits monoamine oxidase A and B</span></div><div class="casAuthors">Hagenow, S.; Stasiak, A.; Ramsay, R. R.; Stark, H.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40541</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ciproxifan is a well-investigated histamine H3 receptor (H3R) inverse agonist/antagonist, showing an exclusively high species-specific affinity at rodent compared to human H3R.  It is well studied as ref. compd. for H3R in rodent models for neurol. diseases connected with neurotransmitter dysregulation, e.g. attention deficit hyperactivity disorder or Alzheimer's disease.  In a screening for potential monoamine oxidase A and B inhibition ciproxifan showed efficacy on both enzyme isoforms.  Further characterization of ciproxifan revealed IC50 values in a micromolar concn. range for human and rat monoamine oxidases with slight preference for monoamine oxidase B in both species.  The inhibition by ciproxifan was reversible for both human isoforms.  Regarding inhibitory potency of ciproxifan on rat brain MAO, these findings should be considered, when using high doses in rat models for neurol. diseases.  As the H3R and monoamine oxidases are all capable of affecting neurotransmitter modulation in brain, we consider dual targeting ligands as interesting approach for treatment of neurol. disorders.  Since ciproxifan shows only moderate activity at human targets, further investigations in animals are not of primary interest.  On the other hand, it may serve as starting point for the development of dual targeting ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3NWO3L7ij4bVg90H21EOLACvtfcHk0ljWmdNGGsayIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvVSitw%253D%253D&md5=b75d06386aed46be0cd50a2a333247bb</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1038%2Fsrep40541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep40541%26sid%3Dliteratum%253Aachs%26aulast%3DHagenow%26aufirst%3DS.%26aulast%3DStasiak%26aufirst%3DA.%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DCiproxifan%252C%2520a%2520histamine%2520H3%2520receptor%2520antagonist%252C%2520reversibly%2520inhibits%2520monoamine%2520oxidase%2520A%2520and%2520B%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D40541%26doi%3D10.1038%2Fsrep40541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fredholm, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klotz, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span> <span> </span><span class="NLM_article-title">International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">552</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1211%2F0022357011775631" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=11734617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVOltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2001&pages=527-552&author=B.+B.+Fredholmauthor=A.+P.+IJzermanauthor=K.+A.+Jacobsonauthor=K.+N.+Klotzauthor=J.+Linden&title=International+Union+of+Pharmacology.+XXV.+Nomenclature+and+classification+of+adenosine+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85aR"><div class="casContent"><span class="casTitleNuber">85a</span><div class="casTitle"><span class="NLM_cas:atitle">International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors</span></div><div class="casAuthors">Fredholm, Bertil B.; IJzerman, Adriaan P.; Jacobson, Kenneth A.; Klotz, Karl-Norbert; Linden, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">527-552</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Four adenosine receptors have been cloned and characterized from several mammalian species.  The receptors are named adenosine A1, A2A, A2B, and A3.  The A2A and A2B receptors preferably interact with members of the Gs family of G proteins and the A1 and A3 receptors with Gi/o proteins.  However, other G protein interactions have also been described.  Adenosine is the preferred endogenous agonist at all these receptors, but inosine can also activate the A3 receptor.  The levels of adenosine seen under basal conditions are sufficient to cause some activation of all the receptors, at least where they are abundantly expressed.  Adenosine levels during, e.g., ischemia can activate all receptors even when expressed in low abundance.  Accordingly, expts. with receptor antagonists and mice with targeted disruption of adenosine A1, A2A, and A3 expression reveal roles for these receptors under physiol. and particularly pathophysiol. conditions.  There are pharmacol. tools that can be used to classify A1, A2A, and A3 receptors but few drugs that interact selectively with A2B receptors.  Testable models of the interaction of these drugs with their receptors have been generated by site-directed mutagenesis and homol.-based modeling.  Both agonists and antagonists are being developed as potential drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJOCrJphTwDrVg90H21EOLACvtfcHk0ljWmdNGGsayIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVOltQ%253D%253D&md5=060ea8a3d7b07fdc4b2c8acc3b4d4745</span></div><a href="/servlet/linkout?suffix=cit85a&amp;dbid=16384&amp;doi=10.1211%2F0022357011775631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1211%252F0022357011775631%26sid%3Dliteratum%253Aachs%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DKlotz%26aufirst%3DK.%2BN.%26aulast%3DLinden%26aufirst%3DJ.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology.%2520XXV.%2520Nomenclature%2520and%2520classification%2520of%2520adenosine%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2001%26volume%3D53%26spage%3D527%26epage%3D552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit85b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robeva, A. S.</span></span> <span> </span><span class="NLM_article-title">Characterization of human A<sub>2B</sub> adenosine receptors: Radioligand binding, western blotting, and coupling to G<sub>q</sub> in human embryonic kidney 293 cells and HMC-1 mast cells</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">705</span>– <span class="NLM_lpage">713</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10496952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADyaK1MXmsVCmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1999&pages=705-713&author=J.+Lindenauthor=T.+Thaiauthor=H.+Figlerauthor=X.+Jinauthor=A.+S.+Robeva&title=Characterization+of+human+A2B+adenosine+receptors%3A+Radioligand+binding%2C+western+blotting%2C+and+coupling+to+Gq+in+human+embryonic+kidney+293+cells+and+HMC-1+mast+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85bR"><div class="casContent"><span class="casTitleNuber">85b</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of human A2B adenosine receptors: radioligand binding, Western blotting, and coupling to Gq in human embryonic kidney 293 cells and HMC-1 mast cells</span></div><div class="casAuthors">Linden, Joel; Thai, Tami; Figler, Heidi; Jin, Xiaowei; Robeva, Anna S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">705-713</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Recombinant human A2B adenosine receptors (A2BARs) and receptors extended on the N-terminus with hexahistidine and the FLAG epitope, DYKDDDDK (H/F-A2B) were stably over-expressed (to > 20,000 fmol/mg protein) in human embryonic kidney 293 cells (HEK-A2B).  By Western blotting, the H/F-A2B receptor runs as a 34.8-kDa glycoprotein.  Pharmacol. properties of A2BARs were characterized with 1251-3-aminobenzyl-8-phenyl-(4-oxyacetic acid)-1-propylxanthine (KD, 36 nM).  In competition binding assays, the affinity of agonists is reduced by substitution on either the N6- or the C-2 position of the adenine ring, whereas 5'-substitutions increase affinity, resulting in the potency order: 5'-N-ethylcarboxamidoadenosine (NECA) » N6-aminobenzyl-NECA ≈2-chloroadenosine > 2-[4-(2-carboxy-ethyl)phenethylamino]-NECA (CGS21680) > N6-aminobenzyladenosine.  The A2BAR is potently blocked by the A2A-selective antagonist 4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo-[2,3-a][1,3,5]triazin-5-yl-amino]ethyl)phenol (ZM241385; KI, 32 nM for A2B, 1,4 nM for A2A) and the A1 selective antagonist 8-cyclopentyl-1,3-dipropylxanthine (KI, 50.5 nM for A2B; 2.5 nM for A1).  The KI values for the antiasthmatic xanthines, theophylline (7.8 μM) and enprofylline (6.4 μM), are below their therapeutic plasma concns. (20 to 50 μM), and agree with KI detns. for inhibition of NECA-stimulated cAMP accumulation in HEK-A2B cells.  NECA or N6-(2-iodo)benzyl-5'-N-methylcarboxamidodoadenosine (IB-MECA) stimulate inositol trisphosphates and calcium accumulation in HEK-A2B or HEK-A3 cells, resp., but only the A3 response is prevented by pertussis toxin.  In human HMC-1 mast cells, A2BAR activation stimulates calcium mobilization and cAMP accumulation.  The authors conclude that HEK-A2B cells and HMC-1 mast cells possess A2BAR glycoproteins that are coupled to both Gq/11 and Gs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJqtHvYLzxoLVg90H21EOLACvtfcHk0lgAD51tWJsQaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsVCmtLY%253D&md5=dc4aa0211ecd1d0f865b1f5f98ed1f30</span></div><a href="/servlet/linkout?suffix=cit85b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLinden%26aufirst%3DJ.%26aulast%3DThai%26aufirst%3DT.%26aulast%3DFigler%26aufirst%3DH.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DRobeva%26aufirst%3DA.%2BS.%26atitle%3DCharacterization%2520of%2520human%2520A2B%2520adenosine%2520receptors%253A%2520Radioligand%2520binding%252C%2520western%2520blotting%252C%2520and%2520coupling%2520to%2520Gq%2520in%2520human%2520embryonic%2520kidney%2520293%2520cells%2520and%2520HMC-1%2520mast%2520cells%26jtitle%3DMol.%2520Pharmacol.%26date%3D1999%26volume%3D56%26spage%3D705%26epage%3D713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bastide, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Crompe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doudnikoff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernagut, P.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boraud, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bézard, E.</span></span> <span> </span><span class="NLM_article-title">Inhibiting lateral habenula improves L-DOPA-induced Dyskinesia</span>. <i>Biol. Psychiatr.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2014.08.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.biopsych.2014.08.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=25442003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOgsbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2016&pages=345-353&author=M.+F.+Bastideauthor=B.+de+la+Crompeauthor=E.+Doudnikoffauthor=P.-O.+Fernagutauthor=C.+E.+Grossauthor=N.+Malletauthor=T.+Boraudauthor=E.+B%C3%A9zard&title=Inhibiting+lateral+habenula+improves+L-DOPA-induced+Dyskinesia&doi=10.1016%2Fj.biopsych.2014.08.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86aR"><div class="casContent"><span class="casTitleNuber">86a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting Lateral Habenula Improves L-DOPA-induced Dyskinesia</span></div><div class="casAuthors">Bastide, Matthieu F.; de la Crompe, Brice; Doudnikoff, Evelyne; Fernagut, Pierre-Olivier; Gross, Christian E.; Mallet, Nicolas; Boraud, Thomas; Bezard, Erwan</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">345-353</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A systematic search of brain nuclei putatively involved in L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID) in Parkinson's disease shed light, notably, upon the lateral habenula (LHb), which displayed an overexpression of the ΔFosB, ARC, and Zif268 immediate-early genes only in rats experiencing abnormal involuntary movements (AIMs).  We thus hypothesized that LHb might play a role in LID.ΔFosB immunoreactivity, 2-deoxyglucose uptake, and firing activity of LHb were studied in exptl. models of Parkinson's disease and LID. ΔFosB-expressing LHb neurons were then targeted using the Daun02-inactivation method.  A total of 18 monkeys and 55 rats were used.  LHb was found to be metabolically modified in dyskinetic monkeys and its neuronal firing frequency significantly increased in ON L-DOPA dyskinetic 6-hydroxydopamine-lesioned rats, suggesting that increased LHb neuronal activity in response to L-DOPA is related to AIM manifestation.  Therefore, to mechanistically test if LHb neuronal activity might affect AIM severity, following induction of AIMs, 6-hydroxydopamine rats were injected with Daun02 in the LHb previously transfected with ss-galactosidase under control of the FosB promoter.  Three days after Daun02 administration, animals were tested daily with L-DOPA to assess LID and L-DOPA-induced rotations.  Inactivation of ΔFosB-expressing neurons significantly reduced AIM severity and also increased rotations.  Interestingly, the dopaminergic D1 receptor was overexpressed only on the lesioned side of dyskinetic rats in LHb and co-localized with ΔFosB, suggesting a D1 receptor-mediated mechanism supporting the LHb involvement in AIMs.  This study highlights the role of LHb in LID, offering a new target to innovative treatments of LID.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow3av5XOgESLVg90H21EOLACvtfcHk0lgAD51tWJsQaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOgsbnL&md5=bf2d6976c807284963d414b42c540fb4</span></div><a href="/servlet/linkout?suffix=cit86a&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2014.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2014.08.022%26sid%3Dliteratum%253Aachs%26aulast%3DBastide%26aufirst%3DM.%2BF.%26aulast%3Dde%2Bla%2BCrompe%26aufirst%3DB.%26aulast%3DDoudnikoff%26aufirst%3DE.%26aulast%3DFernagut%26aufirst%3DP.-O.%26aulast%3DGross%26aufirst%3DC.%2BE.%26aulast%3DMallet%26aufirst%3DN.%26aulast%3DBoraud%26aufirst%3DT.%26aulast%3DB%25C3%25A9zard%26aufirst%3DE.%26atitle%3DInhibiting%2520lateral%2520habenula%2520improves%2520L-DOPA-induced%2520Dyskinesia%26jtitle%3DBiol.%2520Psychiatr.%26date%3D2016%26volume%3D79%26spage%3D345%26epage%3D353%26doi%3D10.1016%2Fj.biopsych.2014.08.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit86b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Porras, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berthet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehay, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladepeche, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normand, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dovero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doudnikoff, E.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">PSD-95 expression controls L-DOPA dyskinesia through dopamine D<sub>1</sub> receptor trafficking</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">3977</span>– <span class="NLM_lpage">3989</span>, <span class="refDoi"> DOI: 10.1172/jci59426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1172%2Fjci59426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=23041629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1CisL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2012&pages=3977-3989&author=G.+Porrasauthor=A.+Berthetauthor=B.+Dehayauthor=Q.+Liauthor=L.+Ladepecheauthor=E.+Normandauthor=S.+Doveroauthor=A.+Martinezauthor=E.+Doudnikoff&title=PSD-95+expression+controls+L-DOPA+dyskinesia+through+dopamine+D1+receptor+trafficking&doi=10.1172%2Fjci59426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86bR"><div class="casContent"><span class="casTitleNuber">86b</span><div class="casTitle"><span class="NLM_cas:atitle">PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking</span></div><div class="casAuthors">Porras, Gregory; Berthet, Amandine; Dehay, Benjamin; Li, Qin; Ladepeche, Laurent; Normand, Elisabeth; Dovero, Sandra; Martinez, Audrey; Doudnikoff, Evelyne; Martin-Negrier, Marie-Laure; Chuan, Qin; Bloch, Bertrand; Choquet, Daniel; Boue-Grabot, Eric; Groc, Laurent; Bezard, Erwan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3977-3989</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">L-DOPA-induced dyskinesia (LID), a detrimental consequence of dopamine replacement therapy for Parkinson's disease, is assocd. with an alteration in dopamine D1 receptor (D1R) and glutamate receptor interactions.  We hypothesized that the synaptic scaffolding protein PSD-95 plays a pivotal role in this process, as it interacts with D1R, regulates its trafficking and function, and is overexpressed in LID.  Here, we demonstrate in rat and macaque models that disrupting the interaction between D1R and PSD-95 in the striatum reduces LID development and severity.  Single quantum dot imaging revealed that this benefit was achieved primarily by destabilizing D1R localization, via increased lateral diffusion followed by increased internalization and diminished surface expression.  These findings indicate that altering D1R trafficking via synapse-assocd. scaffolding proteins may be useful in the treatment of dyskinesia in Parkinson's patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYoh_pGqyGuLVg90H21EOLACvtfcHk0lgAD51tWJsQaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1CisL7I&md5=a16335d2b21baf5bd7eabfb78238ee57</span></div><a href="/servlet/linkout?suffix=cit86b&amp;dbid=16384&amp;doi=10.1172%2Fjci59426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci59426%26sid%3Dliteratum%253Aachs%26aulast%3DPorras%26aufirst%3DG.%26aulast%3DBerthet%26aufirst%3DA.%26aulast%3DDehay%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLadepeche%26aufirst%3DL.%26aulast%3DNormand%26aufirst%3DE.%26aulast%3DDovero%26aufirst%3DS.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DDoudnikoff%26aufirst%3DE.%26atitle%3DPSD-95%2520expression%2520controls%2520L-DOPA%2520dyskinesia%2520through%2520dopamine%2520D1%2520receptor%2520trafficking%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2012%26volume%3D122%26spage%3D3977%26epage%3D3989%26doi%3D10.1172%2Fjci59426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, W. K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tronci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidalgo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simola, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabrizi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carta, M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Antidyskinetic effect of A2Aand 5HT1A/1B receptor ligands in two animal models of Parkinson’s disease</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1002/mds.26475</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2Fmds.26475" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=26871939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVeitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2016&pages=501-511&author=A.+Pinnaauthor=W.+K.+D.+Koauthor=G.+Costaauthor=E.+Tronciauthor=C.+Fidalgoauthor=N.+Simolaauthor=Q.+Liauthor=M.+A.+Tabriziauthor=E.+Bezardauthor=M.+Carta&title=Antidyskinetic+effect+of+A2Aand+5HT1A%2F1B+receptor+ligands+in+two+animal+models+of+Parkinson%E2%80%99s+disease&doi=10.1002%2Fmds.26475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease</span></div><div class="casAuthors">Pinna, Annalisa; Ko, Wai Kin D.; Costa, Giulia; Tronci, Elisabetta; Fidalgo, Camino; Simola, Nicola; Li, Qin; Tabrizi, Mojgan Aghazadeh; Bezard, Erwan; Carta, Manolo; Morelli, Micaela</div><div class="citationInfo"><span class="NLM_cas:title">Movement Disorders</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">501-511</span>CODEN:
                <span class="NLM_cas:coden">MOVDEA</span>;
        ISSN:<span class="NLM_cas:issn">0885-3185</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : The serotonin 5-HT1A/1B receptor agonist eltoprazine suppressed dyskinetic-like behavior in animal models of Parkinson's disease (PD) but simultaneously reduced levodopa (L-dopa)-induced motility.  Moreover, adenosine A2A receptor antagonists, such as preladenant, significantly increased L-dopa efficacy in PD without exacerbating dyskinetic-like behavior.  Objectives : We evaluated whether a combination of eltoprazine and preladenant may prevent or suppress L-dopa-induced dyskinesia, without impairing L-dopa's efficacy in relieving motor signs, in 2 PD models: unilateral 6-hydroxydopamine-lesioned rats and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys.  Methods : Rotational behavior and abnormal involuntary movements, or disability and L-dopa-induced dyskinesia were evaluated in 6-hydroxydopamine-lesioned rats and MPTP-treated monkeys, resp.  Moreover, in the rodent striatum, induction of immediate-early gene zif-268, an index of long-term changes, was correlated with dyskinesia.  Results : In 6-hydroxydopamine-lesioned rats, combined administration of L-dopa (4 mg/kg) plus eltoprazine (0.6 mg/kg) plus preladenant (0.3 mg/kg) significantly prevented or reduced dyskinetic-like behavior without impairing motor activity.  Zif-268 was increased in the striatum of rats treated with L-dopa and L-dopa plus preladenant compared with vehicle.  In contrast, rats treated with eltoprazine (with or without preladenant) had lower zif-268 activation after chronic treatment in both the dyskinetic and L-dopa-non-primed groups.  Moreover, acute L-dopa plus eltoprazine plus preladenant prevented worsening of motor performance (adjusting step) and sensorimotor integration deficit.  Similar results were obtained in MPTP-treated monkeys, where a combination of preladenant with eltoprazine was found to counteract dyskinesia and maintain the full therapeutic effects of a low dose of L-dopa.  Conclusions : Our results suggest a promising nondopaminergic pharmacol. strategy for the treatment of dyskinesia in PD. cpr 2016 International Parkinson and Movement Disorder Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNgI8GG4O9FbVg90H21EOLACvtfcHk0lhnAbhvIfTuuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVeitLY%253D&md5=74b3db2f5792e487ad53afac1706778c</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1002%2Fmds.26475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.26475%26sid%3Dliteratum%253Aachs%26aulast%3DPinna%26aufirst%3DA.%26aulast%3DKo%26aufirst%3DW.%2BK.%2BD.%26aulast%3DCosta%26aufirst%3DG.%26aulast%3DTronci%26aufirst%3DE.%26aulast%3DFidalgo%26aufirst%3DC.%26aulast%3DSimola%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DTabrizi%26aufirst%3DM.%2BA.%26aulast%3DBezard%26aufirst%3DE.%26aulast%3DCarta%26aufirst%3DM.%26atitle%3DAntidyskinetic%2520effect%2520of%2520A2Aand%25205HT1A%252F1B%2520receptor%2520ligands%2520in%2520two%2520animal%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DMov.%2520Disord.%26date%3D2016%26volume%3D31%26spage%3D501%26epage%3D511%26doi%3D10.1002%2Fmds.26475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, W. K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camus, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pioli, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezard, E.</span></span> <span> </span><span class="NLM_article-title">An evaluation of istradefylline treatment on parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2016.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.neuropharm.2016.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=27424102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1GgsrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2016&pages=48-58&author=W.+K.+D.+Koauthor=S.+M.+Camusauthor=Q.+Liauthor=J.+Yangauthor=S.+McGuireauthor=E.+Y.+Pioliauthor=E.+Bezard&title=An+evaluation+of+istradefylline+treatment+on+parkinsonian+motor+and+cognitive+deficits+in+1-methyl-4-phenyl-1%2C2%2C3%2C6-tetrahydropyridine+%28MPTP%29-treated+macaque+models&doi=10.1016%2Fj.neuropharm.2016.07.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88aR"><div class="casContent"><span class="casTitleNuber">88a</span><div class="casTitle"><span class="NLM_cas:atitle">An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models</span></div><div class="casAuthors">Ko, Wai Kin D.; Camus, Sandrine M.; Li, Qin; Yang, Jianzhong; McGuire, Steve; Pioli, Elsa Y.; Bezard, Erwan</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">Part_A</span>),
    <span class="NLM_cas:pages">48-58</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Istradefylline (KW-6002), an adenosine A2A receptor antagonist, is used adjunct with optimal doses of L-3,4-dihydroxyphenylalanine (L-DOPA) to extend on-time in Parkinson's disease (PD) patients experiencing motor fluctuations.  Clin. application of istradefylline for the management of other L-DOPA-induced complications, both motor and non-motor related (i.e. dyskinesia and cognitive impairments), remains to be detd.  In this study, acute effects of istradefylline (60-100 mg/kg) alone, or with optimal and sub-optimal doses of L-DOPA, were evaluated in two monkey models of PD (i) the gold-std. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of parkinsonian and dyskinetic motor symptoms and (ii) the chronic low dose (CLD) MPTP-treated macaque model of cognitive (working memory and attentional) deficits.  Behavioral analyses in L-DOPA-primed MPTP-treated macaques showed that istradefylline alone specifically alleviated postural deficits.  When combined with an optimal L-DOPA treatment dose, istradefylline increased on-time, enhanced therapeutic effects on bradykinesia and locomotion, but exacerbated dyskinesia.  Istradefylline treatment at specific doses with sub-optimal L-DOPA specifically alleviated bradykinesia.  Cognitive assessments in CLD MPTP-treated macaques showed that the attentional and working memory deficits caused by L-DOPA were lowered after istradefylline administration.  Taken together, these data support a broader clin. use of istradefylline as an adjunct treatment in PD, where specific treatment combinations can be utilized to manage various L-DOPA-induced complications, which importantly, maintain a desired anti-parkinsonian response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYuv1lfhLsH7Vg90H21EOLACvtfcHk0lhnAbhvIfTuuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1GgsrbP&md5=614d0aa4aa0b83c2272685f4ef6feaa6</span></div><a href="/servlet/linkout?suffix=cit88a&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2016.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2016.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DKo%26aufirst%3DW.%2BK.%2BD.%26aulast%3DCamus%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DMcGuire%26aufirst%3DS.%26aulast%3DPioli%26aufirst%3DE.%2BY.%26aulast%3DBezard%26aufirst%3DE.%26atitle%3DAn%2520evaluation%2520of%2520istradefylline%2520treatment%2520on%2520parkinsonian%2520motor%2520and%2520cognitive%2520deficits%2520in%25201-methyl-4-phenyl-1%252C2%252C3%252C6-tetrahydropyridine%2520%2528MPTP%2529-treated%2520macaque%2520models%26jtitle%3DNeuropharmacology%26date%3D2016%26volume%3D110%26spage%3D48%26epage%3D58%26doi%3D10.1016%2Fj.neuropharm.2016.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit88b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kanda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, R. K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kase, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwana, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenner, P.</span></span> <span> </span><span class="NLM_article-title">Combined Use of the Adenosine A2A Antagonist KW-6002 with l-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">327</span>, <span class="refDoi"> DOI: 10.1006/exnr.2000.7350</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1006%2Fexnr.2000.7350" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10739638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD3cXitVWqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2000&pages=321-327&author=T.+Kandaauthor=M.+J.+Jacksonauthor=L.+A.+Smithauthor=R.+K.+B.+Pearceauthor=J.+Nakamuraauthor=H.+Kaseauthor=Y.+Kuwanaauthor=P.+Jenner&title=Combined+Use+of+the+Adenosine+A2A+Antagonist+KW-6002+with+l-DOPA+or+with+Selective+D1+or+D2+Dopamine+Agonists+Increases+Antiparkinsonian+Activity+but+Not+Dyskinesia+in+MPTP-Treated+Monkeys&doi=10.1006%2Fexnr.2000.7350"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88bR"><div class="casContent"><span class="casTitleNuber">88b</span><div class="casTitle"><span class="NLM_cas:atitle">Combined Use of the Adenosine A2A Antagonist KW-6002 with l-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys</span></div><div class="casAuthors">Kanda, Tomoyuki; Jackson, Michael J.; Smith, Lance A.; Pearce, Ronald K. B.; Nakamura, Joji; Kase, Hiroshi; Kuwana, Yoshihisa; Jenner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">321-327</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The novel selective adenosine A2A receptor antagonist KW-6002 improves motor disability in MPTP-treated parkinsonian marmosets without provoking dyskinesia.  In this study we have investigated whether KW-6002 in combination with l-DOPA or selective D1 or D2 dopamine receptor agonists enhances antiparkinsonian activity in MPTP-treated common marmosets.  Combination of KW-6002 with the selective dopamine D2 receptor agonist quinpirole or the D1 receptor agonist SKF80723 produced an additive improvement in motor disability.  Coadministration of KW-6002 with a low dose of l-DOPA also produced an additive improvement in motor disability, and increased locomotor activity.  The ability of KW-6002 to enhance antiparkinsonian activity was more marked with l-DOPA and quinpirole than with the D1 agonist.  However, despite producing an enhanced antiparkinsonian response KW-6002 did not exacerbate l-DOPA-induced dyskinesia in MPTP-treated common marmosets previously primed to exhibit dyskinesia by prior exposure to l-DOPA.  Selective adenosine A2A receptor antagonists, such as KW-6002, may be one means of reducing the dosage of l-DOPA used in treating Parkinson's disease and are potentially a novel approach to treating the illness both as monotherapy and in combination with dopaminergic drugs.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsA7cu-aJS8rVg90H21EOLACvtfcHk0lhnAbhvIfTuuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXitVWqsLY%253D&md5=28db343f66ae2a8179d7113246f39ae7</span></div><a href="/servlet/linkout?suffix=cit88b&amp;dbid=16384&amp;doi=10.1006%2Fexnr.2000.7350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fexnr.2000.7350%26sid%3Dliteratum%253Aachs%26aulast%3DKanda%26aufirst%3DT.%26aulast%3DJackson%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DL.%2BA.%26aulast%3DPearce%26aufirst%3DR.%2BK.%2BB.%26aulast%3DNakamura%26aufirst%3DJ.%26aulast%3DKase%26aufirst%3DH.%26aulast%3DKuwana%26aufirst%3DY.%26aulast%3DJenner%26aufirst%3DP.%26atitle%3DCombined%2520Use%2520of%2520the%2520Adenosine%2520A2A%2520Antagonist%2520KW-6002%2520with%2520l-DOPA%2520or%2520with%2520Selective%2520D1%2520or%2520D2%2520Dopamine%2520Agonists%2520Increases%2520Antiparkinsonian%2520Activity%2520but%2520Not%2520Dyskinesia%2520in%2520MPTP-Treated%2520Monkeys%26jtitle%3DExp.%2520Neurol.%26date%3D2000%26volume%3D162%26spage%3D321%26epage%3D327%26doi%3D10.1006%2Fexnr.2000.7350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdett, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredholm, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarzschild, M. A.</span></span> <span> </span><span class="NLM_article-title">Deletion of adenosine A1 or A2A receptors reduces L-3,4- dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson’s disease</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1367</i></span>,  <span class="NLM_fpage">310</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2010.08.099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.brainres.2010.08.099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=20828543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFyltbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1367&publication_year=2011&pages=310-318&author=D.+Xiaoauthor=J.+J.+Cassinauthor=B.+Healyauthor=T.+C.+Burdettauthor=J.-F.+Chenauthor=B.+B.+Fredholmauthor=M.+A.+Schwarzschild&title=Deletion+of+adenosine+A1+or+A2A+receptors+reduces+L-3%2C4-+dihydroxyphenylalanine-induced+dyskinesia+in+a+model+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.brainres.2010.08.099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Deletion of adenosine A1 or A2A receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease</span></div><div class="casAuthors">Xiao, Danqing; Cassin, Jared J.; Healy, Brian; Burdett, Thomas C.; Chen, Jiang-Fan; Fredholm, Bertil B.; Schwarzschild, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1367</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">310-318</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Adenosine A2A receptor antagonism provides a promising approach to developing nondopaminergic therapy for Parkinson's disease (PD).  Clin. trials of A2A antagonists have targeted PD patients with L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID) in an effort to improve parkinsonian symptoms.  The role of adenosine in the development of LID is little known, esp. regarding its actions via A1 receptors.  We aimed to examine the effects of genetic deletion and pharmacol. blockade of A1 and/or A2A receptors on the development of LID, on the induction of mol. markers of LID including striatal preprodynorphin and preproenkephalin (PPE), and on the integrity of dopaminergic nigrostriatal neurons in hemiparkinsonian mice.  Following a unilateral 6-hydroxydopamine lesion A1, A2A and double A1-A2A knockout (KO) and wild-type littermate mice, and mice pretreated with caffeine (an antagonist of both A1 and A2A receptors) or saline were treated daily for 18-21 days with a low dose of L-DOPA.  Total abnormal involuntary movements (AIMs, a measure of LID) were significantly attenuated (p < 0.05) in A1 and A2A KOs, but not in A1-A2A KOs and caffeine-pretreated mice.  An elevation of PPE mRNA ipsilateral to the lesion in WT mice was reduced in all KO mice.  In addn., neuronal integrity assessed by striatal dopamine content was similar in all KOs and caffeine-pretreated mice following 6-hydroxydopamine lesioning.  Our findings raise the possibility that A1 or A2A receptors blockade might also confer a disease-modifying benefit of reduced risk of disabling LID, whereas the effect of their combined inactivation is less clear.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLksjL5wTtsbVg90H21EOLACvtfcHk0liognFJDco-wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFyltbvJ&md5=a9ba0c6e7d1f9b4f07f5cd5e48827663</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2010.08.099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2010.08.099%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DD.%26aulast%3DCassin%26aufirst%3DJ.%2BJ.%26aulast%3DHealy%26aufirst%3DB.%26aulast%3DBurdett%26aufirst%3DT.%2BC.%26aulast%3DChen%26aufirst%3DJ.-F.%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26aulast%3DSchwarzschild%26aufirst%3DM.%2BA.%26atitle%3DDeletion%2520of%2520adenosine%2520A1%2520or%2520A2A%2520receptors%2520reduces%2520L-3%252C4-%2520dihydroxyphenylalanine-induced%2520dyskinesia%2520in%2520a%2520model%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DBrain%2520Res.%26date%3D2011%26volume%3D1367%26spage%3D310%26epage%3D318%26doi%3D10.1016%2Fj.brainres.2010.08.099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C.-L.</span></span> <span> </span><span class="NLM_article-title">A Meta-analysis of adenosine A2A receptor antagonists on levodopa-induced dyskinesia in vivo</span>. <i>Front. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">702</span>, <span class="refDoi"> DOI: 10.3389/fneur.2017.00702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.3389%2Ffneur.2017.00702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=29375464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BC1MvkvVGlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=702&author=W.-W.+Wangauthor=M.-M.+Zhangauthor=X.-R.+Zhangauthor=Z.-R.+Zhangauthor=J.+Chenauthor=L.+Fengauthor=C.-L.+Xie&title=A+Meta-analysis+of+adenosine+A2A+receptor+antagonists+on+levodopa-induced+dyskinesia+in+vivo&doi=10.3389%2Ffneur.2017.00702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">A Meta-Analysis of Adenosine A2A Receptor Antagonists on Levodopa-Induced Dyskinesia In Vivo</span></div><div class="casAuthors">Wang Wen-Wen; Zhang Man-Man; Zhang Xing-Ru; Zhang Zeng-Rui; Chen Jie; Feng Liang; Xie Cheng-Long</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neurology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">702</span>
        ISSN:<span class="NLM_cas:issn">1664-2295</span>.
    </div><div class="casAbstract">Background:  Long-term use of levodopa (l-dopa) is inevitably complicated with highly disabling fluctuations and drug-induced dyskinesias, which pose major challenges to the existing drug therapy of Parkinson's disease.  Methods:  In this study, we conducted a systematic review and meta-analysis to assess the efficacy of A2A receptor antagonists on reducing l-dopa-induced dyskinesias (LID).  Results:  Nine studies with a total of 152 animals were included in this meta-analysis.  Total abnormal involuntary movements (AIM) score, locomotor activity, and motor disability were reported as outcome measures in 5, 5, and 3 studies, respectively.  Combined standardized mean difference (SMD) estimates were calculated using a random-effects model.  We pooled the whole data and found that, when compared to l-dopa alone, A2A receptor antagonists plus l-dopa treatment showed no effect on locomotor activity (SMD -0.00, 95% confidence interval (CI): -2.52 to 2.52, p = 1.0), superiority in improvement of motor disability (SMD -5.06, 95% CI: -9.25 to -0.87, p = 0.02) and more effective in control of AIM (SMD -1.82, 95% CI: -3.38 to -0.25, p = 0.02).  Conclusion:  To sum up, these results demonstrated that A2A receptor antagonists appear to have efficacy in animal models of LID.  However, large randomized clinical trials testing the effects of A2A receptor antagonists in LID patients are always warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAOyr9pbMx6rxanA7vODO6fW6udTcc2ebZ_-t247Kx17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvkvVGlsg%253D%253D&md5=640ce9dbcc9b42a8b133e9c981b5fe27</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.3389%2Ffneur.2017.00702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffneur.2017.00702%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.-W.%26aulast%3DZhang%26aufirst%3DM.-M.%26aulast%3DZhang%26aufirst%3DX.-R.%26aulast%3DZhang%26aufirst%3DZ.-R.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DXie%26aufirst%3DC.-L.%26atitle%3DA%2520Meta-analysis%2520of%2520adenosine%2520A2A%2520receptor%2520antagonists%2520on%2520levodopa-induced%2520dyskinesia%2520in%2520vivo%26jtitle%3DFront.%2520Neurol.%26date%3D2017%26volume%3D8%26spage%3D702%26doi%3D10.3389%2Ffneur.2017.00702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lundblad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirik, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierup, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenci, M. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson’s disease</span>. <i>Eur. J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1046/j.0953-816x.2001.01843.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1046%2Fj.0953-816x.2001.01843.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=11860512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BD387ktFynug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2002&pages=120-132&author=M.+Lundbladauthor=M.+Anderssonauthor=C.+Winklerauthor=D.+Kirikauthor=N.+Wierupauthor=M.+A.+Cenci&title=Pharmacological+validation+of+behavioural+measures+of+akinesia+and+dyskinesia+in+a+rat+model+of+Parkinson%E2%80%99s+disease&doi=10.1046%2Fj.0953-816x.2001.01843.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease</span></div><div class="casAuthors">Lundblad M; Andersson M; Winkler C; Kirik D; Wierup N; Cenci M Angela</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-32</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">In an attempt to define clinically relevant models of akinesia and dyskinesia in 6-hydroxydopamine (6-OHDA)-lesioned rats, we have examined the effects of drugs with high (L-DOPA) vs. low (bromocriptine) dyskinesiogenic potential in Parkinson's disease on three types of motor performance, namely: (i) abnormal involuntary movements (AIMs) (ii) rotational behaviour, and (iii) spontaneous forelimb use (cylinder test).  Rats with unilateral 6-OHDA lesions received single daily i.p. injections of L-DOPA or bromocriptine at therapeutic doses.  During 3 weeks of treatment, L-DOPA but not bromocriptine induced increasingly severe AIMs affecting the limb, trunk and orofacial region.  Rotational behaviour was induced to a much higher extent by bromocriptine than L-DOPA.  In the cylinder test, the two drugs initially improved the performance of the parkinsonian limb to a similar extent.  However, L-DOPA-treated animals showed declining levels of performance in this test because the drug-induced AIMs interfered with physiological limb use, and gradually replaced all normal motor activities.  L-DOPA-induced axial, limb and orolingual AIM scores were significantly reduced by the acute administration of compounds that have antidyskinetic efficacy in parkinsonian patients and/or nonhuman primates (-91%, yohimbine 10 mg/kg; -19%, naloxone 4-8 mg/kg; -37%, 5-methoxy 5-N,N-dimethyl-tryptamine 2 mg/kg; -30%, clozapine 8 mg/kg; -50%, amantadine 40 mg/kg).  L-DOPA-induced rotation was, however, not affected.  The present results demonstrate that 6-OHDA-lesioned rats do exhibit motor deficits that share essential functional similarities with parkinsonian akinesia or dyskinesia.  Such deficits can be quantified using novel and relatively simple testing procedures, whereas rotometry cannot discriminate between dyskinetic and antiakinetic effects of antiparkinsonian treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2N4CuMIbAh5I8NvIb08rbfW6udTcc2ebZ_-t247Kx17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387ktFynug%253D%253D&md5=264e2ded8dc58459f2c82754c5455be1</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1046%2Fj.0953-816x.2001.01843.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.0953-816x.2001.01843.x%26sid%3Dliteratum%253Aachs%26aulast%3DLundblad%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DM.%26aulast%3DWinkler%26aufirst%3DC.%26aulast%3DKirik%26aufirst%3DD.%26aulast%3DWierup%26aufirst%3DN.%26aulast%3DCenci%26aufirst%3DM.%2BA.%26atitle%3DPharmacological%2520validation%2520of%2520behavioural%2520measures%2520of%2520akinesia%2520and%2520dyskinesia%2520in%2520a%2520rat%2520model%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D2002%26volume%3D15%26spage%3D120%26epage%3D132%26doi%3D10.1046%2Fj.0953-816x.2001.01843.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ko, W. K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezard, E.</span></span> <span> </span><span class="NLM_article-title">A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson’s disease</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>813</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2017.07.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.ejphar.2017.07.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=28739086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1equ7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=813&publication_year=2017&pages=10-16&author=W.+K.+D.+Koauthor=Q.+Liauthor=L.+Y.+Chengauthor=M.+Morelliauthor=M.+Cartaauthor=E.+Bezard&title=A+preclinical+study+on+the+combined+effects+of+repeated+eltoprazine+and+preladenant+treatment+for+alleviating+L-DOPA-induced+dyskinesia+in+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.ejphar.2017.07.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease</span></div><div class="casAuthors">Ko, Wai Kin D.; Li, Qin; Cheng, Long Yun; Morelli, Micaela; Carta, Manolo; Bezard, Erwan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">813</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10-16</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Eltoprazine, a serotonergic (5-HT)1A/B receptor agonist, is a potential treatment for L-DOPA-induced dyskinesia (LID) in Parkinson's disease (PD) but notably compromises the anti-parkinsonian effects of L-DOPA, as seen in rodent and monkey models of PD.  Preladenant, a selective adenosine A2a receptor antagonist, mediates modest anti-parkinsonian effects in parkinsonian monkeys.  In a recent investigation, combined eltoprazine and preladenant treatment with a sub-threshold dose of L-DOPA acutely attenuated dyskinesia without exacerbating PD disability in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaques.  The aim of this study was to investigate the daily repeated treatment effects of eltoprazine (1 mg/kg) alone, and in combination with preladenant (5 mg/kg), on the motor symptoms of PD and LID in MPTP-treated macaques.  The anti-dyskinetic and -parkinsonian effects of combinative drug administration with a sub-threshold dose of L-DOPA were measured over 14 days.  Eltoprazine treatment alone produced a near-complete suppression of dyskinesia but consistently increased parkinsonism.  The administration of preladenant with eltoprazine prevented the increased severity of parkinsonian motor symptoms but was unable to maintain a reduced expression of dyskinesia with repeated administration.  These data demonstrate the clin. utility of the modulation of the serotonergic and adenosine neurotransmitter systems with selective pharmacol. agents for only acute treatment of LID.  This multi-targeted approach is unsuitable as a long-term treatment regimen due to unsustainable therapeutic effects on dyskinesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaOU-f4zjeMrVg90H21EOLACvtfcHk0lh-g7S2ArZz6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1equ7bF&md5=3bff68d15cae0212ac2dbb381987d518</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2017.07.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2017.07.030%26sid%3Dliteratum%253Aachs%26aulast%3DKo%26aufirst%3DW.%2BK.%2BD.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DCheng%26aufirst%3DL.%2BY.%26aulast%3DMorelli%26aufirst%3DM.%26aulast%3DCarta%26aufirst%3DM.%26aulast%3DBezard%26aufirst%3DE.%26atitle%3DA%2520preclinical%2520study%2520on%2520the%2520combined%2520effects%2520of%2520repeated%2520eltoprazine%2520and%2520preladenant%2520treatment%2520for%2520alleviating%2520L-DOPA-induced%2520dyskinesia%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2017%26volume%3D813%26spage%3D10%26epage%3D16%26doi%3D10.1016%2Fj.ejphar.2017.07.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solís, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Montes, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Granillo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moratalla, R.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 receptor modulates L-DOPA-induced dyskinesia by targeting D1 receptor-mediated striatal signaling</span>. <i>Cereb. Cortex</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">446</span>, <span class="refDoi"> DOI: 10.1093/cercor/bhv231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1093%2Fcercor%2Fbhv231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=26483399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BC28zjtlGmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=435-446&author=O.+Sol%C3%ADsauthor=J.+R.+Garcia-Montesauthor=A.+Gonz%C3%A1lez-Granilloauthor=M.+Xuauthor=R.+Moratalla&title=Dopamine+D3+receptor+modulates+L-DOPA-induced+dyskinesia+by+targeting+D1+receptor-mediated+striatal+signaling&doi=10.1093%2Fcercor%2Fbhv231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 Receptor Modulates l-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling</span></div><div class="casAuthors">Solis Oscar; Garcia-Montes Jose Ruben; Gonzalez-Granillo Aldo; Moratalla Rosario; Solis Oscar; Garcia-Montes Jose Ruben; Moratalla Rosario; Xu Ming</div><div class="citationInfo"><span class="NLM_cas:title">Cerebral cortex (New York, N.Y. : 1991)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">435-446</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The dopamine D3 receptor (D3R) belongs to the dopamine D2-like receptor family and is principally located in the ventral striatum.  However, previous studies reported D3R overexpression in the dorsal striatum following l-DOPA treatment in parkinsonian animals.  This fact has drawn attention in the importance of D3R in l-DOPA-induced dyskinesia (LID).  Here, we used D3R knockout mice to assess the role of D3R in LID and rotational sensitization in the hemiparkinsonian model.  Mice lacking D3R presented a reduction in dyskinesia without interfering with the antiparkinsonian l-DOPA effect and were accompanied by a reduction in the l-DOPA-induced rotations.  Interestingly, deleting D3R attenuated important molecular markers in the D1R-neurons such as FosB, extracellular signal-regulated kinase, and histone-3 (H3)-activation.  Colocalization studies in D1R-tomato and D2R-green fluorescent protein BAC-transgenic mice indicated that l-DOPA-induced D3R overexpression principally occurs in D1R-containing neurons although it is also present in the D2R-neurons.  Moreover, D3R pharmacological blockade with PG01037 reduced dyskinesia and the molecular markers expressed in D1R-neurons.  In addition, this antagonist further reduced dyskinetic symptoms in D1R heterozygous mice, indicating a direct interaction between D1R and D3R.  Together, our results demonstrate that D3R modulates the development of dyskinesia by targeting D1R-mediated intracellular signaling and suggest that decreasing D3R activity may help to ameliorate LID.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZlMHmvTSGI8-crCu0nI_sfW6udTcc2eZks6tx5g24_bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zjtlGmsQ%253D%253D&md5=8335e5d55089b38756146b45db4befe5</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1093%2Fcercor%2Fbhv231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcercor%252Fbhv231%26sid%3Dliteratum%253Aachs%26aulast%3DSol%25C3%25ADs%26aufirst%3DO.%26aulast%3DGarcia-Montes%26aufirst%3DJ.%2BR.%26aulast%3DGonz%25C3%25A1lez-Granillo%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DMoratalla%26aufirst%3DR.%26atitle%3DDopamine%2520D3%2520receptor%2520modulates%2520L-DOPA-induced%2520dyskinesia%2520by%2520targeting%2520D1%2520receptor-mediated%2520striatal%2520signaling%26jtitle%3DCereb.%2520Cortex%26date%3D2017%26volume%3D27%26spage%3D435%26epage%3D446%26doi%3D10.1093%2Fcercor%2Fbhv231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bézard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leriche, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boraud, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokoloff, P.</span></span> <span> </span><span class="NLM_article-title">Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">762</span>– <span class="NLM_lpage">767</span>, <span class="refDoi"> DOI: 10.1038/nm875</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1038%2Fnm875" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=12740572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktFOnu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=762-767&author=E.+B%C3%A9zardauthor=S.+Ferryauthor=U.+Machauthor=H.+Starkauthor=L.+Lericheauthor=T.+Boraudauthor=C.+Grossauthor=P.+Sokoloff&title=Attenuation+of+levodopa-induced+dyskinesia+by+normalizing+dopamine+D3+receptor+function&doi=10.1038%2Fnm875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function</span></div><div class="casAuthors">Bezard, Erwan; Ferry, Sandrine; Mach, Ulrich; Stark, Holger; Leriche, Ludovic; Boraud, Thomas; Gross, Christian; Sokoloff, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">762-767</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In monkeys rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), expression of the nigrostriatal dopamine D3 receptors was decreased.  However, levodopa-induced dyskinesia (LID), similar to the debilitating and drug-resistant involuntary movements elicited after long-term treatment with levodopa in patients with Parkinson's disease (PD), was assocd. with overexpression of this receptor.  Administration of a D3 receptor-selective partial agonist, BP 897, strongly attenuated the levodopa-induced dyskinesia but left unaffected the therapeutic effect of levodopa.  In contrast, attenuation of dyskinesia by D3 receptor antagonists was accompanied by the reappearance of PD-like symptoms.  These results indicated that the D3 receptor participates in both the dyskinesia and the therapeutic action of levodopa, and that partial agonists may normalize D3 receptor function and correct side effects of levodopa therapy in patients with PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPT5KLDLoCCLVg90H21EOLACvtfcHk0lh-g7S2ArZz6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktFOnu7w%253D&md5=eb546a54dce74d4b5f08f85432221dee</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fnm875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm875%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25A9zard%26aufirst%3DE.%26aulast%3DFerry%26aufirst%3DS.%26aulast%3DMach%26aufirst%3DU.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DLeriche%26aufirst%3DL.%26aulast%3DBoraud%26aufirst%3DT.%26aulast%3DGross%26aufirst%3DC.%26aulast%3DSokoloff%26aufirst%3DP.%26atitle%3DAttenuation%2520of%2520levodopa-induced%2520dyskinesia%2520by%2520normalizing%2520dopamine%2520D3%2520receptor%2520function%26jtitle%3DNat.%2520Med.%26date%3D2003%26volume%3D9%26spage%3D762%26epage%3D767%26doi%3D10.1038%2Fnm875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Visanji, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brotchie, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brotchiea, J. M.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson’s disease</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">184</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2008.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.nbd.2008.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=19118628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFCgt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2009&pages=184-192&author=N.+P.+Visanjiauthor=S.+H.+Foxauthor=T.+Johnstonauthor=G.+Reyesauthor=M.+J.+Millanauthor=J.+M.+Brotchieauthor=J.+M.+Brotchiea&title=Dopamine+D3+receptor+stimulation+underlies+the+development+of+L-DOPA-induced+dyskinesia+in+animal+models+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.nbd.2008.11.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease</span></div><div class="casAuthors">Visanji, Naomi P.; Fox, Susan H.; Johnston, Tom; Reyes, Gabriela; Millan, Mark J.; Brotchie, Jonathan M.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-192</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Development of L-DOPA-induced dyskinesia (LID) remains a major problem in the long-term treatment of Parkinson's disease (PD).  Sensitization to L-DOPA correlates with ectopic expression of D3 dopamine receptors in the striatum, implicating D3 receptors in development of LID.  We demonstrate that the selective D3 antagonist S33084 abolishes development of LID over 30 days in MPTP-lesioned marmosets without effecting the anti-parkinsonian actions of L-DOPA.  Furthermore, following a 14 day washout, when challenged with L-DOPA in the absence of S33084, these animals continued to exhibit reduced LID.  In the 6-OHDA-lesioned rat, S33084 similarly attenuated development of behavioral sensitization to L-DOPA.  Addnl., L-DOPA-induced elevations in striatal pre-proenkephalin-A (PPE-A) (but not PPE-B, phospho[Thr34]DARPP-32, D1, and D2 receptor mRNA or D3 receptor levels) were reduced in S33084 treated animals.  Our data suggest a role for D3 receptors in the development of LID and suggest that initiating L-DOPA treatment with a D3 antagonist may reduce the development of LID in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokMZS17qgpkLVg90H21EOLACvtfcHk0lgV5clkbRnL2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFCgt74%253D&md5=e11479639deb283424a1a680fc98ffee</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2008.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2008.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DVisanji%26aufirst%3DN.%2BP.%26aulast%3DFox%26aufirst%3DS.%2BH.%26aulast%3DJohnston%26aufirst%3DT.%26aulast%3DReyes%26aufirst%3DG.%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26aulast%3DBrotchie%26aufirst%3DJ.%2BM.%26aulast%3DBrotchiea%26aufirst%3DJ.%2BM.%26atitle%3DDopamine%2520D3%2520receptor%2520stimulation%2520underlies%2520the%2520development%2520of%2520L-DOPA-induced%2520dyskinesia%2520in%2520animal%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2009%26volume%3D35%26spage%3D184%26epage%3D192%26doi%3D10.1016%2Fj.nbd.2008.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bibbiani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petzer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagnoli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarzschild, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chase, T. N.</span></span> <span> </span><span class="NLM_article-title">A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1016/s0014-4886(03)00250-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fs0014-4886%2803%2900250-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=14637099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptVektrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2003&pages=285-294&author=F.+Bibbianiauthor=J.+D.+Ohauthor=J.+P.+Petzerauthor=N.+Castagnoliauthor=J.-F.+Chenauthor=M.+A.+Schwarzschildauthor=T.+N.+Chase&title=A2A+antagonist+prevents+dopamine+agonist-induced+motor+complications+in+animal+models+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fs0014-4886%2803%2900250-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease</span></div><div class="casAuthors">Bibbiani, F.; Oh, J. D.; Petzer, J. P.; Castagnoli, N.; Chen, J.-F.; Schwarzschild, M. A.; Chase, T. N.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">285-294</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">Adenosine A2A receptors, abundantly expressed on striatal medium spiny neurons, appear to activate signaling cascades implicated in the regulation of coexpressed ionotropic glutamatergic receptors.  To evaluate the contribution of adenosinergic mechanisms to the pathogenesis of the response alterations induced by dopaminergic treatment, we studied the ability of the selective adenosine A2A receptor antagonist KW-6002 to prevent as well as palliate these syndromes in rodent and primate models of Parkinson's disease.  In rats, KW-6002 reversed the shortened motor response produced by chronic levodopa treatment while reducing levodopa-induced hyperphosphorylation at S845 residues on AMPA receptor GluR1 subunits.  In primates, KW-6002 evidenced modest antiparkinsonian activity when given alone.  Once-daily coadministration of KW-6002 with apomorphine prevented the development of dyskinesias, which appeared in control animals 7-10 days after initiating apomorphine treatment.  Animals initially given apomorphine plus KW-6002 for 3 wk did not begin to manifest apomorphine-induced dyskinesias until 10-12 days after discontinuing the A2A antagonist.  These results suggest that KW-6002 can attenuate the induction as well as the expression of motor response alterations to chronic dopaminergic stimulation in parkinsonian animals, possibly by blocking A2A receptor-stimulated signaling pathways.  Our findings strengthen the rationale for developing A2A antagonists as an early treatment strategy for Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSAWSN7Mb2t7Vg90H21EOLACvtfcHk0lgV5clkbRnL2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptVektrw%253D&md5=081b90c918741d254ff011951ef7bb5e</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fs0014-4886%2803%2900250-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0014-4886%252803%252900250-4%26sid%3Dliteratum%253Aachs%26aulast%3DBibbiani%26aufirst%3DF.%26aulast%3DOh%26aufirst%3DJ.%2BD.%26aulast%3DPetzer%26aufirst%3DJ.%2BP.%26aulast%3DCastagnoli%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DJ.-F.%26aulast%3DSchwarzschild%26aufirst%3DM.%2BA.%26aulast%3DChase%26aufirst%3DT.%2BN.%26atitle%3DA2A%2520antagonist%2520prevents%2520dopamine%2520agonist-induced%2520motor%2520complications%2520in%2520animal%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DExp.%2520Neurol.%26date%3D2003%26volume%3D184%26spage%3D285%26epage%3D294%26doi%3D10.1016%2Fs0014-4886%2803%2900250-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarzschild, M. A.</span></span> <span> </span><span class="NLM_article-title">Role of adenosine A2A receptors in parkinsonian motor impairment and L-DOPA-induced motor complications</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1016/j.pneurobio.2007.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.pneurobio.2007.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=17826884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlags7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2007&pages=293-309&author=M.+Morelliauthor=T.+Di+Paoloauthor=J.+Wardasauthor=F.+Calonauthor=D.+Xiaoauthor=M.+A.+Schwarzschild&title=Role+of+adenosine+A2A+receptors+in+parkinsonian+motor+impairment+and+L-DOPA-induced+motor+complications&doi=10.1016%2Fj.pneurobio.2007.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Role of adenosine A2A receptors in parkinsonian motor impairment and L-DOPA-induced motor complications</span></div><div class="casAuthors">Morelli, Micaela; Di Paolo, Therese; Wardas, Jadwiga; Calon, Frederic; Xiao, Danqing; Schwarzschild, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">293-309</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Adenosine A2A receptors have a unique cellular and regional distribution in the basal ganglia, being particularly concd. in areas richly innervated by dopamine such as the caudate-putamen and the globus pallidus.  Adenosine A2A receptors are selectively located on striatopallidal neurons and are capable of forming functional heteromeric complexes with dopamine D2 and metabotropic glutamate mGlu5 receptors.  Based on the unique cellular and regional distribution of this receptor and in line with data showing that A2A receptor antagonists improve motor symptoms in animal models of Parkinson's disease (PD) and in initial clin. trials, A2A receptor antagonists have emerged as an attractive non-dopaminergic target to improve the motor deficits that characterize PD.  Exptl. data have also shown that A2A receptor antagonists do not induce neuroplasticity phenomena that complicate long-term dopaminergic treatments.  The present review provides an updated summary of results reported in the literature concerning the biochem. characteristics and basal ganglia distribution of A2A receptors.  We subsequently aim to examine the effects of adenosine A2A antagonists in rodent and primate models of PD and of -DOPA-induced dyskinesia.  Finally, concluding remarks are made on post-mortem human brains and on the translation of adenosine A2A receptor antagonists in the treatment of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsCzoxtvHY_LVg90H21EOLACvtfcHk0lgV5clkbRnL2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlags7zM&md5=c5a9a8210856a487ee6ee7d5c3784379</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2007.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2007.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DMorelli%26aufirst%3DM.%26aulast%3DDi%2BPaolo%26aufirst%3DT.%26aulast%3DWardas%26aufirst%3DJ.%26aulast%3DCalon%26aufirst%3DF.%26aulast%3DXiao%26aufirst%3DD.%26aulast%3DSchwarzschild%26aufirst%3DM.%2BA.%26atitle%3DRole%2520of%2520adenosine%2520A2A%2520receptors%2520in%2520parkinsonian%2520motor%2520impairment%2520and%2520L-DOPA-induced%2520motor%2520complications%26jtitle%3DProg.%2520Neurobiol.%26date%3D2007%26volume%3D83%26spage%3D293%26epage%3D309%26doi%3D10.1016%2Fj.pneurobio.2007.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertorelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varty, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachowicz, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forlani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredduzzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen-williams, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Impagnatiello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolussi, E.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Characterization of the potent and highly selective A2A receptor antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">294</span>– <span class="NLM_lpage">303</span>, <span class="refDoi"> DOI: 10.1124/jpet.108.149617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1124%2Fjpet.108.149617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=19332567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFeluro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2009&pages=294-303&author=R.+A.+Hodgsonauthor=R.+Bertorelliauthor=G.+B.+Vartyauthor=J.+E.+Lachowiczauthor=A.+Forlaniauthor=S.+Fredduzziauthor=M.+E.+Cohen-williamsauthor=G.+A.+Higginsauthor=F.+Impagnatielloauthor=E.+Nicolussi&title=Characterization+of+the+potent+and+highly+selective+A2A+receptor+antagonists+Preladenant+and+SCH+412348+%5B7-%5B2-%5B4-2%2C4-difluorophenyl%5D-1-piperazinyl%5Dethyl%5D-2-%282-furanyl%29-7H-pyrazolo%5B4%2C3-e%5D%5B1%2C2%2C4%5Dtriazolo%5B1%2C5-c%5Dpyrimidin-5-amine%5D+in+rodent+models+of+movement+disorders+and+depression&doi=10.1124%2Fjpet.108.149617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression</span></div><div class="casAuthors">Hodgson, Robert A.; Bertorelli, Rosalia; Varty, Geoffrey B.; Lachowicz, Jean E.; Forlani, Angelo; Fredduzzi, Silva; Cohen-Williams, Mary E.; Higgins, Guy A.; Impagnatiello, Francesco; Nicolussi, Elisa; Parra, Leonard E.; Foster, Carolyn; Zhai, Ying; Neustadt, Bernie R.; Stamford, Andrew W.; Parker, Eric M.; Reggiani, Angelo; Hunter, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">294-303</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The adenosine A2A receptor has been implicated in the underlying biol. of various neurol. and psychiatric disorders, including Parkinson's disease (PD) and depression.  Preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] are potent competitive antagonists of the human A2A receptor (Ki = 1.1 and 0.6 nM, resp.) and have > 1000-fold selectivity over all other adenosine receptors, making these compds. the most selective A2A receptor antagonists reported to date.  Both compds. attenuate hypolocomotion induced by the A2A receptor agonist CGS-21680 [2-[p-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamidoadenosine], suggesting that they inhibit A2A receptor activity in vivo.  Their high degree of selectivity and robust in vivo activity make preladenant and SCH 412348 useful tools to investigate the role of the A2A receptor system in animal models of PD and depression.  Oral administration of preladenant and SCH 412348 (0.1-1 mg/kg) to rats potentiated 3,4-dihydroxy-L-phenylalanine (L-Dopa)-induced contralateral rotations after 6-hydroxydopamine lesions in the medial forebrain bundle and potently attenuated the cataleptic effects of haloperidol.  Preladenant (1 mg/kg) inhibited L-Dopa-induced behavioral sensitization after repeated daily administration, which suggests a reduced risk of the development of dyskinesias.  Finally, preladenant and SCH 412348 exhibited antidepressant-like profiles in models of behavioral despair, namely the mouse tail suspension test and the mouse and rat forced swim test.  These studies demonstrate that preladenant and SCH 412348 are potent and selective A2A receptor antagonists and provide further evidence of the potential therapeutic benefits of A2A receptor inhibition in PD (with reduced risk of dyskinesias) and depression (one of the primary nonmotor symptoms of PD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNkJMOfNlLc7Vg90H21EOLACvtfcHk0lhd8fyXTR0tjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFeluro%253D&md5=b8ce809c2d57a994d201ecca4daa39a3</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.149617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.149617%26sid%3Dliteratum%253Aachs%26aulast%3DHodgson%26aufirst%3DR.%2BA.%26aulast%3DBertorelli%26aufirst%3DR.%26aulast%3DVarty%26aufirst%3DG.%2BB.%26aulast%3DLachowicz%26aufirst%3DJ.%2BE.%26aulast%3DForlani%26aufirst%3DA.%26aulast%3DFredduzzi%26aufirst%3DS.%26aulast%3DCohen-williams%26aufirst%3DM.%2BE.%26aulast%3DHiggins%26aufirst%3DG.%2BA.%26aulast%3DImpagnatiello%26aufirst%3DF.%26aulast%3DNicolussi%26aufirst%3DE.%26atitle%3DCharacterization%2520of%2520the%2520potent%2520and%2520highly%2520selective%2520A2A%2520receptor%2520antagonists%2520Preladenant%2520and%2520SCH%2520412348%2520%255B7-%255B2-%255B4-2%252C4-difluorophenyl%255D-1-piperazinyl%255Dethyl%255D-2-%25282-furanyl%2529-7H-pyrazolo%255B4%252C3-e%255D%255B1%252C2%252C4%255Dtriazolo%255B1%252C5-c%255Dpyrimidin-5-amine%255D%2520in%2520rodent%2520models%2520of%2520movement%2520disorders%2520and%2520depression%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D330%26spage%3D294%26epage%3D303%26doi%3D10.1124%2Fjpet.108.149617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urade, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayaishi, O.</span></span> <span> </span><span class="NLM_article-title">The role of adenosine in the regulation of sleep</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1047</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.2174/156802611795347654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.2174%2F156802611795347654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=21401496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvFyktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1047-1057&author=Z.-L.+Huangauthor=Y.+Uradeauthor=O.+Hayaishi&title=The+role+of+adenosine+in+the+regulation+of+sleep&doi=10.2174%2F156802611795347654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">The role of adenosine in the regulation of sleep</span></div><div class="casAuthors">Huang, Zhi-Li; Urade, Yoshihiro; Hayaishi, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1047-1057</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  This paper presents an overview of the current knowledge about the role of adenosine in the sleep-wake regulation with a focus on adenosine in the central nervous system, regulation of adenosine levels, adenosine receptors, and manipulations of the adenosine system by the use of pharmacol. and mol. biol. tools.  The endogenous somnogen prostaglandin (PG) D2 increases the extracellular level of adenosine under the subarachnoid space of the basal forebrain and promotes physiol. sleep.  Adenosine is neither stored nor released as a classical neurotransmitter and is thought to be formed inside cells or on their surface, mostly by breakdown of adenine nucleotides.  The extracellular concn. of adenosine increases in the cortex and basal forebrain during prolonged wakefulness and decreases during the sleep recovery period.  Therefore, adenosine is proposed to act as a homeostatic regulator of sleep and to be a link between the humoral and neural mechanisms of sleep-wake regulation.  Both the adenosine A1 receptor (A1R) and A2AR are involved in sleep induction.  The A2AR plays a predominant role in the somnogenic effects of PGD2.  By use of gene-manipulated mice, the arousal effect of caffeine was shown to be dependent on the A2AR.  On the other hand, inhibition of wake-promoting neurons via the A1R also mediates the sleep-inducing effects of adenosine, whereas activation of A1R in the lateral preoptic area induces wakefulness, suggesting that A1R regulates the sleep-wake cycle in a site-dependent manner.  The potential therapeutic applications of agonists and antagonists of these receptors in sleep disorders are briefly discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg7NbK0sc9MLVg90H21EOLACvtfcHk0lhd8fyXTR0tjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvFyktLc%253D&md5=7b79c819a52140a0bd4eb775642eafce</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.2174%2F156802611795347654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611795347654%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DZ.-L.%26aulast%3DUrade%26aufirst%3DY.%26aulast%3DHayaishi%26aufirst%3DO.%26atitle%3DThe%2520role%2520of%2520adenosine%2520in%2520the%2520regulation%2520of%2520sleep%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D1047%26epage%3D1057%26doi%3D10.2174%2F156802611795347654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherasse, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, W.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bass, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winsky-Sommerer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredholm, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boison, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayaishi, O.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">10067</span>– <span class="NLM_lpage">10075</span>, <span class="refDoi"> DOI: 10.1523/jneurosci.6730-10.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1523%2Fjneurosci.6730-10.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=21734299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptFWqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=10067-10075&author=M.+Lazarusauthor=H.-Y.+Shenauthor=Y.+Cherasseauthor=W.-M.+Quauthor=Z.-L.+Huangauthor=C.+E.+Bassauthor=R.+Winsky-Sommererauthor=K.+Sembaauthor=B.+B.+Fredholmauthor=D.+Boisonauthor=O.+Hayaishi&title=Arousal+effect+of+caffeine+depends+on+adenosine+A2A+receptors+in+the+shell+of+the+nucleus+accumbens&doi=10.1523%2Fjneurosci.6730-10.2011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens</span></div><div class="casAuthors">Lazarus, Michael; Shen, Hai-Ying; Cherasse, Yoan; Qu, Wei-Min; Huang, Zhi-Li; Bass, Caroline E.; Winsky-Sommerer, Raphaelle; Semba, Kazue; Fredholm, Bertil B.; Boison, Detlev; Hayaishi, Osamu; Urade, Yoshihiro; Chen, Jiang-Fan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">10067-10075</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Caffeine, the most widely used psychoactive compd., is an adenosine receptor antagonist.  It promotes wakefulness by blocking adenosine A2A receptors (A2ARs) in the brain, but the specific neurons on which caffeine acts to produce arousal have not been identified.  Using selective gene deletion strategies based on the Cre/loxP technol. in mice and focal RNA interference to silence the expression of A2ARs in rats by local infection with adeno-assocd. virus carrying short-hairpin RNA, we report that the A2ARs in the shell region of the nucleus accumbens (NAc) are responsible for the effect of caffeine on wakefulness.  Caffeine-induced arousal was not affected in rats when A2ARs were focally removed from the NAc core or other A2AR-pos. areas of the basal ganglia.  Our observations suggest that caffeine promotes arousal by activating pathways that traditionally have been assocd. with motivational and motor responses in the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGW5Fzs9wilbVg90H21EOLACvtfcHk0lhd8fyXTR0tjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptFWqsrg%253D&md5=2400a4ba6e294e343814eaf87d4cb5f7</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1523%2Fjneurosci.6730-10.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252Fjneurosci.6730-10.2011%26sid%3Dliteratum%253Aachs%26aulast%3DLazarus%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.-Y.%26aulast%3DCherasse%26aufirst%3DY.%26aulast%3DQu%26aufirst%3DW.-M.%26aulast%3DHuang%26aufirst%3DZ.-L.%26aulast%3DBass%26aufirst%3DC.%2BE.%26aulast%3DWinsky-Sommerer%26aufirst%3DR.%26aulast%3DSemba%26aufirst%3DK.%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26aulast%3DBoison%26aufirst%3DD.%26aulast%3DHayaishi%26aufirst%3DO.%26atitle%3DArousal%2520effect%2520of%2520caffeine%2520depends%2520on%2520adenosine%2520A2A%2520receptors%2520in%2520the%2520shell%2520of%2520the%2520nucleus%2520accumbens%26jtitle%3DJ.%2520Neurosci.%26date%3D2011%26volume%3D31%26spage%3D10067%26epage%3D10075%26doi%3D10.1523%2Fjneurosci.6730-10.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, W.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eguchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarzschild, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredholm, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urade, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayaishi, O.</span></span> <span> </span><span class="NLM_article-title">Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">858</span>– <span class="NLM_lpage">859</span>, <span class="refDoi"> DOI: 10.1038/nn1491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1038%2Fnn1491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=15965471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvFWjs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2005&pages=858-859&author=Z.-L.+Huangauthor=W.-M.+Quauthor=N.+Eguchiauthor=J.-F.+Chenauthor=M.+A.+Schwarzschildauthor=B.+B.+Fredholmauthor=Y.+Uradeauthor=O.+Hayaishi&title=Adenosine+A2A%2C+but+not+A1%2C+receptors+mediate+the+arousal+effect+of+caffeine&doi=10.1038%2Fnn1491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine</span></div><div class="casAuthors">Huang, Zhi-Li; Qu, Wei-Min; Eguchi, Naomi; Chen, Jiang-Fan; Schwarzschild, Michael A.; Fredholm, Bertil B.; Urade, Yoshihiro; Hayaishi, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">858-859</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Caffeine, a component of tea, coffee and cola, induces wakefulness.  It binds to adenosine A1 and A2A receptors as an antagonist, but the receptor subtype mediating caffeine-induced wakefulness remains unclear.  Here we report that caffeine at 5, 10 and 15 mg kg-1 increased wakefulness in both wild-type mice and A1 receptor knockout mice, but not in A2A receptor knockout mice.  Thus, caffeine-induced wakefulness depends on adenosine A2A receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO2QOYwdslRbVg90H21EOLACvtfcHk0liOnlHnvVl7XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvFWjs74%253D&md5=9f2d012c7d8f106b354bf64ac5e7ea8c</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fnn1491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn1491%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DZ.-L.%26aulast%3DQu%26aufirst%3DW.-M.%26aulast%3DEguchi%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DJ.-F.%26aulast%3DSchwarzschild%26aufirst%3DM.%2BA.%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26aulast%3DUrade%26aufirst%3DY.%26aulast%3DHayaishi%26aufirst%3DO.%26atitle%3DAdenosine%2520A2A%252C%2520but%2520not%2520A1%252C%2520receptors%2520mediate%2520the%2520arousal%2520effect%2520of%2520caffeine%26jtitle%3DNat.%2520Neurosci.%26date%3D2005%26volume%3D8%26spage%3D858%26epage%3D859%26doi%3D10.1038%2Fnn1491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Postuma, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munhoz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charland, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moscovich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanatta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rios Romenets, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, R.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Caffeine for treatment of Parkinson disease: A randomized controlled trial</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">658</span>, <span class="refDoi"> DOI: 10.1212/wnl.0b013e318263570d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1212%2Fwnl.0b013e318263570d" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=22855866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ajs7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2012&pages=651-658&author=R.+B.+Postumaauthor=A.+E.+Langauthor=R.+P.+Munhozauthor=K.+Charlandauthor=A.+Pelletierauthor=M.+Moscovichauthor=L.+Fillaauthor=D.+Zanattaauthor=S.+Rios+Romenetsauthor=R.+Altman&title=Caffeine+for+treatment+of+Parkinson+disease%3A+A+randomized+controlled+trial&doi=10.1212%2Fwnl.0b013e318263570d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Caffeine for treatment of Parkinson disease: A randomized controlled trial</span></div><div class="casAuthors">Postuma, Ronald B.; Lang, Anthony E.; Munhoz, Renato P.; Charland, Katia; Pelletier, Amelie; Moscovich, Mariana; Filla, Luciane; Zanatta, Debora; Rios Romenets, Silvia; Altman, Robert; Chuang, Rosa; Shah, Binit</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">651-658</span>CODEN:
                <span class="NLM_cas:coden">NEURAI</span>;
        ISSN:<span class="NLM_cas:issn">0028-3878</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Epidemiol. studies consistently link caffeine, a nonselective adenosine antagonist, to lower risk of Parkinson disease (PD).  However, the symptomatic effects of caffeine in PD have not been adequately evaluated.  We conducted a 6-wk randomized controlled trial of caffeine in PD to assess effects upon daytime somnolence, motor severity, and other nonmotor features.  Patients with PD with daytime somnolence (Epworth >10) were given caffeine 100 mg twice daily ×3 wk, then 200 mg twice daily ×3 wk, or matching placebo.  The primary outcome was the Epworth Sleepiness Scale score.  Secondary outcomes included motor severity, sleep markers, fatigue, depression, and quality of life.  Effects of caffeine were analyzed with Bayesian hierarchical models, adjusting for study site, baseline scores, age, and sex.  Of 61 patients, 31 were randomized to placebo and 30 to caffeine.  On the primary intention-to-treat anal., caffeine resulted in a nonsignificant redn. in Epworth Sleepiness Scale score (-1.71 points; 95% confidence interval [CI] -3.57, 0.13).  However, somnolence improved on the Clin. Global Impression of Change (+0.64; 0.16, 1.13, intention-to-treat), with significant redn. in Epworth Sleepiness Scale score on per-protocol anal. (-1.97; -3.87, -0.05).  Caffeine reduced the total Unified Parkinson's Disease Rating Scale score (-4.69 points; -7.7, -1.6) and the objective motor component (-3.15 points; -5.50, -0.83).  Other than modest improvement in global health measures, there were no changes in quality of life, depression, or sleep quality.  Adverse events were comparable in caffeine and placebo groups.  Caffeine provided only equivocal borderline improvement in excessive somnolence in PD, but improved objective motor measures.  These potential motor benefits suggest that a larger long-term trial of caffeine is warranted.  Classification of evidence: This study provides Class I evidence that caffeine, up to 200 mg BID for 6 wk, had no significant benefit on excessive daytime sleepiness in patients with PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoofrMikXYL27Vg90H21EOLACvtfcHk0liOnlHnvVl7XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ajs7vI&md5=9c675d983bfddd1f3bf81f2d7d6e5155</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1212%2Fwnl.0b013e318263570d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252Fwnl.0b013e318263570d%26sid%3Dliteratum%253Aachs%26aulast%3DPostuma%26aufirst%3DR.%2BB.%26aulast%3DLang%26aufirst%3DA.%2BE.%26aulast%3DMunhoz%26aufirst%3DR.%2BP.%26aulast%3DCharland%26aufirst%3DK.%26aulast%3DPelletier%26aufirst%3DA.%26aulast%3DMoscovich%26aufirst%3DM.%26aulast%3DFilla%26aufirst%3DL.%26aulast%3DZanatta%26aufirst%3DD.%26aulast%3DRios%2BRomenets%26aufirst%3DS.%26aulast%3DAltman%26aufirst%3DR.%26atitle%3DCaffeine%2520for%2520treatment%2520of%2520Parkinson%2520disease%253A%2520A%2520randomized%2520controlled%2520trial%26jtitle%3DNeurology%26date%3D2012%26volume%3D79%26spage%3D651%26epage%3D658%26doi%3D10.1212%2Fwnl.0b013e318263570d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chubukov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structural basis for allosteric regulation of GPCRs by sodium ions</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>337</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1126/science.1219218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1126%2Fscience.1219218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=22798613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVKqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2012&pages=232-236&author=W.+Liuauthor=E.+Chunauthor=A.+A.+Thompsonauthor=P.+Chubukovauthor=F.+Xuauthor=V.+Katritchauthor=G.+W.+Hanauthor=C.+B.+Rothauthor=L.+H.+Heitmanauthor=A.+P.+IJzermanauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structural+basis+for+allosteric+regulation+of+GPCRs+by+sodium+ions&doi=10.1126%2Fscience.1219218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions</span></div><div class="casAuthors">Liu, Wei; Chun, Eugene; Thompson, Aaron A.; Chubukov, Pavel; Xu, Fei; Katritch, Vsevolod; Han, Gye Won; Roth, Christopher B.; Heitman, Laura H.; IJzerman, Adriaan P.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">6091</span>),
    <span class="NLM_cas:pages">232-236</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Pharmacol. responses of G protein-coupled receptors (GPCRs) can be fine-tuned by allosteric modulators.  Structural studies of such effects have been limited due to the medium resoln. of GPCR structures.  We reengineered the human A2A adenosine receptor by replacing its third intracellular loop with apocytochrome b562RIL and solved the structure at 1.8 angstrom resoln.  The high-resoln. structure allowed us to identify 57 ordered water mols. inside the receptor comprising three major clusters.  The central cluster harbors a putative sodium ion bound to the highly conserved aspartate residue Asp2.50.  Addnl., two cholesterols stabilize the conformation of helix VI, and one of 23 ordered lipids intercalates inside the ligand-binding pocket.  These high-resoln. details shed light on the potential role of structured water mols., sodium ions, and lipids/cholesterol in GPCR stabilization and function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvcjQimGnIMLVg90H21EOLACvtfcHk0liOnlHnvVl7XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVKqtbs%253D&md5=782b2235b76ef77b11b6456f8e4485e1</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1126%2Fscience.1219218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1219218%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DChun%26aufirst%3DE.%26aulast%3DThompson%26aufirst%3DA.%2BA.%26aulast%3DChubukov%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DRoth%26aufirst%3DC.%2BB.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructural%2520basis%2520for%2520allosteric%2520regulation%2520of%2520GPCRs%2520by%2520sodium%2520ions%26jtitle%3DScience%26date%3D2012%26volume%3D337%26spage%3D232%26epage%3D236%26doi%3D10.1126%2Fscience.1219218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">MOE</span>.  <i>Molecular operating environment (MOE 2014.09)</i>; <span class="NLM_publisher-name">Chemical Computing Group: Montreal</span>: <span class="NLM_publisher-loc">Quebec: Canada</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=MOE&title=Molecular+operating+environment+%28MOE+2014.09%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26btitle%3DMolecular%2520operating%2520environment%2520%2528MOE%25202014.09%2529%26pub%3DChemical%2520Computing%2520Group%253A%2520Montreal%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isberg, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolajsen, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bibbe, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flock, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deupi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloriam, D. E.</span></span> <span> </span><span class="NLM_article-title">An online resource for GPCR structure determination and analysis</span>. <i>Nat. Methods</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1038/s41592-018-0302-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1038%2Fs41592-018-0302-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=30664776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtFGru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=151-162&author=C.+Munkauthor=E.+Muttauthor=V.+Isbergauthor=L.+F.+Nikolajsenauthor=J.+M.+Bibbeauthor=T.+Flockauthor=M.+A.+Hansonauthor=R.+C.+Stevensauthor=X.+Deupiauthor=D.+E.+Gloriam&title=An+online+resource+for+GPCR+structure+determination+and+analysis&doi=10.1038%2Fs41592-018-0302-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">An online resource for GPCR structure determination and analysis</span></div><div class="casAuthors">Munk, Christian; Mutt, Eshita; Isberg, Vignir; Nikolajsen, Louise F.; Bibbe, Janne M.; Flock, Tilman; Hanson, Michael A.; Stevens, Raymond C.; Deupi, Xavier; Gloriam, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Methods</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-162</span>CODEN:
                <span class="NLM_cas:coden">NMAEA3</span>;
        ISSN:<span class="NLM_cas:issn">1548-7091</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) transduce physiol. and sensory stimuli into appropriate cellular responses and mediate the actions of one-third of drugs.  GPCR structural studies have revealed the general bases of receptor activation, signaling, drug action and allosteric modulation, but so far cover only 13% of nonolfactory receptors.  We broadly surveyed the receptor modifications/engineering and methods used to produce all available GPCR crystal and cryo-electron microscopy (cryo-EM) structures, and present an interactive resource integrated in GPCRdb (http://www.gpcrdb.org) to assist users in designing constructs and browsing appropriate exptl. conditions for structure studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnhlg2FyHfTLVg90H21EOLACvtfcHk0lhFtoIkaWVRBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtFGru74%253D&md5=a0e1ffb48671b58a63764ed4cff86901</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1038%2Fs41592-018-0302-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41592-018-0302-x%26sid%3Dliteratum%253Aachs%26aulast%3DMunk%26aufirst%3DC.%26aulast%3DMutt%26aufirst%3DE.%26aulast%3DIsberg%26aufirst%3DV.%26aulast%3DNikolajsen%26aufirst%3DL.%2BF.%26aulast%3DBibbe%26aufirst%3DJ.%2BM.%26aulast%3DFlock%26aufirst%3DT.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DDeupi%26aufirst%3DX.%26aulast%3DGloriam%26aufirst%3DD.%2BE.%26atitle%3DAn%2520online%2520resource%2520for%2520GPCR%2520structure%2520determination%2520and%2520analysis%26jtitle%3DNat.%2520Methods%26date%3D2019%26volume%3D16%26spage%3D151%26epage%3D162%26doi%3D10.1038%2Fs41592-018-0302-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belew, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodsell, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. J.</span></span> <span> </span><span class="NLM_article-title">AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2785</span>– <span class="NLM_lpage">2791</span>, <span class="refDoi"> DOI: 10.1002/jcc.21256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1002%2Fjcc.21256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=19399780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=2785-2791&author=G.+M.+Morrisauthor=R.+Hueyauthor=W.+Lindstromauthor=M.+F.+Sannerauthor=R.+K.+Belewauthor=D.+S.+Goodsellauthor=A.+J.+Olson&title=AutoDock4+and+AutoDockTools4%3A+Automated+docking+with+selective+receptor+flexibility&doi=10.1002%2Fjcc.21256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock and AutoDockTools: Automated docking with selective receptor flexibility</span></div><div class="casAuthors">Morris, Garrett M.; Huey, Ruth; Lindstrom, William; Sanner, Michel F.; Belew, Richard K.; Goodsell, David S.; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2785-2791</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">We describe the testing and release of AutoDock4 and the accompanying graphical user interface AutoDockTools.  AutoDock4 incorporates limited flexibility in the receptor.  Several tests are reported here, including a redocking expt. with 188 diverse ligand-protein complexes and a cross-docking expt. using flexible sidechains in 87 HIV protease complexes.  We also report its utility in anal. of covalently bound ligands, using both a grid-based docking method and a modification of the flexible sidechain technique. © 2009 Wiley Periodicals, Inc.  J Comput Chem, 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqktE6WAo4GEbVg90H21EOLACvtfcHk0lhFtoIkaWVRBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GitrnK&md5=679ce22fc50e9291c9aa16e7a1855845</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21256%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DG.%2BM.%26aulast%3DHuey%26aufirst%3DR.%26aulast%3DLindstrom%26aufirst%3DW.%26aulast%3DSanner%26aufirst%3DM.%2BF.%26aulast%3DBelew%26aufirst%3DR.%2BK.%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutoDock4%2520and%2520AutoDockTools4%253A%2520Automated%2520docking%2520with%2520selective%2520receptor%2520flexibility%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2009%26volume%3D30%26spage%3D2785%26epage%3D2791%26doi%3D10.1002%2Fjcc.21256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanner, M. F.</span></span> <span> </span><span class="NLM_article-title">Python: a programming language for software integration and development</span>. <i>J. Mol. Graph. Model.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">61</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10660911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtV2rsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=57-61&author=M.+F.+Sanner&title=Python%3A+a+programming+language+for+software+integration+and+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Python: a programming language for software integration and development</span></div><div class="casAuthors">Sanner, M. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Graphics & Modelling</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-61</span>CODEN:
                <span class="NLM_cas:coden">JMGMFI</span>;
        ISSN:<span class="NLM_cas:issn">1093-3263</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The use of interpreted languages in biocomputing has been investigated to create a programmable, dynamic environment in which components can be tied together at a high level.  This work has demonstrated the benefits of such an approach and the features of the interpreted language that are key to successful component integration.  This involved Python, an interpreted, interactive, object-oriented programming language.  It provides high-level data structures such as list and associative arrays, dynamic typing and dynamic binding, modules, classes, exceptions, automatic memory management and others.  Python has been found to be instrumental in the mol. modeling research environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaCFXA1JC8X7Vg90H21EOLACvtfcHk0lhFtoIkaWVRBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtV2rsA%253D%253D&md5=3bf94934548080055dda54f68468c656</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSanner%26aufirst%3DM.%2BF.%26atitle%3DPython%253A%2520a%2520programming%2520language%2520for%2520software%2520integration%2520and%2520development%26jtitle%3DJ.%2520Mol.%2520Graph.%2520Model.%26date%3D1999%26volume%3D17%26spage%3D57%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Namasivayam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Günther, R.</span></span> <span> </span><span class="NLM_article-title"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="7606051936170302191219151d">[email protected]</a>: A fast flexible molecular docking program based on swarm intelligence</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.1111/j.1747-0285.2007.00588.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1111%2Fj.1747-0285.2007.00588.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=17986206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2007&pages=475-484&author=V.+Namasivayamauthor=R.+G%C3%BCnther&title=pso%40autodock%3A+A+fast+flexible+molecular+docking+program+based+on+swarm+intelligence&doi=10.1111%2Fj.1747-0285.2007.00588.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="b1e1e2fef1f0e4e5fef5fef2fa">[email protected]</a>: a fast flexible molecular docking program based on Swarm intelligence</span></div><div class="casAuthors">Namasivayam, Vigneshwaran; Guenther, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">475-484</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">On the quest of novel therapeutics, mol. docking methods have proven to be valuable tools for screening large libraries of compds. detg. the interactions of potential drugs with the target proteins.  A widely used docking approach is the simulation of the docking process guided by a binding energy function.  On the basis of the mol. docking program AUTODOCK, we present <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="6636352926273332292229252d">[email protected]</a> as a tool for fast flexible mol. docking.  Our novel Particle Swarm Optimization (PSO) algorithms varCPSO and varCPSO-Is are suited for rapid docking of highly flexible ligands.  Thus, a ligand with 23 rotatable bonds was successfully docked within as few as 100 000 computing steps (rmsd = 0.87 Å), which corresponds to only 10% of the computing time demanded by AUTODOCK.  In comparison to other docking techniques as GOLD 3.0, DOCK 6.0, FLEXX 2.2.0, AUTODOCK 3.05, and SODOCK, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="1242415d525347465d565d5159">[email protected]</a> provides the smallest rmsd values for 12 in 37 protein-ligand complexes.  The av. rmsd value of 1.4 Å is significantly lower then those obtained with the other docking programs, which are all above 2.0 Å.  Thus, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="0252514d424357564d464d4149">[email protected]</a> is suggested as a highly efficient docking program in terms of speed and quality for flexible peptide-protein docking and virtual screening studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryKHisUEtA_LVg90H21EOLACvtfcHk0ljLdMSXOHrBxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsb3E&md5=a8e0f99d7a51e3b62e42900c05a92b7f</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00588.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00588.x%26sid%3Dliteratum%253Aachs%26aulast%3DNamasivayam%26aufirst%3DV.%26aulast%3DG%25C3%25BCnther%26aufirst%3DR.%26atitle%3Dpso%2540autodock%253A%2520A%2520fast%2520flexible%2520molecular%2520docking%2520program%2520based%2520on%2520swarm%2520intelligence%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2007%26volume%3D70%26spage%3D475%26epage%3D484%26doi%3D10.1111%2Fj.1747-0285.2007.00588.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Filippo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellizzari, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deganutti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Tayeb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiedel, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span> <span> </span><span class="NLM_article-title">A2A and A2B adenosine receptors: The extracellular loop 2 determines high (A2A) or low affinity (A2B) for adenosine</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">113718</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2019.113718</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.bcp.2019.113718" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=31751537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlGitbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2020&pages=113718&author=E.+De+Filippoauthor=S.+Hinzauthor=V.+Pellizzariauthor=G.+Deganuttiauthor=A.+El-Tayebauthor=G.+Navarroauthor=R.+Francoauthor=S.+Moroauthor=A.+C.+Schiedelauthor=C.+E.+M%C3%BCller&title=A2A+and+A2B+adenosine+receptors%3A+The+extracellular+loop+2+determines+high+%28A2A%29+or+low+affinity+%28A2B%29+for+adenosine&doi=10.1016%2Fj.bcp.2019.113718"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">A2A and A2B adenosine receptors: The extracellular loop 2 determines high (A2A) or low affinity (A2B) for adenosine</span></div><div class="casAuthors">De Filippo, Elisabetta; Hinz, Sonja; Pellizzari, Veronica; Deganutti, Giuseppe; El-Tayeb, Ali; Navarro, Gemma; Franco, Rafael; Moro, Stefano; Schiedel, Anke C.; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113718</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A2A and A2B adenosine receptors (ARs) are closely related G protein-coupled receptor subtypes, which represent important (potential) drug targets.  Despite their almost identical binding sites for adenosine, A2AARs are activated by low (nanomolar) adenosine concns., while A2BARs require micromolar concns.  In the present study, we exchanged the extracellular loop 2 (ECL2) of the human A2AAR for that of the A2BAR.  The resulting chimeric A2A(ECL2-A2B)AR was investigated in radioligand binding and cAMP accumulation assays in comparison to the wildtype A2AAR.  While the ribose-modified adenosine analog N-ethylcarboxamidoadenosine (NECA) and its 2-substituted deriv. CGS-21680 did not exhibit significant changes, adenosine showed dramatically reduced potency and affinity for the A2A(ECL2-A2B)AR mutant displaying similarly low potency as for the wt A2BAR.  Supervised mol. dynamics simulation studies predicted a meta-binding site with high affinity for adenosine, but not for NECA, which may contribute to the obsd. effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2YSz82BRuI7Vg90H21EOLACvtfcHk0ljLdMSXOHrBxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlGitbbN&md5=60982342c717b305861e31d07b5673ee</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2019.113718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2019.113718%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BFilippo%26aufirst%3DE.%26aulast%3DHinz%26aufirst%3DS.%26aulast%3DPellizzari%26aufirst%3DV.%26aulast%3DDeganutti%26aufirst%3DG.%26aulast%3DEl-Tayeb%26aufirst%3DA.%26aulast%3DNavarro%26aufirst%3DG.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DMoro%26aufirst%3DS.%26aulast%3DSchiedel%26aufirst%3DA.%2BC.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DA2A%2520and%2520A2B%2520adenosine%2520receptors%253A%2520The%2520extracellular%2520loop%25202%2520determines%2520high%2520%2528A2A%2529%2520or%2520low%2520affinity%2520%2528A2B%2529%2520for%2520adenosine%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2020%26volume%3D172%26spage%3D113718%26doi%3D10.1016%2Fj.bcp.2019.113718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gondard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anaclet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akaoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.-S.</span></span> <span> </span><span class="NLM_article-title">Enhanced histaminergic neurotransmission and sleep-wake alterations, a study in histamine H3-receptor knock-out mice</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1015</span>– <span class="NLM_lpage">1031</span>, <span class="refDoi"> DOI: 10.1038/npp.2012.266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1038%2Fnpp.2012.266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=23303066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt1Shtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=1015-1031&author=E.+Gondardauthor=C.+Anacletauthor=H.+Akaokaauthor=R.-X.+Guoauthor=M.+Zhangauthor=C.+Budaauthor=P.+Francoauthor=H.+Kotaniauthor=J.-S.+Lin&title=Enhanced+histaminergic+neurotransmission+and+sleep-wake+alterations%2C+a+study+in+histamine+H3-receptor+knock-out+mice&doi=10.1038%2Fnpp.2012.266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced Histaminergic Neurotransmission and Sleep-Wake Alterations, a Study in Histamine H3-Receptor Knock-Out Mice</span></div><div class="casAuthors">Gondard, Elise; Anaclet, Christelle; Akaoka, Hideo; Guo, Rui-Xian; Zhang, Mei; Buda, Colette; Franco, Patricia; Kotani, Hidehito; Lin, Jian-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1015-1031</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Long-term abolition of a brain arousal system impairs wakefulness (W), but little is known about the consequences of long-term enhancement.  The brain histaminergic arousal system is under the neg. control of H3-autoreceptors whose deletion results in permanent enhancement of histamine (HA) turnover.  In order to det. the consequences of enhancement of the histaminergic system, we compared the cortical EEG and sleep-wake states of H3-receptor knockout (H3R-/-) and wild-type mouse littermates.  We found that H3R-/-mice had rich phenotypes.  On the one hand, they showed clear signs of enhanced HA neurotransmission and vigilance, i.e., a higher EEG θ power during spontaneous W and a greater extent of W or sleep restriction during behavioral tasks, including environmental change, locomotion, and motivation tests.  On the other hand, during the baseline dark period, they displayed deficient W and signs of sleep deterioration, such as pronounced sleep fragmentation and reduced cortical slow activity during slow wave sleep (SWS), most likely due to a desensitization of postsynaptic histaminergic receptors as a result of const. HA release.  Ciproxifan (H3-receptor inverse agonist) enhanced W in wild-type mice, but not in H3R-/-mice, indicating a functional deletion of H3-receptors, whereas triprolidine (postsynaptic H1-receptor antagonist) or α-fluoromethylhistidine (HA-synthesis inhibitor) caused a greater SWS increase in H3R-/- than in wild-type mice, consistent with enhanced HA neurotransmission.  These sleep-wake characteristics and the obesity phenotypes previously reported in this animal model suggest that chronic enhancement of histaminergic neurotransmission eventually compromises the arousal system, leading to sleep-wake, behavioral, and metabolic disorders similar to those caused by voluntary sleep restriction in humans.  Neuropsychopharmacol. (2013) 38, 1015-1031; doi:10.1038/npp.2012.266; published online 13 Feb. 2013.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplyX0giHLDrbVg90H21EOLACvtfcHk0ljLdMSXOHrBxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmt1Shtbk%253D&md5=1aecabe87c066f33ec172580658a07e5</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2012.266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2012.266%26sid%3Dliteratum%253Aachs%26aulast%3DGondard%26aufirst%3DE.%26aulast%3DAnaclet%26aufirst%3DC.%26aulast%3DAkaoka%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DR.-X.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DBuda%26aufirst%3DC.%26aulast%3DFranco%26aufirst%3DP.%26aulast%3DKotani%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DJ.-S.%26atitle%3DEnhanced%2520histaminergic%2520neurotransmission%2520and%2520sleep-wake%2520alterations%252C%2520a%2520study%2520in%2520histamine%2520H3-receptor%2520knock-out%2520mice%26jtitle%3DNeuropsychopharmacology%26date%3D2013%26volume%3D38%26spage%3D1015%26epage%3D1031%26doi%3D10.1038%2Fnpp.2012.266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duchêne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomasson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauveau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piérard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagarde, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picoli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeanson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouthon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dauvilliers, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaume, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charvériat, M.</span></span> <span> </span><span class="NLM_article-title">Impact of astroglial connexins on modafinil pharmacological properties</span>. <i>Sleep</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1283</span>– <span class="NLM_lpage">1292</span>, <span class="refDoi"> DOI: 10.5665/sleep.5854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.5665%2Fsleep.5854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=27091533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A280%3ADC%252BC28bhtFCluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2016&pages=1283-1292&author=A.+Duch%C3%AAneauthor=M.+Perierauthor=Y.+Zhaoauthor=X.+Liuauthor=J.+Thomassonauthor=F.+Chauveauauthor=C.+Pi%C3%A9rardauthor=D.+Lagardeauthor=C.+Picoliauthor=T.+Jeansonauthor=F.+Mouthonauthor=Y.+Dauvilliersauthor=C.+Giaumeauthor=J.-S.+Linauthor=M.+Charv%C3%A9riat&title=Impact+of+astroglial+connexins+on+modafinil+pharmacological+properties&doi=10.5665%2Fsleep.5854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Astroglial Connexins on Modafinil Pharmacological Properties</span></div><div class="casAuthors">Duchene Adeline; Picoli Christele; Jeanson Tiffany; Mouthon Franck; Charveriat Mathieu; Perier Magali; Zhao Yan; Lin Jian-Sheng; Liu Xinhe; Jeanson Tiffany; Giaume Christian; Thomasson Julien; Chauveau Frederic; Pierard Christophe; Lagarde Didier; Picoli Christele; Dauvilliers Yves</div><div class="citationInfo"><span class="NLM_cas:title">Sleep</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1283-92</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">STUDY OBJECTIVES:  Modafinil is a non-amphetaminic wake-promoting compound used as therapy against sleepiness and narcolepsy.  Its mode of action is complex, but modafinil has been recently proposed to act as a cellular-coupling enhancer in glial cells, through modulation of gap junctions constituted by connexins.  The present study investigated in mice the impact of connexins on the effects of modafinil using connexin inhibitors.  METHODS:  Modafinil was administered alone or combined with inhibitors of astrocyte connexin, meclofenamic acid, or flecainide, respectively, acting on Cx30 and Cx43.  Sleep-wake states were monitored in wild-type and narcoleptic orexin knockout mice.  A spontaneous alternation task was used to evaluate working memory in wild-type mice.  The effects of the compounds on astroglial intercellular coupling were determined using dye transfer in acute cortical slices.  RESULTS:  Meclofenamic acid had little modulation on the effects of modafinil, but flecainide enhanced the wake-promoting and pro-cognitive effects of modafinil.  Co-administration of modafinil/flecainide resulted in a marked decrease in the number and duration of direct transitions to rapid eye movement sleep, which are characteristic of narcoleptic episodes in orexin knockout mice.  Furthermore, modafinil enhanced the connexin-mediated astroglial cell coupling, whereas flecainide reduced it.  Finally, this modafinil-induced effect was reversed by co-administration with flecainide.  CONCLUSIONS:  Our study indicates that flecainide impacts the pharmacological effects of modafinil, likely through the normalization of Cx30-dependent gap junctional coupling in astroglial networks.  The enhancement of the wake-promoting, behavioral, and cognitive outcomes of modafinil demonstrated here with flecainide would open new perspectives in the management of sleep disorders such as narcolepsy.  COMMENTARY:  A commentary on this article appears in this issue on page 1175.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS239Z5xsJnGysZ1x6zOs0vfW6udTcc2eb2iBGInBx3pLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bhtFCluw%253D%253D&md5=33c14356ff136c4d23db1c20e3920dd0</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.5665%2Fsleep.5854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5665%252Fsleep.5854%26sid%3Dliteratum%253Aachs%26aulast%3DDuch%25C3%25AAne%26aufirst%3DA.%26aulast%3DPerier%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DThomasson%26aufirst%3DJ.%26aulast%3DChauveau%26aufirst%3DF.%26aulast%3DPi%25C3%25A9rard%26aufirst%3DC.%26aulast%3DLagarde%26aufirst%3DD.%26aulast%3DPicoli%26aufirst%3DC.%26aulast%3DJeanson%26aufirst%3DT.%26aulast%3DMouthon%26aufirst%3DF.%26aulast%3DDauvilliers%26aufirst%3DY.%26aulast%3DGiaume%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.-S.%26aulast%3DCharv%25C3%25A9riat%26aufirst%3DM.%26atitle%3DImpact%2520of%2520astroglial%2520connexins%2520on%2520modafinil%2520pharmacological%2520properties%26jtitle%3DSleep%26date%3D2016%26volume%3D39%26spage%3D1283%26epage%3D1292%26doi%3D10.5665%2Fsleep.5854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akaoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lintunen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panula, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.-S.</span></span> <span> </span><span class="NLM_article-title">Role of histamine H1-receptor on behavioral states and wake maintenance during deficiency of a brain activating system: A study using a knockout mouse model</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2015.12.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=10.1016%2Fj.neuropharm.2015.12.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=26723880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtFCmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2016&pages=20-34&author=R.+Parmentierauthor=Y.+Zhaoauthor=M.+Perierauthor=H.+Akaokaauthor=M.+Lintunenauthor=Y.+Houauthor=P.+Panulaauthor=T.+Watanabeauthor=P.+Francoauthor=J.-S.+Lin&title=Role+of+histamine+H1-receptor+on+behavioral+states+and+wake+maintenance+during+deficiency+of+a+brain+activating+system%3A+A+study+using+a+knockout+mouse+model&doi=10.1016%2Fj.neuropharm.2015.12.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Role of histamine H1-receptor on behavioral states and wake maintenance during deficiency of a brain activating system: A study using a knockout mouse model</span></div><div class="casAuthors">Parmentier, Regis; Zhao, Yan; Perier, Magali; Akaoka, Hideo; Lintunen, Minnamaija; Hou, Yiping; Panula, Pertti; Watanabe, Takeshi; Franco, Patricia; Lin, Jian-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20-34</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Using knockout KO mice lacking the histamine HA-synthesizing enzyme histidine decarboxylase, HDC, we have previously shown the importance of histaminergic neurons in maintaining wakefulness W under behavioral challenges.  Since the central actions of HA are mediated by several receptor subtypes, it remains to be detd. which one s could be responsible for such a role.  We have therefore compared the cortical-EEG, sleep and W under baseline conditions or behavioral/pharmacol. stimuli in littermate wild-type WT and H1-receptor KO H1-/- mice.  We found that H1-/- mice shared several characteristics with HDC KO mice, i.e. (1) a decrease in W after lights-off despite its normal baseline daily amt.; (2) a decreased EEG slow wave sleep SWS/W power ratio; (3) inability to maintain W in response to behavioral challenges demonstrated by a decreased sleep latency when facing various stimuli.  These effects were mediated by central H1-receptors.  Indeed, in WT mice, injection of triprolidine, a brain-penetrating H1-receptor antagonist increased SWS, whereas ciproxifan H3-receptor antagonist/inverse agonist elicited W; all these injections had no effect in H1-/- mice.  Finally, H1-/- mice showed markedly greater changes in EEG power notably in the 0.8-5 Hz band and sleep-wake cycle than in WT mice after application of a cholinergic antagonist or an indirect agonist, i.e., scopolamine or physostigmine.  Hence, the role of HA in wake-promotion is largely ensured by H1-receptors.  An upregulated cholinergic system may account for a quasi-normal daily amt. of W in HDC or H1-receptor KO mice and likely constitutes a major compensatory mechanism when the brain is facing deficiency of an activating system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaqEix_Ri7zrVg90H21EOLACvtfcHk0liZW5qgglTW6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtFCmtg%253D%253D&md5=6132521779b508023a09f3ffeffd5eff</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2015.12.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2015.12.014%26sid%3Dliteratum%253Aachs%26aulast%3DParmentier%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DPerier%26aufirst%3DM.%26aulast%3DAkaoka%26aufirst%3DH.%26aulast%3DLintunen%26aufirst%3DM.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DPanula%26aufirst%3DP.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DFranco%26aufirst%3DP.%26aulast%3DLin%26aufirst%3DJ.-S.%26atitle%3DRole%2520of%2520histamine%2520H1-receptor%2520on%2520behavioral%2520states%2520and%2520wake%2520maintenance%2520during%2520deficiency%2520of%2520a%2520brain%2520activating%2520system%253A%2520A%2520study%2520using%2520a%2520knockout%2520mouse%2520model%26jtitle%3DNeuropharmacology%26date%3D2016%26volume%3D106%26spage%3D20%26epage%3D34%26doi%3D10.1016%2Fj.neuropharm.2015.12.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EIY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EIY','PDB','4EIY'); return false;">PDB: 4EIY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RZE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RZE','PDB','3RZE'); return false;">PDB: 3RZE</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i44"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00914">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_05312"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00914?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00914</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Spectroscopic and analytical data; general LC–MS analytics; general synthesis, fluorescence characterization of compound <b>12</b> (<b>ST-1992</b>); drug-likeness of synthetized MTLs <b>4</b> (<b>ST-2001</b>) and <b>12</b> (<b>ST-1992</b>); cell viability of human neuroblastoma cells treated with MTLs <b>2</b>, <b>4</b> (<b>ST-2001</b>) , and <b>6</b>; <i>in vitro</i> radioligand binding experiments for compounds <b>4</b> (<b>ST-2001</b>) and <b>12</b> (<b>ST-1992</b>); <i>in vivo</i> studies of compound <b>4</b> (<b>ST-2001</b>); additional <i>in vivo</i> evaluation of compound <b>12</b> (<b>ST-1992</b>); and experimental part with references (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_002.csv">CSV</a>)</p></li><li><p class="inline">Modeling structure of A<sub>2A</sub>R with preladenant (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_003.pdb">PDB</a>)</p></li><li><p class="inline">Modeling structure of A<sub>2A</sub>R with ST-1992 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_004.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_001.pdf">jm0c00914_si_001.pdf (1.93 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_002.csv">jm0c00914_si_002.csv (1.98 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_003.pdb">jm0c00914_si_003.pdb (380.87 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_004.pdb">jm0c00914_si_004.pdb (381.48 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00914&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00914%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-12%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00914" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679943c9aa773c82","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
